{
  "responseHeader":{
    "status":0,
    "QTime":190,
    "params":{
      "q":"(Doc_abstract: \"medullary thyroid carcinoma\"^4 OR MTC OR Doc_title: \"medullary thyroid carcinoma\"^4 OR MTC) AND (Doc_abstract: RET^4 OR \"HSCR1\" OR \"MEN2A\" OR \"MEN2B\" OR \"CDHF12\" OR \"CDHR16\" OR \"RET-ELE1\" OR Doc_title: RET^4 OR \"HSCR1\" OR \"MEN2A\" OR \"MEN2B\" OR \"CDHF12\" OR \"CDHR16\" OR \"RET-ELE1\") AND (Doc_abstract: \"treatment\" OR \"therapy\" OR \"Surgery\" OR \"Radiation\" OR \"Protein kinase inhibitors\")"}},
  "response":{"numFound":237,"start":0,"docs":[
      {
        "Doc_abstract":"The RET proto-oncogene encodes a receptor tyrosine kinase. RET oncogenes arise through sporadic and inherited gene mutations and are involved in the etiopathogenesis of medullary thyroid carcinoma, a cancer that responds poorly to conventional chemotherapy. Medullary thyroid carcinoma is a component of multiple endocrine neoplasia type 2 or MEN2 syndromes.;We investigated the cellular effects of RPI-1, a novel 2-indolinone Ret tyrosine kinase inhibitor on cells that express RET C634 oncogenic mutants common in the MEN2A syndrome: NIH3T3 fibroblasts transfected with RET(C634R) and human medullary thyroid carcinoma TT cells that express endogenous RET(C634W). RPI-1 antiproliferative activity was determined by cell proliferation and anchorage-independent growth assays. Expression and phosphorylation of Ret and of proteins involved in downstream signaling pathways were examined by immunoblotting. Antitumor activity of oral RPI-1 treatment was tested by using two dosing levels in nude mice bearing subcutaneous TT xenograft tumors. All statistical tests were two-sided.;The RPI-1 IC50 value for cell proliferation was 3.6 microM (95% confidence interval [CI] = 1.8 to 5.4 microM) in NIH3T3 cells expressing the Ret mutant compared with 16 microM (95% CI = 12.3 to 19.7 microM) in non-transfected NIH3T3 cells, and that for colony formation in soft agar was 2.4 microM (95% CI = 0.8 to 4.0 microM) and 26 microM (95% CI = 17 to 35 microM) in RET mutant-transfected and H-RAS-transfected NIH3T3 cells, respectively. In NIH3T3 cells expressing the Ret mutant, Ret protein and tyrosine phosphorylation were undetectable after 24 hours of RPI-1 treatment. In TT cells, RPI-1 inhibited proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT. In mice, oral daily RPI-1 treatment inhibited the tumor growth of TT xenografts by 81% (P<.001 versus control mice) and reduced the plasma levels of the specific biomarker calcitonin (P =.01 versus control mice). Twenty-five percent of RPI-1-treated mice were tumor-free.;Ret oncoproteins represent exploitable targets for therapeutic intervention in MEN2A-associated medullary thyroid carcinoma. The antitumor efficacy and oral bioavailability of RPI-1 support its therapeutic potential.",
        "Doc_title":"Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.",
        "Journal":"Journal of the National Cancer Institute",
        "Do_id":"15240784",
        "Doc_ChemicalList":"Antineoplastic Agents;Indoles;Oncogene Proteins;Proto-Oncogene Proteins;RPI-1 compound;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-ret;RET protein, human;Receptor Protein-Tyrosine Kinases;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt;Mitogen-Activated Protein Kinases;Type C Phospholipases;Phospholipase C gamma",
        "Doc_meshdescriptors":"Administration, Oral;Animals;Antineoplastic Agents;Blotting, Western;Carcinoma, Medullary;Cell Division;Female;Gene Expression Regulation, Neoplastic;Indoles;Mice;Mice, Nude;Mitogen-Activated Protein Kinases;Multiple Endocrine Neoplasia Type 2a;Oncogene Proteins;Phospholipase C gamma;Phosphorylation;Precipitin Tests;Protein-Serine-Threonine Kinases;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-akt;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Signal Transduction;Thyroid Neoplasms;Transplantation, Heterologous;Type C Phospholipases",
        "Doc_meshqualifiers":"administration & dosage;pharmacology;drug therapy;etiology;metabolism;drug effects;drug effects;administration & dosage;pharmacology;metabolism;complications;antagonists & inhibitors;metabolism;drug effects;metabolism;antagonists & inhibitors;metabolism;antagonists & inhibitors;metabolism;drug effects;drug therapy;etiology;metabolism;metabolism",
        "_version_":1605880659574784000},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) and the multiple endocrine neoplasia (MEN) type 2 syndromes are rare but important endocrine diseases that are increasingly managed by pediatric providers. MTC is generally associated with a favorable prognosis when diagnosed during childhood, where it frequently occurs secondary to activating mutations in the RET proto-oncogene and arises from pre-existing C-cell hyperplasia. MEN2A accounts for 90-95% of childhood MTC cases and is most commonly due to mutations in codon 634 of RET. MEN2B is associated with the most aggressive clinical presentation of MTC and is almost always due to the Met918Thr mutation of RET. Surgery is the primary treatment and only chance of cure, although the advent of targeted therapies seems to be improving progression-free survival in advanced cases. Since the discovery of the role of RET in MEN2A, considerable advances in the management of this syndrome have occurred, and most of the children with MEN2A who have undergone early thyroidectomy will now lead full, productive lives. Strong genotype-phenotype correlations have facilitated the development of guidelines for interventions. Contemporary approaches for deciding the appropriate age at which surgery should take place incorporate data from ultrasonography and calcitonin measurements in addition to the results of genotyping. To optimize care and to facilitate ongoing research, children with MTC and the MEN2 syndromes are optimally treated at tertiary centers with multidisciplinary expertise.",
        "Doc_title":"Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.",
        "Journal":"Nature reviews. Endocrinology",
        "Do_id":"21862994",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Child;Humans;Multiple Endocrine Neoplasia Type 2a;Thyroid Neoplasms",
        "Doc_meshqualifiers":"diagnosis;therapy;diagnosis;therapy;diagnosis;therapy",
        "_version_":1605761167276376064},
      {
        "Doc_abstract":"Oncogenic conversion of the RET tyrosine kinase is a frequent feature of medullary thyroid carcinoma (MTC). ZD6474 (vandetanib) is an ATP-competitive inhibitor of RET, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor receptors kinases. In this study, we have studied ZD6474 mechanism of action in TT and MZ-CRC-1 human MTC cell lines, carrying cysteine 634 to tryptophan (C634W) and methionine 918 to threonine (M918T) RET mutation respectively. ZD6474 blunted MTC cell proliferation and RET, Shc and p44/p42 mitogen-activated protein kinase (MAPK) phosphorylation. Single receptor knockdown by RNA interference showed that MTC cells depended on RET for proliferation. Adoptive expression of the ZD6474-resistant V804M RET mutant rescued proliferation of TT cells under ZD6474 treatment, showing that RET is a key ZD6474 target in these MTC cells. Upon RET inhibition, adoptive stimulation of EGFR partially rescued TT cell proliferation, MAPK signaling, and expression of cell-cycle-related genes. This suggests that simultaneous inhibition of RET and EGFR by ZD6474 may overcome the risk of MTC cells to escape from RET blockade through compensatory over-activation of EGFR.",
        "Doc_title":"The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.",
        "Journal":"Endocrine-related cancer",
        "Do_id":"20943719",
        "Doc_ChemicalList":"Piperidines;Protein Kinase Inhibitors;Quinazolines;Transforming Growth Factor alpha;Proto-Oncogene Proteins c-ret;RET protein, human;Receptor, Epidermal Growth Factor;Vascular Endothelial Growth Factor Receptor-2;N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Cell Line, Tumor;Cell Proliferation;Humans;Mutation;Piperidines;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-ret;Quinazolines;Receptor, Epidermal Growth Factor;Signal Transduction;Thyroid Neoplasms;Transforming Growth Factor alpha;Vascular Endothelial Growth Factor Receptor-2",
        "Doc_meshqualifiers":"drug therapy;pathology;drug effects;pharmacology;pharmacology;antagonists & inhibitors;genetics;physiology;pharmacology;antagonists & inhibitors;physiology;drug effects;drug therapy;pathology;pharmacology;antagonists & inhibitors",
        "_version_":1605753005789937664},
      {
        "Doc_abstract":"All of the cases of medullary thyroid carcinoma (MTC) express the RET receptor tyrosine kinase. In essentially all of the hereditary cases and approximately 40% of the sporadic cases of MTC, the RET kinase is constitutively activated by mutation. This suggests that RET may be an effective therapeutic target for treatment of MTC. We show that the indolocarbazole derivatives, CEP-701 and CEP-751, inhibit RET in MTC cells. These compounds effectively inhibit RET phosphorylation in a dose-dependent manner at concentrations <100 nM in 0.5% serum and at somewhat higher concentrations in the presence of 16% serum. They also blocked the growth of these MTC cells in culture. CEP-751 and its prodrug, CEP-2563, also inhibited tumor growth in MTC cell xenografts. These results show that inhibiting RET can block the growth of MTC cells and may have a therapeutic benefit in MTC.",
        "Doc_title":"CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.",
        "Journal":"Cancer research",
        "Do_id":"14500395",
        "Doc_ChemicalList":"CEP 751;Carbazoles;Enzyme Inhibitors;Growth Inhibitors;Indoles;Oncogene Proteins;Prodrugs;lestaurtinib;Proto-Oncogene Proteins c-ret;RET protein, human;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Animals;Carbazoles;Carcinoma, Medullary;Cell Division;Dose-Response Relationship, Drug;Enzyme Inhibitors;Growth Inhibitors;Humans;Indoles;Male;Mice;Mice, Nude;Multiple Endocrine Neoplasia Type 2b;Mutation;Oncogene Proteins;Phosphorylation;Prodrugs;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms;Tumor Cells, Cultured;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"pharmacology;drug therapy;enzymology;pathology;drug effects;pharmacology;pharmacology;genetics;antagonists & inhibitors;metabolism;drug effects;pharmacology;antagonists & inhibitors;metabolism;drug therapy;enzymology;pathology",
        "_version_":1605784665990365184},
      {
        "Doc_abstract":"The currently available genetic tests for identification of the RET proto-oncogene mutation offer the possibility of prospective successful therapy before the hyperplasia of C-cells evolve to Medullary Thyroid Carcinoma. We present our experience regarding the preventive thyroidectomy of family members with history of Medullary Thyroid Carcinoma, who were found to be heterozygote for mutant RET proto-oncogene. We have retrospectively reviewed 19 members of 6 families with history of Medullary Thyroid Carcinoma, who were heterozygote for mutant RET protooncogene and underwent prophylactic thyroidectomy. All patients included in this series were below twenty years of age. The Medullary Thyroid Carcinoma was asymptomatic and the mutation of RET protooncogene has been also documented pre-operatively in all of them. All patients had undergone total thyroidectomy, while 1 with pheochromocytoma had undergone also left epinephridectomy. Fourteen patients (73.68%) had undergone lymph-nodes resection (in 10 of them the resection was central, in 3 unilateral and in 1 bilateral). Although none of our patients suffered from hyperparathyroidism, 7 parathyroid glands have been also resected from 3 patients, while auto-transfusion has been performed in one. In all patients, preoperative measurement of the calcitonin blood levels before and after stimulation with pentagastrin has been performed.",
        "Doc_title":"Preventive thyroidectomy in patients with hereditary medullary thyroid carcinoma found heterozygote for mutant RET proto-oncogene.",
        "Journal":"Pediatric endocrinology reviews : PER",
        "Do_id":"21150841",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Carcinoma, Medullary;Carcinoma, Neuroendocrine;Child;Family Health;Heterozygote;Humans;Proto-Oncogene Proteins c-ret;Retrospective Studies;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"genetics;surgery;genetics;genetics;surgery",
        "_version_":1605907909208702976},
      {
        "Doc_abstract":"Proteomics may help to elucidate differential signaling networks underlying the effects of compounds and to identify new therapeutic targets. Using a proteomic-multiplexed analysis of the phosphotyrosine signaling together with antibody-based validation techniques, we identified several candidate molecules for RET (rearranged during transfection) tyrosine kinase receptor carrying mutations responsible for the multiple endocrine neoplasia type 2A and 2B (MEN2A and MEN2B) syndromes in two human medullary thyroid carcinoma (MTC) cell lines, TT and MZ-CRC-1, which express the RET-MEN2A and RET-MEN2B oncoproteins, respectively. Signaling elements downstream of these oncoproteins were identified after treating cells with the indolinone tyrosine kinase inhibitor RPI-1 to knock down RET phosphorylation activity. We detected 23 and 18 affinity-purified phosphotyrosine proteins in untreated TT and MZ-CRC-1 cells, respectively, most of which were shared and sensitive to RPI-1 treatment. However, our data clearly point to specific signaling features of the RET-MEN2A and RET-MEN2B oncogenic pathways. Moreover, the detection of high-level expression of minimally phosphorylated epidermal growth factor receptor (EGFR) in both TT and MZ-CRC-1 cells, together with our data on the effects of EGF stimulation on the proteomic profiles and the response to Gefitinib treatment, suggest the relevance of EGFR signaling in these cell lines, especially since analysis of 14 archival MTC specimens revealed EGFR mRNA expression in all samples. Together, our data suggest that RET/EGFR multi-target inhibitors might be beneficial for therapy of MTC.",
        "Doc_title":"Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.",
        "Journal":"Molecular carcinogenesis",
        "Do_id":"18756447",
        "Doc_ChemicalList":"Antineoplastic Agents;Oncogene Proteins;Quinazolines;Tyrosine;Epidermal Growth Factor;EGFR protein, human;Proto-Oncogene Proteins c-ret;RET protein, human;Receptor, Epidermal Growth Factor;gefitinib",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Carcinoma, Medullary;Epidermal Growth Factor;Female;Germ-Line Mutation;Humans;Mice;Mice, Nude;Multiple Endocrine Neoplasia Type 2a;Multiple Endocrine Neoplasia Type 2b;Oncogene Proteins;Phosphorylation;Proteomics;Proto-Oncogene Proteins c-ret;Quinazolines;Receptor, Epidermal Growth Factor;Signal Transduction;Thyroid Neoplasms;Tyrosine",
        "Doc_meshqualifiers":"pharmacology;drug therapy;genetics;metabolism;pharmacology;genetics;drug therapy;genetics;metabolism;drug therapy;genetics;metabolism;metabolism;drug effects;genetics;metabolism;pharmacology;antagonists & inhibitors;genetics;metabolism;drug therapy;genetics;metabolism;metabolism",
        "_version_":1605783892034322432},
      {
        "Doc_abstract":"Two independent events--the identification of activating mutations of the RET proto-oncogene, a receptor tyrosine kinase, in medullary thyroid carcinoma, and the recognition that small organic molecules could bind to and inhibit phosphorylation of signaling molecules, thereby inactivating the pathway-led to the recognition that kinase inhibitors could be used to treat medullary thyroid carcinoma (MTC). The introduction of these compounds into clinical practice has transformed the treatment of metastatic MTC and provided insight into the mechanisms by which RET causes C-cell transformation. This chapter will review the progress in this field over the past 7 years.",
        "Doc_title":"Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.",
        "Journal":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer",
        "Do_id":"26494392",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Carcinoma, Neuroendocrine;Genetic Predisposition to Disease;Humans;Molecular Targeted Therapy;Mutation;Patient Selection;Phenotype;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-ret;Risk Factors;Signal Transduction;Thyroid Neoplasms;Treatment Outcome",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;drug therapy;enzymology;genetics;pathology;adverse effects;therapeutic use;antagonists & inhibitors;genetics;metabolism;drug effects;drug therapy;enzymology;genetics;pathology",
        "_version_":1605746838796763136},
      {
        "Doc_abstract":"The RET (rearranged during transfection) protooncogene encodes a single pass transmembrane receptor that is expressed in cells derived from the neural crest and the urogenital tract. As part of a cell-surface complex, RET binds glial derived neurotrophic factor (GDNF) ligands in conjunction with GDNF-family alpha co-receptors (GFRalpha). Ligand-induced activation induces dimerization and tyrosine phosphorylation of the RET receptor with downstream activation of several signal transduction pathways. Activating germline RET mutations play a central role in the development of the multiple endocrine neoplasia (MEN) syndromes MEN2A, MEN2B, and familial medullary thyroid carcinoma (FMTC) and also in the development of the congenital abnormality Hirschsprung's disease. Approximately 50% of patients with sporadic MTC have somatic RET mutations, and a significant portion of papillary thyroid carcinomas result from chromosomal inversions or translocations, which activate RET (RET/PTC oncogenes). The RET protooncogene has a significant place in cancer prevention and treatment. Timely thyroidectomy in kindred members who have inherited a mutated RET allele, characteristic of MEN2A, MEN2B, or FMTC, can prevent MTC, the most common cause of death in these syndromes. Also, recently developed molecular therapeutics that target the RET pathway have shown activity in clinical trials of patients with advanced MTC, a disease for which there has been no effective therapy.",
        "Doc_title":"Targeting the RET pathway in thyroid cancer.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"19934298",
        "Doc_ChemicalList":"Tyrosine;Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Alleles;Clinical Trials as Topic;Dimerization;Humans;Medical Oncology;Models, Biological;Mutation;Phenotype;Phosphorylation;Point Mutation;Protein Binding;Proto-Oncogene Proteins c-ret;Signal Transduction;Thyroid Neoplasms;Tyrosine",
        "Doc_meshqualifiers":"methods;metabolism;metabolism;pathology;therapy;chemistry",
        "_version_":1605903625872211968},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) is responsible for 13.4% of the total deaths attributable to thyroid cancer in human beings and research on MTC over the last 40 years has identified the RET proto-oncogene as a very relevant component of development of both sporadic and hereditary MTC. An activating germline RET proto-oncogene mutation responsible for a multiple endocrine neoplasia syndrome type 2 (MEN2) or a familial hereditary MTC syndrome is carried by 25% to 35% of patients with MTC. The recognition of RET proto-oncogene mutations by genetic sequencing has allowed us to differentiate hereditary from sporadic MTC, so that it is now possible to identify and treat children at risk for this disease before development of metastasis. Thanks to this discovery, we can now establish the association of MTC with other tumors in the context of MEN2 syndrome; determine adequate follow-up, prognosis, and treatment for patients with hereditary disease; and use this information to develop new therapies against both sporadic and hereditary MTCs.",
        "Doc_title":"Management of medullary thyroid carcinoma.",
        "Journal":"Endocrinology and metabolism clinics of North America",
        "Do_id":"18502338",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Genetic Predisposition to Disease;Genotype;Humans;Mutation;Proto-Oncogene Proteins c-ret;Syndrome;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;therapy;physiology;genetics;physiology;genetics;therapy",
        "_version_":1605756143336947712},
      {
        "Doc_abstract":"Hereditary medullary thyroid carcinoma (MTC) is caused by germline mutations in the RET proto-oncogene, resulting in constitutive activation of the RET tyrosine kinase. A substantial proportion of sporadic MTCs also have RET mutations, making the RET tyrosine kinase a potential therapeutic target in MTC. We have established a transplantable MTC in nude mice from a sporadic human MTC carrying a RET C634R mutation. Transplanted tumors had an exponential growth rate with an approximate doubling time of about 3 weeks, and expressed a neuroendocrine phenotype characteristic of MTC, e.g., expression of calcitonin, chromogranin A (CgA), synaptophysin, synaptic vesicle protein 2 (SV2), vesicular monoamine transporter-1 and -2, carcinoembryonic antigen, cytokeratin 8/18, epithelial cadherin, and neural cell adhesion molecule. Plasma calcitonin and CgA levels were elevated in tumor-bearing mice and correlated with tumor size. Cytogenetic analysis, including spectral karyotyping, confirmed the human origin of the xenografted tumors and demonstrated an abnormal, near triploid karyotype. Treatment of tumor-bearing nude mice with the tyrosine kinase inhibitor ZD6474, which specifically inhibits RET, epidermal growth factor receptor (EGFR), and vascular endothelium growth factor receptor (VEGFR) tyrosine kinases, resulted in a dose-dependent inhibition of tumor growth. Oral ZD6474 given once daily (250 mg/kg, 5 days/week) reduced tumor volume to 11% when compared with controls after 4 weeks. Our results show that this transplantable MTC, designated GOT2, represents a novel and useful model for studies of MTC and RET tyrosine kinase-dependent tumor growth.",
        "Doc_title":"A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.",
        "Journal":"Endocrine-related cancer",
        "Do_id":"17639056",
        "Doc_ChemicalList":"Chromogranin A;Piperidines;Protein Kinase Inhibitors;Quinazolines;Calcitonin;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-ret;RET protein, human;Receptor, Epidermal Growth Factor;Vascular Endothelial Growth Factor Receptor-1;N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine",
        "Doc_meshdescriptors":"Aged;Animals;Calcitonin;Carcinoma, Medullary;Cell Line, Tumor;Cell Transformation, Neoplastic;Chromogranin A;Disease Models, Animal;Humans;Karyotyping;Male;Mice;Mice, Nude;Mutation;Piperidines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-ret;Quinazolines;Receptor, Epidermal Growth Factor;Thyroid Neoplasms;Vascular Endothelial Growth Factor Receptor-1;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"blood;drug therapy;enzymology;pathology;drug effects;blood;pharmacology;pharmacology;antagonists & inhibitors;genetics;metabolism;antagonists & inhibitors;genetics;metabolism;pharmacology;antagonists & inhibitors;drug therapy;enzymology;pathology;antagonists & inhibitors",
        "_version_":1605746800566730752},
      {
        "Doc_abstract":"The aim of this study was to determine the genomic alterations of cancer-related genes in advanced medullary thyroid carcinoma during the course of clinical care.;Hybrid-capture-based comprehensive genomic profiling was performed on 34 consecutive medullary thyroid carcinoma cases to identify all four classes of genomic alterations, and outcome for an index patient was collected.;RET was mutated in 88% (30/34) of cases, with RET M918T being responsible for 70% (21/30) of the RET alterations. The other RET alterations were RET E632_L633del, C634R, C620R, C618G/R/S, V804M, and RET amplification. Two of the four RET wild-type patients harbored mutations in KRAS or HRAS (1/34 each). The next most frequent genomic alterations were amplifications of CCND1, FGF3, and FGF19 and alterations in CDKN2A (3/34 each). One case with a RET M918T mutation developed acquired resistance to progressively dose-escalated vandetanib. When the mTOR inhibitor everolimus was added to continued vandetanib treatment, the patient achieved a second 25% reduction of tumor volume (RECIST 1.1) for 8 months.;Comprehensive genomic profiling identified the full breadth of RET alterations in metastatic medullary thyroid carcinoma and possible cooperating oncogenic driver alterations. This approach may refine the use of targeted therapy for these patients.",
        "Doc_title":"Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.",
        "Journal":"Oncology",
        "Do_id":"27207748",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605741916841836545},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) is rare in children. MTC is almost always inherited and occurs as part of a multiple endocrine neoplasia type 2A and B, due to germline mutation in the RET proto-oncogene. MTC in the pediatric population is most often diagnosed in the course of a familial genetic investigation. But when the child is the proband, a de novo mutation is most often founded. The main aim is to treat MTC before extrathyroidal extension occurs because when distant metastases are present, it is rarely curable. Treatment is based on total thyroidectomy with cervical lymph node dissection. ",
        "Doc_title":"[Medullary thyroid carcinoma in children].",
        "Journal":"Bulletin du cancer",
        "Do_id":"23831771",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Basal Cell Nevus Syndrome;Carcinoma, Medullary;Child;Genetic Counseling;Genotype;Humans;Multiple Endocrine Neoplasia Type 2a;Mutation;Phenotype;Rare Diseases;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;diagnosis;genetics;pathology;therapy;genetics;genetics;diagnosis;genetics;pathology;therapy;diagnosis;genetics;pathology;therapy",
        "_version_":1605799834083655680},
      {
        "Doc_abstract":"The therapeutic options for patients with metastatic medullary thyroid carcinoma (MTC) have recently increased due to the development of tyrosine kinase inhibitors (TKIs), some of which have achieved remarkable clinical responses in MTC patients. However, the molecular basis for the large variability in TKI responses is unknown. In this exploratory study, we investigated the expression of eight key TKI target proteins (EGFR, KIT, MET, PDGFRB, VEGF (VEGFA), VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4)) by immunohistochemistry in 103 molecularly characterized MTC samples and identified the associated clinical and molecular features. A number of MTC samples exhibited a high expression of VEGFR2 and VEGFR3, which were overexpressed in 57 and 43% of the MTC samples respectively. VEGFR1, PDGFRB, VEGF, KIT, and MET were present in 34-20% of the cases, while EGFR was highly expressed in only 10% of the MTC samples. Some proteins exhibited large differences in expression between sporadic and familial cases, suggesting that different RET mutations may be associated with the immunohistochemical profiles. MTC samples with the C634 RET mutation exhibited a higher expression of VEGFR3 and KIT than the M918T RET-mutated and non-mutated RET tumor samples (P=0.005 and P=0.007 respectively) and a lower expression of VEGFR1 (P=0.04). Non-mutated RET MTC cases exhibited a lower expression of PDGFRB (P=0.04). Overall, this is the first study, to our knowledge, to show that multiple TKI targets are highly expressed in a subset of MTCs, suggesting that molecular stratification of patients may have the potential to improve TKI therapies for MTC. ",
        "Doc_title":"Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.",
        "Journal":"Endocrine-related cancer",
        "Do_id":"23780998",
        "Doc_ChemicalList":"VEGFA protein, human;Vascular Endothelial Growth Factor A;EGFR protein, human;MET protein, human;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-kit;Proto-Oncogene Proteins c-met;Proto-Oncogene Proteins c-ret;Receptor, Epidermal Growth Factor;Receptor, Platelet-Derived Growth Factor beta;Receptors, Vascular Endothelial Growth Factor",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Carcinoma, Neuroendocrine;Child;Exons;Female;Humans;Male;Middle Aged;Mutation;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-kit;Proto-Oncogene Proteins c-met;Proto-Oncogene Proteins c-ret;Receptor, Epidermal Growth Factor;Receptor, Platelet-Derived Growth Factor beta;Receptors, Vascular Endothelial Growth Factor;Thyroid Neoplasms;Vascular Endothelial Growth Factor A;Young Adult",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;metabolism;genetics;metabolism;metabolism;metabolism;genetics;metabolism;metabolism",
        "_version_":1605883664688742401},
      {
        "Doc_abstract":"To emphasize the importance of genetic studies in family members and early prophylactic thyroidectomy in oncogene mutation carriers in the management of familiar medullary thyroid carcinoma.;A retrospective review of families with familiar medullary thyroid carcinoma treated at our center in the last 7 years was performed. We identified a total of 7 families who has isolated prevalences with thyroid malignancies. Forty members of the 7 families were screened for gene RET mutations. Prophylactic total thyroidectomy was performed in every RET mutation gene carriers.;In all families the index case were patients with medullary thyroid carcinoma presenting at a mean age of 37.25 years (range 23-42). The RET oncogen mutation was in codon 634 in exon 11 (multiple endocrine neoplasia type 2A) in all these patients. Fourteen gene carriers were identified with a mean age of 20 years (range 7-37), eleven of whom had medullary thyroid carcinoma at the time of surgery. Five of the gene carriers were children, with a mean age of 11 years (range 7-16), four of whom had microcarcinoma and one had metastatic carcinoma at the time of surgery. After surgery no hypoparathyroidism or recurrent nerve paralysis were documented. No pediatric patient has presented with phaeochromocytoma or hypoparathyroidism to date Four of the five children have normal calcitonin levels (< 2 pg/ml) and they are free of disease. The one who presented metastatic carcinoma has recurrent disease and is awaiting surgical treatment.;Genetic studies of family members related to patients with familiar medullary thyroid carcinoma and RET mutations is indispensable. The RET mutation in codon 634 exon 11 was found to be the most frequent association. Prophylactic thyroidectomy is the only curative treatment and has minimal complications when performed by expert surgeons. Early thyroidectomy is recommended since distant metastatic spread can occur at early age.",
        "Doc_title":"[Is immediate prophylactic thyroidectomy indispensable in familiar medullary thyroid carcinoma?].",
        "Journal":"Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica",
        "Do_id":"18624279",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Carcinoma, Medullary;Child;Humans;Retrospective Studies;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"genetics;prevention & control;genetics;prevention & control",
        "_version_":1605800951358160896},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) is a malignancy of the thyroid C-cells that comprises 5-10% of all thyroid cancers. MTC occurs in both sporadic and familial forms, the latter making up 25% of all MTCs and being comprised of three distinct syndromes--multiple endocrine neoplasia type 2A (MEN 2A), multiple endocrine neoplasia type 2B (MEN 2B), and familial medullary thyroid carcinoma (FMTC). To date, screening for MTC has been performed using the pentagastrin stimulation test, which is a provocative test for calcitonin release. Germline mutations in the RET protooncogene have been identified in families manifesting these syndromes and genetic screening of individuals at risk of one of these syndromes has become integral to their clinical management. The majority of the mutations associated with MEN 2A and FMTC are tightly clustered in a cysteine-rich region of the RET receptor. A single mutation associated with MEN 2B is in the the tyrosine kinase domain of the RET receptor. Somatic mutations have been identified in the tumor tissue of individuals with sporadic MTC and may prove to be helpful markers in discerning the hereditary or sporadic nature of the MTC. There is general agreement that the primary operation for MTC should include total thyroidectomy and central neck lymph node clearance. The role of microdissection for recurrent disease awaits longitudinal evaluation. External radiotherapy, radionuclide therapy, and chemotherapy may have a role in palliation, but have not been proven to have a curative value. Prognostic factors are discussed.",
        "Doc_title":"Medullary thyroid carcinoma: recent advances and management update.",
        "Journal":"Thyroid : official journal of the American Thyroid Association",
        "Do_id":"8563482",
        "Doc_ChemicalList":"Drosophila Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Animals;Carcinoma, Medullary;Drosophila Proteins;Humans;Mutation;Pedigree;Prognosis;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms",
        "Doc_meshqualifiers":"diagnosis;genetics;therapy;genetics;genetics;diagnosis;genetics;therapy",
        "_version_":1605757861049139200},
      {
        "Doc_abstract":"Hereditary medullary thyroid carcinoma (MTC) is the most common and potentially life-shortening phenotypic manifestation of RET (rearranged during transfection) germline mutations. If a distinct time lag between the successive stages of malignant progression were identifiable, the information could be used to individualize prophylactic surgery. The study objective was to investigate the impact of RET genotype on disease progression from C-cell hyperplasia (CCH) to MTC.;An institutional series of 167 (67 index, 100 nonindex) consecutive carriers of RET gene point mutations in exons 10, 11, 13, 14, or 16 who underwent total thyroidectomy between November 1994 and November 2002.;Regarding codons 618, 620, 634, 768, 790, and 804, patient age at diagnosis differed significantly depending on the type of pathology encountered (CCH, MTC without and with nodal metastasis). The variability in age, which may reflect the number of necessary somatic mutations, explained the pathological strata in 38% (codon 634) to 77% (codon 768) of patients. Conversely, 62% (codon 634) to 23% (codon 768) of variability in age at different pathological strata may have been determined by the RET genotype.;The pace of malignant progression of the RET genotype should be taken into account when considering prophylactic thyroidectomy in RET gene carriers.",
        "Doc_title":"Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations.",
        "Journal":"Surgery",
        "Do_id":"14555929",
        "Doc_ChemicalList":"Codon;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Adolescent;Adult;Age Factors;Aged;Carcinoma, Medullary;Child;Child, Preschool;Codon;Germ-Line Mutation;Heterozygote;Humans;Hyperplasia;Lymph Node Excision;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Gland;Thyroid Neoplasms;Thyroidectomy;Time Factors",
        "Doc_meshqualifiers":"etiology;genetics;genetics;genetics;pathology;etiology",
        "_version_":1605764958930337792},
      {
        "Doc_abstract":"This article summarizes the major clinical, pathological, and molecular features of medullary thyroid carcinoma (MTC), based on a review of the most significant advances in our understanding of this tumor type over the last 25 years. MTC is a neuroendocrine carcinoma that shows evidence of C-cell differentiation. The tumor has a distinctive morphologic appearance, including the presence of amyloid deposits. Immunostaining for calcitonin, carcinoembryonic antigen, calcitonin gene-related peptide, and thyroid transcription factor 1 is helpful in differential diagnosis. Identification of RET mutations in familial and sporadic MTC has brought important changes in early diagnosis and treatment. Surgery remains the cornerstone of effective therapy. Understanding the molecular basis of MTC will allow identification of novel approaches for individualized treatment.",
        "Doc_title":"Medullary thyroid carcinoma: a 25-year perspective.",
        "Journal":"Endocrine pathology",
        "Do_id":"24343523",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Neuroendocrine;History, 20th Century;History, 21st Century;Humans;Thyroid Neoplasms",
        "Doc_meshqualifiers":"history;pathology;surgery",
        "_version_":1605895574858498048},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) is a rare tumour arising from neural crest-derived parafollicular C-cells. Metastatic MTC patients are incurable because the cancer does not respond to radiotherapy or chemotherapy. The REarranged during Transfection (RET) proto-oncogene plays a key role in the development of MTC. However, one-half of the sporadic MTC do not carry RET mutations. Mice models and early evidence obtained in human samples suggest that other genes, including those encoding components of the RB1 (retinoblastoma) and TP53 tumour-suppressor pathways, may be involved in MTC formation. Here, we review the data on the involvement of genes acting in the RET and RB1/TP53 pathways in MTC. Understanding genetic lesions that occur in MTC is a prerequisite to identifying molecular therapeutic targets in MTC and in improving the efficacy of RET-targeted therapies.",
        "Doc_title":"Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.",
        "Journal":"Journal of molecular endocrinology",
        "Do_id":"19383830",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Animals;Carcinoma, Medullary;Humans;Mice;Models, Biological;Proto-Oncogene Proteins c-ret;Signal Transduction;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;therapy;genetics;genetics;physiology;genetics;therapy",
        "_version_":1605765910131376128},
      {
        "Doc_abstract":"Medullary thyroid carcinoma accounts for 5-10% of all thyroid cancers. It is sporadic in 75% of cases and familial in 25% of cases. Germ-line REarranged during transfection (RET) proto-oncogene mutations are detected in more than 95% of patients with familial medullary carcinoma whereas somatic RET mutations are detected in 40-70% of sporadic medullary carcinomas. Surgery is the only curative treatment and should consist of total thyroidectomy with central and ipsilateral or bilateral lateral lymph node dissection. Surgery provides successful cure in almost 100% of patients when tumor size measures a few millimeters, in almost 90% of patients with a tumor measuring less than 1 cm, and in only 50% of patients with a tumor larger than 1 cm. Alternative forms of treatment involving radiotherapy or chemotherapy provide little benefit. A perspective of recent trials and research into novel treatment of medullary thyroid carcinoma is summarized in the following paper. In this review we examine immunotherapy, radioimmunotherapy, therapy targeting the RET gene or protein, suicide gene therapy, cyclooxygenase inhibitors and radioiodine therapy following sodium iodide symporter gene expression.",
        "Doc_title":"Recent advances in treatment of medullary thyroid carcinoma.",
        "Journal":"Annales d'endocrinologie",
        "Do_id":"17391636",
        "Doc_ChemicalList":"Cyclooxygenase 2 Inhibitors;Cyclooxygenase Inhibitors;Iodine Radioisotopes;Cyclooxygenase 1;Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Animals;Carcinoma, Medullary;Cyclooxygenase 1;Cyclooxygenase 2 Inhibitors;Cyclooxygenase Inhibitors;Genes, Transgenic, Suicide;Genetic Therapy;Humans;Immunotherapy;Iodine Radioisotopes;Proto-Oncogene Proteins c-ret;Radioimmunotherapy;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;pathology;therapy;metabolism;therapeutic use;therapeutic use;genetics;therapeutic use;genetics;genetics;pathology;therapy",
        "_version_":1605746293959819265},
      {
        "Doc_abstract":"We describe a family harboring RET 790 mutation and review the role of prophylactic thyroidectomy for medullary thyroid carcinoma.;We evaluated in detail both clinical and biological follow-up and reviewed literature reports.;Among 86 family members, 15 of 22 members screened harbored the 790 mutation. Abnormal calcitonin levels were found in 8/15. Total thyroidectomy with lymph node dissection cured the 5 operated patients (range, 45-76 years). Tumor staging was pT1N0M0. Among 10 carriers who did not undergo surgery, 3 patients had abnormal calcitonin levels. For the others, calcitonin levels remained <30 pg/mL. Two asymptomatic carriers were older than 70 years. Four subjects were lost to follow-up.;In RET codon 790 mutations families, a case-by-case decision instead of systematic prophylactic thyroidectomy should be discussed. Difficulties of follow-up should be taken into account and represent the main challenge.",
        "Doc_title":"Role of prophylactic thyroidectomy in RET 790 familial medullary thyroid carcinoma.",
        "Journal":"Head & neck",
        "Do_id":"21688339",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Adolescent;Adult;Age Factors;Aged;Carcinoma, Medullary;DNA Mutational Analysis;Female;Follow-Up Studies;Genetic Testing;Heterozygote;Humans;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Mutation;Neoplastic Syndromes, Hereditary;Pedigree;Primary Prevention;Proto-Oncogene Proteins c-ret;Risk Assessment;Sampling Studies;Sex Factors;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"congenital;methods;genetics;prevention & control;surgery;methods;genetics;genetics;prevention & control;surgery;methods",
        "_version_":1605905974440230912},
      {
        "Doc_abstract":"The heredity of medullary thyroid carcinoma within MEN2 syndrome is caused by heterozygous germline mutations in the RET proto-oncogene. Since MEN2-associated mutations involve only hot spots, the molecular genetic analysis of the RET proto-oncogene constitutes the perfect tool for the diagnosis of MEN2, being thus considered the standard method. The molecular genetic screening for MEN2-associated RET germline mutations should be carried out in all patients with an apparently sporadic medullary thyroid carcinoma or pheochromocytoma. This testing needs to include exons 10, 11, and 13 to 16 of the RET proto-oncogene. Such investigations are aimed at identifying an index person of a new MEN2 family. The detection of such a RET germline mutation is the basis for predictive molecular genetic testing within an affected family, and allows the exclusion or identification of gene carriers. For these family members at risk, prophylactic total thyroidectomy is recommended as a curative procedure, according to a risk-adapted, genetically based treatment algorithm. The management of such affected families should be always complemented by oncological and genetic counselling.",
        "Doc_title":"Management of patients with hereditary medullary thyroid carcinoma.",
        "Journal":"European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie",
        "Do_id":"15630638",
        "Doc_ChemicalList":"Oncogene Proteins;Proto-Oncogene Proteins c-ret;RET protein, human;Receptor Protein-Tyrosine Kinases;Cysteine",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Chromosome Mapping;Cysteine;Genetic Counseling;Hirschsprung Disease;Humans;Multiple Endocrine Neoplasia Type 2a;Mutation, Missense;Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Risk Assessment;Signal Transduction;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"genetics;surgery;genetics;genetics;classification;genetics;genetics;genetics;physiology;genetics;surgery",
        "_version_":1605895480765579264},
      {
        "Doc_abstract":"Recent evidence indicates that the success of molecular targeted therapies may depend on the identification of drug targets which are essential for the survival of subsets of tumors. RET oncogenes that have been implicated in the development of thyroid carcinomas are emerging as potential therapeutic targets. In the present study, we investigated the efficacy and the cellular bases of antitumor activity of the indolinone Ret tyrosine kinase inhibitor RPI-1 against large established s.c. TT tumor xenograft, a human medullary thyroid carcinoma (MTC) harboring oncogenic MEN-2A-type RET mutation. Oral treatment with RPI-1 caused growth arrest or regression in 81% treated tumors. Following treatment suspension, tumor inhibition was maintained (51%, P<0.05, 100 days) and cures were achieved in 2/11 mice. In treated tumors, Ret was tyrosine dephosphorylated. Moreover, compared to control tumors, a significant increase in apoptotic cells (210%, P<0.0001), loss of cellularity (47%, P<0.0001) and reduction of microvessel density (36%, P<0.0005) were detected. In vivo effects of RPI-1 were reflected in activation of BAD, cleavage of caspases, apoptotic DNA fragmentation and inhibition of VEGF production observed in in vitro RPI-1-treated TT cells. These findings thus indicate that RPI-1 antitumor effect on the MTC was characterized by apoptosis induction and angiogenesis inhibition. The results, consistent with a dependence on RET oncogene activation for maintenance and survival of MEN2A-type MTC, provide further preclinical rationale for a pharmacological RET-targeted intervention in thyroid cancer.",
        "Doc_title":"Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.",
        "Journal":"Biochemical pharmacology",
        "Do_id":"16756963",
        "Doc_ChemicalList":"Antineoplastic Agents;Indoles;RPI-1 compound;Vascular Endothelial Growth Factor A;Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Administration, Oral;Animals;Antineoplastic Agents;Apoptosis;Carcinoma, Medullary;Cell Line, Tumor;Female;Flow Cytometry;Humans;Indoles;Mice;Mice, Nude;Mutation;NIH 3T3 Cells;Neovascularization, Pathologic;Phosphorylation;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms;Vascular Endothelial Growth Factor A;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"administration & dosage;pharmacology;therapeutic use;drug effects;drug therapy;pathology;administration & dosage;pharmacology;therapeutic use;prevention & control;drug effects;antagonists & inhibitors;genetics;metabolism;drug therapy;pathology;metabolism",
        "_version_":1605810544707633152},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) management requires determination of the sporadic or familial nature of the disease. RET proto-oncogene mutation analysis in the tumor tissue obtained at surgery and in the peripheral blood identifies somatic vs. germinal mutations. We now report a case of MTC in which a RET somatic mutation at codon 918 was detected in fine-needle aspiration specimens obtained from both the thyroid nodule and two enlarged neck lymph nodes but not in peripheral blood. Therefore, a diagnosis of sporadic MTC was made before surgery. Thus, this approach, by excluding preoperatively multiple endocrine neoplasia disease, permitted immediate thyroidectomy without search for pheochromocytoma. PCR-based genetic analysis in fine-needle aspiration biopsy specimens, therefore, preoperatively identifies genetic abnormalities at an early and easily manageable stage and may well contribute to the management strategy of MTC.",
        "Doc_title":"A case of metastatic medullary thyroid carcinoma: early identification before surgery of an RET proto-oncogene somatic mutation in fine-needle aspirate specimens.",
        "Journal":"The Journal of clinical endocrinology and metabolism",
        "Do_id":"9329372",
        "Doc_ChemicalList":"Codon;DNA, Complementary;Drosophila Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Base Sequence;Biopsy, Needle;Carcinoma, Medullary;Codon;DNA, Complementary;Drosophila Proteins;Humans;Lymphatic Metastasis;Male;Middle Aged;Mutation;Polymerase Chain Reaction;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;pathology;surgery;genetics;genetics;pathology;genetics;genetics;genetics;pathology;surgery",
        "_version_":1605853478377226240},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) accounts for 5-8% of all thyroid cancers. MTC is mainly sporadic in nature, but an hereditary pattern [multiple endocrine neoplasia type 2 (MEN 2)] is present in 20-30% of cases, transmitted as an autosomal-dominant trait due to germline mutations of the RET proto-oncogene. About 98% of patients with MEN 2 have germline mutations in exons 5, 8, 10, 11, 13, 14, 15 or 16 of the RET gene. The primary treatment of both hereditary and sporadic forms of MTC is total thyroidectomy and removal of all neoplastic tissue present in the neck. The therapeutic option for lymph node surgery should be dictated by the results of presurgical evaluation. After total thyroidectomy, measurements of serum calcitonin (CT) and carcinoembryonic antigen are of paramount importance in the postsurgical follow-up of patients with MTC as they reflect the presence of persistent or recurrent disease. Complete remission is demonstrated by undetectable and stimulated serum CT measurement. On the contrary, if serum CT is detectable under basal conditions or becomes detectable after stimulation, the patient is probably not cured, but imaging techniques will not demonstrate any disease until serum CT approaches levels >150 pg/ml. The tumour metastasises early to both paratracheal and lateral cervical lymph nodes. Metastases outside the neck may occur in the liver, lungs, bones and, less frequently, brain and skin. Surgery is the main treatment for local and distant metastases whenever feasible. Systemic chemotherapy with dacarbazine, 5-fluorouracil and doxorubicin (alone or in combination) has shown very limited efficacy, achieving only partial responses in the range of 10-20% and of short duration. Several kinase inhibitors are currently under evaluation and preliminary results are promising. Familial cases must be identified by searching for RET proto-oncogene mutations in the proband and in family members. Carriers of the RET gene are candidates for prophylactic thyroidectomy at different ages depending on the risk associated with the specific RET mutations.",
        "Doc_title":"Medullary thyroid carcinoma.",
        "Journal":"Clinical oncology (Royal College of Radiologists (Great Britain))",
        "Do_id":"20627492",
        "Doc_ChemicalList":"Biomarkers, Tumor;Carcinoembryonic Antigen;Calcitonin;Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Calcitonin;Carcinoembryonic Antigen;Carcinoma, Medullary;Genetic Predisposition to Disease;Humans;Multiple Endocrine Neoplasia Type 2a;Mutation;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome",
        "Doc_meshqualifiers":"blood;blood;blood;blood;genetics;pathology;surgery;genetics;genetics;genetics;blood;genetics;pathology;surgery",
        "_version_":1605747052084461569},
      {
        "Doc_abstract":"To elucidate the pitfalls in the diagnosis of medullary thyroid carcinoma (MTC) by fine needle aspiration cytology (FNAC) and the relationship of cytomorphology to RET proto-oncogene mutations.;Cytomorphology was reviewed in the fine needle aspiration slides of 34 patients with MTC proven by surgery and pathology. Germline or somatic RET proto-oncogene mutations were determined using polymerase chain reaction-based sequencing in 15 of 34 patients, and the relationship to cytomorphology was evaluated.;Twenty-eight (82.4%) of 34 cases were diagnosed correctly as MTC by FNAC, 3 cases were misdiagnosed as follicular neoplasm and 1 as desmoid, and 2 cases were suspicious for MTC. The main reason for misdiagnosis was overlooking the slight angular shape of the nuclei or atypical changes. In 15 of 34 cases with germline or somatic RET proto-oncogene mutations determined, 10 cases had a germline mutation, and 1 had only a somatic mutation. There were 4 cases that had neither germline nor somatic RET proto-oncogene mutations. Cells with small/round and spindled forms were the predominant findings of codon 918 ATG-->ACG mutation, and cells with small/round and large oval to polygonal forms were the main findings of codon 634 mutations. There were no misdiagnoses in patients with RET proto-oncogene mutations.;FNAC is a good diagnostic method for MTC. Codon 918 mutation correlates mainly with small/round and spindled cells and codon 634 with small/round, large oval to polygonal forms.",
        "Doc_title":"Medullary thyroid carcinoma: pitfalls in diagnosis by fine needle aspiration cytology and relationship of cytomorphology to RET proto-oncogene mutations.",
        "Journal":"Acta cytologica",
        "Do_id":"16334022",
        "Doc_ChemicalList":"Codon;DNA;Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Biopsy, Fine-Needle;Carcinoma, Medullary;Cell Nucleus;Cell Shape;Codon;DNA;DNA Mutational Analysis;Diagnosis, Differential;Diagnostic Errors;Epithelial Cells;Female;Germ-Line Mutation;Humans;Male;Middle Aged;Mutation;Polymerase Chain Reaction;Predictive Value of Tests;Proto-Oncogene Proteins c-ret;Reproducibility of Results;Thyroid Gland;Thyroid Neoplasms",
        "Doc_meshqualifiers":"standards;genetics;pathology;pathology;genetics;analysis;genetics;prevention & control;pathology;genetics;genetics;genetics;pathology;genetics;pathology",
        "_version_":1605755777949106176},
      {
        "Doc_abstract":"Patients with hereditary medullary thyroid carcinoma (MTC) associated with multiple endocrine neoplasia (MEN) types 2A and 2B and familial MTC (FMTC) have mutations in the RET proto-oncogene. Approximately 40 percent of patients with papillary thyroid carcinoma (PTC) typically have either intrachromosomal or extrachromosomal rearrangements that join the promoter and NH(2)-terminal domains of unrelated genes to the COOH-terminal fragment of RET. The RET point mutations associated with MEN2A, MEN2B, or FMTC, or the chromosomal breakpoints and translocations associated with PTC, typically activate the RET receptor tyrosine kinase (RTK). RET kinase inhibitors are likely to be beneficial for patients with hereditary MTC, where currently there is no effective chemotherapy or radiation therapy. Recently, the low molecular weight tyrosine kinase inhibitor ZD6474 was found to block the enzymatic activity of RET-derived oncoproteins in cultured cell lines. We have developed a Drosophila model for MEN2A and MEN2B diseases by targeting oncogenic forms of RET to the developing Drosophila eye. Here we show that, when fed orally, ZD6474 suppressed RET-mediated phenotypes within the context of this in vivo model. Importantly, ZD6474 showed high efficacy and very low toxicity. This compound failed to significantly suppress an activated form of another RTK, the Drosophila epidermal growth factor receptor, nor did it suppress the activity of downstream components of the RET/Ras pathway. Our results support the view that targeting chemical kinase inhibitors such as ZD6474 to tissues with oncogenic forms of RET is a useful treatment strategy for RET-dependent carcinomas.",
        "Doc_title":"ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.",
        "Journal":"Cancer research",
        "Do_id":"15867345",
        "Doc_ChemicalList":"Drosophila Proteins;Piperidines;Protein Isoforms;Quinazolines;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Receptor, Epidermal Growth Factor;Ret oncogene protein, Drosophila;raf Kinases;ras Proteins;N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine",
        "Doc_meshdescriptors":"Animals;Carcinoma, Papillary;Disease Models, Animal;Drosophila;Drosophila Proteins;Eye Abnormalities;Multiple Endocrine Neoplasia Type 2a;Multiple Endocrine Neoplasia Type 2b;Piperidines;Protein Isoforms;Proto-Oncogene Proteins c-ret;Quinazolines;Receptor Protein-Tyrosine Kinases;Receptor, Epidermal Growth Factor;Thyroid Neoplasms;raf Kinases;ras Proteins",
        "Doc_meshqualifiers":"drug therapy;genetics;metabolism;antagonists & inhibitors;genetics;metabolism;genetics;drug therapy;genetics;metabolism;drug therapy;genetics;metabolism;pharmacology;pharmacology;antagonists & inhibitors;genetics;metabolism;antagonists & inhibitors;genetics;metabolism;drug therapy;genetics;metabolism;antagonists & inhibitors;genetics;metabolism;antagonists & inhibitors;genetics;metabolism",
        "_version_":1605818587594883072},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 (MEN 2) and familial medullary thyroid carcinoma (FMTC) are autosomal dominantly inherited cancer syndromes that predispose to C-cell hyperplasia and MTC. MEN 2A and FMTC are caused by mutations in the RET proto-oncogene.;We used a multiplex polymerase chain reaction-based assay to screen exons 10, 11, 13, and 14 of RET for mutations in 2 families with FMTC. We correlated mutation status with calcitonin and pathologic studies to determine genotype-phenotype correlations.;We identified a mutation in codon 804 in exon 14 (GTG-->ATG; V804M) in both families. An 86-year-old person who was a gene carrier and other individuals over age 70 who were suspected by pedigree analysis to be gene carriers had no overt clinical evidence of MTC. Four of 21 patients who underwent a thyroidectomy also had papillary thyroid cancer. One individual in each family had metastatic MTC at age 30 and 32 years, and all 26 people having thyroidectomies had either MTC or C-cell hyperplasia, leading us to continue to recommend prophylactic thyroidectomy for all identified patients who were gene carriers.;Because of active MTC in younger members of these families, including metastases, we have continued to advocate thyroid surgery in mutation-positive individuals. While DNA diagnosis of gene carriers and subsequent genetic counseling was relatively straightforward, the acceptance of surgical recommendations was more difficult for some individuals. These families demonstrate that the search for RET mutations should include exons 13, 14, 15, and 16 in patients whose studies in exons 10 and 11 are negative.",
        "Doc_title":"Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation.",
        "Journal":"Surgery",
        "Do_id":"10876191",
        "Doc_ChemicalList":"Drosophila Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Adult;Age of Onset;Aged;Aged, 80 and over;Carcinoma, Medullary;Drosophila Proteins;Exons;Family Health;Female;Humans;Male;Middle Aged;Pedigree;Phenotype;Point Mutation;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"genetics;surgery;genetics;genetics;genetics;surgery",
        "_version_":1605928263894433792},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) is a rare, accounting for 5% of thyroid malignancies. It is a neuroendocrine tumor wich origins from thyroid parafollicular cells. It may be sporadic, mostly in adult patients, or inherited as autosomal dominant pattern, mostly in pediatric patients. As familial cancer, MTC may presented isolated as familial medullary thyroid carcinoma (FMTC) - 10% of cases - or, most often, as part of multiple endocrine neoplasm type 2 (MEN 2A or MEN 2B) syndromes - 90% of cases. The therapy for sporadic or hereditary MTC is surgical resection and consists in total thyroidectomy associated with central compartment lymph nodal dissection; the radicality of this intervention is fundamental to obtain a definitive cure. Genetic screening in children of parents with MEN2 or FMTC has led to prophylactic total thyroidectomy. The type of prophylactic surgery required is focus of great attention, and it is reported that total thyroidectomy, central neck dissection associated with parathyroid autotransplantation is the proper management. In children, the recommended age of surgery based on genetic testing is 5 years for patients with MEN 2A and FMTC, and 1 year for children possessing the RET mutation responsible for MEN 2B. The surgical management changes depending on the type of codon mutated.",
        "Doc_title":"Surgical Management of Medullary thyroid carcinoma in pediatric age.",
        "Journal":"Current pediatric reviews",
        "Do_id":"27834132",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605765085801742336},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) originates in the thyroid C cells, accounting for 5% to 10% of all thyroid malignancies. Approximately 75% of cases are sporadic. Significant advances have been made in the molecular biology of MTC, but some aspects of diagnosis and management still remain controversial.;We reviewed relevant articles published in major English-language medical journals. We used the MEDLINE database, selected bibliographies, and articles available in our personal files.;Mutations of the RET proto-oncogene have been identified in the germline DNA of patients with familial MTC syndromes. Genetic testing can identify patients affected by multiple endocrine neoplasia types IIA and IIB and familial MTC, allowing early diagnosis and possible cure. Surgical treatment is total thyroidectomy. Plasma calcitonin measurements are excellent markers for postoperative follow-up. Adjunctive therapy includes radiotherapy and chemotherapy. The overall prognosis is worse than papillary thyroid carcinoma.;Recent advances in genetic testing allow early diagnosis and treatment of familial MTC syndromes. Despite some advances in treatment, optimal management remains controversial.",
        "Doc_title":"Current diagnosis and management of medullary thyroid carcinoma.",
        "Journal":"Annals of oncology : official journal of the European Society for Medical Oncology",
        "Do_id":"9739433",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Combined Modality Therapy;Genetic Testing;Humans;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"diagnosis;pathology;therapy;diagnosis;pathology;therapy",
        "_version_":1605874237977919488},
      {
        "Doc_abstract":"Medullary thyroid carcinomas (MTC) metastasize early into the regional lymph nodes. Calcitonin is a highly specific and sensitive marker for these tumors, which is feasible for follow-up and for screening. Additionally, in families with hereditary MTC the responsible mutations of the RET-proto-oncogene can be identified, and prophylactic surgery can be provided. We operated on 127 patients for MTC, 114 of whom had diagnosed carcinomas; 13 operations were performed with prophylactic intention. A total of 101 patients needed microsurgical dissection of the cervical compartments. Of these, 31% could be cured, and a further 46% showed postoperatively normalized basal calcitonin concentrations. Thirteen patients who needed mediastinal dissection had persistent increased levels of pentagastrin-stimulated or basal calcitonin values. All patients who underwent prophylactic surgery could be cured.",
        "Doc_title":"[The concept of \"microsurgical\" technique in medullary thyroid carcinoma].",
        "Journal":"Langenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress",
        "Do_id":"9931710",
        "Doc_ChemicalList":"Biomarkers;Calcitonin",
        "Doc_meshdescriptors":"Adult;Biomarkers;Calcitonin;Carcinoma, Medullary;Child;Follow-Up Studies;Humans;Lymphatic Metastasis;Microsurgery;Neck Dissection;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome",
        "Doc_meshqualifiers":"blood;blood;genetics;pathology;surgery;genetics;pathology;surgery",
        "_version_":1605818655699894274},
      {
        "Doc_abstract":"Lateral lymph node dissection (LND) in the absence of macroscopic nodal metastasis remains controversial in sporadic medullary thyroid carcinoma (MTC).;The aims of our study were to determine the risk of lateral lymph node (LN) metastases with a focus on lateral contralateral N1, and to define a risk-adapted surgical treatment for these patients.;All patients who underwent surgery from 1980 to 2012 for previously untreated RET-negative MTC were reviewed. We focused on the lateral compartments of LN metastases and identified three groups: no lateral LN metastases, ipsilateral lateral (ILL)-LN metastases with no contralateral LN involvement, and contralateral lateral (CLL)-LN metastases.;Overall, 131 patients underwent surgery for RET-negative MTC. A total thyroidectomy with LND was performed in 112 patients (85%), including 97 patients who had an ILL-LND and 92 patients who had a CLL-LND. Lateral LN metastases (N1) occurred in 40 patients (37%): 31 patients (32%) had ILL-LN metastases with no contralateral LN involvement, and 9 patients (10%) had CLL-LN metastases. The preoperative cut-offs for LN metastases in the ILL compartment were very low, with a smallest tumor size of 5mm, and lowest serum calcitonin level of 38pg/ml. Disease-free survival rates decreased from 92% for patients with no lateral LN metastases to 41% for patients with ILL-LN metastases and 0% for patients with CLL-LN metastases.;ILL-LND should be performed in every patient and only a minority of MTC patients with small micro-MTC, and low serum calcitonin levels should not have a CLL-LND.",
        "Doc_title":"Can We Predict the Lateral Compartment Lymph Node Involvement in RET-Negative Patients with Medullary Thyroid Carcinoma?",
        "Journal":"Annals of surgical oncology",
        "Do_id":"27271930",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605824561617567744},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor derived from the thyroid C cells producing calcitonin. MTC accounts for 0.6% of all thyroid cancers and incidence of MTC increased steadily between 1997 and 2011 in Korea. It occurs either sporadically or in a hereditary form based on germline rearranged during transfection (RET) mutations. MTC can be cured only by complete resection of the thyroid tumor and any loco-regional metastases. The most appropriate treatment is still less clear in patients with residual or recurrent disease after initial surgery or those with distant metastases because most patients even with metastatic disease have indolent courses with slow progression for several years and MTC is not responsive to either radioactive iodine therapy or thyroid-stimulating hormone suppression. Recently, two tyrosine kinase inhibitors (TKIs), vandetanib and cabozantinib, are approved for use in patients with advanced, metastatic or progressive MTC. In this review, we summarize the current approach according to revised American Thyroid Association guidelines and recent advances in systemic treatment such as TKIs for patients with persistent or recurrent MTC after surgery.",
        "Doc_title":"Recent Updates on the Management of Medullary Thyroid Carcinoma.",
        "Journal":"Endocrinology and metabolism (Seoul, Korea)",
        "Do_id":"27586449",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605893141517303808},
      {
        "Doc_abstract":"Medullary thyroid carcinoma currently accounts for 5-8% of all thyroid cancers. The clinical course of this disease varies from extremely indolent tumors that can go unchanged for years to an extremely aggressive variant that is associated with a high mortality rate. As many as 75% of all medullary thyroid carcinomas are sporadic, with an average age at presentation reported as 60 years, and the remaining 25% are hereditary with an earlier age of presentation, ranging from 20 to 40 years. Germline RET proto-oncogene mutations are the genetic causes of multiple endocrine neoplasia type 2 and a strong genotype-phenotype correlation exists, particularly between a specific RET codon mutation and the (a) age-related onset and (b) thyroid tumor progression, from C-cell hyperplasia to medullary thyroid carcinoma and, ultimately, to nodal metastases. RET mutations predispose an individual to the development of medullary thyroid carcinomas and can also influence the individual response to RET protein receptor-targeted therapies. RET codon 609 point mutations are rare genetic events belonging to the intermediate risk category for the onset of medullary thyroid carcinoma. A large genealogy resulting in a less aggressive form of medullary thyroid carcinoma is associated with the high penetrance of pheochromocytoma and has been reported in the literature. In this short review article, we comment on our previous report of a large multiple endocrine neoplasia type 2A kindred with the same Cys609Ser germline RET mutation in which, conversely, the syndrome was characterized by a slightly aggressive, highly penetrant form of medullary thyroid carcinoma that was associated with low penetrance of pheochromocytoma and primary hyperparathyroidism.",
        "Doc_title":"RET codon 609 mutations: a contribution for better clinical managing.",
        "Journal":"Clinics (Sao Paulo, Brazil)",
        "Do_id":"22584703",
        "Doc_ChemicalList":"Codon;Serine;Proto-Oncogene Proteins c-ret;RET protein, human;Cysteine",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Carcinoma, Neuroendocrine;Codon;Cysteine;Genetic Association Studies;Germ-Line Mutation;Humans;Hyperparathyroidism;Italy;Multiple Endocrine Neoplasia Type 2a;Pedigree;Proto-Oncogene Proteins c-ret;Serine;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605806906659569664},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC), a neoplasm of thyroid C-cells, is characterized by dominant activating mutations in the RET proto-oncogene. Currently therapy is restricted to surgical removal of all neoplastic tissue lacking alternative forms of treatment such as chemotherapy or radiotherapy. Therefore MTC is a particularly attractive target for gene therapeutic approaches. Many promising gene therapy strategies have been used in various animal models of MTC, showing enhanced antitumoral efficacy, and these will hopefully extend our current standard of care in the future. These approaches can tentatively be subdivided into four groups: (a) Inhibition of oncogenic RET signaling, (b) suicide gene therapy, (c) immunotherapy, and (d) combination of immunotherapy and suicide approaches. To block oncogenic signal transduction dominant-negative RET mutants were delivered into tumor cells and found to possess strong antineoplastic activity, including tumor growth suppression and increased animal survival. Suicide gene therapeutic approaches applied to MTC treatment featured either gene transfer of herpes simplex virus thymidine kinase with concomitant application of ganciclovir or delivery of nitric oxide synthase II. Here antitumor effects were attributed to the occurrence of substantial bystander activities. Immunotherapy approaches comprised stimulation of immune response by delivery of interleukin 2 or 12. Finally, treatment with herpes simplex virus thymidine kinase/ganciclovir in combination with interleukin 2 was found to be superior over either treatment alone. This review discusses the various gene therapeutic approaches applied to MTC treatment in detail, gives an overview on the diverse vector systems used to achieve efficient transduction of thyroid cancer cells, and points out the strategies employed to accomplish target cell selective gene expression thereby contributing to enhanced safety of gene therapy for MTC",
        "Doc_title":"Gene therapeutic approaches for medullary thyroid carcinoma treatment.",
        "Journal":"Journal of molecular medicine (Berlin, Germany)",
        "Do_id":"12811413",
        "Doc_ChemicalList":"Oncogene Proteins;Proto-Oncogene Proteins c-ret;RET protein, human;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Animals;Carcinoma, Medullary;Combined Modality Therapy;Gene Expression Regulation, Neoplastic;Genes, Transgenic, Suicide;Genetic Therapy;Genetic Vectors;Humans;Immunotherapy;Oncogene Proteins;Proto-Oncogene Proteins c-ret;Proto-Oncogenes;Receptor Protein-Tyrosine Kinases;Signal Transduction;Thyroid Neoplasms",
        "Doc_meshqualifiers":"immunology;therapy;genetics;metabolism;genetics;metabolism;immunology;therapy",
        "_version_":1605836203466162176},
      {
        "Doc_abstract":"To evaluate the relationship of the cytomorphology of medullary thyroid carcinomas (MTC) between family members with the same RET proto-oncogene mutation.;Review of the fine-needle aspiration slides of 13 cases with MTC proven by surgery and pathology from 5 unrelated families with either multiple endocrine neoplasia (MEN) type 2A or familial MTC (FMTC).;Small, round, and abundant large oval-to-polygonal cells were major cytomorphologic findings in 66.7% of family members with exon 11, codon 634 TGC  CGC germline mutation. Small, round cells and only a few or no polygonal cells were found in 66.7% of family members with exon 11, codon 634 TGC  TTC germline mutation and in 100% of family members with codon 634 TGC  TGG germline mutations, as well as in 100% of family members with exon 10, codon 620 TGC  GGC germline mutation.;The high rate of similarity of cytomorphology (66.7-100%) in the family members with MEN type 2A or FMTC might be related to the same etiology in the production of MTC in the same family. The relationship of the respective cytomorphology with the long-term prognosis is worth elucidating further.",
        "Doc_title":"The relationship of cytomorphology of medullary thyroid carcinomas between family members with the same RET proto-oncogene mutation.",
        "Journal":"Acta cytologica",
        "Do_id":"22156466",
        "Doc_ChemicalList":"Codon;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adult;Biopsy, Fine-Needle;Carcinoma, Medullary;Codon;DNA Mutational Analysis;Exons;Female;Genetic Variation;Germ-Line Mutation;Histocytochemistry;Humans;Introns;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Pedigree;Prognosis;Proto-Oncogene Proteins c-ret;Thyroid Gland;Thyroid Neoplasms",
        "Doc_meshqualifiers":"classification;congenital;genetics;pathology;classification;genetics;pathology;genetics;pathology;classification;genetics;pathology",
        "_version_":1605741937281728512},
      {
        "Doc_abstract":"Hereditary medullary thyroid carcinoma (MTC) therapy is surgical resection. Because the genetic screening was available, the early diagnosis of the disease has been possible. The purpose of this study was to evaluate the role of the genetic test in the management of these children and to draw some information about the surgical timing.;Thirteen patients underwent total thyroidectomy at our institute between 1995 and 2007. Seven patients underwent a curative thyroidectomy, and 6 patients underwent a prophylactic thyroidectomy. Two patients were operated with a minimally invasive video-assisted technique. We studied the following parameters: age, risk level associated to the RET gene mutations, aim of surgery (curative or prophylactic), tumor histopathologic features, lymph node involvement, and distal metastases.;We found a statistical association between cancer maximum diameter and some parameters analyzed: age of patients, aim of surgery, single or multifocal MTC, and number of organs involved by distal metastases. Cancer diameter at the moment of diagnosis seems to increase according to the aggressiveness of RET gene mutation found.;The best strategy to cure MTC is to prevent it. Genetic screening could be a fundamental tool in the management of multiple endocrine neoplasm type 2 children. An improvement of scientific knowledge regarding RET gene alterations and an early and appropriate use of genetic tests could allow a better understanding of the correct surgical timing and a wider use of less aggressive surgical procedures.",
        "Doc_title":"Role of RET codonic mutations in the surgical management of medullary thyroid carcinoma in pediatric age multiple endocrine neoplasm type 2 syndromes.",
        "Journal":"Journal of pediatric surgery",
        "Do_id":"20713208",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Adolescent;Carcinoma, Medullary;Child;Female;Genetic Predisposition to Disease;Genetic Testing;Humans;Male;Multiple Endocrine Neoplasia Type 2a;Mutation;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome;Video-Assisted Surgery",
        "Doc_meshqualifiers":"genetics;prevention & control;surgery;methods;genetics;prevention & control;surgery;genetics;genetics;genetics;prevention & control;surgery;methods;methods",
        "_version_":1605844028769697792},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) is a manifestation of multiple endocrine neoplasia type 2 (MEN2) syndromes caused by germline, activating mutations in the RET (REarranged during Transfection) proto-oncogene. Vandetanib, a VEGF and EGF receptor inhibitor, blocks RET tyrosine kinase activity and is active in adults with hereditary MTC.;We conducted a phase I/II trial of vandetanib for children (5-12 years) and adolescents (13-18 years) with MTC to define a recommended dose and assess antitumor activity. The starting dose was 100 mg/m(2) administered orally, once daily, continuously for 28-day treatment cycles. The dose could be escalated to 150 mg/m(2)/d after two cycles. Radiographic response to vandetanib was quantified using RECIST (v1.0), biomarker response was measured by comparing posttreatment serum calcitonin and carcinoembryonic antigen (CEA) levels to baseline, and a patient-reported outcome was used to assess clinical benefit.;Sixteen patients with locally advanced or metastatic MTC received vandetanib for a median (range) 27 (2-52) cycles. Eleven patients remain on protocol therapy. Diarrhea was the primary dose-limiting toxicity. In subjects with M918T RET germline mutations (n = 15) the confirmed objective partial response rate was 47% (exact 95% confidence intervals, 21%-75%). Biomarker partial response was confirmed for calcitonin in 12 subjects and for CEA in 8 subjects.;Using an innovative trial design and selecting patients based on target gene expression, we conclude that vandetanib 100 mg/m(2)/d is a well-tolerated and highly active new treatment for children and adolescents with MEN2B and locally advanced or metastatic MTC.",
        "Doc_title":"Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.",
        "Journal":"Clinical cancer research : an official journal of the American Association for Cancer Research",
        "Do_id":"23766359",
        "Doc_ChemicalList":"Piperidines;Quinazolines;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-ret;RET protein, human;N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine",
        "Doc_meshdescriptors":"Adolescent;Carcinoma, Medullary;Carcinoma, Neuroendocrine;Child;Child, Preschool;Drug-Related Side Effects and Adverse Reactions;Gene Expression Regulation, Neoplastic;Germ-Line Mutation;Humans;Multiple Endocrine Neoplasia Type 2b;Neoplasm Metastasis;Neoplasm Recurrence, Local;Piperidines;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-ret;Quinazolines;Thyroid Neoplasms",
        "Doc_meshqualifiers":"drug therapy;genetics;pathology;drug therapy;genetics;pathology;drug therapy;pathology;administration & dosage;adverse effects;genetics;genetics;administration & dosage;adverse effects;drug therapy;genetics;pathology",
        "_version_":1605757204634271744},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor arising from \"C\" cells of the thyroid; it is a RET associated cancer that can be sporadic or familial in origin. Advances in understanding the genetic changes associated with the development of MTC explain the growing interest in the therapeutic potential of tyrosine kinase inhibitors. Sunitinib is an orally administered multikinase inhibitor likely to target multiple pathways in the tumor, stromal, and endothelial compartments. Its role in the treatment of MTC patients has not yet been established.;To present the case of a patient with a sporadic and unresectable MTC who was successfully treated with sunitinib.;A 55-year-old man with locally advanced MTC, without germinal and/or somatic RET mutations, was started on sunitinib (50 mg/day for 28 days, followed by 14 days of no treatment). At the time of writing, he had received four consecutive cycles. At the end of the first cycle, his serum calcitonin level had dropped by 81%. In the following cycles, a long-lasting minor response was observed. An early and dramatic tumor reduction, particularly of a cervical lymph node conglomerate, was observed and confirmed by the Response Evaluation Criteria in Solid Tumors.;Sunitinib may play a role in the management of patients with locally advanced MTC or distant metastatic disease, for which no effective systemic therapy exists. Moreover, the absence of RET mutations does not seem to be an exclusion criterion for sunitinib treatment.",
        "Doc_title":"A case of advanced medullary thyroid carcinoma successfully treated with sunitinib.",
        "Journal":"The oncologist",
        "Do_id":"19887470",
        "Doc_ChemicalList":"Antineoplastic Agents;Indoles;Pyrroles;Proto-Oncogene Proteins c-ret;RET protein, human;sunitinib",
        "Doc_meshdescriptors":"Antineoplastic Agents;Carcinoma, Medullary;Humans;Indoles;Male;Middle Aged;Mutation;Prognosis;Proto-Oncogene Proteins c-ret;Pyrroles;Thyroid Neoplasms;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;genetics;pathology;therapeutic use;genetics;genetics;therapeutic use;drug therapy;genetics;pathology",
        "_version_":1605821802913726464},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) is often associated with gain-of-function mutations in the RET proto-oncogene, which is found in all hereditary cases and most sporadic cases. The activated RET receptor tyrosine kinase can be inhibited by tyrosine kinase inhibitors in vitro. We evaluated the efficacy of treatment with imatinib mesylate, a tyrosine kinase inhibitor, in patients with advanced MTC.;In this open-label clinical trial, nine patients, eight with sporadic and one with hereditary MTC, with unresectable, measurable, progressive metastases were treated with imatinib mesylate 600 mg daily. The tumour response to imatinib was evaluated after 3, 6 and 12 months by computed tomography and after 1 month by (18)F-fluoro-2-deoxy D-glucose position-emission tomographic scanning. The median duration of therapy was 8 months.;Overall, stable disease occurred in five patients for up to 6 months and in one patient for up to 12 months, with a median duration of progression-free survival of 6 months. Four patients had progressive disease after 12 months. One patient stopped therapy after 2 weeks because of worsening of diarrhoea. Therapy was well tolerated, although transient mild-to-moderate nausea (n = 3), oedema (n = 3), diarrhoea (n = 2) and skin rash (n = 2) were observed.;Imatinib mesylate is well tolerated, no tumour remission was observed, only transient stable disease was achieved in some patients with advanced MTC.",
        "Doc_title":"Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma.",
        "Journal":"European journal of endocrinology",
        "Do_id":"17656601",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Pyrimidines;Fluorodeoxyglucose F18;Imatinib Mesylate;Calcitonin",
        "Doc_meshdescriptors":"Adult;Aged;Antineoplastic Agents;Benzamides;Calcitonin;Carcinoma, Medullary;Female;Fluorodeoxyglucose F18;Germ-Line Mutation;Humans;Imatinib Mesylate;Male;Middle Aged;Piperazines;Positron-Emission Tomography;Pyrimidines;Survival Analysis;Thyroid Neoplasms",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;blood;diagnostic imaging;drug therapy;genetics;adverse effects;therapeutic use;adverse effects;therapeutic use;diagnostic imaging;drug therapy",
        "_version_":1605757974323658752},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) is a rare thyroid malignancy, which is familial in 25-29% of cases. Familial MTC is due to germ-line mutations in the RET proto-oncogene. It can occur either alone or as the thyroid manifestation of MEN 2 syndromes; the disease is inherited in an autosomal dominant fashion with age-related penetrance. The treatment of choice is surgery. Early diagnosis and an adeguate initial operation provide the best chance of cure. Hence, the diagnosis should be made preoperatively. Genetic testing can identify almost all affected individuals with hereditary disease and permits prophylactic/early thyroidectomy in gene carriers. Total thyroidectomy and lymphadenectomy of the cervicocentral compartment is mandatory in all patients. In addition, bilateral dissection of the cervicolateral compartment should be done in all cases with more than microscopic disease. Plasma calcitonin is an excellent marker for postoperative follow-up. Treatment of persistent/recurrent disease is primarily surgical. Hence, a reoperative cervical lymphadenectomy should be considered in patients with persistently elevated calcitonin levels and no signs of distant metastases. Chemotherapy and external radiotherapy have little impact on the course of avanced disease; more promising is metabolic radiotherapy with Y90-DOTATOC in patients with somatostatin receptor-positive tumours.",
        "Doc_title":"[Treatment of familial medullary thyroid carcinoma].",
        "Journal":"Minerva chirurgica",
        "Do_id":"14663408",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Carcinoma, Medullary;Child;Female;Follow-Up Studies;Humans;Male;Middle Aged;Prognosis;Thyroid Neoplasms",
        "Doc_meshqualifiers":"diagnosis;genetics;surgery;diagnosis;genetics;surgery",
        "_version_":1605844839786610688},
      {
        "Doc_abstract":"To present an unusual case of multiple endocrine neoplasia type 2A (MEN 2A) syndrome and to describe how this case differs from the typical clinical features and usual genetic variations seen in classic MEN 2A syndrome.;We describe the work-up, diagnosis, and treatment course of a patient who presented with multi-focal pheochromocytomas, parathyroid adenoma, thyroid abnormalities, and a RET mutation.;A 65-year-old man with previously treated pheochromocytoma presented with a parathyroid adenoma, multiple thyroid nodules, and a RET polymorphism. C-cell hyperplasia (CCH) or medullary thyroid carcinoma (MTC) occurs with nearly 100% penetrance in patients with MEN 2A syndrome. Our patient did not have CCH or frank MTC, but he expressed the other manifestations of the MEN 2A syndrome.;MEN 2A syndrome is characterized by the occurrence of MTC, pheochromocytomas, and parathyroid hyperplasia or adenomas. It is inherited in an autosomal dominant fashion, and more than 80% of patients with MEN 2A have a specific substitution on codon 634 of the RET proto-oncogene. Despite the nearly 100% penetrance of MTC or CCH in patients with MEN 2A, our patient did not have this. Additionally, he exhibited a RET mutation that is uncommonly seen in classic MEN 2A syndrome. Our patient may have a MEN 2A variant or a pseudo-MEN 2A syndrome.",
        "Doc_title":"Unusual case of multiple endocrine neoplasia type 2A syndrome without medullary thyroid carcinoma.",
        "Journal":"Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists",
        "Do_id":"21134882",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Aged;Carcinoma, Medullary;Carcinoma, Neuroendocrine;Humans;Male;Multiple Endocrine Neoplasia Type 2a;Thyroid Neoplasms",
        "Doc_meshqualifiers":"diagnosis;diagnosis;pathology;diagnosis",
        "_version_":1605844987490074624},
      {
        "Doc_abstract":"In children with RET proto-oncogene mutation, curative treatment of medullary thyroid carcinoma (MTC) is possible by prophylactic thyroidectomy. Recommendations on the timing and extent of thyroidectomy are based upon a model that utilises genotype-phenotype correlations to stratify mutations into three risk groups.;We evaluated the long-term outcome (mean follow-up 6.4 years, 15 patients more than 10 years, 26 patients more than 5 years) of operated gene carriers stratified into two risk groups (levels 1 and 2) based on the biological aggressiveness of MTC.;In 46 RET gene carriers, prophylactic thyroidectomy was carried out between the ages of 4 and 21 years. Level 1 mutations were harboured by 11 patients (codons 790, 791, 804 and 891). Histology was completely normal in two patients; in seven patients C-cell hyperplasia (CCH) and in two patients T1 tumours were diagnosed. All patients with level 1 mutations were cured. Level 2 mutations were harboured by 35 patients (codons 618, 620, 630 and 634). Histology of these patients showed CCH in 11 patients, T1 tumours in 21, T2 tumour in 1, T3 tumour in 1 and Tx in 1 patient. Histology showed no lymph node involvement. Five patients with level 2 mutations failed to be cured; in two patients, persistence of MTC was diagnosed directly after thyroidectomy and in three during follow-up. In two patients carrying a 634 mutation, other endocrinopathies (hyperparathyroidism and bilateral pheochromocytoma) manifested during follow-up.;If prophylactic thyroidectomy is done at early ages, cure rate is high. Timing and extent of prophylactic thyroidectomy can be modified by individual RET mutation.",
        "Doc_title":"Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype.",
        "Journal":"European journal of endocrinology",
        "Do_id":"16868135",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Adult;Carcinoma, Medullary;Child;Child, Preschool;Female;Follow-Up Studies;Genetic Predisposition to Disease;Genotype;Heterozygote;Humans;Male;Mutation;Phenotype;Postoperative Care;Proto-Oncogene Proteins c-ret;Risk Assessment;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome",
        "Doc_meshqualifiers":"epidemiology;genetics;surgery;epidemiology;genetics;epidemiology;genetics;surgery",
        "_version_":1605752997335269376},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) comprises approximately 4% of all malignant thyroid neoplasms. Although the majority of patients have a good prognosis, a subgroup of patients develops progressive disease and requires systemic therapy. Here, we focused on the current MTC therapeutic approaches and discussed the advantages and disadvantages of molecular targeted therapies.;Targeted molecular therapies that inhibit RET and other tyrosine kinase receptors involved in angiogenesis have been shown to improve progression-free survival in patients with advanced MTC. Two drugs, vandetanib and cabozantinib, have been approved for the treatment of progressive or symptomatic MTC, and several others have exhibited variable efficacy. No tyrosine kinase inhibitor has been shown to improve survival. Although no definitive recommendation can currently be made, cumulative data indicate that knowledge of the tumor mutational profile may facilitate improvements in targeted therapy for MTC.;Tyrosine kinase inhibitors are effective therapeutic agents for the treatment of progressive MTC. Nevertheless, it is not clear who will benefit the most from therapy, and the decision regarding when and how to initiate the treatment should be made based on the patient's medical history and tumor behavior. Hopefully, in the near future, molecular profiling of MTC can be used to determine the most effective molecular therapeutic target.",
        "Doc_title":"Advances and controversies in the management of medullary thyroid carcinoma.",
        "Journal":"Current opinion in oncology",
        "Do_id":"27792051",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605892255412912128},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) is a neoplasm of the endocrine system, which originates from parafollicular C-cells of the thyroid gland. For MTC therapy, the Food and Drug Administration recently approved vandetanib and cabozantinib, multi-kinase inhibitors targeting RET and other tyrosine kinase receptors of vascular endothelial growth factor, epidermal growth factor, or hepatocyte growth factor. Nevertheless, not all patients with the progressive MTC respond to these drugs, requiring the development of additional therapeutic modalities that have distinct activity. Previously, we reported that expression of activated Ras or Raf in the human MTC cell lines, TT and MZ-CRC-1, can induce growth arrest and RET downregulation via a leukemia inhibitory factor (LIF)-mediated autocrine/paracrine loop. In this study, we aimed to evaluate bacterially-produced recombinant human LIF for its efficacy to suppress human MTC xenografts in mice. Here, we report that, consistent with its effects in vitro, locally or systemically administered recombinant LIF effectively suppressed growth of TT and MZ-CRC-1 xenografts in mice. Further, as predicted from its effects in TT and MZ-CRC-1 cell cultures in vitro, recombinant LIF activated the JAK/STAT pathway and downregulated RET and E2F1 expression in tumors in mice. These results suggest that LIF is a potent cytostatic agent for MTC cells, which regulates unique mechanisms that are not targeted by currently available therapeutic agents.",
        "Doc_title":"Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice.",
        "Journal":"Cancer letters",
        "Do_id":"23856028",
        "Doc_ChemicalList":"E2F1 Transcription Factor;Leukemia Inhibitory Factor;Recombinant Proteins;STAT Transcription Factors;Proto-Oncogene Proteins c-ret;Janus Kinases",
        "Doc_meshdescriptors":"Animals;Carcinoma, Neuroendocrine;Cell Line, Tumor;Disease Models, Animal;E2F1 Transcription Factor;Female;Humans;Janus Kinases;Leukemia Inhibitory Factor;Mice;Proto-Oncogene Proteins c-ret;Recombinant Proteins;STAT Transcription Factors;Signal Transduction;Thyroid Neoplasms;Tumor Burden;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"metabolism;metabolism;administration & dosage;pharmacology;metabolism;metabolism;drug effects;drug therapy;metabolism;pathology;drug effects",
        "_version_":1605844614624837632},
      {
        "Doc_abstract":"Hereditary medullary thyroid carcinoma (MTC) is caused by germline mutations of the RET proto-oncogene. A genotype - phenotype correlation has been established, showing clustering of mutations in exons 10 and 11 in classical MEN 2 A syndrome, in exon 16 codon 918 in MEN 2 B syndrome and in exons 13-15 in familial MTC. A line of evidence suggested that the development and the aggressiveness of MTC in the different cancer syndromes is variable. Aim of this study was to compare the phenotype of exon 13-15 mutations with that of exon 11 mutation and possibly draw therapeutical consequences.;We compared the phenotype of 47 patients with mutations in exon 13-15 with 66 patients with exon 11, codon 634 mutation, the classical MEN2A. Patients were further subdivided as index and screening patients.;Mean age of 19 index patients with codon 790, 791, 804 or 891 mutation was significant higher compared with 18 index patients with codon 634 mutation (mean age at diagnosis 50+/-12 years; range 30-69 y vs mean age 31+/-9 years; range 17-49 y), tumor stage at operation was favourable (C-cell hyperplasia n = 1; stage I n = 8; II n = 3; III n = 2; IV n = 2; no operation n = 1; no information n = 2 vs stage I n = 3; stage II n = 6; stage III n = 4, no information n =5), cure rate was better (56 % vs 38 %) and the death rate was lower (n = 2 vs n = 4). In screening patients no differences concerning the age, tumor stage, cure and death rate between patients with exons 13-15 and codon 634 mutations were seen.;MTC in patients with exon 790, 791, 804, 891 mutations displayed a late onset and an indolent course compared to codon 634 mutation, this has to be taken into account when recommending timing and extent of prophylactic surgery.",
        "Doc_title":"[Hereditary medullary thyroid carcinoma--genotype-phenotype characterization].",
        "Journal":"Deutsche medizinische Wochenschrift (1946)",
        "Do_id":"14508694",
        "Doc_ChemicalList":"Codon;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Adolescent;Adult;Age Factors;Aged;Carcinoma, Medullary;Codon;Exons;Female;Genotype;Humans;Male;Mass Screening;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Multiple Endocrine Neoplasia Type 2b;Mutation;Neoplasm Staging;Phenotype;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Proto-Oncogenes;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;mortality;pathology;genetics;genetics;genetics;mortality;pathology;genetics;mortality;pathology;genetics;genetics;genetics;genetics;mortality;pathology",
        "_version_":1605882574512586752},
      {
        "Doc_abstract":"Successful treatment of MTC depends heavily on early diagnosis and treatment. Often, this is not possible for sporadic MTC; however, genetic testing for hereditary MTC makes this possible if genetic carriers have surgery before C cells undergo malignant transformation. All patients who have MTC should be tested for RET mutations, including putative sporadic cases. The leukocytes of suspected carriers and sporadic MTC cases should be tested for MEN2-associated germ-line mutations by polymerase chain reaction amplification of the appropriate RET gene exons, including 10, 11,13, 14, 15, and 16 (see Table I). When a RET mutation is found, all first-degree relatives must be screened to determine which individuals carry the gene. If these exons are negative, the other 15 should be sequenced because a small risk of hereditary MTC remains if no germ-line mutation is found. The probability that a first-degree relative will inherit an autosomal dominant gene for MTC from an individual who has sporadic MTC in whom no germ-line mutation is found is 0.18% . Patients who have MEN2B or RET codon 883 or 918 mutation should have a total thyroidectomy within the first 6 months of life, preferably within the first month of life. Patients who have 634 mutations, which account for approximately 70% of all MTC mutations, should undergo thyroidectomy by age 5 years. The recommendations for the timing of prophylactic thyroidectomy are not consistent for the less common mutations (see Table 2). There is a balance between performing prophylactic thyroidectomy earlier than at the youngest age at with MTC has been reported to occur for a specific RET mutation (see Fig. 3 and Table 2) and the complications of thyroidectomy, including permanent hypoparathyroidism and laryngeal nerve damage. Preoperative measurement of plasma free metanephrine and neck ultrasonography always should be done if the diagnosis of MTC is known preoperatively. Initial treatment of MTC is total thyroidectomy, regardless of its genetic type or putative sporadic nature, because surgery offers the only chance for a cure. Treatment with 1311 has no place in the management of MTC. Plasma CT measurements provide an accurate estimate of tumor burden and are especially useful in identifying patients who have residual tumor. Pentagastrin- or calcium-stimulated plasma CT testing is useful in identifying CCH or early MTC in carriers of RET mutations that are associated with late onset MTC. Pheochromocytoma may occur before or after MTC and is an important cause of mortality, even in young patients. HPT is an important aspect of MEN2A and requires surgery according to current guidelines for the management of primary HPT. Early thyroidectomy and appropriate management of pheochromocytoma clearly have modified the course of this disease, but more research is necessary in kindreds who have rare MTC mutations. Moreover, new treatments for widespread MTC are necessary because current chemotherapy agents offer little benefit. New drugs that lock the action of tyrosine kinase offer some hope.",
        "Doc_title":"Diagnosis and management of medullary thyroid carcinoma.",
        "Journal":"Clinics in laboratory medicine",
        "Do_id":"15157557",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Humans;Thyroid Neoplasms",
        "Doc_meshqualifiers":"diagnosis;therapy;diagnosis;therapy",
        "_version_":1605794890009018368},
      {
        "Doc_abstract":"The RET gene encodes a single-pass transmembrane receptor tyrosine kinase. RET is the oncogene that causes papillary thyroid carcinoma and medullary thyroid carcinoma. The latter may arise as a component of multiple endocrine neoplasia type 2 syndromes; germline mutations in RET are responsible for multiple endocrine neoplasia type 2 inheritance. In this report we review data on the mechanisms leading to RET oncogenic conversion and on RET targeting as a strategy in thyroid cancer treatment.",
        "Doc_title":"Minireview: RET: normal and abnormal functions.",
        "Journal":"Endocrinology",
        "Do_id":"15331579",
        "Doc_ChemicalList":"Oncogene Proteins;Proto-Oncogene Proteins c-ret;RET protein, human;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Gene Expression Regulation, Neoplastic;Humans;Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;physiology;genetics;physiology;physiopathology;therapy",
        "_version_":1605742753489092608},
      {
        "Doc_abstract":"We report a Chinese pedigree with familial medullary thyroid carcinoma. Direct sequencing of the entire coding sequences of Rearranged during Transfection (RET) identified a recurrent c.T1852A (p.C618S) mutation in 13 of 23 members. The polymorphisms c.A135G (p.A45A), c.A1296G (p.A432A), c.T2307G (p.L769L) and IVS19 + 15T > C were also found in 13 carriers, and c.G2073A (p.G691S) was found in 1 carrier. Of the 13 carriers, seven (mean age: 42.6 years, range: 27-64) presented MTC as the isolated clinical phenotype, with elevated basal serum calcitonin (average: 1077.9 ng/L, range: 504-2,652) and a mean diameter of thyroid nodules of 2.97 cm (range: 1.6-4.3); they underwent a total thyroidectomy with modified bilateral/unilateral neck dissection and/or level VI lymph node dissection. The other 6 carriers did not accept surgery (4 rejected, 2 awaited). These were 2 older patients (63 and 32 years) with elevated calcitonin (1359 and 41.4 ng/L) and multi-centric hypoechoic nodules (1.5 and 0.6 cm) with calcifications in both/left thyroid lobes; and Doppler ultrasound showed normal bilateral thyroids in 4 younger carriers (median age: 8.3 years, range: 4-12) but with increased calcitonin (average: 9.7 ng/L, range: 7.87-12.2) in 3 of them. The phenotype here is consistent with the clinical symptoms reported worldwide. We recommend that screening of hotspot regions of RET should be preferentially carried out, while whole-exon sequencing should be performed when clinical signs fail to reveal hotspot mutations or different phenotype discrepancies. Moreover, we strongly suggest prophylactic thyroidectomy should be performed before age 5 in carriers with p.C618S to prevent the occurrence and metastasis of MTC.",
        "Doc_title":"Case report: a p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma.",
        "Journal":"Familial cancer",
        "Do_id":"22068382",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Asian Continental Ancestry Group;Carcinoma, Medullary;Child;Female;Germ-Line Mutation;Humans;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Neoplastic Syndromes, Hereditary;Pedigree;Phenotype;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms;Thyroidectomy;Young Adult",
        "Doc_meshqualifiers":"genetics;congenital;genetics;genetics;pathology;surgery;genetics;genetics;pathology;surgery",
        "_version_":1605818664002519040},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor mainly caused by mutations in the rearranged during transfection (RET) proto-oncogene. Not all patients with progressive MTC respond to current therapy inhibiting RET, demanding additional therapeutic strategies. We recently demonstrated that disrupting mitochondrial metabolism using a mitochondria-targeted agent or by depleting a mitochondrial chaperone effectively suppressed human MTC cells in culture and in mouse xenografts by inducing apoptosis and RET downregulation. These observations led us to hypothesize that mitochondria are potential therapeutic targets for MTC. This study further tests this hypothesis using1-ethyl-2-[[3-ethyl-5-(3-methylbenzothiazolin-2-yliden)]-4-oxothiazolidin-2-ylidenemethyl] pyridinium chloride (MKT-077), a water-soluble rhodocyanine dye analogue, which can selectively accumulate in mitochondria.;The effects of MKT-077 on cell proliferation, survival, expression of RET and tumor protein 53 (TP53), and mitochondrial activity were determined in the human MTC lines in culture and in mouse xenografts.;MKT-077 induced cell cycle arrest in TT and MZ-CRC-1. Intriguingly, MKT-077 also induced RET downregulation and strong cell death responses in TT cells, but not in MZ-CRC-1 cells. This discrepancy was mainly due to the difference between the capacities of these cell lines to retain MKT-077 in mitochondria. The cytotoxicity of MKT-077 in TT cells was mainly attributed to oxidative stress while being independent of TP53. MKT-077 also effectively suppressed tumor growth of TT xenografts.;MKT-077 can suppress cell survival of certain MTC subtypes by accumulating in mitochondria and interfering with mitochondrial activity although it can also suppress cell proliferation via other mechanisms. These results consistently support the hypothesis that mitochondrial targeting has therapeutic potential for MTC.",
        "Doc_title":"Selective Mitochondrial Uptake of MKT-077 Can Suppress Medullary Thyroid Carcinoma Cell Survival In Vitro and In Vivo.",
        "Journal":"Endocrinology and metabolism (Seoul, Korea)",
        "Do_id":"26485469",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605908068832378880},
      {
        "Doc_abstract":"Thyroidectomy and radical cervical lymph node dissection have been suggested as primary and secondary operations aimed at achieving biochemical cure in cases of medullary thyroid carcinoma (MTC). The purpose of this study was to find out behaviour of MTC in long-term follow-up, and to estimate possible difference in biological virulence between sporadic MTC and MTC in MEN2A.;From 1967 through 1994, 39 patients with MTC, including 9 patients with hereditary disease, were operated on at the Second Department of Surgery, Helsinki University Central Hospital. Enlarged lymph nodes were dissected selectively. The main outcome measure was carcinoma-specific survival.;In sporadic MTC, ten-year carcinoma-specific survival was 57.9% (95% CI 39.1%-76.7%) and ten-year survival after reoperation due to lymphatic node recurrence was 51.4% (CI 18.7%-84.2%). The presence of distant metastases at diagnosis (p = 0.0001) and extrathyroidal growth of the primary tumor (p = 0.0008) were independent predictors of carcinoma-specific survival in the Cox model. The risk ratio of sporadic MTC to MTC in MEN2A was 5.40 (CI 0.67-43.2) after adjusting the survival time for the size of the primary tumor.;Distant metastases and the local extrathyroidal extent of the primary tumor have a significant effect on the prognosis of MTC, lymphatic node metastases and other clinical factors being less important. The biological virulence of sporadic MTC may be clinically significantly higher than that of MTC in MEN2A.",
        "Doc_title":"Long term prognosis of medullary thyroid carcinoma in 39 patients.",
        "Journal":"Annales chirurgiae et gynaecologiae",
        "Do_id":"11204961",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Medullary;Female;Humans;Lymphatic Metastasis;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Prognosis;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"complications;mortality;surgery;complications;complications;mortality;surgery",
        "_version_":1605795671011491840},
      {
        "Doc_abstract":"Germline missense point mutations of the ret proto-oncogene have been shown as causative in multiple endocrine neoplasia type 2 (MEN 2A and 2B) and in familial medullary thyroid carcinoma (FMTC). Most of the mutations are found in exon 10, 11, or 16 of the gene and are easily recognized by restriction analysis.;Using restriction analysis, we screened 58 subjects from nine kindreds.;Family members (n = 16) already known to be affected with the disease carried the germline mutation. Among the 42 subjects apparently unaffected, 37 were not gene carriers and 5 were gene carriers. Basal and pentagastrin-stimulated serum calcitonin levels were normal in two patients and abnormal in three. All patients were treated with total thyroidectomy and central node dissection. In all cases multiple foci of MTC were shown at histologic examination.;Our data indicate that genetic screening of MEN2 pedigrees allows the early identification of gene carriers. Because surgery of MTC in the preclinical phase has high probability of curing these patients, we suggest genetic screening soon after birth and total thyroidectomy in gene carriers as early as possible.",
        "Doc_title":"Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations.",
        "Journal":"Surgery",
        "Do_id":"7491519",
        "Doc_ChemicalList":"Drosophila Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Base Sequence;Carcinoma, Medullary;Drosophila Proteins;Heterozygote Detection;Humans;Molecular Sequence Data;Multiple Endocrine Neoplasia Type 2a;Point Mutation;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;pathology;surgery;genetics;genetics;genetics;genetics;pathology;surgery",
        "_version_":1605876350311202816},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant hereditary cancer syndrome caused by missense gain-of-function mutations of the RET proto-oncogene. Three distinct clinical subtypes of MEN 2 have been characterized: MEN 2A, MEN 2B, and familial medullary thyroid carcinoma (FMTC). The specific RET mutation may suggest a predilection toward a particular phenotype and clinical course, with strong genotype-phenotype correlations. Recommendations on the timing of prophylactic thyroidectomy and extent of surgery are based on classification of RET mutations into risk levels according to genotype-phenotype correlations. The excellent prognosis for MTC diagnosed at its earliest stage underscores the importance of prospective screening (calcitonin screening) for sporadic MTC and early diagnosis by RET-mutation analysis for hereditary MTC. MEN 2 provides a unique model for early prevention and cure of cancer and for the roles of stratified mutation-based diagnosis and therapy of carriers.",
        "Doc_title":"Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC.",
        "Journal":"Molecular and cellular endocrinology",
        "Do_id":"20083156",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Genetic Association Studies;Humans;Multiple Endocrine Neoplasia Type 2a;Multiple Endocrine Neoplasia Type 2b;Mutation;Phenotype;Prognosis;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605818737049468928},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant tumour syndrome caused by germline activating mutations of the RET proto-oncogene. It has a strong penetrance of medullary thyroid carcinoma (MTC) and can be associated with bilateral pheochromocytoma and primary hyperparathyroidism (MEN2A) within a single patient or family. Based on the phenotype three distinct clinical forms have been described: (1) classical MEN2A, (2) MEN2B, an association of MTC, pheochromocytoma and mucosal neuroma and (3) familial MTC (FMTC), which is associated with a very low incidence of other endocrinopathies. Each variant of MEN2 results from a different RET gene mutation, with a good genotype-phenotype correlation with regard to aggressiveness of MTC, time of onset of MTC and the presence or absence of other endocrine tumours. Recommendations on the timing of prophylactic thyroidectomy and extent of surgery are based on a classification of RET mutations into three risk levels using the genotype-phenotype correlations. MEN2 provides a unique model for early prevention and cure of cancer and for stratified roles of mutation-based diagnosis of carriers.",
        "Doc_title":"Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management.",
        "Journal":"Hormones (Athens, Greece)",
        "Do_id":"19269918",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Genotype;Humans;Multiple Endocrine Neoplasia Type 2a;Multiple Endocrine Neoplasia Type 2b;Phenotype;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"genetics;prevention & control;surgery;diagnosis;genetics;surgery;diagnosis;genetics;genetics;genetics;prevention & control;surgery",
        "_version_":1605755066123288576},
      {
        "Doc_abstract":"Medullary Thyroid Carcinoma (MTC) is a rare malignancy of the parafollicular C cells of the thyroid gland. Aim of our study is reporting retrospective analysis of our experience about the surgical treatment of MTC, especially pointing on lymphadenectomy.;from January 2000 to March 2006, were performed 546 thyroidectomy, 6 of them for MTC (1.09%): 5 sporadic and 1 familiar. All the patients were operated with standard technique (total thyroidectomy) and submitted to endocrinologic and instrumental follow-up.;in our experience, we do not registered early or late complications as bleeding, laryngeal nerves lesions and parathyroid lesions or intra-postoperative deaths.;MTC occurs sporadically or as part of the multiple endocrine neoplasia type 2 (MEN 2 a/b) syndromes in patients who have inherited a mutation in the RET proto-oncogene. The diagnosis is made by fine needle aspiration biopsy (FNAB) and by measuring calcitonin levels in the blood. Primary treatment consists of surgical resection including a total thyroidectomy, central neck nodal dissection and functional lateral neck nodal dissections. Most patients with a palpable primary tumour have nodal disease at the time of operation, and nodal involvement is often bilateral.;adequate resection of the primary tumour and cervical lymph nodes is important to optimize outcome and minimize the risk of recurrent disease. Following primary surgical resection, more than 50% of the patients will have recurrent disease with persistent elevation of calcitonin levels. Currently, there is no adequate systemic therapy for recurrent disease. Surgical reoperation or conservative observation are the best available options.",
        "Doc_title":"[Surgical management of medullary thyroid carcinoma. Personal experience].",
        "Journal":"Il Giornale di chirurgia",
        "Do_id":"17915054",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Biopsy, Needle;Carcinoma, Medullary;Female;Humans;Lymph Node Excision;Lymphatic Metastasis;Male;Middle Aged;Neck;Prognosis;Retrospective Studies;Risk Factors;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"diagnosis;genetics;pathology;surgery;diagnosis;genetics;pathology;surgery;methods",
        "_version_":1605766901377531904},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 (MEN 2) is a genetic disorder associated with nearly 100% of lifetime risk of medullary thyroid carcinoma (MTC). MTC is the first tumour of the syndrome to manifest, it shows a nearly 100% penetrance and is the most common cause of death in patients with MEN 2. MEN 2A accounts for over 60-90% of patients with hereditary MTC and is characterized by a combination of MTC, pheochromocytoma and parathyroid adenoma. MEN 2B has a high risk of MTC, pheochromocytoma and includes additional clinical features such as mucosal neuromas, ganglioneuromatosis of the gastrointestinal tract, and a marfanoid habitus. Familial MTC, the third subtype of MEN 2, is characterized by MTC in the objective absence of adrenal and parathyroid gland involvement. The identification of the RET proto-oncogene as the susceptibility gene for MEN 2 has fundamentally changed diagnosis and treatment of the disease since 1993. Availability of genetic screening of at-risk children in MEN 2 kindreds made prophylactic thyroidectomy in asymptomatic mutation carriers possible and genotype-phenotype correlations led to codonoriented prophylactic surgery. In this context, MEN 2 has become a disease of the young child.",
        "Doc_title":"Hereditary medullary thyroid carcinoma: how molecular genetics made multiple endocrine neoplasia type 2 a paediatric disease.",
        "Journal":"Endocrine development",
        "Do_id":"17684396",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Child;Genetic Predisposition to Disease;Genetic Testing;Heterozygote;Humans;Molecular Biology;Multiple Endocrine Neoplasia Type 2a;Mutation;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"genetics;classification;genetics;pathology;prevention & control;surgery;genetics;genetics",
        "_version_":1605805381027627008},
      {
        "Doc_abstract":"The RET proto-oncogene is responsible for the development of several human inherited and non-inherited diseases. Germline point mutations were identified in multiple endocrine neoplasia types 2A and 2B, and familial medullary thyroid carcinoma. More than 10 rearranged forms of RET, referred to as RET/PTC 1-9, ELKS/RET and RFP/RET, have been cloned from sporadic and radiation-associated papillary thyroid carcinomas. These mutations induced oncogenic activation of RET tyrosine kinase by different mechanisms. To date, various kinds of therapeutic approaches have been developed for the treatment of RET-associated cancers, including tyrosine kinase inhibitors, gene therapy with dominant negative RET mutants, and RNA interference to abrogate oncogenic mutant RET expression. RET and some signaling molecules that function downstream of RET could be potential targets for the development of selective cancer therapeutics.",
        "Doc_title":"The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.",
        "Journal":"Cancer science",
        "Do_id":"15771616",
        "Doc_ChemicalList":"Antineoplastic Agents;Enzyme Inhibitors;Oncogene Proteins;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-ret;RET protein, human;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Enzyme Inhibitors;Germ-Line Mutation;Humans;Neoplasms;Oncogene Proteins;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-ret;RNA Interference;Receptor Protein-Tyrosine Kinases;Signal Transduction",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug therapy;genetics;physiopathology;biosynthesis;genetics;antagonists & inhibitors;pharmacology;biosynthesis;genetics",
        "_version_":1605746284311871489},
      {
        "Doc_abstract":"CDKN1B encodes the cyclin-dependent kinase inhibitor p27Kip1 and is mutated in multiple endocrine neoplasia-like syndromes. CDKN1B also harbors single nucleotide polymorphisms; the T/G transversion at nucleotide 326 (the V109G variant) has been reported to be protective in breast, hereditary prostate, and pancreatic tumors. Association of CDNK1B mutations or polymorphisms with sporadic medullary thyroid carcinoma (MTC) has not been investigated yet.;We screened germline DNA from 84 patients affected by sporadic MTC and 90 healthy age- and gender-matched controls for CDKN1B mutations or polymorphisms by PCR amplification and sequencing of the amplicons. We also tested all germline and 50 tumor tissue DNA for RET proto-oncogene mutations. Computed tomography, ultrasound scans, and serum calcitonin were carried out before surgery and during the follow-up and associated with CDKN1B polymorphism and disease remission.;The T/G transversion at nucleotide 326 was the only DNA variation detected. The overall frequency of the T/G and G/G alleles in combination was 46.4%. This variant (V109G) was correlated with post-operative calcitonin levels in the normal range and biochemical remission. Conversely, the wild-type (T/T) allele was associated with post-operative calcitonin levels above normal and a higher risk to develop clinical recurrence and distant metastases. Somatic RET mutations were significantly associated with a more aggressive behavior especially in wild-type allele-bearing patients.;Collectively, in sporadic MTC, the CDKN1B V109G polymorphism correlates with a more favorable disease progression than the wild-type allele and might be considered a new promising prognostic marker.",
        "Doc_title":"CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma.",
        "Journal":"European journal of endocrinology",
        "Do_id":"21177330",
        "Doc_ChemicalList":"CDKN1B protein, human;Intracellular Signaling Peptides and Proteins;Cyclin-Dependent Kinase Inhibitor p27;Calcitonin",
        "Doc_meshdescriptors":"Adult;Calcitonin;Carcinoma, Neuroendocrine;Cyclin-Dependent Kinase Inhibitor p27;Female;Humans;Intracellular Signaling Peptides and Proteins;Male;Middle Aged;Multivariate Analysis;Polymorphism, Single Nucleotide;Proportional Hazards Models;Thyroid Neoplasms",
        "Doc_meshqualifiers":"blood;genetics;genetics;blood;genetics",
        "_version_":1605783617430093824},
      {
        "Doc_abstract":"The nosology of familial medullary thyroid carcinoma (FMTC) has been described as a distinct pathology, genetically determined and with autosomal dominant transmission with a gene penetrance of almost 100%. The diagnosis of this morbid condition can be made if at least four members of the same family are affected by calcitonin-secreting C-cell carcinoma.;We report the analysis of a family in which FMTC was diagnosed between 1993 and 1998. Of the five patients we confirmed as being affected by FMTC, we were able to perform a prophylactic thyroidectomy in only one case. The high possibility of lymph-node metastasis at the time of clinical diagnosis (52-75%), and the high morbidity and radio-chemo-resistance to adjuvant therapies, indicate total thyroidectomy with central lymph-node dissection.;It appears that preventive lymphadenectomy does not substantially improve survival, while pre-clinical diagnosis is of greater importance than surgery in improving survival and preventing recurrence. Total preventive thyroidectomy has been recommended in all carriers of ret genetic defects, even in families at risk with mutations of the 618 or 620 codon, because the penetrance of FMTC approaches 100%, and a 100% accordance between presence of the disease and gene carrier status is reported. This procedure would therefore represent the only possibility of achieving a 100% cure in subjects affected by familial medullary thyroid carcinoma.",
        "Doc_title":"Familial medullary thyroid carcinoma (FMTC). Study of one family (treatment criteria).",
        "Journal":"European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology",
        "Do_id":"11289752",
        "Doc_ChemicalList":"Drosophila Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Adolescent;Adult;Carcinoma, Medullary;Child;Drosophila Proteins;Family Health;Female;Genealogy and Heraldry;Genetic Predisposition to Disease;Humans;Male;Mutation;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"genetics;surgery;genetics;genetics;genetics;surgery",
        "_version_":1605746419995508738},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) and pheochromocytoma/paraganglioma (PHEO/PGL) are rare neuroendocrine tumors. Because of the increased metastatic rates in certain genetic backgrounds, early diagnosis and treatment are essential to improved patient outcomes. Our objective was to summarize recent findings related to the genetics, diagnosis, and management of MTC and PHEO/PGL.;A literature review was performed.;MTC is primarily associated with mutations in the rearranged during transfection (RET) proto-oncogene. Determining the specific genetic mutation can guide patient management and screening. Early detection and appropriate surgical management of MTC is critical to prevent or limit metastatic spread, as treatment options for patients with metastatic disease are limited. PHEO/PGL also has a strong genetic component, with approximately 50% of cases linked to germline and somatic mutations in 15 genes. Although most PHEO/PGLs are benign, factors such as genetic background, size, tumor location, and high methoxytyramine levels are associated with higher rates of metastatic disease. The state-of-the-art diagnosis and localization of PHEO/PGLs is based on measurement of plasma metanephrines and methoxytyramine and functional imaging studies. For both PHEO/PGL and MTC, surgery is the only curative treatment. Treatment options for patients with metastatic disease are limited.;As genetic testing becomes more widely available, the diagnosis of MTC and PHEO/PGL will be made earlier due to routine screening of at-risk patients. In addition, continued advances in basic science, diagnostic methods, and imaging techniques will improve understanding of the pathogenesis of these diseases and facilitate the introduction of novel treatment strategies for patients with metastatic disease.",
        "Doc_title":"Genetics, diagnosis, and management of medullary thyroid carcinoma and pheochromocytoma/paraganglioma.",
        "Journal":"Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists",
        "Do_id":"24449662",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adrenal Gland Neoplasms;Carcinoma, Neuroendocrine;Genetic Testing;Humans;Paraganglioma;Pheochromocytoma;Thyroid Neoplasms",
        "Doc_meshqualifiers":"diagnosis;genetics;therapy;diagnosis;genetics;therapy;diagnosis;genetics;therapy;diagnosis;genetics;therapy;diagnosis;genetics;therapy",
        "_version_":1605764297224355840},
      {
        "Doc_abstract":"Preliminary results of treatment of inherited medullary thyroid carcinoma, diagnosed primarily with genetic analysis of mutation of protooncogene RET are presented. Among 16 carriers of mutation identical with mutation diagnosed earlier in proband, there were 4 patients with clinically obvious medullary thyroid carcinoma and 12 asymptomatic carriers. In all patients, in whom calcitonin level was increased preoperatively, its normalization was obtained. The paper summarizes these aspects of cooperation between geneticians and physicians in which diagnostic results influence clinical decisions (indication and time of thyroid and lymph nodes surgery and it's spectrum, range of diagnostic procedures towards pheochromocytoma and parathyroid hyperplasia in relation to the found mutation).",
        "Doc_title":"[Consequences of clinical genetic analysis of RET proto-oncogene].",
        "Journal":"Wiadomosci lekarskie (Warsaw, Poland : 1960)",
        "Do_id":"12182057",
        "Doc_ChemicalList":"Drosophila Proteins;Proto-Oncogene Proteins;Calcitonin;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Adolescent;Adrenal Gland Neoplasms;Adult;Calcitonin;Carcinoma, Medullary;Child;Drosophila Proteins;Heterozygote;Humans;Mutation;Parathyroid Diseases;Pheochromocytoma;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"diagnosis;genetics;analysis;diagnosis;genetics;therapy;diagnosis;genetics;diagnosis;genetics;genetics;genetics;diagnosis;genetics;therapy",
        "_version_":1605742080182714368},
      {
        "Doc_abstract":"The spectrum of mutations of the RET protooncogene was analyzed in Russian patients with inherited or sporadic medullary thyroid carcinoma (MTC). Four RET exons (11, 13, 15, and 16) were subjected to molecular analysis, and mutations were revealed and identified in 47.4% (9/19) patients with sporadic MTC. In total, six mutations (including three new ones) were observed. The most common mutation affected codon 918 to cause substitution of methionine with threonine and accounted for 31.6% alleles. Analysis of exons 11 and 16 revealed four mutations in patients with inherited multiple endocrine neoplasia type 2 (MEN 2). Mutations were found in each patient. Thyroidectomy was performed in four asymptomatic carriers of RET mutations from three MET 2A families (in two families, affected relatives had bilateral pheochromocytoma). In two patients, analysis of the surgery material revealed MTC microfoci in both lobes of the thyroid gland. The results provide the ground for constructing a bank of genetic information on Russian MTC patients with the clinically verified diagnosis.",
        "Doc_title":"[Analysis of mutations in the RET proto-oncogene in patients with medullary thyroid tumor].",
        "Journal":"Genetika",
        "Do_id":"12884527",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;Threonine;Methionine;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Carcinoma, Medullary;Exons;Female;Humans;Male;Methionine;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Multiple Endocrine Neoplasia Type 2b;Mutation;Pedigree;Pheochromocytoma;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Russia;Threonine;Thyroid Gland;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics;genetics;genetics;pathology;surgery;genetics",
        "_version_":1605802126313783296},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) responds very poorly to chemotherapy. Mutations in the RET gene are critical for MTC pathogenesis. RET therefore represents a rational target for the development of novel MTC therapies. The accumulation of evidence from laboratory studies strongly suggests that PP1 inhibitor is a cytostatic agent for cells expressing RET oncoproteins. PP1 functions as a potent and selective inhibitor of RET oncoprotein phosphorylation, promoting its proteasomal degradation.",
        "Doc_title":"RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor.",
        "Journal":"Tumori",
        "Do_id":"14870784",
        "Doc_ChemicalList":"4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine;Antineoplastic Agents;Oncogene Proteins;Pyrazoles;Pyrimidines;Proto-Oncogene Proteins c-ret;RET protein, human;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Carcinoma, Medullary;Humans;Multiple Endocrine Neoplasia Type 2a;Multiple Endocrine Neoplasia Type 2b;Oncogene Proteins;Phosphorylation;Proto-Oncogene Proteins c-ret;Pyrazoles;Pyrimidines;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms",
        "Doc_meshqualifiers":"pharmacology;drug therapy;metabolism;metabolism;metabolism;drug effects;metabolism;drug effects;pharmacology;pharmacology;drug effects;metabolism;drug therapy;metabolism",
        "_version_":1605874518238167040},
      {
        "Doc_abstract":"Since the majority of multiple endocrine neoplasia type 2A (MEN 2A) patients have missense mutations at codon 634 and those with the Cys630 RET genotype mutations are extremely rare, limited clinical information is available about this rare type. We report here three members of one Japanese MEN 2A family with the Cys630Tyr genotype. A 67-year-old woman presented a firm thyroid nodule, and preoperative examination revealed medullary thyroid carcinoma with primary hyperparthyoidism and no pheochromocytoma. At surgery, bilateral medullary thyroid carcinomas and parathyroid adenoma were found. No lymph node metastasis was identified. Computed tomography scans and laboratory examination of blood have shown no evidence of tumor recurrence and no abnormality of parathyroid function during the 4 years after surgery. A 40-year-old man, the proband's son, was shown to have the same RET mutation, underwent total thyroidectomy prophylactically, and only microscopic foci of medullary thyroid carcinoma were found. A 10-year-old boy, the proband's grandson also having the same RET mutation, showed normal basal serum calcitonin level and has been followed up conservatively. To our knowledge, 18 patients of 6 families with the Cys630 mutations have been reported so far. This is only the second reported case with primary hyperparathyroidism. RET 630 mutations might be associated with lower penetrance of primary hyperparthyoidism and pheochromocytoma.",
        "Doc_title":"A family of multiple endocrine neoplasia type 2A (MEN 2A) with Cys630Tyr RET germline mutation: report of a case.",
        "Journal":"Endocrine journal",
        "Do_id":"17527003",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adenoma;Adult;Aged;Child;Family Health;Female;Genotype;Germ-Line Mutation;Humans;Hyperparathyroidism, Primary;Male;Multiple Endocrine Neoplasia Type 2a;Mutation, Missense;Parathyroid Neoplasms;Pedigree;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;pathology;genetics;pathology;genetics;genetics;pathology",
        "_version_":1605874806214885376},
      {
        "Doc_abstract":"Neuroendocrine tumors (NET) of the thyroid gland are rare. Apart from medullary thyroid carcinoma (MTC), metastases of gastroenteropancreatic (GEP) NET may also occur. Features of six patients (five men, one female: age range, 39-67 years) with thyroid metastases from a GEP-NET are described. Thyroid metastases were bilateral in all patients and were associated with enlarged neck lymph nodes in five. In four cases, the thyroid tumor was either the first sign of the disease (n = 2) or was an isolated site of recurrence (n = 2). The tumors were well (n = 3) or poorly differentiated (n = 3). Five tumors for which the primary site could be determined corresponded to foregut-derived tumors (3 lungs, 1 thymus and 1 pancreatic NET). One tumor demonstrated calcitonin (CT) production as shown by immunohistochemistry and elevated plasma CT levels. However, the disease history and the clinical features strongly favored a metastasizing GEP-NET. No tumoral RET proto-oncogene mutation was found in this patient. The differential diagnosis between metastatic GEP-NET and MTC is crucial because prognosis, work-up, and treatment differ greatly.",
        "Doc_title":"Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma.",
        "Journal":"European journal of endocrinology",
        "Do_id":"10216512",
        "Doc_ChemicalList":"Carcinoembryonic Antigen;DNA, Neoplasm;Calcitonin",
        "Doc_meshdescriptors":"Adult;Aged;Calcitonin;Carcinoembryonic Antigen;Carcinoma, Medullary;DNA, Neoplasm;Diagnosis, Differential;Enzyme-Linked Immunosorbent Assay;Female;Humans;Immunohistochemistry;Lung Neoplasms;Male;Middle Aged;Neuroendocrine Tumors;Pancreatic Neoplasms;Polymorphism, Single-Stranded Conformational;Prospective Studies;Thymus Neoplasms;Thyroid Neoplasms",
        "Doc_meshqualifiers":"blood;blood;diagnosis;blood;pathology;pathology;secondary;pathology;pathology;diagnosis;secondary",
        "_version_":1605840878508703744},
      {
        "Doc_abstract":"Carcinoembryonic antigen (CEA), a tumor marker with a glycoprotein structure, is frequently used in follow-up gastrointestinal malignancies. CEA levels may also increase in neuroendocrine tumors, including medullary thyroid carcinoma (MTC), and in some benign diseases. Patients whose blood tests show high CEA levels should have additional tests regarding MTC. Although MTC comprises only 3%-11% of all thyroid cancers, it should be tested because it has a poor prognosis and may accompany multiple endocrine neoplasia. We present the case of a 76-year-old man with subclinical hyperthyroidism with sporadic MTC who presented with initial high serum CEA levels. He underwent total thyroidectomy and left modified neck dissection. Pathologic specimens stained strongly for CEA. The patient's blood was analyzed for mutations in exons 10, 11, 13, 14, 15, and 16, but the RET proto-oncogene revealed no mutations. The patient was regularly followed by measurement of serum CEA levels and performance of positron emission tomography-computed tomography. Seventeen months after surgery, the patient has remained well and showed no signs of tumor recurrence.",
        "Doc_title":"A high level of carcinoembryonic antigen as initial manifestation of medullary thyroid carcinoma in a patient with subclinical hyperthyroidism.",
        "Journal":"International surgery",
        "Do_id":"22216705",
        "Doc_ChemicalList":"Carcinoembryonic Antigen",
        "Doc_meshdescriptors":"Aged;Carcinoembryonic Antigen;Carcinoma, Medullary;Esophagitis, Peptic;Humans;Hyperthyroidism;Immunohistochemistry;Incidental Findings;Male;Positron-Emission Tomography;Thyroid Neoplasms",
        "Doc_meshqualifiers":"blood;complications;diagnosis;surgery;complications;complications;complications;diagnosis;surgery",
        "_version_":1605824850592530432},
      {
        "Doc_abstract":"The RET gene encodes a receptor tyrosine kinase that is expressed in neural crest-derived cell lineages. The RET receptor plays a crucial role in regulating cell proliferation, migration, differentiation, and survival through embryogenesis. Activating mutations in RET lead to the development of several inherited and noninherited diseases. Germline point mutations are found in the cancer syndromes multiple endocrine neoplasia (MEN) type 2, including MEN 2A and 2B, and familial medullary thyroid carcinoma. These syndromes are autosomal dominantly inherited. The identification of mutations associated with these syndromes has led to genetic testing to identify patients at risk for MEN 2 and familial medullary thyroid carcinoma and subsequent implementation of prophylactic thyroidectomy in mutation carriers. In addition, more than 10 somatic rearrangements of RET have been identified from papillary thyroid carcinomas. These mutations, as those found in MEN 2, induce oncogenic activation of the RET tyrosine kinase domain via different mechanisms, making RET an excellent candidate for the design of molecular targeted therapy. Recently, various kinds of therapeutic approaches, such as tyrosine kinase inhibition, gene therapy with dominant negative RET mutants, monoclonal antibodies against oncogene products, and nuclease-resistant aptamers that recognize and inhibit RET have been developed. The use of these strategies in preclinical models has provided evidence that RET is indeed a potential target for selective cancer therapy. However, a clinically useful therapeutic option for treating patients with RET-associated cancer is still not available.",
        "Doc_title":"RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.",
        "Journal":"Endocrine reviews",
        "Do_id":"16849421",
        "Doc_ChemicalList":"Ligands;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Animals;Endocrine Gland Neoplasms;Fetal Development;Gene Targeting;Genetic Therapy;Haplotypes;Humans;Ligands;Models, Biological;Multiple Endocrine Neoplasia Type 2a;Polymorphism, Genetic;Proto-Oncogene Proteins c-ret;Signal Transduction",
        "Doc_meshqualifiers":"diagnosis;genetics;therapy;genetics;diagnosis;genetics;therapy;antagonists & inhibitors;genetics;physiology;drug effects",
        "_version_":1605820308901593088},
      {
        "Doc_abstract":"To report the uncommon case of a woman with abdominal pain and a complex adnexal mass, who was subsequently found to have medullary thyroid carcinoma (MTC) metastatic to the ovary.;We present the clinical history, physical findings, laboratory and imaging studies, and pathologic findings in a woman with metastatic MTC and locally aggressive disease. The genetic associations, variable clinical course, and histopathologic findings in MTC are reviewed.;A 38-year-old woman with abdominal and pelvic pain underwent a computed tomographic scan of the abdomen, which showed a complex left adnexal mass. After laparoscopic left oophorectomy, histopathologic analysis of the resected ovary suggested the presence of a metastatic neuroendocrine tumor. The patient recovered but was referred to the surgery clinic 3 months later because of hoarseness, a left neck mass, and left-sided vocal cord paralysis. Further work-up was suggestive of MTC, which prompted RET testing for multiple endocrine neoplasia. The patient underwent left thyroid lobectomy and selective lymph node dissection but later required tracheostomy because of tumoral invasion of the trachea, laser debulking of the tumor, and external beam radiation therapy. One year postoperatively, development of a metastatic lesion in her right ovary necessitated a second oophorectomy.;MTC usually manifests as a solitary thyroid nodule but should be considered in patients with metastatic lesions characterized by neuroendocrine features. This unusual case highlights the biologic and clinical variability of this often aggressive thyroid cancer, which necessitates an attentive work-up, a rigorous operative strategy, and a periodic postoperative surveillance program.",
        "Doc_title":"Medullary thyroid carcinoma manifesting as an ovarian mass: case report and review of literature.",
        "Journal":"Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists",
        "Do_id":"18463043",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Carcinoma, Medullary;Female;Humans;Ovarian Neoplasms;Ovariectomy;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"diagnosis;secondary;surgery;diagnosis;secondary;surgery;diagnosis;pathology;surgery",
        "_version_":1605901817596608512},
      {
        "Doc_abstract":"The hereditary form of medullary thyroid carcinoma may occur isolated as a familial medullary thyroid carcinoma (FMTC) or as part of Multiple Endocrine Neoplasia 2A (MEN2A) and 2B (MEN2B). MEN2B is a rare syndrome, its phenotype may usually, but not always, be noted by the physician. In the infant none of the MEN2B characteristics are present, except by early gastrointestinal dysfunction caused by intestinal neuromas. When available, genetic analysis confirms the diagnosis and guides pre-operative evaluation and extent of surgery. Here we report four cases of MEN2B in which the late diagnosis had a significant impact in clinical evolution and, potentially, in overall survival.;We report four cases, 2 men and 2 women, with differences in their phenotypes and with a late diagnosis. The first case has a history of severe gastrointestinal obstruction requiring a surgery intervention two days after his birth. The second told had nodules in the oral mucosa and constipation since childhood. The third case referred a history of constipation from birth until 5 months of life. The fourth has had a history of chronic constipation since childhood.;New concepts have emerged since the RET oncogene was identified in 1993 as the responsible gene for hereditary medullary thyroid carcinoma. The majority of MEN2B individuals have M918T mutation in the exon 16 of RET, with a few cases having a mutation A883F or the association of V804M with E805K, Y806C or S904C mutations. The consensus classifies the RET mutation in codon 918 as of highest risk and recommends total thyroidectomy and central lymph node dissection until 6 months after birth. A fast and precise diagnosis is essential to reach these goals. The identification of early manifestations such as intestinal ganglioneuromatosis and oral mucosal neuromas should prompt the physician to initiate an investigation for multiple endocrine neoplasia type 2B.;The diagnosis of MEN2B is very important to allow appropriate investigation of associated diseases and to allow counseling and appropriate screening of relatives for a RET mutation. Even patients with MEN2B, which often have typical physical features, may not be properly recognized and be followed as a sporadic case. Based on this, all suspicious cases of multiple endocrine neoplasia should undergo a molecular genetic test.",
        "Doc_title":"Early diagnosis of multiple endocrine neoplasia type 2B: a challenge for physicians.",
        "Journal":"Arquivos brasileiros de endocrinologia e metabologia",
        "Do_id":"19169500",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Adolescent;Carcinoma, Medullary;Early Detection of Cancer;Female;Humans;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2b;Phenotype;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms;Young Adult",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;genetics;pathology",
        "_version_":1605846944827047936},
      {
        "Doc_abstract":"Since medullary thyroid cancer (MTC) was first recognized as a distinct tumor in 1959, it became clear that MTC is more difficult to cure than papillary thyroid cancer and has higher rates of recurrence and mortality. MTC represents 5-8% of thyroid cancers. It derives from parafollicular cells of the ultimobranchial body derived from the neural crest. MTC secretes calcitonin and other hormonal peptides and is considered part of the amine precursor uptake and decarboxilation system. MTC may occur either as a hereditary or nonhereditary entity. Hereditary MTC can occur either alone as the familial MTC or as the thyroid manifestation of multiple endocrine neoplasia (MEN) type 2 syndromes (MEN 2A MEN 2B). Activating point mutations of the RET proto-oncogene have demonstrated to be causative of the familial form of medullary thyroid cancer, both isolated familial MTC and associated with MEN 2A and 2B. In the last 10 years, major improvements and new technologies have been proposed and applied in thyroid surgery; among these are molecular diagnosis with genetic screening and mini-invasive video-assisted thyroidectomy. The history of thyroid surgery starts with Billroth, Kocher and Halsted, who developed the technique for thyroidectomy between 1873 and 1910. Prophylactic surgery for patients carrying a positive RET proto-oncogene has proven to be highly effective in curing those likely to experience the development of MTC. Video-assisted procedures with central compartment dissection have proved feasible for patients carrying a positive RET proto-oncogene. This paper reviews relevant medical literature published in the English language on surgery of MTC in well-controlled trials. We discuss the particular ethical and legal issues that thyroid prophylactic surgery raises. Searches were last updated in February 2007.",
        "Doc_title":"Medullary thyroid carcinoma: surgical treatment advances.",
        "Journal":"Expert review of anticancer therapy",
        "Do_id":"17555398",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Humans;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"surgery;surgery",
        "_version_":1605880555726962688},
      {
        "Doc_abstract":"In the last ten years, research has confirmed the role of the RET proto-oncogene in the pathogenesis of thyroid cancer such as medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC), multiple endocrine neoplasia type 2 (MEN 2) and Hirschsprung's disease that can be associated with MTC or MEN 2. Through the use of molecular genetic testing, we are able to detect gene mutations and the course the disease might take can be predicted, thus enabling us to cure mutation carriers among the high-risk patients can at a very early, clinically asymptomatic stage of the disease; prophylactic total thyreoidectomy in said patients is recommended. At this juncture, there is extensive on-going research on the physiological role played by the RET proto-oncogene on the normal proliferation, differentiation and survival of the cell. Thanks to the new findings there are now possibilities of the theurapeutic use of gene therapy on an RET signaling cascade level in near future.",
        "Doc_title":"[Thyroid carcinomas and Hirschsprung's disease--10-year experience with molecular genetic testing of the RET proto-oncogene].",
        "Journal":"Vnitrni lekarstvi",
        "Do_id":"17063805",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Carcinoma, Papillary;Hirschsprung Disease;Humans;Multiple Endocrine Neoplasia Type 2a;Mutation;Proto-Oncogene Proteins c-ret;Signal Transduction;Thyroid Neoplasms",
        "Doc_meshqualifiers":"diagnosis;genetics;diagnosis;genetics;diagnosis;genetics;diagnosis;genetics;genetics;physiology;diagnosis;genetics",
        "_version_":1605824323100082176},
      {
        "Doc_abstract":"Different forms of RET mutations are found in papillary and medullary thyroid carcinomas. Rearrangements with other genes (RET/PTC oncogene) play a causative role in a significant proportion of papillary thyroid carcinomas. In this case, several factors influence the frequency and the type of RET/PTC, such as exposure to radiation, age and histological variant of the papillary tumor. On the other hand, the presence of the mutation does not seem to influence the biological behavior of the tumor or its response to conventional treatment modalities. In the setting of medullary thyroid cancer, germline RET point-mutations are implicated in the pathogenesis of virtually all hereditary forms and somatic point-mutations in nearly half of the sporadic forms. The clinical impact of this finding is that family members at-risk of hereditary MTC may be screened by genetic analysis, to distinguish those carrying or not-carrying the mutation. The last can be reassured on their status and relieved from further follow-up. Those with the mutation may be treated at a pre-clinical stage of the disease or even before the disease is started. The present review is focused on the clinical implication of RET gene mutations in thyroid cancer patients.",
        "Doc_title":"RET proto-oncogene mutations in thyroid carcinomas: clinical relevance.",
        "Journal":"Journal of endocrinological investigation",
        "Do_id":"10882153",
        "Doc_ChemicalList":"Drosophila Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Carcinoma, Papillary;Drosophila Proteins;Heterozygote;Humans;Multiple Endocrine Neoplasia Type 2a;Neoplasms, Radiation-Induced;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Radioactive Hazard Release;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms;Ukraine",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;etiology;genetics",
        "_version_":1605840002361589760},
      {
        "Doc_abstract":"RET (REarranged during Transfection) is a receptor tyrosine kinase, which plays pivotal roles in regulating cell survival, differentiation, proliferation, migration and chemotaxis. Activation of RET is a mechanism of oncogenesis in medullary thyroid carcinomas where both germline and sporadic activating somatic mutations are prevalent. At present, there are no known specific RET inhibitors in clinical development, although many potent inhibitors of RET have been opportunistically identified through selectivity profiling of compounds initially designed to target other tyrosine kinases. Vandetanib and cabozantinib, both multi-kinase inhibitors with RET activity, are approved for use in medullary thyroid carcinoma, but additional pharmacological activities, most notably inhibition of vascular endothelial growth factor - VEGFR2 (KDR), lead to dose-limiting toxicity. The recent identification of RET fusions present in ~1% of lung adenocarcinoma patients has renewed interest in the identification and development of more selective RET inhibitors lacking the toxicities associated with the current treatments. In an earlier publication [Newton et al, 2016; 1] we reported the discovery of a series of 2-substituted phenol quinazolines as potent and selective RET kinase inhibitors. Here we describe the development of the robust screening cascade which allowed the identification and advancement of this chemical series. Furthermore we have profiled a panel of RET-active clinical compounds both to validate the cascade and to confirm that none display a RET-selective target profile. ",
        "Doc_title":"Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade.",
        "Journal":"F1000Research",
        "Do_id":"27429741",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605895402888888320},
      {
        "Doc_abstract":"The variety of diseases caused by mutations in RET receptor tyrosine kinase provides a classic example of phenotypic heterogeneity. Gain-of-function mutations of RET are associated with human cancer. Gene rearrangements juxtaposing the tyrosine kinase domain to heterologous gene partners have been found in sporadic papillary carcinomas of the thyroid (PTC). These rearrangements generate chimeric RET/PTC oncogenes. In the germline, point mutations of RET are responsible for multiple endocrine neoplasia type 2 (MEN 2A and 2B) and familial medullary thyroid carcinoma (FMTC). Both MEN 2 mutations and PTC gene rearrangements potentiate the intrinsic tyrosine kinase activity of RET and, ultimately, activate the RET downstream targets. Loss-of-function mutations of RET cause Hirschsprung's disease (HSCR) or colonic aganglionosis. A deeper understanding of the molecular signaling of normal versus abnormal RET activity in cancer will enable the development of potential new treatments for patients with sporadic and inherited thyroid cancer or MEN 2 syndrome. We now review the role and mechanisms of RET signaling in development and carcinogenesis.",
        "Doc_title":"RET tyrosine kinase signaling in development and cancer.",
        "Journal":"Cytokine & growth factor reviews",
        "Do_id":"15982921",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Hirschsprung Disease;Humans;Mutation;Neoplasms;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Signal Transduction;Thyroid Neoplasms",
        "Doc_meshqualifiers":"enzymology;genetics;enzymology;genetics;metabolism;genetics;physiology;genetics;physiology;physiology;genetics;metabolism",
        "_version_":1605875130582433793},
      {
        "Doc_abstract":"Medullary thyroid cancer is a rare, neuroendocrine, tumor. It arises from parafollicular or C-cells with the ability to produce and secrete different bioactive substances like calcitonin (TC) and CEA (1-5) TC is ideal tumor marker in early diagnosis, in patents' follow up and in evaluation of their treatment. TC determinations after ca/pentagastrine stimulation test give us even more accurate results and the procedure is used for biochemical family screening. MTC occurs as a sporadic tumor or in hereditary settings MEN 2A, MEN 2B and FMCT. Germ/line point mutations in RET proto/onkogene are responsible for tumor arise and inheritance of settings. Genetic screening provides information of these RET mutations in family members even before pathologic changes occur. These individuals with MEN 2A, 2B and FMCT characteristic RET mutations are almost certain to acquire MTC (95% penetrance) in their lives and are candidates for preventive total thyroidectomy (TT), with or without central neck dissection (CND). Surgery is still the treatment of choice for MTC and only C-cell hyperplasia and early stage of MTC can be cured. Prophylactic thyroid surgery eliminates the possibility of MTC but doesn't influence appearance of other diseases (PHEO, HPTH) of MEN 2 syndromes.",
        "Doc_title":"Medullary thyroid carcinoma. Genetic screening and prophylactic thyroidectomies.",
        "Journal":"Acta chirurgica Iugoslavica",
        "Do_id":"15179767",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Carcinoma, Medullary;Child;Female;Genetic Predisposition to Disease;Genetic Testing;Germ-Line Mutation;Humans;Male;Middle Aged;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"diagnosis;genetics;prevention & control;genetics;genetics;diagnosis;genetics;prevention & control",
        "_version_":1605794735425847296},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) accounts only for 1.4% of all thyroid malignancies in Japan. Since 1996, we have performed hemithyroidectomy, instead of total thyroidectomy, for sporadic nonhereditary MTC when the primary lesion is located in only one lobe. Regarding lymph node dissection, modified radical neck dissection (MND) at least ipsilateral to the tumor has been routinely performed, even if there is no clinically apparent metastasis. We investigated the clinical outcomes of MTC patients in our department.;A series of 118 patients with MTC who underwent initial surgery between 1975 and 2005 were enrolled in this study. The RET gene mutations were analyzed for all patients and 46 had germline RET gene mutations. Of those 46 patients, 26 were diagnosed as MEN 2A and 2 were diagnosed as MEN 2B. Postoperative follow-up periods averaged 141 months.;Of 115 patients who did not have distant metastasis at surgery and who underwent locally curative surgery, 78 (67.8%) were biochemically cured. All patients without pathological lymph node metastasis were biochemically cured, and 44.8% of patients with node metastasis were also biochemically cured. The 10-year and 20-year disease-free survival rates were 89.0% and 82.5%, respectively. None of the patients who did not show lymph node metastasis and only 2 (2.6%) of 78 patients who were biochemically cured showed clinically apparent carcinoma recurrence. The 10-year and 20-year cause-specific survival rates were 96.6% and 91.7%, respectively. Lymph node metastasis, tumor size>4 cm, extrathyroid and extranodal tumor extensions significantly affected cause-specific survival of patients.;Clinical outcomes of MTC patients in our series were better than those in Western countries, a result that might have resulted in part because of our routine MND regardless of whether clinically apparent node metastasis was detected.",
        "Doc_title":"Alternative surgical strategies and favorable outcomes in patients with medullary thyroid carcinoma in Japan: experience of a single institution.",
        "Journal":"World journal of surgery",
        "Do_id":"19005720",
        "Doc_ChemicalList":"Receptors, Cell Surface;carcinoembryonic antigen binding protein, human;Calcitonin;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Calcitonin;Carcinoma, Medullary;Disease-Free Survival;Female;Humans;Japan;Longitudinal Studies;Lymph Nodes;Male;Middle Aged;Neck Dissection;Neoplasm Recurrence, Local;Proto-Oncogene Proteins c-ret;Receptors, Cell Surface;Survival Rate;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome",
        "Doc_meshqualifiers":"blood;epidemiology;genetics;surgery;epidemiology;surgery;genetics;blood;epidemiology;genetics;surgery;methods",
        "_version_":1605753304852201472},
      {
        "Doc_abstract":"Mutations in REarranged during Transfection (RET) receptor tyrosine, followed by the oncogenic activation of RET kinase is responsible for the development of medullary thyroid carcinoma (MTC) that responds poorly to conventional chemotherapy. Targeting RET, therefore, might be useful in tailoring surveillance of MTC patients. Here we showed that theaflavins, the bioactive components of black tea, successfully induced apoptosis in human MTC cell line, TT, by inversely modulating two molecular pathways: (i) stalling PI3K/Akt/Bad pathway that resulted in mitochondrial transmembrane potential (MTP) loss, cytochrome-c release and activation of the executioner caspases-9 and -3, and (ii) upholding p38MAPK/caspase-8/caspase-3 pathway via inhibition of Ras/Raf/ERK. Over-expression of either constitutively active myristoylated-Akt-cDNA (Myr-Akt-cDNA) or dominant-negative-caspase-8-cDNA (Dn-caspase-8-cDNA) partially blocked theaflavin-induced apoptosis, while co-transfection of Myr-Akt-cDNA and Dn-caspase-8-cDNA completely eradicated the effect of theaflavins thereby negating the possibility of existence of other pathways. A search for the upstream signaling revealed that theaflavin-induced disruption of lipid raft caused interference in anchorage of RET in lipid raft that in turn stalled phosphorylation of Ras and PI3Kinase. In such anti-survival cellular micro-environment, pro-apoptotic signals were triggered to culminate into programmed death of MTC cell. These findings not only unveil a hitherto unexplained mechanism underlying theaflavin-induced MTC death, but also validate RET as a promising and potential target for MTC therapy.",
        "Doc_title":"Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways.",
        "Journal":"Apoptosis : an international journal on programmed cell death",
        "Do_id":"23329180",
        "Doc_ChemicalList":"Antineoplastic Agents, Phytogenic;BAD protein, human;Biflavonoids;DNA, Complementary;bcl-Associated Death Protein;theaflavin;Catechin;Cytochromes c;Phosphatidylinositol 3-Kinases;Proto-Oncogene Proteins c-ret;RET protein, human;Proto-Oncogene Proteins c-akt;p38 Mitogen-Activated Protein Kinases;Caspase 8;Oncogene Protein p21(ras)",
        "Doc_meshdescriptors":"Antineoplastic Agents, Phytogenic;Apoptosis;Biflavonoids;Carcinoma, Neuroendocrine;Caspase 8;Catechin;Cell Line, Tumor;Cytochromes c;DNA, Complementary;Gene Expression Regulation, Neoplastic;Humans;Membrane Microdomains;Membrane Potential, Mitochondrial;Mitochondria;Oncogene Protein p21(ras);Phosphatidylinositol 3-Kinases;Proto-Oncogene Proteins c-akt;Proto-Oncogene Proteins c-ret;Signal Transduction;Thyroid Neoplasms;Transfection;bcl-Associated Death Protein;p38 Mitogen-Activated Protein Kinases",
        "Doc_meshqualifiers":"pharmacology;pharmacology;genetics;metabolism;pharmacology;metabolism;drug effects;drug effects;drug effects;drug effects;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;genetics;metabolism;drug effects;genetics;metabolism;pathology;genetics;metabolism;genetics;metabolism",
        "_version_":1605746423903551490},
      {
        "Doc_abstract":"The REarranged during Transfection (RET) proto-oncogene and its activated signalling pathways have been shown to play an important role in cancer. RET genetic alterations including germline, somatic mutations and gene rearrangements have been demonstrated in several solid tumours, and numerous clinical trials using multikinase inhibitors containing RET as a target have shown significant activity against RET. Sorafenib and sunitinib have been approved for the treatment of renal, hepatocellular, gastrointestinal and pancreatic neuoendocrine carcinomas. Vandetanib has recently been approved for the treatment of unresectable locally advanced or metastatic medullary thyroid carcinomas. Novel genomic rearrangements and RET signalling interactions are now being studied in a variety of tumours and will provide the basis for new therapeutic strategies. Combination or sequential targeted therapies that are based on solid preclinical data regarding the inhibition of RET-mediated parallel or different -signalling pathways will likely be more effective.",
        "Doc_title":"Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.",
        "Journal":"Current pharmaceutical design",
        "Do_id":"22973956",
        "Doc_ChemicalList":"Antineoplastic Agents;Indoles;Phenylurea Compounds;Piperidines;Pyrroles;Quinazolines;Niacinamide;sorafenib;Proto-Oncogene Proteins c-ret;sunitinib;N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Drug Design;Humans;Indoles;Molecular Targeted Therapy;Neoplasms;Niacinamide;Phenylurea Compounds;Piperidines;Proto-Oncogene Proteins c-ret;Pyrroles;Quinazolines;Signal Transduction",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug therapy;genetics;pathology;analogs & derivatives;pharmacology;pharmacology;pharmacology;genetics;metabolism;pharmacology;pharmacology;drug effects",
        "_version_":1605842087566114816},
      {
        "Doc_abstract":"Evidence that germline mutations in the RET proto-oncogene are the underlying cause of the familial form of medullary thyroid carcinoma (MTC) made it possible to identify gene carriers with a very high degree of accuracy. Aiming to define the mutational profile observed in our patients and to assess gene carriers' compliance with an early surgery, we reviewed results of molecular analysis of RET performed at our institution since 1994.;One hundred fifty-eight individuals were screened for germline mutations of the RET proto-oncogene. Seventy-seven patients had apparently sporadic MTC; 8 patients had both MTC and pheochromocytoma or MTC and clinical features of multiple endocrine neoplasia type 2B despite a negative family history; 8 patients were known to belong to affected kindreds; and 65 individuals were at-risk individuals to develop MTC.;A germline mutation in RET was identified in 4% of apparently sporadic MTC patients, in 100% of patients with MTC and pheochromocytoma or MTC and clinical features of multiple endocrine neoplasia type 2B, and in 100% of probands of clinically established kindreds. The most affected codon was 634 (58%) followed by codon 804 (16%). Among at-risk individuals, 49% were identified as gene carriers. Seven individuals were submitted to prophylactic thyroidectomy (mean age, 17.7 +/- 12.5 years; range: 3-42 years), and all but 1 had MTC.;RET mutational spectrum observed in the present population disclosed a higher frequency of codon 804 mutations than expected. Compliance with an early prophylactic surgery seemed to be influenced not only by medical advice and cultural factors but also by the aggressiveness of disease in gene carriers' families.",
        "Doc_title":"Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre.",
        "Journal":"Surgery",
        "Do_id":"17188172",
        "Doc_ChemicalList":"DNA, Neoplasm;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Adrenal Gland Neoplasms;Adult;Base Sequence;Cancer Care Facilities;Carcinoma, Medullary;Child;Child, Preschool;DNA Mutational Analysis;DNA, Neoplasm;Female;Germ-Line Mutation;Heterozygote Detection;Humans;Male;Multiple Endocrine Neoplasia Type 2b;Pheochromocytoma;Portugal;Proto-Oncogene Proteins c-ret;Proto-Oncogenes;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"genetics;genetics;prevention & control;genetics;genetics;genetics;genetics;genetics;prevention & control",
        "_version_":1605826788160700416},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant disease characterized by the presence of medullary thyroid carcinoma, primary hyperparathyroidism, and pheochromocytoma. Multiple endocrine neoplasia type 2 is still an underdiagnosed, or late-diagnosed condition in many areas of the world. Since 1993, when the first missense RET proto-oncogene (RET) mutations were reported in MEN2, up to 46 different RET-causing disease mutations have been described. Since a strong genotype-phenotype correlation exists for MEN2, the detection of RET mutations has produced a major impact in early recognition and treatment of MTC and MEN2. Presently, RET mutation analysis should be performed for all MEN2 cases and their at-risk familial relatives. Further, prophylactic total thyroidectomy is indicated in all cases harboring activating gametic RET mutations. In most RET mutation carriers, prophylactic total thyroidectomy is indicated at ages as early as a few months to 4 years of age, promoting longer survival and improvement of quality of life or even definitive cure. We discuss the large impact of RET proto-oncogene analysis on the clinical management of MEN2 and the role of early RET molecular DNA diagnosis in providing clinicians and surgeons with valuable information that enables them to indicate early total thyroidectomy.",
        "Doc_title":"Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2.",
        "Journal":"Clinics (Sao Paulo, Brazil)",
        "Do_id":"16532227",
        "Doc_ChemicalList":"Genetic Markers;Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Genetic Markers;Genetic Testing;Genotype;Humans;Multiple Endocrine Neoplasia Type 2a;Phenotype;Pheochromocytoma;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"genetics;surgery;genetics;surgery;genetics;surgery;genetics;genetics;surgery",
        "_version_":1605741947869200384},
      {
        "Doc_abstract":"Current surgical standard of care in sporadic medullary thyroid carcinoma (sMTC) consists of a minimum of total thyroidectomy with central neck dissection. Some have suggested thyroid lobectomy with isthmusectomy and central neck dissection for patients with sMTC, given their lower frequency of bilateral disease, although this topic has not been thoroughly studied. This study assessed the prevalence of multifocality in sMTC via a large international multi-institutional retrospective review to quantify this prevalence, including the impact of geography, to assess more accurately the risks associated with alternative surgical approaches.;A retrospective chart review of sMTC patients from 11 institutions over 29 years (1983-2011) was undertaken. Data regarding focality, extent of disease, RET germline analysis plus family and clinical history for multiple endocrine neoplasia type 2 (MEN2), and demographic data were collected and analyzed.;Patients from four continents and seven countries were included in the sample. Data for 313 patients with documented sMTC were collected. Of these, 81.2% were confirmed with negative RET germline testing, while the remaining 18.8% demonstrated a negative family history and no manifestations of MEN2 syndromes other than MTC. Bilateral disease was identified in 17/306 (5.6%) patients, while multifocal disease was noted in 50/312 (16.0%) sMTC patients. When only accounting for germline negative patients, these rates were not significantly different (5.6% and 17%, respectively). Among them, when disease was unifocal in the ipsilateral lobe and isthmus, bilateral disease was present in 6/212 (2.8%) cases. When disease was multifocal in the ipsilateral lobe or isthmus, then bilateral disease was present in 8/37 (21.6%) cases (p<0.001). No geographic differences in focality were identified.;The 5.6% prevalence of bilateral foci in sMTC suggests that total thyroidectomy should remain the standard of care for initial surgery, as less complete thyroid surgery may fail to address fully the primary site of disease. Whether ipsilateral tumor focality should be an independent factor determining the need for completion thyroidectomy when sMTC is diagnosed after hemithyroidectomy remains to be determined.",
        "Doc_title":"Multifocality in Sporadic Medullary Thyroid Carcinoma: An International Multicenter Study.",
        "Journal":"Thyroid : official journal of the American Thyroid Association",
        "Do_id":"27604949",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605839696456318976},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 is characterized by germline mutations in RET. For exon 10, comprehensive molecular and corresponding phenotypic data are scarce. The International RET Exon 10 Consortium, comprising 27 centers from 15 countries, analyzed patients with RET exon 10 mutations for clinical-risk profiles. Presentation, age-dependent penetrance, and stage at presentation of medullary thyroid carcinoma (MTC), pheochromocytoma, and hyperparathyroidism were studied. A total of 340 subjects from 103 families, age 4-86, were registered. There were 21 distinct single nucleotide germline mutations located in codons 609 (45 subjects), 611 (50), 618 (94), and 620 (151). MTC was present in 263 registrants, pheochromocytoma in 54, and hyperparathyroidism in 8 subjects. Of the patients with MTC, 53% were detected when asymptomatic, and among those with pheochromocytoma, 54%. Penetrance for MTC was 4% by age 10, 25% by 25, and 80% by 50. Codon-associated penetrance by age 50 ranged from 60% (codon 611) to 86% (620). More advanced stage and increasing risk of metastases correlated with mutation in codon position (609620) near the juxtamembrane domain. Our data provide rigorous bases for timing of premorbid diagnosis and personalized treatment/prophylactic procedure decisions depending on specific RET exon 10 codons affected.",
        "Doc_title":"Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10.",
        "Journal":"Human mutation",
        "Do_id":"20979234",
        "Doc_ChemicalList":"Codon;Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Adolescent;Adrenal Gland Neoplasms;Adult;Aged;Aged, 80 and over;Carcinoma, Neuroendocrine;Child;Child, Preschool;Codon;Exons;Female;Germ-Line Mutation;Humans;Hyperparathyroidism;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Neoplasm Staging;Penetrance;Pheochromocytoma;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms;Young Adult",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;genetics;pathology;genetics;pathology;genetics;pathology;genetics;metabolism;genetics;pathology",
        "_version_":1605797183515262976},
      {
        "Doc_abstract":"Persistent RET activation is a frequent event in papillary thyroid carcinoma (PTC) and medullary thyroid carcinoma (MTC). In these cancers, RET activates the ERK/MAPK, the PI3K/AKT/mTOR and the JAK/STAT3 pathways. Here, we tested the efficacy of a JAK1/2- inhibitor, AZD1480, in the in vitro and in vivo growth of thyroid cancer cell lines expressing oncogenic RET. Thyroid cancer cell lines harboring RET/PTC1 (TPC-1), RET M918T (MZ-CRC1) and RET C634W (TT) alterations, as well as TPC-1 xenografts, were treated with JAK inhibitor, AZD1480. This inhibitor led to growth inhibition and/or apoptosis of the thyroid cancer cell lines in vitro, as well as to tumor regression of TPC-1 xenografts, where it efficiently blocked STAT3 activation in tumor and stromal cells. This inhibition was associated with decreased proliferation, decreased blood vessel density, coupled with increased necrosis. However, AZD1480 repressed the growth of STAT3- deficient TPC-1 cells in vitro and in vivo, demonstrating that its effects in this cell line were independent of STAT3 in the tumor cells. In all cell lines, the JAK inhibitor reduced phospho-Y1062 RET levels, and mTOR effector phospho-S6, while JAK1/2 downregulation by siRNA did not affect cell growth nor RET and S6 activation. In conclusion, AZD1480 effectively blocks proliferation and tumor growth of activated RET- thyroid cancer cell lines, likely through direct RET inhibition in cancer cells as well as by modulation of the microenvironment (e.g. via JAK/phospho-STAT3 inhibition in endothelial cells). Thus, AZD1480 should be considered as a therapeutic agent for the treatment of RET- activated thyroid cancers.",
        "Doc_title":"AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.",
        "Journal":"PloS one",
        "Do_id":"23056499",
        "Doc_ChemicalList":"AZD 1480;Protein Kinase Inhibitors;Pyrazoles;Pyrimidines;Tyrosine;Phosphatidylinositol 3-Kinases;TOR Serine-Threonine Kinases;Proto-Oncogene Proteins c-ret;RET protein, human;Proto-Oncogene Proteins c-akt",
        "Doc_meshdescriptors":"Animals;Cell Line, Tumor;Cell Proliferation;Enzyme Activation;Female;Humans;Mice;Phosphatidylinositol 3-Kinases;Phosphorylation;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-akt;Proto-Oncogene Proteins c-ret;Pyrazoles;Pyrimidines;Signal Transduction;TOR Serine-Threonine Kinases;Thyroid Neoplasms;Tyrosine;Xenograft Model Antitumor Assays",
        "Doc_meshqualifiers":"drug effects;drug effects;metabolism;drug effects;pharmacology;metabolism;chemistry;metabolism;pharmacology;pharmacology;drug effects;metabolism;pathology;metabolism",
        "_version_":1605806465910571008},
      {
        "Doc_abstract":"Multiple endocrine neoplasia (MEN) type 2, a cancer syndrome inherited in the dominant fashion, is defined by the occurrence of medullary thyroid carcinoma (MTC), either as a singular lesion (familial medullary thyroid carcinoma, FMTC) or with the variable expression of pheochromocytoma, hyperparathyroidism (MEN 2A), ganglioneuromas, buccal neuromas and Marfanoid-like phenotype (MEN 2B).;Germline mutations of the RET proto-oncogene, localized on chromosome 10q11.2, have been identified as the underlying genetic cause of the disorder. In the majority of patients with MEN 2A/FMTC missense mutations at exon 10 or exon 11 are identifiable. Cysteine to arginine exchange at codon 634 is the mutation most frequently found. In MEN 2B approximately 95% of patients present with a mutation at codon 918 (exon 16). Additionally, less frequent mutations in other codons have been found in both syndromes. The DNA-based genotype analysis enables the identification of gene carriers at risk of developing MTC and offer them prophylactic thyroidectomy prior to development of any thyroid pathologies. Prophylactic surgery is generally recommended for MEN 2A/FMTC gene carriers at the age of 4-6 years. Due to the aggressiveness of the MEN 2B syndrome gene carriers should be operated by the age of 1 year. Presumably some less virulent mutations allow postponement of the prophylactic treatment to the second to fourth decade of life.;Compared to standard presymptomatic biochemical screening, genetic testing and consecutive prophylactic treatment contribute to better outcome of individuals at risk for MTC.",
        "Doc_title":"Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET proto-oncogene.",
        "Journal":"Langenbeck's archives of surgery",
        "Do_id":"12690476",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Genotype;Humans;Lymphatic Metastasis;Multiple Endocrine Neoplasia;Phenotype;Phosphorylation;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Signal Transduction;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;prevention & control",
        "_version_":1605750916524277760},
      {
        "Doc_abstract":"Inhibitors of RET, a tyrosine kinase receptor encoded by a gene that is frequently mutated in medullary thyroid cancer, have emerged as promising novel therapies for the disease. Rapalogs and other mammalian target of rapamycin (mTOR) inhibitors are effective agents in patients with gastroenteropancreatic neuroendocrine tumors, which share lineage properties with medullary thyroid carcinomas. The objective of this study was to investigate the contribution of mTOR activity to RET-induced signaling and cell growth and to establish whether growth suppression is enhanced by co-targeting RET and mTOR kinase activities. Treatment of the RET mutant cell lines TT, TPC-1, and MZ-CRC-1 with AST487, a RET kinase inhibitor, suppressed growth and showed profound and sustained inhibition of mTOR signaling, which was recapitulated by siRNA-mediated RET knockdown. Inhibition of mTOR with INK128, a dual mTORC1 and mTORC2 kinase inhibitor, also resulted in marked growth suppression to levels similar to those seen with RET blockade. Moreover, combined treatment with AST487 and INK128 at low concentrations suppressed growth and induced apoptosis. These data establish mTOR as a key mediator of RET-mediated cell growth in thyroid cancer cells and provide a rationale for combinatorial treatments in thyroid cancers with oncogenic RET mutations.",
        "Doc_title":"Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.",
        "Journal":"Endocrine-related cancer",
        "Do_id":"23828865",
        "Doc_ChemicalList":"Benzoxazoles;Carbanilides;INK128;NVP-AST487;Protein Kinase Inhibitors;Pyrimidines;RNA, Small Interfering;MTOR protein, human;TOR Serine-Threonine Kinases;Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Animals;Benzoxazoles;Carbanilides;Cell Line, Tumor;Cell Proliferation;Humans;Mice;Mice, Transgenic;Mutation;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-ret;Pyrimidines;RNA, Small Interfering;TOR Serine-Threonine Kinases;Thyroid Neoplasms",
        "Doc_meshqualifiers":"pharmacology;pharmacology;drug effects;pharmacology;antagonists & inhibitors;genetics;metabolism;pharmacology;genetics;antagonists & inhibitors;metabolism;drug therapy;metabolism",
        "_version_":1605883855937470464},
      {
        "Doc_abstract":"Medullary thyroid cancer (MTC) accounts for 5% to 10% of all thyroid cancers. The high frequency of familial cases mandates screening and genetic testing. The aggressiveness and age of onset of familial MTC differs depending on the specific genetic mutation, and this should determine the timing and extent of surgery. Sporadic MTC can present at any age, and it is usually associated with a palpable mass and the presence of nodal metastases. Surgery is standard treatment for any patient presenting with resectable MTC. Further studies are needed to investigate the role of radiation therapy in the palliation and local control of postresection and advanced-stage MTC. New systemic therapies for metastatic disease are being investigated. Targeted molecular therapies, based on knowledge of the pathways affected by RET mutations, are being tested in multiple clinical trials.",
        "Doc_title":"Sporadic and familial medullary thyroid carcinoma: state of the art.",
        "Journal":"The Surgical clinics of North America",
        "Do_id":"19836492",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma, Medullary;Combined Modality Therapy;Diagnosis, Differential;Diagnostic Imaging;Genetic Predisposition to Disease;Genotype;Humans;Multiple Endocrine Neoplasia Type 2a;Multiple Endocrine Neoplasia Type 2b;Phenotype;Prognosis;Thyroid Neoplasms",
        "Doc_meshqualifiers":"analysis;diagnosis;genetics;therapy;diagnosis;genetics;therapy;diagnosis;genetics;therapy;diagnosis;genetics;therapy",
        "_version_":1605795075484286976},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 and a subset of apparently sporadic medullary thyroid carcinoma (AS-MTC) are caused by germ line activating point mutations of the rearranged during transfection (RET) proto-oncogene. RET encodes a receptor with tyrosine kinase activity that targets several intracellular signaling cascades, such as RAS-RAF-ERK1/2, PIK3-AKT, and STAT transcription factors. The objective of this study was to assess the function of three germ line RET variants Arg886Trp, Ser649Leu, and Glu511Lys of undetermined pathogenic significance, which were found in three kindreds of isolated AS-MTC. For this purpose, we employed vectors expressing each of the RET variants and measured the number of NIH3T3 transformation foci and soft agar colonies, the degree of activation of known RET intracellular signaling targets (ERK1/2, STAT1, STAT3, and TCF4), and the extent of ERK1/2 inhibition on sorafenib treatment. We found that RET variants Arg886Trp and Glu511Lys have shown increased in vitro transforming potential in a glial-derived neurotrophic factor-dependent manner. In contrast, the Ser649Leu variant did not significantly increased the number of foci and agar colonies relative to wild-type RET (RET-WT). The variants Glu511Lys and Arg886Trp showed 10- and 12.5-fold ERK1/2 activation respectively, that was significantly higher than that observed for RET-WT (fivefold). Increased levels of STAT1 and TCF4 activation were only observed for RET Arg886Trp (2.5- and 3-fold versus 1.2- and 2-fold in RET-WT respectively). The three RET variants analyzed here were sensitive to treatment with sorafenib. In conclusion, our results allow to classify previously uncharacterized RET genotypes, which may be of use to define follow-up and therapeutic regimens.",
        "Doc_title":"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",
        "Journal":"Endocrine-related cancer",
        "Do_id":"21551259",
        "Doc_ChemicalList":"Basic Helix-Loop-Helix Leucine Zipper Transcription Factors;Benzenesulfonates;Phenylurea Compounds;Protein Kinase Inhibitors;Pyridines;STAT3 Transcription Factor;TCF4 protein, human;Transcription Factors;Niacinamide;sorafenib;Luciferases;Proto-Oncogene Proteins c-ret;RET protein, human;Proto-Oncogene Proteins c-akt;MAPK1 protein, human;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3",
        "Doc_meshdescriptors":"Adult;Aged;Animals;Basic Helix-Loop-Helix Leucine Zipper Transcription Factors;Benzenesulfonates;Blotting, Western;Carcinoma, Medullary;Case-Control Studies;Cell Transformation, Neoplastic;Cells, Cultured;Female;Germ-Line Mutation;Humans;Kidney;Luciferases;Male;Mice;Middle Aged;Mitogen-Activated Protein Kinase 1;Mitogen-Activated Protein Kinase 3;Mutagenesis, Site-Directed;NIH 3T3 Cells;Niacinamide;Pedigree;Phenylurea Compounds;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-akt;Proto-Oncogene Proteins c-ret;Pyridines;STAT3 Transcription Factor;Signal Transduction;Thyroid Neoplasms;Transcription Factors;Young Adult",
        "Doc_meshqualifiers":"metabolism;pharmacology;genetics;metabolism;genetics;cytology;drug effects;metabolism;metabolism;metabolism;metabolism;analogs & derivatives;pharmacology;metabolism;genetics;metabolism;pharmacology;metabolism;genetics;metabolism;metabolism",
        "_version_":1605896730536050688},
      {
        "Doc_abstract":"Thyroid tumors are the most common endocrine malignancy. The main genetic changes are point mutations in the RET proto-oncogene (somatic or germ-line) in medullary thyroid carcinoma and point mutations in BRAF and RAS genes or RET/PTC rearrangements in carcinomas developing from follicular cells. Moleculargenetic diagnosis of RET mutations in patients with medullary thyroid carcinoma and their relatives is now the part of clinical approach. Currently, knowledge about genetic causes of thyroid tumors has begun applying into target gene therapy providing new therapeutic drugs and more individualized treatment. This review summarizes main genetic causes of thyroid tumors and their application in target gene therapy.",
        "Doc_title":"[Thyroid tumors--moleculargenetic causes and choices for target therapy].",
        "Journal":"Casopis lekaru ceskych",
        "Do_id":"22679698",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Humans;Molecular Targeted Therapy;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;therapy",
        "_version_":1605820877335691264},
      {
        "Doc_abstract":"The occurrence of papillary thyroid carcinoma in patients with RET germline mutations has been described in only eight cases since 1993. We report three women with a RET germline mutation in exon 13 and 14, affecting codon 790, 791, and 804, respectively, who underwent prophylactic thyroidectomy at the age of 29, 39, and 24 years, respectively. Histologic examination revealed C-cell hyperplasia and a small medullary thyroid carcinoma in the first patient and no pathologic changes of the C-cells in either of the other patients. However, all patients had papillary thyroid carcinoma (PTC). Concerning the frequency of PTC in patients with RET germline mutations who underwent surgery at our center (n = 104), it was found in 9.1% of all patients with RET mutation in codon 790, 791, and 804 (n = 33) but in none of the 104 patients with RET germline mutations not affecting codon 790, 791, or 804 (p = 0.0015). Our data and the data from the literature suggest a possible pathogenesis of PTC caused by exon 13 and 14 RET mutations that affect the intracellular domain of the encoded protein. Further investigation is necessary to confirm a potential pathogenetic role of exon 13 and 14 RET mutations with regard to the development of PTC.",
        "Doc_title":"Papillary thyroid carcinoma in patients with RET proto-oncogene germline mutation.",
        "Journal":"Thyroid : official journal of the American Thyroid Association",
        "Do_id":"12193298",
        "Doc_ChemicalList":"Drosophila Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Adolescent;Adult;Carcinoma, Papillary;Child;Drosophila Proteins;Female;Germ-Line Mutation;Humans;Male;Middle Aged;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics",
        "_version_":1605846419841744896},
      {
        "Doc_abstract":"When mutations of the RETproto-oncogene were found in 1993 to account for hereditary medullary thyroid carcinoma (MTC), surgeons obtained the opportunity to operate on patients prophylactically (i. e., at a clinically asymptomatic stage). Whether this approach is justified, and, if so, when and to which extent surgery should be performed remained to be clarified. A questionnaire was sent to all surgical departments in Germany and Austria. All of the patients who fulfilled the following criteria were enrolled: (1) preoperatively proved RET mutation; (2) age </= 20 years, (3) clinically asymptomatic thyroid C cell disease; and (4) TNM classification pT0-1/pNX/pN0-1/M0. Seventy-five patients were identified, and fifteen mutations were detected in six codons. Two adolescents had unilateral pheochromocytomas as part of the multiple endocrine neoplasia II (MEN-II) syndrome. No hyperparathyroidism was noted. All patients underwent total thyroidectomy, and 57 patients went on to have lymph node dissection. Parathyroid glands were removed in 34 patients and autografted in 11. Histopathology revealed MTC in 46 patients (61%, youngest 4 years); C cell hyperplasia (CCH) only was detected in the other 29 patients. Three patients had lymph node metastases (LNMs) the youngest being age 14 years. Calcitonin levels were not useful for differentiating between CCH and MTC, but in all patients with LNMs at least the stimulated calcitonin levels were assayed. After surgery, five patients (6.7%) sustained permanent hypoparathyroidism, and one patient (1.3%) had a permanent unilateral recurrent nerve palsy. All but three patients (96%) were biochemically cured. In conclusion, prophylactic total thyroidectomy can be performed safely in experienced centers. We recommend prophylactic total thyroidectomy at age 6. Cervicocentral lymph node dissection should be included when calcitonin levels are elevated or if patients are older than 10 years. Bilateral lymph node dissection should be performed if LNMs are suspected or when patients with elevated calcitonin are older than 15 years.",
        "Doc_title":"Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience.",
        "Journal":"World journal of surgery",
        "Do_id":"9606292",
        "Doc_ChemicalList":"Calcitonin",
        "Doc_meshdescriptors":"Adolescent;Adult;Austria;Calcitonin;Carcinoma, Medullary;Child;Child, Preschool;Female;Germany;Humans;Male;Neoplastic Syndromes, Hereditary;Thyroidectomy",
        "Doc_meshqualifiers":"blood;genetics;prevention & control;pathology",
        "_version_":1605756795968552960},
      {
        "Doc_abstract":"All patients with a thyroid nodule should have their plasma CT measured. Stimulated CT is generally better than basal, but in the lower ranges false negatives and false positives still occur. In families with hereditary MTC, RET gene mutation analysis has superseded measurement of plasma CT in the detection of asymptomatic disease gene carriers. All individuals with apparently sporadic MTC, but in whom there is some suspicion of familial disease, should also have RET genetic analysis. A negative DNA result practically excludes the possibility of hereditary MTC in families where an index case has been investigated and obviates the need for further biochemical evaluation. Disease gene carriers may be divided into three distinct risk groups depending on the specific RET gene mutation in the family. The age at which presymptomatic surgery has to be performed depends on the risk group to which the patient belongs. Compared with the results of DNA analysis, the results of CT stimulation tests have become less important in the assessment of timing of surgery. During follow-up of patients who underwent surgery, measurement of plasma basal CT is still useful. The high sensitivity of measuring stimulated CT levels does not outweigh the burden of life-long periodic stimulation tests and the limited clinical consequences of slightly elevated levels. Stimulation tests are inevitable for persons at risk who prefer not to have genetic testing.",
        "Doc_title":"Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement.",
        "Journal":"Annals of clinical biochemistry",
        "Do_id":"11392493",
        "Doc_ChemicalList":"Drosophila Proteins;Proto-Oncogene Proteins;Calcitonin;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Calcitonin;Carcinoma;Drosophila Proteins;Exons;Female;Genetic Testing;Genotype;Humans;Introns;Male;Models, Genetic;Phenotype;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Sensitivity and Specificity;Sex Factors;Thyroid Neoplasms",
        "Doc_meshqualifiers":"biosynthesis;genetics;diagnosis;genetics;therapy;biosynthesis;biosynthesis;diagnosis;genetics;therapy",
        "_version_":1605908502543335424},
      {
        "Doc_abstract":"RET (Rearranged during Transfection) is a transmembrane tyrosine kinase expressed in central and peripheral nervous system and neural crest-derived cells and acts as a co-receptor of GDNF family neurotrophic factor in complex with GRF family proteins. RET protein comprises an extracellular portion with four cadherine-like domains and a cysteine- rich region important for intermolecular interactions; a hydrophobic transmembrane domain; an intracellular part comprising the juxtamembrane domain with regulatory function and the catalytic domain that phosphorylates the tyrosine residues of substrates. RET is involved in the development of enteric nervous system and renal organogenesis during embryonic life. Mutations of RET are associated to a subset of colorectal cancer and are commonly found in hereditary and sporadic thyroid cancer. Activating point mutations in the cystein-rich or the kinase domain of RET cause multiple endocrine neoplasia type 2 (MEN2), a group of familial cancer syndromes characterized by medullary thyroid carcinoma, pheochromocytoma, parathyroid hyperplasia and ganglioneuromatosis of the gastroenteric mucosa. Rearranged forms of RET (termed RET/PTC) are detected in the majority of papillary thyroid carcinomas (PTC). At present, the therapeutic treatment available for these pathologies is the total or partial surgical removal of thyroid, associated with radio-iodine therapy or chemotherapy: despite widespread use of multimodality treatment, survival rates have not improved much in the past few decades, which suggests that new treatment options should be explored. Several small-molecule inhibitors of RET kinase activity have been described in the last decade, some of which are currently undergoing clinical evaluation. Here, I review the large preclinical effort to the development of specific RET inhibitors, including medicinal chemistry analyses that may help refine potency and selectivity of future RET-targeted inhibitors.",
        "Doc_title":"Development of RET kinase inhibitors for targeted cancer therapy.",
        "Journal":"Current medicinal chemistry",
        "Do_id":"21110809",
        "Doc_ChemicalList":"Antineoplastic Agents;Indoles;Protein Kinase Inhibitors;Pyrimidines;Quinazolines;Urea;Proto-Oncogene Proteins c-ret;Staurosporine",
        "Doc_meshdescriptors":"Antineoplastic Agents;Humans;Indoles;Neoplasms;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-ret;Pyrimidines;Quinazolines;Staurosporine;Urea",
        "Doc_meshqualifiers":"chemistry;therapeutic use;chemistry;therapeutic use;drug therapy;chemistry;therapeutic use;antagonists & inhibitors;genetics;metabolism;chemistry;therapeutic use;chemistry;therapeutic use;chemistry;therapeutic use;chemistry;therapeutic use",
        "_version_":1605842009312985088},
      {
        "Doc_abstract":"Multiple endocrine neoplasia 2B (MEN2B) has a classic childhood phenotypic presentation characterized by mucosal neuromas and marfanoid habitus. However, the diagnosis of MEN2B is often delayed beyond childhood, at which time medullary thyroid carcinoma (MTC) may be regionally advanced or metastatic. We examined the extent of this delay and its impact on the treatment of MTC.;Patients in the MEN database were retrospectively analyzed to determine the age at first presentation for a MEN2B-related complaint and the subsequent time to correct diagnosis. Operative and pathology reports were reviewed to determine the extent of thyroidectomy and cervical lymphadenectomy during the initial and subsequent neck operations.;We identified 22 patients with MEN2B, 20 were de novo cases and a M918T RET gene mutation was confirmed in 18 of the 22 patients. Median age at diagnosis of MTC was 13 years (range 6-25 years). The median delay in diagnosis was 26 months (range 0-18 years). Persistent local-regional MTC was present following the initial cervical operation in 12 of 22 patients (55%); including 4 of 13 with MEN2B diagnosed prior to initial surgery and 8 of 9 with MEN2B diagnosed after initial surgery.;Most patients displayed phenotypic characteristics of MEN2B long before the correct diagnosis was made. Half of the patients failed to undergo complete resection of MTC at their initial thyroid surgery. Early recognition of the MEN2B phenotype with a thoughtful approach to preoperative staging and surgery will maximize control of MTC and minimize the need for reoperation.",
        "Doc_title":"Failure to recognize multiple endocrine neoplasia 2B: more common than we think?",
        "Journal":"Annals of surgical oncology",
        "Do_id":"17963006",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Adult;Age Distribution;Carcinoma, Medullary;Child;Child, Preschool;Female;Humans;Infant;Infant, Newborn;Lymph Node Excision;Male;Multiple Endocrine Neoplasia Type 2b;Mutation;Neoplasm Recurrence, Local;Proto-Oncogene Proteins c-ret;Retrospective Studies;Thyroid Neoplasms;Thyroidectomy;Time Factors",
        "Doc_meshqualifiers":"diagnosis;surgery;diagnosis;surgery;genetics;diagnosis;surgery;genetics;metabolism;diagnosis;surgery",
        "_version_":1605764595268452352},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 (MEN2) is a autosomal dominat inherited tumour-syndrome caused by germline activating mutations of the RET proto-oncogene on chromosome 10. It is clinically characterized by the presence of medullary thyroid carcinoma (MTC), bilateral pheochromocytoma and primary hyperparathyroidism (MEN2A) within a single patient. Three distinct clinical forms have been described depending on the phenotype: the classical MEN 2A, MEN 2B, an association of MTC, pheochromocytoma and mucosal neuroma, (FMTC) familial MTC with a low incidence of other endocrinopathies. Each variant of MEN2 results from different RET gene mutation, with a good genotype phenotype correlation. Genetic testing detects nearly 100% of mutation carriers and is considered the standard of care for all first degree relatives of patients with newly diagnosed MTC. Recommendations on the timing of prophylactic thyroidectomy and extent of surgery are based on a classification into four risk levels utilizing the genotype-phenotype correlations. MEN 2 gives a unique model for early prevention and cure of cancer and for stratified roles of mutation-based diagnosis of carriers.",
        "Doc_title":"Update multiple endocrine neoplasia type 2.",
        "Journal":"Familial cancer",
        "Do_id":"20087666",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Genetic Association Studies;Humans;Multiple Endocrine Neoplasia Type 2a;Risk Factors",
        "Doc_meshqualifiers":"classification;genetics;pathology",
        "_version_":1605792122526498816},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 (MEN-2) is an inherited tumor syndrome that includes medullary thyroid carcinoma (MTC), primary hyperparathyroidism, pheochromocytoma and other non-endocrine diseases. Since the first RET missense mutations in association with MEN-2 were identified, RET mutation analysis had a great impact in the clinical management of MEN-2, such as in early diagnosis and treatment of MTC. Presently, early total thyroidectomy provides real cure of MTC for cases in which molecular diagnosis has been performed at early ages. After RET mutation identification, family members should be screened for this mutation by using methods as DGGE, SSCP, restriction enzyme, genetic sequencing or mini-sequencing. In this paper, we briefly review our experience with the direct RET gene sequencing and DGGE approaches. In 50 typical MEN-2 patients analyzed using both methods, we found no false results suggesting that DGGE is a reliable screening method for RET proto-oncogene mutation analysis.",
        "Doc_title":"[Genetic screening of multiple endocrine neoplasia type 2: experience of the USP Endocrine Genetics Unit].",
        "Journal":"Arquivos brasileiros de endocrinologia e metabologia",
        "Do_id":"16628270",
        "Doc_ChemicalList":"Genetic Markers;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Algorithms;Carcinoma, Medullary;Genetic Markers;Genetic Testing;Humans;Molecular Sequence Data;Multiple Endocrine Neoplasia Type 2a;Mutation;Phenotype;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms",
        "Doc_meshqualifiers":"diagnosis;genetics;methods;diagnosis;genetics;genetics;genetics;diagnosis;genetics",
        "_version_":1605819519718129664},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) originates in the thyroid parafollicular cells and represents 3-4% of the malignant neoplasms that affect this gland. Approximately 25% of these cases are hereditary due to activating mutations in the REarranged during Transfection (RET) proto-oncogene. The course of MTC is indolent, and survival rates depend on the tumor stage at diagnosis. The present article describes clinical evidence-based guidelines for the diagnosis, treatment, and follow-up of MTC.;The aim of the consensus described herein, which was elaborated by Brazilian experts and sponsored by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism, was to discuss the diagnosis, treatment, and follow-up of individuals with MTC in accordance with the latest evidence reported in the literature.;After clinical questions were elaborated, the available literature was initially surveyed for evidence in the MedLine-PubMed database, followed by the Embase and Scientific Electronic Library Online/Latin American and Caribbean Health Science Literature (SciELO/Lilacs) databases. The strength of evidence was assessed according to the Oxford classification of evidence levels, which is based on study design, and the best evidence available for each question was selected.;Eleven questions corresponded to MTC diagnosis, 8 corresponded to its surgical treatment, and 13 corresponded to follow-up, for a total of 32 recommendations. The present article discusses the clinical and molecular diagnosis, initial surgical treatment, and postoperative management of MTC, as well as the therapeutic options for metastatic disease.;MTC should be suspected in individuals who present with thyroid nodules and family histories of MTC, associations with pheochromocytoma and hyperparathyroidism, and/or typical phenotypic characteristics such as ganglioneuromatosis and Marfanoid habitus. Fine-needle nodule aspiration, serum calcitonin measurements, and anatomical-pathological examinations are useful for diagnostic confirmation. Surgery represents the only curative therapeutic strategy. The therapeutic options for metastatic disease remain limited and are restricted to disease control. Judicious postoperative assessments that focus on the identification of residual or recurrent disease are of paramount importance when defining the follow-up and later therapeutic management strategies.",
        "Doc_title":"Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.",
        "Journal":"Arquivos brasileiros de endocrinologia e metabologia",
        "Do_id":"25372577",
        "Doc_ChemicalList":"Biomarkers;Biomarkers, Tumor;Calcitonin;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adrenal Gland Neoplasms;Biomarkers;Biomarkers, Tumor;Biopsy, Fine-Needle;Brazil;Calcitonin;Carcinoma, Medullary;Carcinoma, Neuroendocrine;Diagnosis, Differential;Evidence-Based Medicine;Family Health;Follow-Up Studies;Humans;Mutation;Pheochromocytoma;Prognosis;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms;Thyroid Nodule;Thyroidectomy",
        "Doc_meshqualifiers":"diagnosis;metabolism;therapy;analysis;blood;blood;metabolism;diagnosis;secondary;therapy;methods;diagnosis;metabolism;therapy;genetics;diagnosis;secondary;therapy;diagnosis;surgery;methods",
        "_version_":1605750809866272768},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant inherited endocrine malignancy syndrome. Early and normative surgery is the only curative method for MEN 2-related medullary thyroid carcinoma (MTC). In patients with adrenal pheochromocytoma, cortical-sparing adrenalectomy (CSA) can be utilized to preserve adrenocortical function.;We present twenty-six of 33 MEN2 patients underwent prophylactic thyroidectomy with varying neck dissection and eight of 24 MEN2A patients with PHEO underwent adrenal-sparing surgery. Direct sequencing of entire RET exons was performed in all participants.;The RET mutations (p.C634Y [n=10], p.C634R [n=9], p.C634F [n=2], p.C618Y [n=8], p.C618R [n=3], and p.M918T [n=1]) were confirmed in 20 symptomatic patients and identified in 13 at-risk relatives (RET carriers). Twenty-six of 33 MEN2 patients underwent thyroidectomies with neck dissections; the mean age at the time of the first thyroid surgery and the tumor diameter of the 6 RET carriers was decreased compared with 20 symptomatic patients (P < 0.001 and P=0.007, respectively), while the disease-free survival was increased (80% vs.10%, P=0.0001). Seven RET carriers who were declined surgery. One of 20 symptomatic patients with MTC bone metastases after surgery received vandetanib therapy for 20months and responded well. Additionally, 8 of 24 MEN2A patients who initially had unilateral pheochromocytomas underwent CSA, 1 developed contralateral pheochromo cytomas 10years later, then also accepted and also agreed to a CSA. None of the patients required steroid replacement therapy.;Based on our results, integrated RET screening and the pre-operative calcitonin level is an excellent strategy to ensure earlier diagnosis and standard thyroidectomy. CSA can be utilized to preserve adrenocortical function in patients with pheochromocytomas.",
        "Doc_title":"Molecular diagnosis and comprehensive treatment of multiple endocrine neoplasia type 2 in Southeastern Chinese.",
        "Journal":"Hereditary cancer in clinical practice",
        "Do_id":"25628771",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605746976020758528},
      {
        "Doc_abstract":"Due to a strong genotype-phenotype correlation, the timing of prophylactic thyroidectomy in rearranged during transfection (RET) gene mutation carriers is usually dictated by genetic analysis.;We report a nationwide retrospective study of the clinical data of 77 French patients from 19 families with a mutation in codon 790 of the RET proto-oncogene.;The average age at diagnosis was 35.6 years  20.5. Thirty-nine patients were women. Fifty-five patients underwent operations for the treatment of medullary thyroid carcinoma (MTC) at the mean age of 38 years (4-82 years). The mean follow-up duration was 89 months. TNM staging was as follows: T0NxMx in 19, TxNxMx in 1, T1NxMx in 22, T1N1Mx in 8, T2N1Mx in 1 and T3N1Mx in four patients. In the T1/x-Nx group, 96% were considered cured after surgery. In the N1 group (n=13), six patients had multifocal disease and five patients were cured. Age and gender were not significant predictors of remission. Twenty-two patients did not undergo an operation (age 1.5-78 years); among them, 11 patients had a mean basal calcitonin (CT) level of 9.8 pg/ml (2-24) after 53 months of follow-up. One patient had been operated on for phaeochromocytoma (PHEO), and their CT level remained normal for 262 months.;This study confirms that RET 790 mutation is associated with a non-aggressive form of multiple endocrine neoplasia type 2, as 28% of the patients were followed up without thyroidectomy, 25% had been thyroidectomised with no tumour being detected and even patients with MTC had slow-evolving disease. Moreover, only one patient had PHEO, and no-one had primary hyperparathyroidism.",
        "Doc_title":"The clinical spectrum of RET proto-oncogene mutations in codon 790.",
        "Journal":"European journal of endocrinology",
        "Do_id":"23756355",
        "Doc_ChemicalList":"Codon;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Carcinoma;Carcinoma, Neuroendocrine;Child;Child, Preschool;Codon;Female;France;Genetic Association Studies;Humans;Longitudinal Studies;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Mutation;Neoplasm Staging;Proto-Oncogene Proteins c-ret;Retrospective Studies;Thyroid Gland;Thyroid Neoplasms;Thyroidectomy;Young Adult",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;surgery;genetics;metabolism;pathology;surgery;genetics;metabolism;pathology;surgery;genetics;metabolism;pathology;surgery;adverse effects",
        "_version_":1605843933590454272},
      {
        "Doc_abstract":"We report the experience of the Institute of Surgical Pathology of the University of Parma on three patients with sporadic medullary thyroid carcinoma (MTC). MTC is a tumor of parafollicolor cells origin (C cells). The surgical excision of the thyroid tumor and cervical node metastases is potentially curative. The other therapeutic options are limited. Considerable emphasis has been placed on early diagnosis and surgery for multiple endocrine neoplasia (MEN) related MTC. Genetic screening promises earlier and accurate diagnosis (RET gene mutations are found in MEN).",
        "Doc_title":"[Medullary carcinoma of the thyroid gland].",
        "Journal":"Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma",
        "Do_id":"11424598",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Carcinoma, Medullary;Female;Humans;Male;Middle Aged;Thyroid Neoplasms",
        "Doc_meshqualifiers":"diagnosis;surgery;diagnosis;surgery",
        "_version_":1605799074138685441},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant inherited cancer syndrome. Predisposition to MEN 2 is caused by germline mutations of the RET proto-oncogene on chromosome 10q11.2 [1]. There are three clinically distinct forms of MEN 2 syndrome -- MEN 2A, familial medullary thyroid carcinoma (FMTC), and MEN 2B. In all of these subtypes, medullary thyroid carcinoma (MTC) is a key. MEN 2A is the most common subtype of MEN 2. Clinical features of the MEN 2A syndrome include medullary thyroid carcinoma (MTC) and/or C-cell hyperplasia (CCH) in almost all affected individuals, pheochromocytoma (approximately 50%) and hyperparathyroidism (HPT) (15-30%). MEN type 2B is the most aggressive of the MEN 2 variants and accounts for approximately 5% of all cases of MEN 2. MEN 2B is similar to MEN 2A but is characterized by the earlier onset of the disease and by developmental abnormalities. In FMTC, the third form of MEN 2, MTC is the only clinical feature. Introduced in recent years and still developing genetic testing of individuals at highest hereditary risk of MEN 2 syndrome holds the possibility of early detection and improved treatment and prognosis.",
        "Doc_title":"Multiple endocrine neoplasia type 2.",
        "Journal":"Familial cancer",
        "Do_id":"15883707",
        "Doc_ChemicalList":"Oncogene Proteins;Proto-Oncogene Proteins c-ret;RET protein, human;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Genetic Predisposition to Disease;Genetic Testing;Germ-Line Mutation;Humans;Hyperparathyroidism;Multiple Endocrine Neoplasia Type 2a;Oncogene Proteins;Pheochromocytoma;Prognosis;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;physiopathology;genetics;physiopathology;genetics;physiopathology;genetics;genetics;physiopathology;genetics;genetics;physiopathology",
        "_version_":1605757721746866176},
      {
        "Doc_abstract":"In rare families RET tyrosine kinase receptor substitutions located in exon 10 (especially at positions 609, 618, and 620) can concomitantly cause the MEN 2A (multiple endocrine neoplasia type 2A) or FMTC (familial medullary thyroid carcinoma) cancer syndromes, and Hirschsprung's disease (HSCR). No animal model mimicking the co-existence of the MEN 2 pathology and HSCR is available, and the association of these activating mutations with a developmental defect still represents an unresolved problem. The aim of this work was to investigate the significance of the RET(C620R) substitution in the pathogenesis of both gain- and loss-of-function RET-associated diseases. We report the generation of a line of mice carrying the C620R mutation in the Ret gene. Although Ret(C620R) homozygotes display severe defects in kidney organogenesis and enteric nervous system development leading to perinatal lethality. Ret(C620R) heterozygotes recapitulate features characteristic of HSCR including hypoganglionosis of the gastrointestinal tract. Surprisingly, heterozygotes do not show any defects in the thyroid that might be attributable to a gain-of-function mutation. The Ret(C620R) allele is responsible for HSCR and affects the development of kidneys and the enteric nervous system (ENS). These mice represent an interesting model for studying new therapeutic approaches for the treatment of HSCR disease.",
        "Doc_title":"The Ret(C620R) mutation affects renal and enteric development in a mouse model of Hirschsprung's disease.",
        "Journal":"The American journal of pathology",
        "Do_id":"16565500",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret;Ret protein, mouse",
        "Doc_meshdescriptors":"Amino Acid Substitution;Animals;Cells, Cultured;Disease Models, Animal;Enteric Nervous System;Female;Ganglia, Spinal;Gastrointestinal Tract;Hirschsprung Disease;Kidney;Male;Mice;Mice, Mutant Strains;Proto-Oncogene Proteins c-ret;Thyroid Gland",
        "Doc_meshqualifiers":"abnormalities;embryology;metabolism;metabolism;pathology;embryology;innervation;metabolism;embryology;genetics;pathology;embryology;pathology;genetics;metabolism;abnormalities;embryology;metabolism",
        "_version_":1605841768593489920},
      {
        "Doc_abstract":"To explore the clinical characteristics and significance of RET proto-oncogene screening in multiple endocrine neoplasia type 2A (MEN2A).;Comprehensive medical history was obtained for 5 members from a 3-generation family from southern China. Clinical investigations have included biochemical testing, imaging, and screening of germline RET proto-oncogene mutations.;Genetic screening has revealed a missense mutation at codon 618(TGC>CGC) of exon 10 in 3 patients(p.C618R), which was consistent with their clinical manifestations. For the 3 individuals, the age at diagnosis was 21, 26 and 36 yr, and the maximum diameter of medullary thyroid carcinoma was 22, 25 and 39 cm, respectively. The 36-year-old female patient initially underwent right total thyroidectomy plus right neck lymph node dissection. Four years later, she again underwent left adrenal tumorectomy and left total thyroidectomy plus left neck lymph node dissection. The 21-year-old male patient underwent right total thyroidectomy plus right modified neck dissection. The follow-up was respectively 146 and 26 months following the initial operation. Two patients still presented elevated calcitonin and had bilateral neck lymph node masses and/or left thyroid masses on imaging examination. The 26-year-old female patient, who presented bilateral thyroid masses and elevated calcitonin, has refused thyroidectomy.;Combined family survey and RET gene screening can facilitate early diagnosis and surgical treatment to improve the prognosis.",
        "Doc_title":"[Multiple endocrine neoplasia type 2A caused by a p.C618R RET proto-oncogene mutation in a Chinese pedigree].",
        "Journal":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics",
        "Do_id":"24928018",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adult;Asian Continental Ancestry Group;Base Sequence;Carcinoma, Neuroendocrine;Exons;Female;Humans;Male;Molecular Sequence Data;Multiple Endocrine Neoplasia Type 2a;Mutation, Missense;Pedigree;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms;Young Adult",
        "Doc_meshqualifiers":"genetics;enzymology;genetics;genetics;enzymology;genetics",
        "_version_":1605839878825705472},
      {
        "Doc_abstract":"Reliable and effective primary screening of mutation carriers is the key condition for common diagnostic use. The objective of this study is to validate the method high resolution melting (HRM) analysis for routine primary mutation screening and accomplish its optimization, evaluation and validation. Due to their heterozygous nature, germline point mutations of c-RET proto-oncogene, associated to multiple endocrine neoplasia type 2 (MEN2), are suitable for HRM analysis. Early identification of mutation carriers has a major impact on patients' survival due to early onset of medullary thyroid carcinoma (MTC) and resistance to conventional therapy.;The authors performed a series of validation assays according to International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines for validation of analytical procedures, along with appropriate design and optimization experiments. After validated evaluation of HRM, the method was utilized for primary screening of 28 pathogenic c-RET mutations distributed among nine exons of c-RET gene.;Validation experiments confirm the repeatability, robustness, accuracy and reproducibility of HRM. All c-RET gene pathogenic variants were detected with no occurrence of false-positive/false-negative results.;The data provide basic information about design, establishment and validation of HRM for primary screening of genetic variants in order to distinguish heterozygous point mutation carriers among the wild-type sequence carriers. HRM analysis is a powerful and reliable tool for rapid and cost-effective primary screening, e.g., of c-RET gene germline and/or sporadic mutations and can be used as a first line potential diagnostic tool.",
        "Doc_title":"Establishing high resolution melting analysis: method validation and evaluation for c-RET proto-oncogene mutation screening.",
        "Journal":"Clinical chemistry and laboratory medicine",
        "Do_id":"21973105",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Genetic Testing;Humans;Mutation;Nucleic Acid Denaturation;Proto-Oncogene Proteins c-ret;Reproducibility of Results",
        "Doc_meshqualifiers":"methods;genetics;genetics;genetics",
        "_version_":1605801026760212480},
      {
        "Doc_abstract":"Many crucial problems are associated with the diagnosis of inherited cancer susceptibility. One of the most important is related to the psychosocial consequences of the knowledge by the patients and their relatives of their own genetical status. Little data are available in the literature, mainly from studies including small numbers of selected and motivated patients.;From January till December 1997, we studied the psychometric and quality of life parameters of 77 subjects followed in two French specialized centers. These subjects had been treated for either sporadic or familial or were at risk for medullary thyroid carcinoma. All patients had previously attended genetic counselling with detection of germline Ret-mutations, were informed on their own genetic risk, had good short-term prognosis and performance status and did not receive recent cancer treatment. Each patient was invited to answer two questionnaires, the hospital anxiety and depression scale (HADS) and the subjective quality of life profile (SQLP).;We report herein the descriptive results of this study (HADS and SQLP scores and distributions) and describe the individual clinical covariates that might explain the observed differences between subgroups of individuals. Although psychometric scores appeared similar in these subgroups, quality of life scores were lower in Ret-mutation carriers. Genetically-predisposed patients were less satisfied and expressed more expectations for favourable change in their quality of life.;This finding suggests a high level of frustration and latent unsatisfaction related either to the management of the genetic information given by the clinicians and its psychosocial consequences or simply to the knowledge of the genetic risk of cancer. Further studies on the individual consequences of genetic testing, information delivery and when necessary psychotherapeutic interventions, are needed to insure the quality of presymptomatic genetic testing in this field of oncology.",
        "Doc_title":"Psychosocial impact of genetic testing in familial medullary-thyroid carcinoma: a multicentric pilot-evaluation.",
        "Journal":"Annals of oncology : official journal of the European Society for Medical Oncology",
        "Do_id":"10076727",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Medullary;Female;France;Genetic Predisposition to Disease;Genetic Testing;Health Knowledge, Attitudes, Practice;Heterozygote;Humans;Male;Middle Aged;Patient Satisfaction;Pilot Projects;Psychology;Quality of Life;Thyroid Neoplasms",
        "Doc_meshqualifiers":"diagnosis;genetics;psychology;methods;psychology;diagnosis;genetics",
        "_version_":1605906067216138240},
      {
        "Doc_abstract":"Accumulating evidences suggest RET gene's involvement in development of the kidney in mice and humans. Although it is well known that RET mutation causes multiple endocrine neoplasia type 2A (MEN2A), thus far only 3 individuals have been reported to have MEN2A and renal agenesis/dysgenesis. We report a MEN2A family with RET mutation in which two asymptomatic carriers presented with unilateral renal agenesis. A 48-year-old woman underwent total thyroidectomy with regional lymph node dissection in our department for medullary thyroid carcinoma. She had earlier surgical treatment for a left adrenal pheochromocytoma at the age of 45. In the screening for MEN type 2 for her three sons, a CT scan for adrenal pheochromocytoma incidentally found unilateral renal agenesis in two of the sons, one of whom had suffered from Hirschsprung's disease (HSCR). They had contralateral kidneys exhibiting compensatory hypertrophy and normal renal function. Genetic analysis detected C618R RET mutation in the proband and her 3 sons, and no other mutations were found in RET as well as glial cell line-derived neurotrophic factor (GDNF). Our data lend support to the hypothesis that constitutive active RET mutation in MEN type 2 might partially impair RET function and thereby cause loss of function phenotype such as renal agenesis or HSCR. ",
        "Doc_title":"A MEN2A family with two asymptomatic carriers affected by unilateral renal agenesis.",
        "Journal":"Endocrine journal",
        "Do_id":"24152999",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adrenal Gland Neoplasms;Carcinoma, Medullary;Congenital Abnormalities;Female;Genotyping Techniques;Hirschsprung Disease;Humans;Kidney;Kidney Diseases;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Mutation;Pedigree;Pheochromocytoma;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms;Tomography, X-Ray Computed",
        "Doc_meshqualifiers":"diagnosis;genetics;surgery;congenital;genetics;surgery;diagnosis;genetics;genetics;surgery;abnormalities;congenital;diagnosis;genetics;genetics;surgery;diagnosis;genetics;surgery;genetics;genetics;surgery",
        "_version_":1605763494629605376},
      {
        "Doc_abstract":"Medullary and papillary thyroid carcinoma (MTC and PTC) are two types of thyroid cancer that can originate from activating mutations or rearrangements in the RET gene. Therapeutic options are limited in recurrent disease, but because RET is a tyrosine kinase (TK) receptor involved in cellular growth and proliferation, treatment with a TK inhibitor might be promising. Several TK inhibitors have been tested in clinical trials, but it is unknown which inhibitor is most effective and whether there is any specificity for particular RET mutations.;We aimed to compare the effect of four TK inhibitors (axitinib, sunitinib, vandetanib, and XL184) on cell proliferation, RET expression and autophosphorylation, and ERK activation in cell lines expressing a MEN2A (MTC-TT), a MEN2B (MZ-CRC-1) mutation, and a RET/PTC (TPC-1) rearrangement.;The three cell lines were cultured and treated with the four TK inhibitors. Effects on cell proliferation and RET and ERK expression and activation were determined.;XL184 and vandetanib most effectively inhibited cell proliferation, RET autophosphorylation in combination with a reduction of RET expression, and ERK phosphorylation in MTC-TT and MZ-CRC-1, respectively. TPC-1 cells showed a decrease in RET autophosphorylation after treatment with XL184, but no effect was observed on ERK activation.;There is indeed specificity for different RET mutations, with XL184 being the most potent inhibitor in MEN2A and PTC and vandetanib the most effective in MEN2B in vitro. No TK inhibitor was superior for all the cell lines tested, indicating that mutation-specific therapies could be beneficial in treating MTC and PTC.",
        "Doc_title":"The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.",
        "Journal":"The Journal of clinical endocrinology and metabolism",
        "Do_id":"21470995",
        "Doc_ChemicalList":"Anilides;Imidazoles;Indazoles;Indoles;Piperidines;Protein Kinase Inhibitors;Pyridines;Pyrroles;Quinazolines;cabozantinib;axitinib;Proto-Oncogene Proteins c-ret;RET protein, human;Receptor Protein-Tyrosine Kinases;sunitinib;N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine",
        "Doc_meshdescriptors":"Anilides;Blotting, Western;Cell Line, Tumor;Cell Proliferation;Humans;Imidazoles;Indazoles;Indoles;Phosphorylation;Piperidines;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-ret;Pyridines;Pyrroles;Quinazolines;Receptor Protein-Tyrosine Kinases;Reverse Transcriptase Polymerase Chain Reaction;Signal Transduction;Thyroid Gland;Tumor Cells, Cultured",
        "Doc_meshqualifiers":"pharmacology;drug effects;pharmacology;pharmacology;pharmacology;drug effects;pharmacology;pharmacology;metabolism;pharmacology;pharmacology;pharmacology;antagonists & inhibitors;drug effects;cytology;drug effects;metabolism",
        "_version_":1605906053843648512},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) is a calcitonin (CT)-producing C-cell tumor. In hereditary cases, a germline RET mutation is found in 98% of families. Because MTC is cured only if intrathyroidal, prophylactic thyroidectomy is recommended in the gene carrier (GC).;The aim was to determine whether thyroidectomy performed when stimulated CT becomes detectable is as safe as prophylactic thyroidectomy and to identify the serum CT cutoff able to distinguish intrathyroidal from extrathyroidal MTC.;Eighty-four GC were prospectively enrolled; 53 of the 84 underwent total thyroidectomy, one refused surgery, and 30 with normal basal and stimulated CT were under surveillance. The follow-up ranged from 2 to 18 yr.;GC operated on for elevated stimulated CT included 27 GC with a positive peak CT at the screening and four cases who became positive after 4 yr. All of them had intrathyroidal MTC and no node metastases; all were cured after a mean follow-up of 7.5 yr. Among those operated on for detectable basal CT, intrathyroidal tumors were found when CT was below 60 pg/ml, whereas either node metastases or larger tumors were observed when CT was above 60 pg/ml. No correlation among serum CT, age, and type of RET mutation was observed. Thirty GC were still biochemically negative at the annual control.;The time of thyroidectomy in GC with negative CT could be personalized and safely planned when stimulated CT becomes positive, independent of the type of RET mutation and patient's age. In this series, a basal CT below 60 pg/ml was always associated to an intrathyroidal localization of MTC.",
        "Doc_title":"The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center.",
        "Journal":"The Journal of clinical endocrinology and metabolism",
        "Do_id":"22162466",
        "Doc_ChemicalList":"Calcitonin;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Calcitonin;Carcinoma, Neuroendocrine;Child;Child, Preschool;Female;Follow-Up Studies;Heterozygote;Humans;Male;Middle Aged;Mutation;Patient Care Planning;Patient Safety;Precision Medicine;Proto-Oncogene Proteins c-ret;Retrospective Studies;Thyroid Neoplasms;Thyroidectomy;Time Factors;Young Adult",
        "Doc_meshqualifiers":"blood;methods;genetics;blood;epidemiology;genetics;surgery;adverse effects;methods;statistics & numerical data;utilization",
        "_version_":1605748044153749504},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 (MEN 2) is an inherited disorder as an autosomal dominant trait, characterized by medullary thyroid carcinoma (MTC). MEN 2 is classified with associated diseases into three subtypes: MEN 2A, MEN 2B and familial MTC. It has recently been shown to be associated with germline mutation in the RET proto-oncogene. Genetic testing allows easily for accurate diagnosis of presymptomatic gene carriers and surgical treatment at an early stage of the disease. In this review we delivered the classification, clinical feature, mutation in RET, mutation analysis, and management of MEN 2, and we discuss recent progress of research on the molecular basis and how genetic testing could be used for clinical management of affected patients or individuals in at-risk families.",
        "Doc_title":"[Multiple endocrine neoplasia type 2; MEN 2].",
        "Journal":"Nihon rinsho. Japanese journal of clinical medicine",
        "Do_id":"10921320",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Germ-Line Mutation;Humans;Multiple Endocrine Neoplasia Type 2a;Proto-Oncogenes;Reverse Transcriptase Polymerase Chain Reaction;Sequence Analysis, DNA;Thyroid Neoplasms",
        "Doc_meshqualifiers":"diagnosis;genetics;diagnosis;genetics;genetics;diagnosis;genetics",
        "_version_":1605757111888773120},
      {
        "Doc_abstract":"The treatment for metastasised medullary thyroid cancer is still a topic of discussion. One of the main challenges remains to find effective adjuvant and palliative options for patients with metastatic disease. The diagnostic and treatment strategies for this tumour are discussed and possible new developments commented. Approaches that target rearranged during transfection (RET) are preferable to those that target RET downstream proteins as, theoretically, blocking RET downstream targets will block only one of the many pathways activated by RET. Combining several agents would seem to be more promising, in particular agents that target RET with those that independently target RET signalling pathways or the more general mechanism of tumour progression. ",
        "Doc_title":"Endocrine tumours: progressive metastatic medullary thyroid carcinoma: first- and second-line strategies.",
        "Journal":"European journal of endocrinology",
        "Do_id":"25627652",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Neuroendocrine;Humans;Neoplasm Metastasis;Thyroid Neoplasms",
        "Doc_meshqualifiers":"therapy;diagnosis;genetics;therapy",
        "_version_":1605845260935626752},
      {
        "Doc_abstract":"The RET proto-oncogene is implicated in medullary thyroid cancer (MTC) and has been shown to signal indirectly to focal adhesion kinase (FAK) in cell types other than MTC. We have previously shown that FAK is phosphorylated in MTC cells. We hypothesized that inhibition of RET with pharmacologic inhibitors or by depletion with siRNA would decrease FAK phosphorylation in MTC cells, thereby implicating a RET-FAK signaling pathway.;Human MTC cells (TT cells) were treated with pharmacologic inhibitors or transfected with RET siRNA. Total protein was detected by immunoblotting. Phosphorylated FAK was detected by immunoprecipitating total FAK and immunoblotting with antiphosphotyrosine.;Treatment of MTC cells with the inhibitor PP2 significantly inhibited RET phosphorylation and, to a lesser extent, FAK phosphorylation. Imatinib mesylate inhibited FAK phosphorylation only at high doses. RET siRNA significantly decreased RET expression and FAK phosphorylation.;RET signals through FAK in MTC cells. Whether this is due to a direct or indirect interaction is not yet clear. PP2 or a similar inhibitor might be a useful treatment for MTC.",
        "Doc_title":"RET signals through focal adhesion kinase in medullary thyroid cancer cells.",
        "Journal":"Surgery",
        "Do_id":"15657578",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Piperazines;Proto-Oncogene Proteins;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Focal Adhesion Kinase 1;Focal Adhesion Protein-Tyrosine Kinases;PTK2 protein, human",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Carcinoma, Medullary;Cell Line, Tumor;Focal Adhesion Kinase 1;Focal Adhesion Protein-Tyrosine Kinases;Humans;Imatinib Mesylate;Piperazines;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Proto-Oncogenes;Pyrimidines;Receptor Protein-Tyrosine Kinases;Signal Transduction;Thyroid Neoplasms",
        "Doc_meshqualifiers":"therapeutic use;drug therapy;physiopathology;therapeutic use;physiology;physiology;genetics;therapeutic use;physiology;drug therapy;physiopathology",
        "_version_":1605761109140176896},
      {
        "Doc_abstract":"Genetic screening for germline mutations in the RET proto-oncogene has been extensively exploited worldwide to optimize the diagnostic and clinical management of multiple endocrine neoplasia type 2 (MEN2) patients and their relatives. However, a distinct lag period exists not only in the recognition but also in the medical treatment of patients with MEN2. Here we present a comprehensive genetic and clinical analysis of MEN2 among Chinese families followed from 1975 to 2011. Our series comprises 36 index cases and 134 relatives from 11 independent families.;Genetic diagnosis was performed in all participants by direct sequencing all relevant RET exons. Thyroidectomy was performed in 50 patients with varying cervical neck dissection procedures. Patients with pheochromocytoma (PHEO) underwent specific surgery. Demographic, clinical profiles, mutation types, tumor histopathologic features, and follow-up records were systematically analyzed.;The RET mutations p.C634Y (n=34), p.C634R (n=6), p.C618S (n=13), p.V292M/R67H/R982C (n=7), p.L790F (n=2), and p.C634Y/V292M/R67H/R982C (n=1) were confirmed in 31 index cases and then identified in 32 at-risk relatives (mutation carriers), with MEN2A as the most common clinical subtype. The overall penetrance of PHEO in patients with MEN2A was 46.7%. A total of 50 patients underwent thyroidectomy, and there was a significant lowering of their mean age at thyroidectomy and the tumor diameter of the mutation carriers that were detected and operated on compared with the index cases (age at first surgery: 29.3 vs. 39.3 years, p<0.05; maximum size: 1.1 vs. 3.3 cm, p<0.001). There was also a decrease in the TNM staging and the proportion of patients who underwent inappropriate initial thyroid surgery (pN1: 31.6% vs. 100%, p<0.001; inappropriate surgery: 0% vs. 29%). Meanwhile, disease-free survival (DFS) increased (DFS: 100% vs. 58.1%, p<0.05). Both medullary thyroid carcinoma-specific (n=1) and PHEO-specific (n=5) deaths were reported during the study period.;Our results further substantiate that gene scanning of all relevant RET exons is a powerful tool in the management of MEN2 patients, especially in asymptomatic carriers, and has led to earlier diagnosis and more complete initial treatment of patients with MEN2 in China.",
        "Doc_title":"RET proto-oncogene genetic screening of families with multiple endocrine neoplasia type 2 optimizes diagnostic and clinical management in China.",
        "Journal":"Thyroid : official journal of the American Thyroid Association",
        "Do_id":"23210566",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Adrenal Gland Neoplasms;Adult;Aged;Child;Child, Preschool;Female;Genetic Testing;Germ-Line Mutation;Humans;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Pheochromocytoma;Proto-Oncogene Proteins c-ret;Proto-Oncogenes;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"surgery;diagnosis;genetics;surgery;surgery;genetics;surgery",
        "_version_":1605897848214257664},
      {
        "Doc_abstract":"Medullary thyroid carcinoma is the most common cause of death in patients with multiple endocrine neoplasia (MEN) type 2A (MEN-2A) or type 2B or familial medullary thyroid carcinoma. We sought to determine whether total thyroidectomy in asymptomatic young members of kindreds with MEN-2A who had a mutated allele of the RET proto-oncogene could prevent or cure medullary thyroid carcinoma.;A total of 50 patients 19 years of age or younger who were consecutively identified through a genetic screening program as carriers of a RET mutation characteristic of MEN-2A underwent total thyroidectomy. Five to 10 years after the surgery, each patient was evaluated by physical examination and by determination of plasma calcitonin levels after stimulation with provocative agents.;In 44 of the 50 patients, basal and stimulated plasma calcitonin levels were at or below the limits of detection of the assay (proportion, 0.88; 95 percent confidence interval, 0.76 to 0.95). Two patients had basal and stimulated plasma calcitonin levels above the normal range. Stimulated plasma calcitonin levels had increased but remained within the normal range in four patients. The data suggest that there was a lower incidence of persistent or recurrent disease in children who underwent total thyroidectomy before eight years of age and in children in whom there were no metastases to cervical lymph nodes.;In this study, young patients identified by direct DNA analysis as carriers of a RET mutation characteristic of MEN-2A had no evidence of persistent or recurrent medullary thyroid carcinoma five or more years after total thyroidectomy. A longer period of evaluation will be necessary to confirm that they are cured.",
        "Doc_title":"Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A.",
        "Journal":"The New England journal of medicine",
        "Do_id":"16162881",
        "Doc_ChemicalList":"Codon;Oncogene Proteins;Calcitonin;Proto-Oncogene Proteins c-ret;RET protein, human;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Adolescent;Adult;Age Factors;Calcitonin;Carcinoma, Medullary;Child;Child, Preschool;Codon;DNA Mutational Analysis;Female;Heterozygote;Humans;Logistic Models;Male;Multiple Endocrine Neoplasia Type 2a;Mutation;Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Gland;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"blood;prevention & control;blood;genetics;pathology;surgery;genetics;genetics;anatomy & histology;pathology;prevention & control",
        "_version_":1605788842662559744},
      {
        "Doc_abstract":"Medullary thyroid carcinoma in both sporadic and familial forms is a curable disease if detected early and treated by the proper surgery. The advent of genetic screening for the RET protooncogene portends great promise in the earlier diagnosis and treatment of familial forms of MTC. New chemotherapy protocols have produced some tumor regression in patients with metastatic MTC. Improved use of Adriamycin and hyper-fractionated radiotherapy combined with debulking procedures has prolonged survival in anaplastic thyroid cancer. Thyroid gland lymphoma, if diagnosed early and treated by combined chemoradiotherapy, carries a good prognosis for survival. The best treatment for thyroid sarcomas and SCC of the thyroid is early diagnosis and aggressive surgery combined with radiotherapy.",
        "Doc_title":"Thyroid cancers. II. Medullary, anaplastic, lymphoma, sarcoma, squamous cell.",
        "Journal":"Otolaryngologic clinics of North America",
        "Do_id":"8844733",
        "Doc_ChemicalList":"Antibiotics, Antineoplastic;Doxorubicin",
        "Doc_meshdescriptors":"Antibiotics, Antineoplastic;Carcinoma;Carcinoma, Medullary;Carcinoma, Squamous Cell;Chemotherapy, Adjuvant;Combined Modality Therapy;Doxorubicin;Genetic Testing;Humans;Lymphoma;Prognosis;Proto-Oncogenes;Radiotherapy, Adjuvant;Sarcoma;Survival Rate;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"therapeutic use;diagnosis;surgery;diagnosis;genetics;secondary;surgery;diagnosis;surgery;therapeutic use;diagnosis;therapy;genetics;diagnosis;surgery;diagnosis;genetics;surgery",
        "_version_":1605898878535598080},
      {
        "Doc_abstract":"Objective. Until recently, advanced medullary thyroid cancer (MTC) had few treatment options except surgery. The mTOR inhibitor everolimus has shown encouraging results in neuroendocrine tumors. As part of a prospective phase II study, we analyzed the safety and efficacy of everolimus in advanced MTC. Methods. Seven patients with per RECIST 1.1 documented advanced MTC were included and received everolimus 10mg daily. The primary objective was determining treatment efficacy. Secondary endpoints included progression-free survival (PFS), overall survival (OS), toxicity, and pharmacokinetics (PK). Results. Median follow-up duration was 28 weeks (17-147). Five patients (71%) showed SD, of which 4 (57%) showed SD >24 weeks. Median PFS and OS were 33 (95%CI: 8-56) and 30 (95%CI: 15-45) weeks, respectively. Toxicity was predominantly grade 1/2 and included mucositis (43%), fatigue (43%), and hypertriglyceridemia (43%). Four MTCs harbored the somatic RET mutation c.2753T>C, p.Met918Thr. The best clinical response was seen in a MEN2A patient. PK characteristics were consistent with phase I data. One patient exhibited extensive toxicity accompanying elevated everolimus plasma concentrations. Conclusions. This study suggests that everolimus exerts clinically relevant antitumor activity in patients with advanced MTC. Given the high level of clinical benefit and the relatively low toxicity profile, further investigation of everolimus in these patients is warranted. ",
        "Doc_title":"Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial.",
        "Journal":"International journal of endocrinology",
        "Do_id":"26294908",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605742116821008385},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) originates from the parafollicular C cells of the thyroid gland. Mutations of the RET proto-oncogene are implicated in the pathogenesis of MTC. Germline activating mutations of this gene have been reported in about 88-98% of familial MTCs, while somatic mutations of RET gene have been detected in about 23-70% of sporadic forms. Although these genetic events are well characterized, much less is known about the role of epigenetic abnormalities in MTC.;The present review reports a detailed description of epigenetic abnormalities (DNA methylation, histone modifications and miRNA profile), probably involved in the pathogenesis and progression of MTC.;A systematic review was performed using Pubmed and Google patents databases.;We report the current understanding of epigenetic patterns in MTC and discuss the potential use of current knowledge in designing novel therapeutic strategies through epigenetic drugs, focusing on recent patents in this field.;Taking into account the reversibility of epigenetic alterations and the recent development in this field, epigenetic therapy may emerge for clinical use in the near future for patients with advanced MTC.",
        "Doc_title":"Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy.",
        "Journal":"Recent patents on anti-cancer drug discovery",
        "Do_id":"27306881",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605822517762588672},
      {
        "Doc_abstract":"C-cell cancer of the thyroid or medullary thyroid carcinoma (MTC) exists in a sporadic and a hereditary form, the latter of which is part of the multiple endocrine neoplasia type-2 (MEN-2) syndromes.;MTC metastasises early to local (lymph nodes) and distant sites (liver, lung, bone). Therefore, early detection is mandatory to enable a chance of cure. In sporadic MTC, the sensitive tumour marker calcitonin enables detection of the disease at an early stage. In hereditary MTC, more than 95% of the patients have germline RET mutations. Thus, MEN-2 has become the paradigm for the practice of molecular medicine, and gene carriers can be identified before MTC even occurs. Surgery is the only chance of cure and recently developed surgical techniques provide the therapeutic prerequisite to achieve calcitonin normalisation in both sporadic and hereditary MTC.",
        "Doc_title":"C-cell cancer--prevention and treatment.",
        "Journal":"Langenbeck's archives of surgery",
        "Do_id":"10367625",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Humans;Multiple Endocrine Neoplasia Type 2a;Thyroid Neoplasms",
        "Doc_meshqualifiers":"prevention & control;surgery;diagnosis;surgery;prevention & control;surgery",
        "_version_":1605851519561760768},
      {
        "Doc_abstract":"Currently, molecular genetic diagnostics allow familial types of medullary thyroid carcinoma to be detected at an asymptomatic stage and surgery thus to be performed at a time when prognosis is good. The current report aims to determine the appropriate age for safe prophylactic thyroidectomy in children with multiple endocrine neoplasia (MEN) 2A and mutations at codon 609 according to genotype-phenotype correlations and will discuss surgical procedures.;The authors describe the case of a family with hereditary MEN 2A syndrome. A DNA analysis of 7 family members confirmed the diagnosis by a mutation at codon 609 of the RET proto-oncogene.;A phaeochromocytoma developed in 2 family members. Four had medullary thyroid carcinoma. A grandson underwent a prophylactic thyroidectomy at the age of 5 on account of genetic evidence. Despite the negative preoperative and intraoperative findings he already had an invasive medullary thyroid carcinoma.;Few genotype-phenotype correlations have been established for MEN 2A disease. According to the natural history of the disease, families with the genotype RET cys609gly should have a more benign disease than high-risk families (mutations at codon 634, 618). From this report the authors conclude that prophylactic thyroidectomy in \"609\" families should be performed earlier than actually recommended, favorably at the age of 2 to 4 years. Further multicenter studies are needed to provide more clinical and prognostic data for less frequent (codon 609, 630, 791, and 891) RET genotypes.",
        "Doc_title":"Multiple endocrine neoplasia 2A syndrome: Surgical management.",
        "Journal":"Journal of pediatric surgery",
        "Do_id":"12037758",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Child, Preschool;Female;Genotype;Humans;Intraoperative Period;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Pedigree;Thyroidectomy",
        "Doc_meshqualifiers":"diagnosis;genetics;surgery",
        "_version_":1605741941866102786},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) is an uncommon thyroid tumor that has attracted a great deal of interest because of its frequent presentation as a familial tumor and its primary involvement in the type II multiple endocrine neoplasia (MEN) syndromes MEN-IIA and MEN-IIB and familial medullary thyroid carcinoma (FMTC). The MTC tumor cells secrete the polypeptide hormone calcitonin, which serves as an excellent tumor marker, useful for defining the presence of disease, preoperatively or following thyroidectomy. The discovery that mutations in the RET proto-oncogene are associated with MEN-II syndromes was highly significant in that it demonstrated a clear correlation between genotype and phenotype; and most importantly it provided a mechanism whereby family members at risk could be identified by direct DNA analysis. Virtually all patients with MEN-IIA, MEN-IIB, and FMTC develop MTC; therefore there is a clear rationale for performing thyroidectomy as soon as a RET mutation has been identified. Because MTC appears to be much more aggressive in patients with MEN-IIB, thyroidectomy is performed during the first year of life in this setting, whereas in patients with MEN-IIA, where the tumor appears to be more indolent, the procedure can be safety delayed until age 5 years. Reoperative neck exploration in patients with evidence of persistent or recurrent MTC has been effective in a significant number of patients, although the success of the operation requires careful patient selection and preoperative assessment. MTC, as expressed in the MEN-II syndromes, is an excellent model to evaluate the usefulness of interventional therapy in patients demonstrated to have a genetic predisposition for cancer.",
        "Doc_title":"Medullary carcinoma of the thyroid gland.",
        "Journal":"World journal of surgery",
        "Do_id":"10865039",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Humans;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"pathology;surgery;pathology;surgery",
        "_version_":1605785421592133632},
      {
        "Doc_abstract":"Medullary thyroid cancer (MTC) is generally resistant to chemotherapy and the frequent constitutive activation of RET (rearranged during transfection gene) in these tumors might inhibit drug-induced apoptosis.;Each RET isoform was separately expressed in SK-N-MC cells (neural crest-derived tumor) and the impact of RET activation on doxorubicin-induced apoptosis was examined.;The activation of RET9 and RET51 in the SK-N-MC cells significantly reduced the doxorubicin-induced apoptosis by 50%, compared to untreated cells. RET activation also induced phosphorylation of ERK (extracellular regulated kinase), but no changes in AKT (serine/threonine kinase) phosphorylation were noted. In the presence of a MAP (mitogen-activated protein) kinase inhibitor or a RET kinase inhibitor, the RET-activated/drug-treated cells displayed nearly 75% and 100% of the doxorubicin-induced apoptosis of the drug-treated cells without RET activation, respectively.;In SK-N-MC cells, downstream activation of MAP kinase, by both RET9 and RET51, appears to mediate the majority of RET-dependent resistance to chemotherapeutically induced apoptosis. MTC might be rendered more responsive to chemotherapeutic agents by the co-administration of a RET kinase inhibitor.",
        "Doc_title":"RET activation inhibits doxorubicin-induced apoptosis in SK-N-MC cells.",
        "Journal":"Anticancer research",
        "Do_id":"18751369",
        "Doc_ChemicalList":"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one;Flavonoids;Protein Isoforms;Doxorubicin;Proto-Oncogene Proteins c-ret;RET protein, human;Mitogen-Activated Protein Kinases",
        "Doc_meshdescriptors":"Apoptosis;Cell Line, Tumor;Doxorubicin;Flavonoids;Humans;MAP Kinase Signaling System;Mitogen-Activated Protein Kinases;Multiple Endocrine Neoplasia Type 2a;Neuroblastoma;Phosphorylation;Protein Isoforms;Proto-Oncogene Proteins c-ret;Signal Transduction",
        "Doc_meshqualifiers":"drug effects;physiology;antagonists & inhibitors;pharmacology;pharmacology;antagonists & inhibitors;metabolism;drug therapy;metabolism;pathology;drug therapy;metabolism;pathology;antagonists & inhibitors;biosynthesis;metabolism",
        "_version_":1605811492607754240},
      {
        "Doc_abstract":"To review significant advances in the early diagnosis and treatment of medullary thyroid carcinoma in patients with the multiple endocrine neoplasia II (MEN II) syndromes, advances made possible by the application of recently discovered genetic information.;Recently published English-language literature on linkage analysis and DNA analysis in the MEN II syndromes.;Articles on familial and sporadic forms of medullary thyroid carcinoma; pentagastrin-calcitonin determination; and genetic testing.;Information from recent studies on 1) the usefulness and limitations of genetic testing, especially DNA and linkage analysis, in the early diagnosis of the familial form of thyroid carcinoma and 2) the correlation between the results of genetic testing and the results of biochemical screening.;Medullary thyroid carcinoma accounts for most of the morbidity and mortality among patients with the familial medullary thyroid carcinoma syndromes. Multiple endocrine neoplasia IIa and IIb and familial medullary thyroid carcinoma are inherited conditions with autosomal dominance and incomplete penetrance. Traditionally, diagnosis and screening for these conditions have been done using pentagastrin stimulation tests and plasma calcitonin determinations. Recent genetic mapping, however, has assigned the genes responsible for these tumors to the pericentromeric region of chromosome 10. Available data suggest that mutations in exon 10, 11, or 16 of the RET proto-oncogene are responsible for MEN IIa and IIb and familial non-MEN medullary thyroid carcinoma. Thus, genetic testing can identify affected members of a kindred and will probably lead to early thyroidectomy and possible cure for gene carriers.;Early studies confirm the usefulness of DNA analysis in the diagnosis and treatment of patients with familial forms of medullary thyroid carcinoma. We review changes in the diagnosis and treatment of these patients and offer a strategy for operative intervention based on results of genetic testing.",
        "Doc_title":"Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II.",
        "Journal":"Annals of internal medicine",
        "Do_id":"7992986",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Algorithms;Genetic Linkage;Genetic Techniques;Genetic Testing;Humans;Multiple Endocrine Neoplasia Type 2a;Mutation",
        "Doc_meshqualifiers":"diagnosis;therapy",
        "_version_":1605852568339087360},
      {
        "Doc_abstract":"Most medullary thyroid cancers (MTC) express somatostatin receptors; therefore, (111)In-octreotide somatostatin receptor scintigraphy (SRS) may be useful in detecting sites of metastases in children with MTC.;The aim of the study was to evaluate tumor metastases in children and adolescents with MTC using SRS in comparison to conventional imaging.;A case series was conducted as part of baseline evaluation for cancer treatment protocol at the National Institutes of Health Clinical Center.;Eleven patients with a median age of 15 (range, 9-17) yr participated in the study, 10 with histologically proven, metastatic MTC due to the M918T mutation of the RET protooncogene, and one with a known RET polymorphism.;After receiving 0.086 mCi/kg (111)Indium-pentreotide, patients were examined with a single photon emission computed tomography scan 4 and 24 h after injection. Baseline conventional imaging, including computed tomography (neck, chest, abdomen,  pelvis, adrenals), magnetic resonance imaging (neck), and bone scan, was performed on all patients.;SRS results were compared with conventional imaging.;Five of the 11 patients had abnormal findings on SRS. Of the 53 total target lesions present in the patients, only 24.5% were accurately identified through SRS.;SRS appears to be less sensitive than conventional imaging at detecting the full extent of metastatic disease in children and adolescents with hereditary MTC. SRS incompletely identified sites of tumor and failed to visualize small sites of tumor or liver and lung metastases, and it has a limited role in the evaluation of metastatic disease in pediatric MTC patients.",
        "Doc_title":"(111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents.",
        "Journal":"The Journal of clinical endocrinology and metabolism",
        "Do_id":"22162469",
        "Doc_ChemicalList":"Biomarkers, Tumor;Receptors, Somatostatin;indium-111-octreotide;Octreotide",
        "Doc_meshdescriptors":"Adolescent;Biomarkers, Tumor;Carcinoma, Neuroendocrine;Child;Female;Humans;Male;Neoplasm Metastasis;Octreotide;Receptors, Somatostatin;Thyroid Neoplasms;Tomography, Emission-Computed;Tumor Burden;Whole Body Imaging",
        "Doc_meshqualifiers":"analysis;blood;analogs & derivatives;metabolism;blood;diagnostic imaging;metabolism;pathology;methods",
        "_version_":1605801941426765824},
      {
        "Doc_abstract":"Four types of thyroid cancer comprise more than 98% of all thyroid malignancies. Papillary thyroid carcinoma (PTC) may have a very benign course while undifferentiated thyroid carcinoma (UTC) belongs to the most aggressive human malignancies. A variety of genes have been identified to be involved in the pathogenesis of thyroid carcinoma. Somatic Ras mutations seem to be an early event and are frequently found in follicular thyroid carcinomas. Somatic rearrangements of RET and TRK are almost exclusively found in PTC and may be found in early stages. Germline RET missense mutations lead to hereditary medullary thyroid carcinoma (MTC). In contrast, the significance of somatic RET mutations in sporadic MTC is unknown. p53 seems to play a crucial role in the dedifferentiation process of thyroid carcinoma. The precise role of PTEN remains to be elucidated. The only clearly identified exogenous factor that may lead to thyroid carcinoma (mainly PTC) is radiation. Of interest, radiation is capable to induce RET rearrangements. In general, early diagnosis is mandatory to enable the chance of cure. Surgery is the treatment of choice. Depending on the tumour type, surgery in combination with either radioiodine, external radiation or chemotherapy often enables the control of local tumour burden. In MTC and UTC, once thyroid cancer is spread to distant organs, efficacious therapeutic agents are almost non-existing. However, our growing knowledge of genes involved in thyroidal oncogenesis may contribute to the development of more effective treatment modalities. Some preliminary data on gene therapy are quite promising.",
        "Doc_title":"Thyroid cancer.",
        "Journal":"Cancer letters",
        "Do_id":"11165748",
        "Doc_ChemicalList":"Iodine Radioisotopes;NCOA4 protein, human;Nuclear Receptor Coactivators;Oncogene Proteins;Radiopharmaceuticals;Transcription Factors",
        "Doc_meshdescriptors":"Adenocarcinoma, Follicular;Age Factors;Biopsy, Needle;Carcinoma, Papillary;Genes, Tumor Suppressor;Genes, p53;Humans;Iodine Radioisotopes;Nuclear Receptor Coactivators;Oncogene Proteins;Radiopharmaceuticals;Survival Rate;Thyroid Gland;Thyroid Neoplasms;Thyroidectomy;Transcription Factors",
        "Doc_meshqualifiers":"epidemiology;etiology;pathology;therapy;epidemiology;etiology;pathology;therapy;genetics;genetics;therapeutic use;genetics;therapeutic use;pathology;epidemiology;etiology;pathology;therapy",
        "_version_":1605892500114898944},
      {
        "Doc_abstract":"Multiple Endocrine Neoplasia Type 2 (MEN2) is a rare hereditary complex disorder characterized by the presence of medullary thyroid carcinoma (MTC), unilateral or bilateral pheochromocytoma (PHEO) and other hyperplasia and/or neoplasia of different endocrine tissues within a single patient. MEN2 has been reported in approximately 500 to 1000 families worldwide and the prevalence has been estimated at approximately 1:30,000. Two different forms, sporadic and familial, have been described for MEN2. Sporadic form is represented by a case with two of the principal MEN2-related endocrine tumors. The familial form, which is more frequent and with an autosomal pattern of inheritance, consists of a MEN2 case with at least one first degree relative showing one of the characteristic endocrine tumors. Familial medullary thyroid carcinoma (FMTC) is a subtype of MEN2 in which the affected individuals develop only medullary thyroid carcinoma, without other clinical manifestations of MEN2. Predisposition to MEN2 is caused by germline activating mutations of the c-RET proto-oncogene on chromosome 10q11.2. The RET gene encodes a single-pass transmembrane tyrosine kinase that is the receptor for glial-derived neurotrophic growth factors. The combination of clinical and genetic investigations, together with the improved understanding of the molecular and clinical genetics of the syndrome, helps the diagnosis and treatment of patients. Currently, DNA testing makes possible the early detection of asymptomatic gene carriers, allowing to identify and treat the neoplastic lesions at an earlier stage. In particular, the identification of a strong genotype-phenotype correlation in MEN2 syndrome may enable a more individualized treatment for the patients, improving their quality of life. At present, surgical treatment offers the only chance of cure and therefore, early clinical and genetic detection and prophylactic surgery in subjects at risk are the main therapeutic goal.",
        "Doc_title":"Multiple endocrine neoplasia type 2.",
        "Journal":"Orphanet journal of rare diseases",
        "Do_id":"17105651",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Genetic Predisposition to Disease;Genetic Testing;Humans;Multiple Endocrine Neoplasia Type 2a;Mutation;Pheochromocytoma;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms",
        "Doc_meshqualifiers":"pathology;genetics;pathology;prevention & control;pathology;genetics;pathology",
        "_version_":1605881229267173376},
      {
        "Doc_abstract":"The diagnosis and treatment of multiple endocrine neoplasias type 2A (MEN 2A) requires interdisciplinary management. The association of RET proto-oncogene mutations and medullary thyroid carcinoma (MTC) in children is well-known, but the optimal timing for elective surgery is controversial. Besides the risk of MTC, associated anomalies like hyperparathyroidism have to be considered. We report the results of molecular genetic investigations, the pentagastrin stimulation test, pre- and postoperative staging, and histologic examinations of four children who had a positive family history for MEN 2A. Histologic specimens of the removed thyroid glands showed MTC in all four cases. The patients had an uneventful postoperative clinical course. In view of the recent literature and our patients' results, we suggest a concept for diagnostic strategy and timing of the elective thyroidectomy.",
        "Doc_title":"Multiple endocrine neoplasias type 2A and thyroid medullary carcinoma: an interdisciplinary challenge.",
        "Journal":"Pediatric surgery international",
        "Do_id":"12721726",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Carcinoma, Medullary;Child;Female;Humans;Male;Multiple Endocrine Neoplasia Type 2a;Mutation;Neoplasm Staging;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome",
        "Doc_meshqualifiers":"complications;genetics;surgery;complications;genetics;surgery;complications;genetics;surgery",
        "_version_":1605742686959042562},
      {
        "Doc_abstract":"Multiple endocrine neoplasia (MEN) 2B is a hereditary syndrome including medullary thyroid carcinoma (MTC), pheochromocytoma, gastrointestinal (GI) disorders, marfanoid facies, and multiple ganglioneuromas. MTC is the major cause of mortality, and often appears during the 1st decade of life. RET proto-oncogene mutations are responsible for MEN 2B. Other RET mutations cause MEN 2A syndrome, familial MTC, or Hirschsprung's disease. We studied three MEN 2B patients with the aim of delineating the best diagnostic and therapeutic protocol. The gold standards for diagnosis are histochemical study of the rectal mucosa and molecular analysis of RET, which in familial cases detects MEN 2B at a preclinical stage so that early total prophylactic thyroidectomy can be performed. In non-familial cases, the diagnosis can be suggested by the presence of GI symptoms, ganglioneuromas, and/or the typical facies. The intestinal innervation pattern, analyzed with the acetylcholinesterase technique, is pathognomonic for MEN 2B. In our protocol a rectal biopsy is, therefore, the first measure. The surgical treatment of MEN 2B is total thyroidectomy with cervical lymphadenectomy of the central compartment of the neck. When possible, this intervention should be performed prophylactically before 1 year of age.",
        "Doc_title":"Diagnostic and therapeutic approach to multiple endocrine neoplasia type 2B in pediatric patients.",
        "Journal":"Pediatric surgery international",
        "Do_id":"12415360",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Algorithms;Child, Preschool;Fatal Outcome;Female;Humans;Lymph Node Excision;Multiple Endocrine Neoplasia Type 2b;Thyroidectomy",
        "Doc_meshqualifiers":"diagnosis;pathology;surgery",
        "_version_":1605783681088094208},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) originates in the thyroid C cells, or parafollicular cells, secreting calcitonin. It may be either sporadic or familial. Familial form can be isolated or expression of a multiple endocrine neoplasia type II. Mutations of the RET proto-oncogene have been identified in the germline DNA of patients with familial MTC syndromes. Genetic testing can identify patients affected by multiple endocrine neoplasia and familial MTC, allowing early diagnosis and possible cure. The initial treatment is surgical and the adequate surgery consists of total thyroidectomy. The treatment of occult or minimal disease can be curative. Plasma calcitonin measurements are excellent markers for post-operative follow-up. Imaging study can help to discover recurrent or metastatic disease. Adjunctive therapy includes radiotherapy and chemotherapy. Radiotherapy is reserved for bone metastases or for non resectable neck recurrences. Chemotherapy is reserved for patients with progressive MTC. Many chemotherapeutic regimens have been tried, results are controversial.",
        "Doc_title":"[Medullary carcinoma of the thyroid: diagnosis and therapy].",
        "Journal":"La Clinica terapeutica",
        "Do_id":"10822879",
        "Doc_ChemicalList":"Neoplasm Proteins;Calcitonin",
        "Doc_meshdescriptors":"Calcitonin;Carcinoma, Medullary;Genetic Testing;Humans;Multiple Endocrine Neoplasia Type 2b;Neoplasm Proteins;Prognosis;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"blood;diagnosis;genetics;therapy;classification;genetics;blood;diagnosis;genetics;therapy",
        "_version_":1605756066941894656},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) is a rare malignant tumor originating from thyroid parafollicular C cells. This tumor accounts for 3%-4% of thyroid gland neoplasias. MTC may occur sporadically or be inherited. Hereditary MTC appears as part of the multiple endocrine neoplasia syndrome type 2A or 2B, or familial medullary thyroid cancer. Germ-line mutations of the RET proto-oncogene cause hereditary forms of cancer, whereas somatic mutations can be present in sporadic forms of the disease. The RET gene encodes a receptor tyrosine kinase involved in the activation of intracellular signaling pathways leading to proliferation, growth, differentiation, migration, and survival. Nowadays, early diagnosis of MTC followed by total thyroidectomy offers the only possibility of cure. Based on the knowledge of the pathogenic mechanisms of MTC, new drugs have been developed in an attempt to control metastatic disease. Of these, small-molecule tyrosine kinase inhibitors represent one of the most promising agents for MTC treatment, and clinical trials have shown encouraging results. Hopefully, the cumulative knowledge about the targets of action of these drugs and about the tyrosine kinase inhibitor-associated side effects will help in choosing the best therapeutic approach to enhance their benefits.",
        "Doc_title":"Advanced medullary thyroid cancer: pathophysiology and management.",
        "Journal":"Cancer management and research",
        "Do_id":"23696715",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605759228590424064},
      {
        "Doc_abstract":"The American Thyroid Association (ATA) published recommendations for the timing of prophylactic surgery for medullary thyroid carcinoma based on the specific mutation, patient age, family history, and serum calcitonin levels. The aim of this study was to assess the role of preoperative basal calcitonin (prebCt) levels in predicting the presence of medullary carcinoma of the thyroid in patients with RET mutations.;We conducted a retrospective study in two endocrine surgery departments. Between 1986 and 2012, a total of 32 patients with RET mutations underwent prophylactic thyroidectomy. The patients were stratified into four ATA risk levels: A, B, C, and D.;All of the patients were biologically cured. Microcarcinoma was observed in the final pathology report for four of the 20 patients with normal prebCt (25%) and for nine of the 12 patients with elevated prebCt (75%). In the level A group, four patients with normal prebCt and one patient with elevated prebCt presented with microcarcinoma. In the level C group, one patient with normal prebCt and six of the seven patients with elevated prebCt (86%) presented with microcarcinoma.;PrebCt can predict the presence of microcarcinoma according to surgical pathological analysis. Patients with microcarcinoma can be biochemically and clinically cured using prophylactic thyroidectomy.",
        "Doc_title":"Role of preoperative basal calcitonin levels in the timing of prophylactic thyroidectomy in patients with germline RET mutations.",
        "Journal":"World journal of surgery",
        "Do_id":"24357249",
        "Doc_ChemicalList":"Biomarkers;Biomarkers, Tumor;Calcitonin;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Adult;Biomarkers;Biomarkers, Tumor;Calcitonin;Carcinoma, Medullary;Carcinoma, Neuroendocrine;Child;Child, Preschool;Female;Germ-Line Mutation;Humans;Infant;Male;Middle Aged;Preoperative Period;Proto-Oncogene Proteins c-ret;Retrospective Studies;Thyroid Neoplasms;Thyroidectomy;Time Factors;Young Adult",
        "Doc_meshqualifiers":"blood;genetics;blood;blood;diagnosis;genetics;prevention & control;genetics;blood;diagnosis;genetics;prevention & control",
        "_version_":1605876232374714368},
      {
        "Doc_abstract":"Pheochromocytomas, paragangliomas, and medullary thyroid carcinomas (MTCs) originate in cells that share a common neuroectodermal origin. Like other neuroendocrine neoplasms, they are characterized by a propensity to secrete amines (epinephrine and norepinephrine) and peptide hormones (calcitonin). Improved understanding of underlying molecular pathways, such as mutations of the RET (rearranged during transfection) proto-oncogene, has led to new rational targeted therapies. Adrenocortical carcinomas (ACCs) originate in the steroid hormone-producing adrenal cortex. While tumors of the adrenal cortex are not, strictly speaking, part the \"diffuse neuroendocrine system,\" they are often included in neuroendocrine tumor guidelines due to their orphan status. In this update on management of unusual neuroendocrine tumors, we review the biology and treatment of these rare neoplasms.",
        "Doc_title":"Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma.",
        "Journal":"Seminars in oncology",
        "Do_id":"23391119",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adrenal Cortex Neoplasms;Adrenal Gland Neoplasms;Adrenocortical Carcinoma;Carcinoma, Neuroendocrine;Genetic Predisposition to Disease;Humans;Paraganglioma;Pheochromocytoma;Thyroid Neoplasms;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;pathology;therapy;genetics;pathology;therapy;genetics;pathology;therapy;genetics;pathology;therapy;genetics;pathology;therapy;genetics;pathology;therapy",
        "_version_":1605792365655621632},
      {
        "Doc_abstract":"Activating mutations in the RET receptor tyrosine kinase are responsible for the development of medullary thyroid cancer (MTC) in persons with Multiple Endocrine Neoplasia type 2. We hypothesized that STI571 (Gleevec) would inhibit RET kinase and be a useful agent in the treatment of MTC.;We determined the IC50 of STI571 for RET using an in vitro kinase assay and also examined the effects of STI571 on cellular proliferation and viability in TT cells, a human MTC cell line.;The average in vitro IC50 of STI571 for RET is 37 microM +/- 4 microM. Additionally, TT cells incubated with 10 microM STI571 for up to 8 days showed no apparent reduction in cell proliferation or viability. Higher concentrations of STI571, from 25 to 100 microM, induced necrosis of TT cells.;The concentrations of STI571 required to significantly inhibit RET and to inhibit TT cell proliferation are not clinically achievable. We conclude that STI571 is not likely to be an effective treatment for MTC.",
        "Doc_title":"RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571.",
        "Journal":"Anticancer research",
        "Do_id":"14666655",
        "Doc_ChemicalList":"Antineoplastic Agents;Benzamides;Enzyme Inhibitors;Piperazines;Proto-Oncogene Proteins;Pyrimidines;Imatinib Mesylate;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Benzamides;Carcinoma, Medullary;Cell Death;Cell Division;Cell Line, Tumor;Enzyme Inhibitors;Humans;Imatinib Mesylate;Inhibitory Concentration 50;Phosphorylation;Piperazines;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Pyrimidines;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms",
        "Doc_meshqualifiers":"pharmacology;drug therapy;enzymology;pathology;drug effects;drug effects;pharmacology;drug effects;pharmacology;antagonists & inhibitors;metabolism;pharmacology;antagonists & inhibitors;metabolism;drug therapy;enzymology;pathology",
        "_version_":1605841351983759360},
      {
        "Doc_abstract":"BACKGROUND Multiple endocrine neoplasia type 2 (MEN 2) is caused by a RET mutation in chromosome 10. All MEN 2 patients develop medullary thyroid carcinoma (MTC). The age-related risk of MTC is associated with the type of RET mutation. Our aim was to identify prognostic factors associated with recurrent MTC in MEN 2 patients. METHODS In a nationwide case-control study, all patients who underwent total thyroidectomy in the Netherlands under the age of 20 years were classified into standard (1), high (2), or very high risk (3) for MTC based on RET-mutation type. Disease-free patients were compared with those with recurrent disease. RESULTS A total of 93 patients were included in the study. Sixty-six percent had MTC on histology, the youngest being 1 year old. Codon 634 was most affected. Sixteen (18%) patients had persistent or recurrent disease, one of whom died. Significantly associated determinants of outcome in univariate analysis were higher age at surgery, no age-appropriate prophylactic surgery according to risk level, elevated preoperative calcitonin levels, affected codon, and the presence of lymph node metastases at surgery. On multivariate analysis only age of surgery was the single independent factor associated with persistent disease. CONCLUSIONS Prophylactic thyroidectomy beyond the recommended age is associated with persistent/recurrent disease. In addition, codon 634 mutation is associated with a high risk of recurrence requiring early surgery for all these patients.",
        "Doc_title":"Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study.",
        "Journal":"World journal of surgery",
        "Do_id":"20063095",
        "Doc_ChemicalList":"Codon",
        "Doc_meshdescriptors":"Adolescent;Analysis of Variance;Case-Control Studies;Chi-Square Distribution;Child;Child, Preschool;Codon;Female;Follow-Up Studies;Humans;Longitudinal Studies;Male;Multiple Endocrine Neoplasia Type 2a;Mutation;Neoplasm Staging;Netherlands;Predictive Value of Tests;Risk Factors;Statistics, Nonparametric;Thyroidectomy;Treatment Outcome",
        "Doc_meshqualifiers":"epidemiology;genetics;pathology;surgery;epidemiology",
        "_version_":1605775363257925632},
      {
        "Doc_abstract":"Although the gene responsible for multiple endocrine neoplasia type 2 (MEN2) was discovered many years ago, the exact mechanisms of tumor development in patients affected with RET germline mutations remain unknown. In vitro studies have certain pitfalls, one of which is the use of cell culture systems such as the NIH3T3 cells, in which RET usually is not expressed in contrast to the in vivo situation. Recent data suggest that an overrepresentation of mutant RET as a 'second hit' event might trigger tumorigenesis. However, alterations in other genes might contribute to this overrepresentation of RET or impact on MEN 2-related tumor development through completely different mechanisms and pathways. The final goal of further elucidating the natural history and pathogenesis of MEN2-related tumors should be the chance to offer patients with RET germline mutations an optimal cancer prevention (e.g. codon specific recommendations for prophylactic thyroidectomy) and treatment program, especially for metastatic medullary thyroid carcinoma for which presently no effective therapy other than surgery exists.",
        "Doc_title":"Molecular pathogenesis of MEN2-associated tumors.",
        "Journal":"Familial cancer",
        "Do_id":"15883703",
        "Doc_ChemicalList":"Oncogene Proteins;Proto-Oncogene Proteins c-ret;RET protein, human;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Cell Culture Techniques;Cell Transformation, Neoplastic;Germ-Line Mutation;Humans;Multiple Endocrine Neoplasia Type 2a;Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"genetics;genetics;physiopathology;genetics;physiology;genetics;physiology",
        "_version_":1605756865072857088},
      {
        "Doc_abstract":"Since the association of RET proto-oncogene mutations and medullary thyroid carcinoma in children there has been much discussion regarding timing of surgery. Our study group was formed from a brother and sister (8 and 5) and 3 brothers (9, 13, 16) selected on the basis of a positive family history for thyroid medullary carcinoma. Histological examinations of the thyroidectomy specimens showed that the 8- and 9-year old had microinvasive carcinoma and the remaining three had C-cell hyperplasia. Our recommendation is for prophylactic thyroidectomy for children with RET proto oncogene mutations at an early age, clearly before age 5.",
        "Doc_title":"Prophylactic thyroidectomy in the treatment of thyroid medullary carcinoma. Age for surgery?",
        "Journal":"European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie",
        "Do_id":"11194546",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Age Factors;Carcinoma, Medullary;Child;Child, Preschool;Female;Follow-Up Studies;Genetic Predisposition to Disease;Humans;Male;Multiple Endocrine Neoplasia Type 2a;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"genetics;prevention & control;genetics;surgery;genetics;prevention & control",
        "_version_":1605908019449692160},
      {
        "Doc_abstract":"We present a two-generation family with multiple endocrine neoplasia (MEN) type IIb diagnosed by their ophthalmologists based on characteristic ophthalmic findings.;A family consisting of a 33-year-old female proband and her 8- and 7-year-old children had prominent corneal nerves; eyelid, lip, and tongue nodules; and a characteristic facies. A polymerase chain reaction-based genetic assay was obtained to detect the genetic mutation most commonly associated with MEN type IIb. Serum calcitonin and urine catecholamine studies were obtained.;Molecular genetic studies detected in all 3 patients a mutation at codon 918 of the RET proto-oncogene known to be present in 95% of the cases of MEN type IIb. Serum calcitonin was elevated in the proband and her son. Urine catecholamine levels were elevated in the proband. Surgical treatment and histologic analysis confirmed pheochromocytoma and medullary thyroid carcinoma (MTC) in the proband. Surgical exploration revealed the MTC to be metastatic to the liver.;This family demonstrates the characteristic findings of MEN type IIb: prominent corneal nerves in a clear stroma and multiple submucosal neuromas of the conjunctiva, eyelids, lips, and tongue. Ophthalmologists have a critical role to play in recognizing these signs, because the early diagnosis of medullary thyroid carcinoma and pheochromocytoma may be life saving.",
        "Doc_title":"From eyelid bumps to thyroid lumps: report of a MEN type IIb family and review of the literature.",
        "Journal":"Ophthalmic plastic and reconstructive surgery",
        "Do_id":"11388386",
        "Doc_ChemicalList":"Catecholamines;Drosophila Proteins;Proto-Oncogene Proteins;Calcitonin;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Adrenal Gland Neoplasms;Adult;Calcitonin;Carcinoma, Medullary;Catecholamines;Child;Cornea;DNA Mutational Analysis;Drosophila Proteins;Eyelid Neoplasms;Female;Humans;Lip Neoplasms;Liver Neoplasms;Male;Multiple Endocrine Neoplasia Type 2b;Neuroma;Pheochromocytoma;Point Mutation;Polymerase Chain Reaction;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms;Tongue Neoplasms;Trigeminal Nerve",
        "Doc_meshqualifiers":"diagnosis;blood;diagnosis;urine;innervation;diagnosis;diagnosis;secondary;diagnosis;genetics;diagnosis;diagnosis;genetics;genetics;diagnosis;diagnosis;pathology",
        "_version_":1605822641123360768},
      {
        "Doc_abstract":"Mutations in the RET proto-oncogene have been implicated in the pathogenesis of several forms of medullary thyroid cancer (MTC). Multiple endocrine neoplasia type 2 (MEN-2) is an autosomal dominant syndrome caused by germline activating mutations of the RET proto-oncogene and has been categorized into three distinct clinical forms. MEN-2A is associated with MTC, bilateral pheochromocytoma, and primary hyperparathyroidism. MEN-2B is associated with MTC, bilateral pheochromocytoma, and mucosal neuromas. The rarest clinical form of MEN-2 is familial MTC (FMTC), which is also associated with MTC, but other endocrinopathies are characteristically not present. Each clinical form of MEN-2 results from a specific RET gene mutation, with a strong correlation of phenotype expression with regard to the onset and course of MTC and the presence of other endocrine tumors and a corresponding genotype. Recommendations for screening of RET mutations are necessary as their presence or absence will influence interventional strategies such as the timing of a prophylactic thyroidectomy and extent of surgery. Timing of screenings and development of interventional strategies are extremely important in caring for patients with certain RET mutations as evidence of metastatic MTC has been documented as early as 6 years of age. Interventional strategies should consider the risks of complications of these interventions based on certain characteristics of each individual case such as age of the patient, course of disease in affected family members, and the invasiveness of any proposed surgical procedure.",
        "Doc_title":"RET gene abnormalities and thyroid disease: who should be screened and when.",
        "Journal":"Journal of clinical research in pediatric endocrinology",
        "Do_id":"23455356",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Humans;Mass Screening;Mutation;Proto-Oncogene Proteins c-ret;Thyroid Diseases",
        "Doc_meshqualifiers":"genetics;genetics;diagnosis;genetics;therapy",
        "_version_":1605825749120450560},
      {
        "Doc_abstract":"The RET kinase has emerged as a promising target for the therapy of medullary thyroid cancers (MTC) and of a subset of papillary thyroid cancers. NVP-AST487, a N,N'-diphenyl urea with an IC(50) of 0.88 mumol/L on RET kinase, inhibited RET autophosphorylation and activation of downstream effectors, and potently inhibited the growth of human thyroid cancer cell lines with activating mutations of RET but not of lines without RET mutations. NVP-AST487 induced a dose-dependent growth inhibition of xenografts of NIH3T3 cells expressing oncogenic RET, and of the MTC cell line TT in nude mice. MTCs secrete calcitonin, a useful indicator of tumor burden. Human plasma calcitonin levels derived from the TT cell xenografts were inhibited shortly after treatment, when tumor volume was still unchanged, indicating that the effects of RET kinase inhibition on calcitonin secretion were temporally dissociated from its tumor-inhibitory properties. Accordingly, NVP-AST487 inhibited calcitonin gene expression in vitro in TT cells, in part, through decreased gene transcription. These data point to a previously unknown physiologic role of RET signaling on calcitonin gene expression. Indeed, the RET ligands persephin and GDNF robustly stimulated calcitonin mRNA, which was blocked by pretreatment with NVP-AST487. Antagonists of RET kinase activity in patients with MTC may result in effects on plasma calcitonin that are either disproportionate or dissociated from the effects on tumor burden, because RET kinase mediates a physiologic pathway controlling calcitonin secretion. The role of traditional tumor biomarkers may need to be reassessed as targeted therapies designed against oncoproteins with key roles in pathogenesis are implemented.",
        "Doc_title":"The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.",
        "Journal":"Cancer research",
        "Do_id":"17638907",
        "Doc_ChemicalList":"Antineoplastic Agents;Carbanilides;Enzyme Inhibitors;Glial Cell Line-Derived Neurotrophic Factor;NVP-AST487;Calcitonin;Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Calcitonin;Carbanilides;Cell Line, Tumor;Enzyme Inhibitors;Female;Gene Expression Regulation, Neoplastic;Glial Cell Line-Derived Neurotrophic Factor;Humans;Inhibitory Concentration 50;Mice;Neoplasm Transplantation;Phosphorylation;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms",
        "Doc_meshqualifiers":"pharmacology;antagonists & inhibitors;metabolism;pharmacology;pharmacology;metabolism;antagonists & inhibitors;drug therapy;enzymology",
        "_version_":1605907854221377536},
      {
        "Doc_abstract":"Since its first description in 1951, a timely diagnosis of medullary thyroid carcinoma (MTC) may represent a diagnostic challenge in clinical practice. Several contributions have been addressed to the treatment and follow-up of MTC, but review articles focused on the diagnostic problems of this cancer in clinical practice are sparse. As a delayed diagnosis and an inadequate initial treatment may severely affect the prognosis of this thyroid malignancy, the appropriate use and the correct interpretation of the available diagnostic tools for MTC are of crucial importance. The purpose of the present article is to provide an easy-to-use guide reviewing the main issues of MTC diagnosis: (1) basal serum calcitonin; (2) stimulated serum calcitonin; (3) additional serum markers for MTC; (4) ultrasound and other imaging techniques; (5) fine-needle aspiration (FNA) cytology; (6) calcitonin measurement on FNA washout; (7) rearranged during transfection (RET) mutations; and (8) scope of the problem.",
        "Doc_title":"Medullary thyroid cancer diagnosis: an appraisal.",
        "Journal":"Head & neck",
        "Do_id":"23955938",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Biopsy, Fine-Needle;Carcinoma, Neuroendocrine;Humans;Mutation;Thyroid Gland;Thyroid Neoplasms",
        "Doc_meshqualifiers":"analysis;methods;pathology;diagnosis",
        "_version_":1605747096911085569},
      {
        "Doc_abstract":"Identification of RET gene mutations in patients at-risk for the development of the hereditary forms of medullary thyroid carcinoma has simplified management and expanded the scope of indications for surgical intervention. Patients who carry this mutation can be offered thyroidectomy at a very young age, hopefully at a point when the cancer has not yet developed or spread. Those who are found not to have inherited the mutation are spared further genetic and biochemical screening. This achievement marks a new paradigm in surgery--the recommendation that an operation be performed based on the result of a genetic test. Experience with management of patients with multiple endocrine neoplasia types 2A and 2B and with familial, non-multiple endocrine neoplasia medullary thyroid carcinoma will provide information that will aid in the future management of patients with other hereditary cancers.",
        "Doc_title":"The molecular genetics of multiple endocrine neoplasia type 2A and related syndromes.",
        "Journal":"Annual review of medicine",
        "Do_id":"9046972",
        "Doc_ChemicalList":"Drosophila Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Carcinoma, Medullary;DNA Mutational Analysis;Drosophila Proteins;Genetic Counseling;Genetic Testing;Heterozygote Detection;Humans;Molecular Biology;Multiple Endocrine Neoplasia Type 2a;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"genetics;surgery;genetics;surgery;genetics;genetics;genetics;surgery",
        "_version_":1605818768394551296},
      {
        "Doc_abstract":"Multiple endocrine neoplasias (MEN) are familial diseases characterized by endocrine neoplasms and transmitted in an autosomal dominant manner. In MEN type 1, the major lesions affect parathyroid glands, pancreatic islet cells and anterior pituitary. The MEN-1 gene has been mapped to chromosome 11q13 and a set of DNA-polymorphic markers localized close to this region provides a useful tool for presymptomatic diagnosis in MEN-1 families. MEN type 2 refers to the inherited forms of medullary thyroid carcinoma (MTC) associated or not with pheochromocytoma and hyperparathyroidism. In MEN-2, germinal mutations of the C-RET proto-oncogene which is localized on chromosome 10q11 have been found in the three clinical and allelic forms of the syndrome respectively, MEN-2 type A, B and familial isolated MTC. Mutations of C-RET are found in more than 90% of MEN-2 patients and genetic screening leads to accurate risk evaluation in families and consequently a preventive treatment of MTC and adrenal neoplasms. Recent discoveries on MEN syndromes and related familial endocrine disorders have a major clinical impact and allow a better understanding of the physiological pathways involved in familial as well as in sporadic endocrine tumor pathogenesis.",
        "Doc_title":"Genetic testing in presymptomatic diagnosis of multiple endocrine neoplasia.",
        "Journal":"Hormone research",
        "Do_id":"9167953",
        "Doc_ChemicalList":"Drosophila Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Chromosomes, Human, Pair 10;Chromosomes, Human, Pair 11;Drosophila Proteins;Female;Humans;Male;Multiple Endocrine Neoplasia;Multiple Endocrine Neoplasia Type 1;Multiple Endocrine Neoplasia Type 2a;Mutation;Pedigree;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"diagnosis;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605810538594435072},
      {
        "Doc_abstract":"Although endocrine tumors are often slow growing, most can be life threatening and are considered resistant to conventional cytotoxic chemotherapy. The recent emergence of molecularly targeted therapy in oncology has brought renewed interest in the development of novel agents for this rare group of diseases. Preliminary results from phase II studies have shown promising results for VEGF and mTOR inhibitors in carcinoid and islet cell carcinoma and RET inhibitors in medullary thyroid carcinoma. Large confirmatory studies are planned.",
        "Doc_title":"Molecular targeted therapy for neuroendocrine tumors.",
        "Journal":"Hematology/oncology clinics of North America",
        "Do_id":"17548041",
        "Doc_ChemicalList":"Antineoplastic Agents;Lymphokines;PDGFD protein, human;Platelet-Derived Growth Factor;Protein Kinase Inhibitors;Protein Kinases;MTOR protein, human;TOR Serine-Threonine Kinases;Proto-Oncogene Proteins c-ret;Receptors, Vascular Endothelial Growth Factor",
        "Doc_meshdescriptors":"Antineoplastic Agents;Humans;Lymphokines;Neuroendocrine Tumors;Platelet-Derived Growth Factor;Protein Kinase Inhibitors;Protein Kinases;Proto-Oncogene Proteins c-ret;Receptors, Vascular Endothelial Growth Factor;Structure-Activity Relationship;TOR Serine-Threonine Kinases",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;antagonists & inhibitors;drug therapy;antagonists & inhibitors;pharmacology;therapeutic use;drug effects;antagonists & inhibitors;antagonists & inhibitors",
        "_version_":1605784614025035776},
      {
        "Doc_abstract":"Medullary thyroid cancer is a type of thyroid cancer of neuroendocrine origin. It occurs in hereditary and sporadic forms, and its aggressive behavior is associated with the clinical presentation and type of RET mutation. Total thyroidectomy remains the ideal choice of treatment. Early diagnosis and treatment are the fundamental for a 100% cure rate. In this study, we present our experience of 3 cases, along with a complete review of the literature derived from a Pubmed Database search.",
        "Doc_title":"Medullary thyroid carcinoma: The third most common thyroid cancer reviewed.",
        "Journal":"Oncology letters",
        "Do_id":"22870127",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605795907793584128},
      {
        "Doc_abstract":"The thyroid parafollicular cell, or commonly named \"C-cell,\" functions in serum calcium homeostasis. Elevations in serum calcium trigger release of calcitonin from the C-cell, which in turn functions to inhibit absorption of calcium by the intestine, resorption of bone by the osteoclast, and reabsorption of calcium by renal tubular cells. Oncogenic transformation of the thyroid C-cell is thought to progress through a hyperplastic process prior to malignancy with increasing levels of serum calcitonin serving as a biomarker for tumor burden. The discovery that multiple endocrine neoplasia type 2 is caused by activating mutations of the RET gene serves to highlight the RET-RAS-MAPK signaling pathway in both initiation and progression of medullary thyroid carcinoma (MTC). Thyroid C-cells are known to express RET at high levels relative to most cell types; therefore, aberrant activation of this receptor is targeted primarily to the C-cell, providing one possible cause of tissue-specific oncogenesis. The role of RET signaling in normal C-cell function is unknown though calcitonin gene transcription appears to be sensitive to RET activation. Beyond RET, the modeling of oncogenesis in animals and screening of human tumors for candidate gene mutations have uncovered mutation of RAS family members and inactivation of Rb1 regulatory pathway as potential mediators of C-cell transformation. A growing understanding of how RET interacts with these pathways, both in normal C-cell function and during oncogenic transformation, will help in the development of novel molecular-targeted therapies. ",
        "Doc_title":"Thyroid C-Cell Biology and Oncogenic Transformation.",
        "Journal":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer",
        "Do_id":"26494382",
        "Doc_ChemicalList":"Biomarkers, Tumor;Calcitonin",
        "Doc_meshdescriptors":"Animals;Biomarkers, Tumor;Calcitonin;Carcinoma, Neuroendocrine;Cell Lineage;Cell Transformation, Neoplastic;Genetic Predisposition to Disease;Humans;Oncogenes;Phenotype;Signal Transduction;Thyroid Gland;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;metabolism;genetics;metabolism;pathology;genetics;metabolism;pathology;metabolism;pathology;genetics;metabolism;pathology",
        "_version_":1605747006528028673},
      {
        "Doc_abstract":"Mutations of RET tyrosine kinase are associated with the development of medullary thyroid cancer (MTC). The heat shock protein (HSP) 90 chaperone is required for folding and stability of RET mutants. HSP90 is a molecular target for the HIV protease inhibitor nelfinavir (NFV).;We hypothesized that treatment with NFV may lead to the inhibition of RET signaling and induction of apoptosis in MTC cells.;Two human MTC cell lines, TT and MZ-CRC-1, which harbor endogenous C634W or M918T RET mutations, respectively, were exposed to clinically achievable concentrations of NFV. JC-1 staining and caspase-3 cleavage assays were performed to measure mitochondrial membrane potential and apoptosis. Activation of RET signaling was examined by Western blot. Autophagy was monitored by the detection of the light-chain 3BII. Expression of HSP90 and LC3B were examined in 36 human MTCs.;At a therapeutic serum concentration (10 M), NFV inhibited the viability of TT and MZ-CRC-1 cells by 55% and 10%, respectively. In a dose-dependent manner, NFV inhibited cyclin D1 and caused caspase-3 cleavage. NFV decreased the level of RET protein and blocked the activation of RET downstream targets (phosphorylated ERK, phosphorylated AKT, and p70S6K/pS6). NFV induced metabolic stress, activated AMP-activated protein kinase and increased autophagic flux. Pharmacological inhibition of autophagy (chloroquine) augmented NFV-inducible cytotoxicity, suggesting that autophagy was protective in NFV-treated cells. NFV led to mitochondrial membrane depolarization and induced both oxidative stress and DNA damage. An antioxidant (n-acetylcysteine) attenuated DNA damage and prevented NFV-inducible apoptosis. HSP90 overexpression was found in 17 of 36 human MTCs and correlated with metastases and RET mutations. LC3B was detected in 20 of 36 human MTCs.;NFV has a wide spectrum of activity against MTC cells, and its cytotoxicity can be augmented by inhibiting autophagy. Expression of NFV molecular targets in metastatic MTC suggests that NFV has a potential to become a thyroid cancer therapeutic agent.",
        "Doc_title":"The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.",
        "Journal":"The Journal of clinical endocrinology and metabolism",
        "Do_id":"24483157",
        "Doc_ChemicalList":"HIV Protease Inhibitors;HSP90 Heat-Shock Proteins;Proto-Oncogene Proteins c-ret;RET protein, human;Nelfinavir",
        "Doc_meshdescriptors":"Adult;Aged;Apoptosis;Autophagy;Carcinoma, Medullary;Cell Line, Tumor;Cell Proliferation;Down-Regulation;Endoplasmic Reticulum Stress;Female;HIV Protease Inhibitors;HSP90 Heat-Shock Proteins;Humans;Male;Middle Aged;Mutation;Nelfinavir;Oxidative Stress;Proto-Oncogene Proteins c-ret;Signal Transduction;Thyroid Neoplasms",
        "Doc_meshqualifiers":"drug effects;drug effects;genetics;metabolism;pathology;drug effects;drug effects;drug effects;pharmacology;genetics;metabolism;pharmacology;drug effects;genetics;metabolism;drug effects;genetics;metabolism;pathology",
        "_version_":1605757434454867968},
      {
        "Doc_abstract":"This paper intends to review for the oral and maxillofacial surgery community the MEN abnormalities generally, to emphasize the maxillofacial abnormalities peculiar to the MEN2B variant particularly, and to demonstrate the importance of early recognition of its most important component, medullary thyroid carcinoma.;The findings in five individuals with confirmed diagnoses of MEN2B are arranged to demonstrate the various manifestations of the disorder, and together represent the largest single group in the oral and maxillofacial surgery literature to date.;Tabulation of the patients' individual findings demonstrates the variants and severity of the disorder, discloses findings not previously emphasized in the literature, and stresses the significance of early recognition of medullary thyroid carcinoma.;The evidence in this study group suggests that the oral mucosal lesions are more commonly neurofibromas than neuromas as previously reported, that the characteristic dental central diastemas may occur independent of tongue size or the presence of oral soft tissue lesions, and that the characteristic apertognathia potentially requires surgical correction.",
        "Doc_title":"Multiple endocrine neoplasia type 2B: maxillofacial significance in 5 cases.",
        "Journal":"Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons",
        "Do_id":"25454714",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Child;Face;Female;Humans;Male;Maxilla;Multiple Endocrine Neoplasia Type 2b;Young Adult",
        "Doc_meshqualifiers":"pathology;pathology;pathology",
        "_version_":1605746811003207684},
      {
        "Doc_abstract":"While there is no doubt that total thyroidectomy is necessary for medullary thyroid carcinoma (MTC) in multiple endocrine neoplasia type 2A (MEN2A) patients, there is still controversy regarding the management of the parathyroid glands. Although most, but not all, endocrine surgeons leave normal-appearing parathyroid glands in situ during thyroid surgery for MEN2A, we have employed total parathyroidectomy with autotransplantation. Between 1994 and 2006, 12 MEN2A patients underwent therapeutic total or completion thyroidectomy and lymph nodes dissection at least in the central compartment for MTC. Total or completion parathyroidectomy with autotransplantation was performed concurrently with above-mentioned surgery. All patients were over 25 years old, and the median age was 48.5 years. There were 5 males and 7 females from 8 families. The average number of transplanted parathyroid glands was 3. Serum calcium and intact PTH levels have been maintained during the median follow up of 107 months in all patients except for one who of died of advanced MTC one year after surgery. Total parathyroidectomy with autotransplantation at the time of primary surgery for MTC, i.e. total thyroidectomy with bilateral central neck dissection, is a feasible approach for managing the risk of hyperparathyroidism.",
        "Doc_title":"Long term parathyroid function following total parathyroidectomy with autotransplantation in adult patients with MEN2A.",
        "Journal":"Endocrine journal",
        "Do_id":"19318731",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Female;Humans;Lymph Node Excision;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Parathyroid Glands;Parathyroidectomy;Thyroidectomy;Transplantation, Autologous",
        "Doc_meshqualifiers":"physiopathology;surgery;physiology;transplantation",
        "_version_":1605820278380691456},
      {
        "Doc_abstract":"Analysis of the RET proto-oncogen is very important for diagnosis and prognosis of medullary thyroid cancer (MTC). Genotype-phenotype correlation is also well known. Here we report features of the largest known family in Turkey with the V804M-mutated RET proto-oncogene.;Thirty members from three generations were evaluated. A RET proto-oncogen mutation, calcitonin (Ct) measurement and thyroid ultrasound were performed on all individuals. Seventeen members had V804M mutation. Fourteen of these patients underwent total thyroidectomy and additional central lymph node dissection for five subjects.;The mean age of patients with MTC was 46.5 (30-61) years. The mean calcitonin level of RET positive members was 13.27 pg/mL (1-49.8 pg/mL). Three had a basal Ct level above normal limits. Seven of the 14 patients were diagnosed with MTC, and two were diagnosed with papillary thyroid cancer without MTC. One patient had central neck metastasis. Hyperparathyroidism or pheochromocytoma was not detected in any case. Patients who were RET negative, had normal Ct levels and no suspected nodule on ultrasound examination.;Our study revealed a relatively good prognosis in patients with V804M mutation. Despite the surgery was performed in older age no advance disease was observed.",
        "Doc_title":"Characterization of V804M-mutated RET proto-oncogene associated with familial medullary thyroid cancer, report of the largest Turkish family.",
        "Journal":"Journal of endocrinological investigation",
        "Do_id":"25501606",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Adult;Carcinoma, Medullary;Female;Humans;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Mutation;Pedigree;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms;Turkey",
        "Doc_meshqualifiers":"congenital;genetics;surgery;genetics;surgery;genetics;genetics;surgery",
        "_version_":1605840233326182400},
      {
        "Doc_abstract":"Medullary thyroid carcinoma (MTC) occurs sporadically in 75% of patients. Metastatic disease is associated with significantly poorer survival. The aim of this study was to identify prognostic markers for progressive MTC and oncogenic factors associated with response to vandetanib therapy.;Clinical courses of 32 patients with sporadic MTC (n=10 pN0cM0, n=8 pN1cM0, n=14 pN1cM1) were compared with genetic profiles of the patients' primary tumour tissue. Analysis for RET proto-oncogene mutations was performed by Sanger sequencing and next-generation sequencing (NGS). The mRNA expression (mRNA count) of 33 targets was measured by nCounter NanoString analysis.;Somatic RET mutations occurred in 21/32 patients. The RET918 mutation was found in 8/14 pN1cM1 patients. BRAF (P=0.019), FGFR2 (P=0.007), FGFR3 (P=0.044) and VEGFC (P=0.042) mRNA expression was significantly lower in pN1cM0/pN1cM1 compared with pN0cM0 patients, whereas PDGFRA (P=0.026) mRNA expression was significantly higher in pN1cM0/pN1cM1 when compared with pN0cM0 patients. Among the 10/32 vandetanib-treated patients, 5 showed partial response (PR), all harbouring the RET918 mutation. mRNA expression of FLT1 (P=0.039), FLT4 (P=0.025) and VEGFB (P=0.042) was significantly higher in therapy responders.;In this study, we identified molecular markers in primary tumour tissue of sporadic MTC associated with the development of metastasis (both lymph node and organ metastasis) as well as response to vandetanib therapy.",
        "Doc_title":"Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.",
        "Journal":"European journal of endocrinology",
        "Do_id":"27283290",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605825378627092480},
      {
        "Doc_abstract":"Thyroid carcinoma is the most commonly diagnosed endocrine malignancy. Its incidence is currently rising worldwide. The discovery of genetic mutations associated with the development of thyroid cancer, such as BRAF and RET, has lead to the development of new drugs which target the pathways which they influence. Despite recent advances, the prognosis of anaplastic thyroid carcinoma is still unfavourable. In this review we look at emerging novel therapies for the treatment of well-differentiated and medullary thyroid carcinoma, and advances and future directions in the management of anaplastic thyroid carcinoma.",
        "Doc_title":"Emerging therapies for thyroid carcinoma.",
        "Journal":"The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland",
        "Do_id":"22233555",
        "Doc_ChemicalList":"Antineoplastic Agents;Biomarkers, Tumor;Protein Kinase Inhibitors",
        "Doc_meshdescriptors":"Antineoplastic Agents;Biomarkers, Tumor;Carcinoma, Neuroendocrine;Humans;Protein Kinase Inhibitors;Signal Transduction;Thyroid Carcinoma, Anaplastic;Thyroid Neoplasms",
        "Doc_meshqualifiers":"therapeutic use;metabolism;therapeutic use;drug therapy;metabolism",
        "_version_":1605896508182364160},
      {
        "Doc_abstract":"Patients with Multiple Endocrine Neoplasia type 2 (MEN 2) are at high risk of developing aggressive medullary thyroid carcinoma (MTC) in childhood, with the highest risk in those with MEN type 2B (of whom >95% have an M918T RET proto-oncogene mutation). Metastatic MTC has been reported as young as 3months of age. Current guidelines recommend prophylactic thyroidectomy within the first year of life for MEN 2B.;We report a 9-week-old infant with MTC due to familial MEN 2B. A full-term male infant, born to a mother with known MEN 2B and metastatic MTC, had an M918T RET proto-oncogene mutation confirmed at 4weeks of age. He underwent prophylactic total thyroidectomy at 9weeks of age. Pathology showed a focal calcitonin-positive nodule (2.5mm), consistent with microscopic MTC.;This case highlights the importance of early prophylactic thyroidectomy in MEN 2B. Although current guidelines recommend surgery up to a year of life, MTC may occur in the first few weeks of life, raising the question of how early we should intervene. In this report, we discuss the risks, benefits and barriers to performing earlier thyroidectomy, soon after the first month of life, and make suggestions to facilitate timely intervention. Prenatal anticipatory surgical scheduling could be considered in familial MEN 2B. Multidisciplinary collaboration between adult and pediatric specialists is key to the optimal management of the infant at risk.",
        "Doc_title":"Medullary thyroid cancer in a 9-week-old infant with familial MEN 2B: Implications for timing of prophylactic thyroidectomy.",
        "Journal":"International journal of pediatric endocrinology",
        "Do_id":"22992277",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605845135801712640},
      {
        "Doc_abstract":"Despite development of current targeted therapies for medullary thyroid cancer (MTC), long-term survival remains unchanged. Recently isolated novel withanolide compounds from Solanaceae physalis are highly potent against MTCs. We hypothesize that these withanolides uniquely inhibit RET phosphorylation and the mammalian target of rapamycin (mTOR) pathway in MTC cells as a mechanism of antiproliferation and apoptosis.;MTC cells were treated with novel withanolides and MTC-targeted drugs. In vitro studies assessed cell viability and proliferation (MTS; trypan blue assays), apoptosis (flow cytometry with Annexin V/PI staining; confirmed by Western blot analysis), long-term cytotoxic effects (clonogenic assay), and suppression of key regulatory proteins such as RET, Akt, and mTOR (by Western blot analysis).;The novel withanolides potently reduced MTC cell viability (half maximal inhibitory concentration [IC(50)], 270-2,850 nmol/L; 250-1,380 nmol/L for vandetanib; 360-1,640 nmol/L for cabozantinib) with induction of apoptosis at <1,000 nmol/L of drug. Unique from other targeted therapies, withanolides suppressed RET and Akt phosphorylation and protein expression (in a concentration- and time-dependent manner) as well as mTOR activity and translational activity of 4E-BP1 and protein synthesis mediated by p70S6kinase activation at IC(50) concentrations.;Novel withanolides from Physalis selectively and potently inhibit MTC cells in vitro. Unlike other MTC-targeted therapies, these compounds uniquely inhibit both RET kinase activity and the Akt/mTOR prosurvival pathway. Further translational studies are warranted to evaluate their clinical potential.",
        "Doc_title":"Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway.",
        "Journal":"Surgery",
        "Do_id":"23158190",
        "Doc_ChemicalList":"Antineoplastic Agents, Phytogenic;Withanolides;MTOR protein, human;TOR Serine-Threonine Kinases;Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Antineoplastic Agents, Phytogenic;Apoptosis;Carcinoma, Neuroendocrine;Cell Cycle;Cell Line, Tumor;Cell Proliferation;Humans;Phosphorylation;Proto-Oncogene Proteins c-ret;Signal Transduction;TOR Serine-Threonine Kinases;Thyroid Neoplasms;Tumor Stem Cell Assay;Withanolides",
        "Doc_meshqualifiers":"therapeutic use;drug effects;drug effects;drug effects;metabolism;drug effects;antagonists & inhibitors;metabolism;drug therapy;metabolism;pathology;therapeutic use",
        "_version_":1605784809559293952},
      {
        "Doc_abstract":"Traditionally available treatments, like cytotoxic chemotherapy and external-beam radiation therapy, are limited and essentially ineffective for metastatic medullary thyroid carcinoma (MTC). In the last decade, small-molecule tyrosine kinase inhibitors (TKI) have been introduced in the field of thyroid cancer, after having been shown effective in a wide variety of other tumors. This review focuses on vandetanib (ZD6474, Zactima; AstraZeneca) and its role in the treatment of MTC. Vandetanib is an oral TKI that targets VEGF receptors 2 and 3, RET, and at higher concentrations, the epidermal growth factor (EGF) receptor. This drug has been tested in two important phase II studies which demonstrated that both the 100 and 300 mg/day dosage of vandetanib have antitumor activity on advanced MTC. A phase III trial (ZETA trial) evaluating vandetanib in 331 patients with locally advanced or metastatic MTC showed a significant prolongation of PFS for patients receiving vandetanib compared with placebo. Toxicity surveillance in all studies reported high rates of adverse effects with diarrhea, rash, fatigue and nausea being the most commonly experienced by patients. Vandetanib is currently approved in the United States for unresectable locally advanced or metastatic MTC and has become a new standard of care in this rare and indolent pathology.",
        "Doc_title":"Role of vandetanib in the management of medullary thyroid cancer.",
        "Journal":"Biologics : targets & therapy",
        "Do_id":"22500115",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605807037316333568},
      {
        "Doc_abstract":"This study was aimed to demonstrate the clinical benefits of rearranged during transfection (RET) genetic screening in patients with apparently sporadic medullary thyroid cancer (MTC) not only to identify the hereditary nature of the disease in the index case but also to discover family members harbouring the same germline mutations (i.e. gene carriers) who are unaware of their condition.;RET genetic screening allowed the identification of germline RET mutations in apparently sporadic MTC resulting in their re-classification as hereditary forms.;RET genetic screening was performed in 729 apparently sporadic MTC patients by direct sequencing RET exons 5, 8, 10, 11 and 13-16. Clinical and biochemical evaluation of gene carriers was also performed.;We discovered an unsuspected germline RET mutation in 47 of 729 (65%) apparently sporadic MTC who were re-classified as hereditary. We found 60 of 146 (411%) gene carriers, 35 of whom had biochemical or clinical evidence of MTC. Thirty gene carriers underwent total thyroidectomy and 27 of 30 (90%) were persistently cured after a mean follow-up of 60 years. As a further result of RET genetic screening, we observed a significantly higher prevalence of familial medullary thyroid cancer (FMTC) in our series with respect to the largest series of the International RET Consortium (P = 00002).;RET genetic screening of patients with apparently sporadic MTC represents a major tool for the preclinical diagnosis and early treatment of unsuspected affected family members and allows the identification of a relevant percentage of hidden FMTC.",
        "Doc_title":"RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC).",
        "Journal":"Clinical endocrinology",
        "Do_id":"21054478",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Aged, 80 and over;Carcinoma;Carcinoma, Medullary;Carcinoma, Neuroendocrine;Female;Genetic Testing;Humans;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Neoplastic Syndromes, Hereditary;Polymerase Chain Reaction;Thyroid Neoplasms;Young Adult",
        "Doc_meshqualifiers":"diagnosis;genetics;congenital;methods;genetics;diagnosis;genetics;diagnosis;genetics",
        "_version_":1605824531661848576},
      {
        "Doc_abstract":"Treatment of medullary thyroid carcinoma (MTC) includes total thyroidectomy with at least bilateral central neck dissection. Systematic measurement of thyrocalcitonin (CT) levels in thyroid nodules allows for early diagnosis of MTC. As central neck dissection (CND) is associated with high morbidity, the aim of this study was to investigate the necessity of this procedure in the treatment of sporadic medullary thyroid microcarcinoma (S-mMTC).;Prospective multicentric study including 43 patients with sporadic micro-MTC who underwent CND between January 1991 and August 2001.;26 women and 17 men with sporadic micro-MTC, aged 28-87 (mean age was 58 years), without family history of multiple endocrine neoplasia, underwent surgery. Total thyroidectomy was performed in all patients and combined with 'picking' (n=7) or CND (n=36). Size of tumours ranged from 0.2 to 9mm (mean size was 4.1mm). Solitary (32/43 patients) and multiple S-mMTC lesions (11/43 patients) were seen. 601 lymph nodes from the 41 subclinical patients were analysed. Mean follow-up period for these patients was 32 months. No mutations in the RET oncogene were seen.;As lymph node involvement is uncommon in S-mMTC, systematic CND is of questionable value.",
        "Doc_title":"Central neck dissection in the management of sporadic medullary thyroid microcarcinoma.",
        "Journal":"European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology",
        "Do_id":"15925476",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Carcinoma, Medullary;Female;Humans;Lymphatic Metastasis;Male;Middle Aged;Neck Dissection;Prospective Studies;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"pathology;surgery;pathology;surgery",
        "_version_":1605906029041680384},
      {
        "Doc_abstract":"Carcinoma of the thyroid gland is the most common malignancy of the endocrine system. Differentiated tumors are often curable with surgical resection and radioactive iodine. A small percentage of such patients, however, do not undergo remission and need new therapeutic approaches. Both anaplastic and medullary thyroid carcinomas exhibit aggressive behavior and are usually resistant to current therapeutic modalities. Thyroid carcinoma represents a fascinating model and a particularly promising paradigm for targeted therapy because some of the key oncogenic events are activating mutations of genes coding for tyrosine kinases, and these occur early in cancer development. A prototype is the RET proto-oncogene, a receptor tyrosine kinase, which is a key regulator of development and a 'hotspot' for oncogenic mutations. Mutations in the RET proto-oncogene have been identified as causative for papillary carcinoma and familial medullary thyroid carcinoma, making it an attractive target for selective inhibition in these subtypes. ZD 6474 has shown promising activity in preclinical models against RET kinase, and its contemporary inhibition of vascular endothelial growth factor and epidermal growth factor pathways renders it a very attractive drug for clinical trials in thyroid cancer. Activating point mutation of B-RAF can occur early in the development of papillary carcinoma. Moreover, papillary carcinomas with these mutations have more aggressive properties and are diagnosed more often at an advanced stage. Clinical evaluation of B-RAF-targeting drugs is undergoing and trials in thyroid cancer are planned. Agents that restore radioiodine uptake, such as histone deacetylase inhibitors and retinoids, represent another exciting field in new drug development in thyroid cancer.",
        "Doc_title":"New molecular targeted therapies in thyroid cancer.",
        "Journal":"Anti-cancer drugs",
        "Do_id":"16940797",
        "Doc_ChemicalList":"Antineoplastic Agents;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Antineoplastic Agents;Carcinoma;Cell Membrane;Cell Nucleus;Cytoplasm;Humans;Models, Biological;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms",
        "Doc_meshqualifiers":"metabolism;pharmacology;therapeutic use;drug therapy;drug effects;metabolism;drug effects;metabolism;drug effects;metabolism;therapeutic use;genetics;metabolism;metabolism;drug therapy",
        "_version_":1605742674945507329},
      {
        "Doc_abstract":"Early diagnosis for thyroid carcinoma, potentially before neoplastic transformation has taken place, would allow preventive and thus curative surgical intervention. Identifying and characterizing the RET proto-oncogene as the disease-causing gene for hereditary medullary thyroid carcinoma and then establishing a genotype-phenotype correlation served as the prerequisite for the risk-adapted prophylactic surgical approach practised today. Carriers of RET mutations associated with very aggressive tumour behaviour should be subjected to prophylactic thyroidectomy within the 1st year of life. For individuals harbouring less virulent types of mutations, prophylactic intervention is recommended at 5-20 years. Although genetic research on hereditary nonmedullary thyroid cancer is still in progress, initial results indicate the need of prophylactic surgical treatment also for this subgroup of thyroid neoplasia.",
        "Doc_title":"[Prophylactic thyroid surgery].",
        "Journal":"Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen",
        "Do_id":"16328197",
        "Doc_ChemicalList":"Codon;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Adult;Carcinoma, Medullary;Cell Transformation, Neoplastic;Child;Child, Preschool;Codon;DNA Mutational Analysis;Early Diagnosis;Genetic Testing;Genotype;Humans;Infant;Multiple Endocrine Neoplasia Type 2a;Phenotype;Proto-Oncogene Proteins c-ret;Risk Assessment;Thyroid Gland;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"genetics;mortality;pathology;prevention & control;genetics;pathology;genetics;genetics;mortality;pathology;surgery;genetics;pathology;genetics;mortality;pathology;prevention & control",
        "_version_":1605851515035058176},
      {
        "Doc_abstract":"In multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid cancer (FMTC), the majority of germline mutations are restricted to specific positions in exons 10 and 11 of the RET gene. However, germline mutations may very occasionally occur in other exons, including exon 14 of the RET gene. Interestingly, an increased frequency of a rare germline sequence variant of the RET exon 14, S836S, has been detected in patients with sporadic medullary thyroid cancer (MTC), and this variant has been proposed to play a role in the genesis of MTC and, perhaps, FMTC. In this study we report the segregation of a germline V804L mutation and a germline sequence variant S836S in exon 14 of the RET gene in an extended Hungarian FMTC kindred comprising 80 individuals of four generations. Molecular analysis of the RET gene was performed by direct DNA sequencing in 23 family members, of whom 12 had the V804L mutation, three had the V804L mutation and S836S polymorphism in separate alleles, and six had the S836S polymorphism, all in heterozygous forms. Two of the family members had neither mutation nor polymorphism of the RET gene. Three of the family members who had the V804L mutation and one member who could not be tested for mutation were operated for non-metastatic MTC, while one member with MTC who had the V804L mutation refused surgery. In all patients affected with MTC, the disease developed relatively late in life and never caused death. None of the other family members carrying the V804L mutation and/or the S836S polymorphism had clinical or biochemical evidence of MTC. These observations suggest that the co-existence of the V804L mutation and S836S polymorphism in separate alleles does not seem to aggravate the relatively low-risk disease phenotype characteristic in most patients with codon 804 mutations of the RET exon 14.",
        "Doc_title":"Segregation of the V804L mutation and S836S polymorphism of exon 14 of the RET gene in an extended kindred with familial medullary thyroid cancer.",
        "Journal":"Clinical genetics",
        "Do_id":"12694233",
        "Doc_ChemicalList":"DNA Primers;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Carcinoma, Medullary;DNA Mutational Analysis;DNA Primers;Female;Genetic Variation;Humans;Hungary;Male;Multiple Endocrine Neoplasia Type 2a;Pedigree;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics",
        "_version_":1605826770337005568},
      {
        "Doc_abstract":"In hereditary medullary thyroid carcinoma (HMTC), prophylactic surgery is the only curative option, which should be properly defined both in time and extent.;To identify and characterize prognostic factors associated with disease-free survival (DFS) in children from HMTC families.;We conducted a retrospective analysis of a multi-center cohort of 170 patients below age 21 at surgery. Demographic, clinical, genetic, biological data [basal and pentagastrine-stimulated calcitonin (CT and CT/Pg, respectively)], and tumor node metastasis (TNM) status were collected. DFS was assessed based on basal CT levels. Kaplan-Meier curves, Cox regression, and logistic regression models were used to determine factors associated with DFS and TNM staging.;No patients with a preoperative basal CT <31 ng/ml had persistent or recurrent disease. Medullary thyroid carcinoma defined by a diameter 10 mm [hazard ratio (HR): 6.0; 95% confidence interval (95% CI): 1.8-19.8] and N1 status (HR: 20.8; 95% CI: 3.9-109.8) were independently associated with DFS. Class D genotype [odds ratio (OR): 48.5, 95% CI: 10.6-225.1], preoperative basal CT >30 ng/liter (OR: 43.4, 95% CI: 5.2-359.8), and age >10 (OR: 5.5, 95% CI: 1.4-21.8) were associated with medullary thyroid carcinoma 10 mm. No patient with a preoperative basal CT <31 ng/ml had a N1 status. Class D genotype (OR: 48.6, 95% CI: 8.6-274.1), and age >10 (OR: 4.6, 95% CI: 1.1-19.0) were associated with N1 status.;In HMTC patients, DFS is best predicted by TNM staging and preoperative basal CT level below 30 pg/ml. Basal CT, class D genotype, and age constitute key determinants to decide preoperatively timely surgery.",
        "Doc_title":"Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines.",
        "Journal":"The Journal of clinical endocrinology and metabolism",
        "Do_id":"21190982",
        "Doc_ChemicalList":"Calcitonin;DNA;Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Adolescent;Adult;Calcitonin;Carcinoma, Medullary;Child;Child, Preschool;DNA;Disease-Free Survival;Female;Genotype;Guidelines as Topic;Humans;Infant;Longitudinal Studies;Male;Micronucleus, Germline;Multiple Endocrine Neoplasia Type 2a;Mutation;Prognosis;Proto-Oncogene Proteins c-ret;Retrospective Studies;Reverse Transcriptase Polymerase Chain Reaction;Risk Assessment;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"blood;genetics;pathology;surgery;genetics;genetics;genetics;genetics;genetics;pathology;surgery",
        "_version_":1605905787194966016},
      {
        "Doc_abstract":"In the thyroid, primary neuroendocrine tumors encompass medullary thyroid carcinoma (MTC) and, rarely, other tumors such as paragangliomas. MTCs are derived from C-cells and express calcitonin and neuroendocrine markers. Besides classic MTC, some reports have documented thyroid neuroendocrine tumors, which show no calcitonin expression and raise difficult diagnostic problems. A 76-year-old man presented with a mass in the left thyroid with neither serological calcitonin elevation nor familial history. A thorough clinico-laboratorial study did not disclose any other mass elsewhere. A left hemithyroidectomy was performed, and the histological examination revealed a neuroendocrine carcinoma resembling a paraganglioma-like MTC displaying unequivocal signs of vascular invasion. Immunohistochemically, the tumor cells showed reactivity for chromogranin A, synaptophysin, thyroid transcription factor-1 (TTF-1), paired box gene 8 (PAX8), cytokeratins (AE1/AE3 and CK8/18), and calcitonin gene-related peptide (CGRP) and negativity for calcitonin, carcinoembryonic antigen, TTF-2, thyroperoxidase, and thyroglobulin. In situ hybridization showed that the tumor cells lacked expression for calcitonin and thyroglobulin mRNA. Genetic analysis did not disclose any RET mutation. A diagnosis of C-cell-derived primary neuroendocrine carcinoma of the thyroid without calcitonin expression was made, and the patient remains free of metastasis or recurrence 18 months after surgery. ",
        "Doc_title":"C-cell-derived calcitonin-free neuroendocrine carcinoma of the thyroid: the diagnostic importance of CGRP immunoreactivity.",
        "Journal":"International journal of surgical pathology",
        "Do_id":"24599901",
        "Doc_ChemicalList":"Calcitonin",
        "Doc_meshdescriptors":"Aged;Calcitonin;Carcinoma, Neuroendocrine;Humans;Immunohistochemistry;In Situ Hybridization;Male;Thyroid Neoplasms",
        "Doc_meshqualifiers":"biosynthesis;diagnosis;diagnosis",
        "_version_":1605896506307510272},
      {
        "Doc_abstract":"Evaluation of treatment of children who are proven carriers of a multiple endocrine neoplasia type 2 (MEN 2)-associated rearranged during transfection (RET) gene mutation.;Retrospective case study and review of the literature.;Between 1976 and 2005, 6 boys and 14 girls with a proven RET mutation or biochemical indication of MEN 2 had thyroid surgery at the University Medical Center, Groningen, The Netherlands. The median age was 10 years (range: 0-08). Preoperative assessment, surgical procedure, pathological findings, postoperative complications and treatment results were studied and compared with data from the literature.;All 20 children underwent total thyroidectomy. In 17 children with preoperatively abnormal basal or stimulated calcitonin levels, total thyroidectomy was combined with tracheo-oesophageal exploration (n = 6) or central compartment dissection (n = 11). C-cell hyperplasia was found in 19 cases (95%) and medullary thyroid carcinoma in 14 (70%; aged 3-18 years). Lymph-node metastases were found in 3 children (15%), all over the age of 10. They underwent additional selective lateral neck dissection, unilateral in 2 cases and bilateral in 1. Two children developed hypoparathyroidism postoperatively, no recurrent laryngeal-nerve palsy was observed. All patients are clinically free of disease after a median follow-up of 9 years (range: 0.6-27). The patients with node metastases still have biochemical evidence of disease. The literature indicates that the progression of the malignant transformation to medullary thyroid carcinoma is connected to the type of RET-mutation. The treatment plan depends on the type of mutation.;Medullary thyroid cancer occurs at a very young age in carriers ofgermline RET mutations. In patients with high-risk mutations prophylactic thyroidectomy is likely to be recommended before the child reaches the age of 2. Elective central lymph-node dissection can be omitted in this instance. After this age, however, the risk of lymph-node metastases increases and, for cases with increased basal or stimulated calcitonin levels, total thyroidectomy with central compartment dissection is indicated.",
        "Doc_title":"[Prophylactic thyroidectomy in children who are carriers of a multiple endocrine neoplasia type 2 mutation: description of 20 cases and recommendations based on the literature].",
        "Journal":"Nederlands tijdschrift voor geneeskunde",
        "Do_id":"16503023",
        "Doc_ChemicalList":"Calcitonin;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Calcitonin;Carcinoma, Medullary;Child;Child, Preschool;Disease-Free Survival;Female;Follow-Up Studies;Germ-Line Mutation;Heterozygote;Humans;Infant;Lymph Node Excision;Male;Multiple Endocrine Neoplasia Type 2a;Proto-Oncogene Proteins c-ret;Retrospective Studies;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;prevention & control;surgery;genetics;prevention & control;surgery;genetics;genetics;prevention & control;surgery;methods",
        "_version_":1605746810667663360},
      {
        "Doc_abstract":"In endocrine malignancies (thyroid carcinoma, parathyroid carcinoma, adrenocortical carcinoma, malignant pheochromocytoma) surgery is currently the treatment of choice, in case of differentiated thyroid carcinomas followed by 131-I-radioiodine administration. This approach is often successful in early disease; however, treatment options for advanced endocrine malignancies remain unsatisfactory and prognosis is poor. In particular, cytotoxic chemotherapy and radiation therapy often show only limited and transient efficacy and are associated with significant toxicity. Thus, new treatment options are urgently needed. Advances in the understanding of the molecular pathology of endocrine malignancies has recently led to identification of key events in endocrine oncogenesis (e.g. oncogenic RET mutations in medullary thyroid carcinoma or RET/PTC rearrangements in papillary thyroid carcinoma). These new insights are increasingly matched by new compounds (e.g. tyrosine kinase inhibitors) targeting signaling pathways essential for tumor cell survival, proliferation and metastases. Accordingly, a rapidly growing number of preclinical investigations and early clinical trials in endocrine malignancies have been initiated. First results of \"targeted therapies\" in medullary and differentiated thyroid carcinoma are impressive: phase II trials targeting RET or VEGF receptor kinases led to objective tumor response in up to 50% of patients. This review covers these recent molecular and clinical advances which most likely will dramatically alter the treatment of endocrine malignancies within the coming decade.",
        "Doc_title":"New targets and therapeutic approaches for endocrine malignancies.",
        "Journal":"Pharmacology & therapeutics",
        "Do_id":"19374919",
        "Doc_ChemicalList":"Antibodies, Monoclonal;Protein Kinase Inhibitors",
        "Doc_meshdescriptors":"Antibodies, Monoclonal;Clinical Trials as Topic;Drug Design;Endocrine Gland Neoplasms;Humans;Protein Kinase Inhibitors",
        "Doc_meshqualifiers":"pharmacology;therapeutic use;drug therapy;metabolism;pathology;pharmacology;therapeutic use",
        "_version_":1605842510852128768},
      {
        "Doc_abstract":"We report the case of a 24-yr-old man with a typical phenotype of multiple endocrine neoplasia type 2B (MEN 2B). The patient had previously undergone minor surgery to remove multiple tumors on the lip, but he had no further examinations. MEN 2B was suspected owing to characteristic multiple ganglioneuromatosis when the patient presented with a goiter associated with high levels of plasma calcitonin and CEA. Aspiration biopsy cytology revealed medullary thyroid carcinoma (MTC), and abdominal computed tomography and nuclear scanning with metaiodobenzylguanidine revealed bilateral adrenomedullary tumors. Adrenomedullary function tests showed high levels of serum and urinary fractionated catecholamines, and genetic analysis showed a point mutation in the codon 918 (M918T) of the RET gene. The patient was diagnosed with MEN 2B and underwent right adrenalectomy and total thyroidectomy. No distant metastasis of the MTC was noted although MEN 2B had remained undiagnosed since the ganglioneuromatosis was first noticed. MEN 2B is a rare hereditary disorder, but the occurrence of characteristic ganglioneuromatosis was quite helpful in making the diagnosis.",
        "Doc_title":"A case of multiple endocrine neoplasia type 2B undiagnosed for many years despite its typical phenotype.",
        "Journal":"Endocrine",
        "Do_id":"11720239",
        "Doc_ChemicalList":"Carcinoembryonic Antigen;Catecholamines;Drosophila Proteins;Proto-Oncogene Proteins;Calcitonin;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Adrenal Gland Neoplasms;Adrenal Medulla;Adrenalectomy;Adult;Biopsy, Needle;Calcitonin;Carcinoembryonic Antigen;Carcinoma, Medullary;Catecholamines;Conjunctival Neoplasms;Drosophila Proteins;Ganglioneuroma;Goiter;Humans;Male;Multiple Endocrine Neoplasia Type 2b;Phenotype;Point Mutation;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms;Thyroidectomy;Tomography, X-Ray Computed;Tongue Neoplasms",
        "Doc_meshqualifiers":"complications;diagnosis;surgery;blood;blood;complications;diagnosis;surgery;blood;urine;complications;diagnosis;complications;diagnosis;complications;diagnosis;genetics;genetics;genetics;complications;diagnosis;surgery;complications;diagnosis",
        "_version_":1605758882400960512},
      {
        "Doc_abstract":"According to the literature, thyroid nodules (TNs) are quite rare in the first two decades of life and are predominantly non-cancerous, although cancerous TNs are more common in the first two decades of life than in adults. Therefore, it is important for clinicians to distinguish benign from malignant lesions preoperatively because the latter require a total thyroidectomy with or without neck lymph node dissection. A careful work-up and a fine-needle aspiration biopsy (FNAB) are mandatory to improve the preoperative diagnosis. High-resolution thyroid ultrasound and real-time elastosonography are adjuvant presurgical tools in selecting patients for surgery, particularly those with indeterminate or non-diagnostic cytology. Elevated thyroid-stimulating hormone (TSH) level in a patient with a thyroid nodule is a new laboratory predictor of thyroid cancer risk. The majority of thyroid carcinomas derive from the follicular cell, whereas medullary thyroid carcinoma (MTC) derives from calcitonin-producing cells. Patients with MTC are screened for germ-line RET mutations to detect carriers and identify family members for prophylactic or therapeutic thyroidectomy. ",
        "Doc_title":"Thyroid nodules.",
        "Journal":"Best practice & research. Clinical endocrinology & metabolism",
        "Do_id":"24629865",
        "Doc_ChemicalList":"DNA-Binding Proteins;Nuclear Proteins;TRIM27 protein, human;BRAF protein, human;Proto-Oncogene Proteins B-raf",
        "Doc_meshdescriptors":"Adolescent;Biopsy, Fine-Needle;Carcinoma, Neuroendocrine;Child;Child, Preschool;DNA-Binding Proteins;Humans;Infant, Newborn;Nuclear Proteins;Proto-Oncogene Proteins B-raf;Thyroid Gland;Thyroid Neoplasms;Thyroid Nodule;Ultrasonography;Young Adult",
        "Doc_meshqualifiers":"genetics;genetics;genetics;diagnostic imaging;diagnosis;diagnosis;diagnostic imaging;genetics;surgery",
        "_version_":1605792167543963648},
      {
        "Doc_abstract":"Pheochromocytomas (Pheo) can occur sporadically, isolated or in association with other neuroendocrine lesions. In multiple endocrine neoplasia type 2A (MEN-2A), Pheo is associated to medullary thyroid carcinoma (MTC) or its precursor, C-cell hyperplasia (CCH) and parathyroid hyperplasia. Genetic screening provides early diagnosis and preventive treatment. In order to validate DNA analysis as a reliable method of early identification of gene carriers, we compared the results of genetic screening with clinical, biochemical, imaging and pathological findings in the members of an affected family.;The diagnosis of a bilateral necrotic Pheo in a female patient led to the study of a family with four generations, aged 3 to 78 years (mean = 30.3 yrs). The study included a clinical examination; basal and pentagastrin stimulated calcitonin values; urinary catecholamines and their metabolites; serum calcium and a genetic study (direct sequence of PCR products from genomic DNA isolated from leucocytes using specific primers in exon 11 of the RET protooncogene of chromosome 10). The radiologic study, gammagraphic study (131I-MIBG) and magnetic resonance study were performed in members with clinical suspicion of Pheo.;Seven out of nine patients had a mutation on codon 634 of exon 11 of RET (TGC-CGC), leading to cysteine arginine substitution in the codified protein; all gene carriers had biochemical markers of MTC/CCH and four of Pheo. The Pheo patients underwent adrenalectomy (bilateral in three) and all the gene carriers underwent prophylactic thyroidectomy. The pathologic findings were: MTC in four (metastasized in one); CCH in three and parathyroid hyperplasia in one.;Phenotypic penetration of RET mutation was 100% for MTC/CCH, but only 57% of the gene carriers had Pheo. Genetic screening allowed early prophylactic treatment in four out of seven patients; pathologic findings revealed several evolutionary stages of the disease. Patients not yet showing Pheo are under close clinical and laboratory surveillance.",
        "Doc_title":"Multiple endocrine neoplasia type 2A. Study of a family.",
        "Journal":"Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology",
        "Do_id":"10731788",
        "Doc_ChemicalList":"Codon;Drosophila Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Adolescent;Adrenal Gland Neoplasms;Adult;Aged;Child;Child, Preschool;Codon;Drosophila Proteins;Female;Heterozygote;Humans;Hypertension;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Mutation;Pedigree;Phenotype;Pheochromocytoma;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases",
        "Doc_meshqualifiers":"diagnosis;genetics;pathology;genetics;diagnosis;genetics;pathology;diagnosis;genetics;pathology;diagnosis;genetics;pathology;genetics;genetics",
        "_version_":1605804218159988736},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2B (MEN 2B) is a rare disease caused by germline mutations in the RET proto-oncogene and is transmitted in an autosomal dominant fashion. It is characterized by medullary thyroid carcinoma, pheochromocytoma and mucosal neuroma developing in the tongue, lip, intestinal tract, palate etc. Among these neoplasias, mucosal neuroma generally develops from early childhood. Therefore, early detection and proper treatment can minimize the disease course. Here we describe a 9-year-old male who presented with multiple verrucous papules and nodules on his lips, tongue and gingiva that were there since birth. Histologic findings of his lips and tongue showed well-defined nerve bundles and DNA analysis revealed a M918T mutation at codon 918 of the RET oncogene. He was diagnosed early as having MEN 2B according to his genetic and phenotypic features.",
        "Doc_title":"Multiple Endocrine Neoplasia Type 2B: Early Diagnosis by Multiple Mucosal Neuroma and Its DNA Analysis.",
        "Journal":"Annals of dermatology",
        "Do_id":"21165219",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605883239337033728},
      {
        "Doc_abstract":"The origin, characteristics, and lifetime risk for the following five types of hereditary cancer (HCS) syndromes are briefly described in this review: hereditary breast and ovarian cancer (HBOC) syndrome, familial adenomatous polyposis (FAP), and hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, hereditary diffuse gastric cancer (HDGC) syndrome, and medullary thyroid carcinoma (MTC). Most are caused by mutations in tumor suppressor genes. In HCS, a single copy of the mutated tumor suppressor gene is inherited, and mutation of the second wild type allele of the gene is required for tumorigenesis. Patients with HCS have a higher than normal risk of a second malignancy. Management strategies to address increased cancer risk in HCS include genetic counseling and testing, targeted surveillance, chemoprevention, and prophylactic surgery. Genetic testing for high-risk family members is strongly recommended. Available data indicate surgical prophylaxis is more successful than surveillance in reducing cancer risk in carriers of BRCA, CDH1, APC, and RET mutation.",
        "Doc_title":"Molecular genetics and management strategies in hereditary cancer syndromes.",
        "Journal":"The Journal of the Kentucky Medical Association",
        "Do_id":"12674901",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Genetic Counseling;Genetic Testing;Humans;Molecular Biology;Neoplasms;Neoplasms, Second Primary;Neoplastic Syndromes, Hereditary",
        "Doc_meshqualifiers":"methods;prevention & control;genetics;genetics;therapy",
        "_version_":1605752795664744448},
      {
        "Doc_abstract":"In 1995, the incidence of childhood thyroid cancer in England and Wales was only 0.5 cases per million children per year. Papillary cancers in younger children were histologically distinct from tumors in older individuals. The incidence of thyroid cancer in the vicinity of Chernobyl increased by 62 times within 5 years of the nuclear explosion. Mutations of the RET protooncogene (a growth factor receptor) occur in nearly all familial medullary thyroid carcinomas and may be used for family screening. RET is involved in chromosomal rearrangements in a majority of childhood papillary thyroid cancers. Fine-needle aspiration biopsy identifies the childhood thyroid nodules that are at greatest risk for cancer. It should be noted, however, that approximately 2% of aspirates are falsely negative. The adequacy of unilateral surgery for papillary thyroid cancers is controversial. Aggressive surgery for persistent medullary carcinoma produces remission in one third of patients. Novel radionuclide techniques are useful in detecting and treating metastatic medullary carcinoma.",
        "Doc_title":"Thyroid neoplasia in children.",
        "Journal":"Current opinion in pediatrics",
        "Do_id":"9300200",
        "Doc_ChemicalList":"Drosophila Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Biopsy, Needle;Child;Cocarcinogenesis;Drosophila Proteins;England;Gene Rearrangement;Humans;Incidence;Mutation;Neoplasms, Radiation-Induced;Power Plants;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Radioactive Hazard Release;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms;Ukraine;Wales",
        "Doc_meshqualifiers":"epidemiology;genetics;genetics;diagnosis;epidemiology;therapy;genetics;genetics;diagnosis;epidemiology;therapy;epidemiology",
        "_version_":1605818717451583488},
      {
        "Doc_abstract":"Multiple endocrine neoplasia (MEN) is characterized by the occurrence of tumors involving two or more endocrine glands within a single patient. Four major forms of MEN, which are autosomal dominant disorders, are recognized and referred to as: MEN type 1 (MEN1), due to menin mutations; MEN2 (previously MEN2A) due to mutations of a tyrosine kinase receptor encoded by the rearranged during transfection (RET) protoncogene; MEN3 (previously MEN2B) due to RET mutations; and MEN4 due to cyclin-dependent kinase inhibitor (CDNK1B) mutations. Each MEN type is associated with the occurrence of specific tumors. Thus, MEN1 is characterized by the occurrence of parathyroid, pancreatic islet and anterior pituitary tumors; MEN2 is characterized by the occurrence of medullary thyroid carcinoma (MTC) in association with phaeochromocytoma and parathyroid tumors; MEN3 is characterized by the occurrence of MTC and phaeochromocytoma in association with a marfanoid habitus, mucosal neuromas, medullated corneal fibers and intestinal autonomic ganglion dysfunction, leading to megacolon; and MEN4, which is also referred to as MENX, is characterized by the occurrence of parathyroid and anterior pituitary tumors in possible association with tumors of the adrenals, kidneys, and reproductive organs. This review will focus on the clinical and molecular details of the MEN1 and MEN4 syndromes. The gene causing MEN1 is located on chromosome 11q13, and encodes a 610 amino-acid protein, menin, which has functions in cell division, genome stability, and transcription regulation. Menin, which acts as scaffold protein, may increase or decrease gene expression by epigenetic regulation of gene expression via histone methylation. Thus, menin by forming a subunit of the mixed lineage leukemia (MLL) complexes that trimethylate histone H3 at lysine 4 (H3K4), facilitates activation of transcriptional activity in target genes such as cyclin-dependent kinase (CDK) inhibitors; and by interacting with the suppressor of variegation 3-9 homolog family protein (SUV39H1) to mediate H3K methylation, thereby silencing transcriptional activity of target genes. MEN1-associated tumors harbor germline and somatic mutations, consistent with Knudson's two-hit hypothesis. Genetic diagnosis to identify individuals with germline MEN1 mutations has facilitated appropriate targeting of clinical, biochemical and radiological screening for this high risk group of patients for whom earlier implementation of treatments can then be considered. MEN4 is caused by heterozygous mutations of CDNK1B which encodes the 196 amino-acid CDK1 p27Kip1, which is activated by H3K4 methylation. ",
        "Doc_title":"Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4).",
        "Journal":"Molecular and cellular endocrinology",
        "Do_id":"23933118",
        "Doc_ChemicalList":"Proto-Oncogene Proteins",
        "Doc_meshdescriptors":"Humans;Multiple Endocrine Neoplasia;Multiple Endocrine Neoplasia Type 1;Proto-Oncogene Proteins",
        "Doc_meshqualifiers":"genetics;pathology;diagnosis;genetics;pathology;therapy;metabolism",
        "_version_":1605742690416197634},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant cancer syndrome with major components of medullary thyroid carcinoma (MTC), pheochromocytoma and hyperparathyroidism. The disease is caused by germline mutations of the RET proto-oncogene. Subtypes of MEN 2 include MEN 2A, MEN 2B and familial MTC (FMTC) which differ in pattern of additional lesions or--in FMTC--lack of pheochromocytoma. In 2009, after extensive review of the literature, the guidelines of the American Thyroid Association made several recommendations regarding clinical and genetic diagnostic testing and treatment options. In this article, the recently published literature is reviewed and concerns regarding future perspectives are added. In particular, a critical handling of rare DNA variants and double mutations is necessary. Up to now, mutation-specific risk profiles and mutation-associated treatment recommendations are unavailable. We emphasise the need for approved centres for treatment of patients affected by MEN 2, not only adults but young children as well. As a high level of skill is required for endoscopic adrenal-sparing surgery, surgeons should declare their expertise before operating such patients. Registry-based follow-up should be mandatory including documentation of short- and long-term outcome in order to provide valid data for future counselling of patients with MEN 2.",
        "Doc_title":"Multiple endocrine neoplasia type 2.",
        "Journal":"Best practice & research. Clinical endocrinology & metabolism",
        "Do_id":"20833330",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Adrenal Gland Neoplasms;Adult;Carcinoma, Medullary;Child;Germ-Line Mutation;Humans;Hyperparathyroidism;Multiple Endocrine Neoplasia Type 2a;Pheochromocytoma;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;pathology;genetics;pathology;genetics;pathology;genetics;pathology;genetics;pathology;genetics;genetics;pathology",
        "_version_":1605874582319792128},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 (MEN2) is a rare autosomal dominant syndrome caused by mutations in the RET protooncogene and is characterized by a strong penetrance of medullary thyroid carcinoma (all subtypes) and is often accompanied by pheochromocytoma (MEN2A/2B) and primary hyperparathyroidism (MEN2A). The evaluation and management of MEN2-related tumours is often different from that of sporadic counterparts. This review article provides an overview of clinical manifestations, diagnosis and surgical management of MEN2 patients. This review also presents applications of the most up-to-date imaging modalities to MEN2 patients that are tightly linked to the clinical management and aims to guide physicians towards a rationale for the use of imaging prior to prophylactic thyroidectomy, initial surgery and reoperations for persistent/recurrent disease. This review also concludes that, in the near future, it is expected that these patients will indeed benefit from newly developed positron emission tomography approaches which will target peptide receptors and protein kinases. Identification of MEN2-specific radiopharmaceuticals will also soon arise from molecular profiling studies. Furthermore, subtotal (cortical-sparing) adrenalectomy, which is a valid option in MEN2 for avoiding long-term steroid replacement, will benefit from an accurate estimation through imaging of differential adrenocortical function. ",
        "Doc_title":"Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions.",
        "Journal":"Clinical endocrinology",
        "Do_id":"24889858",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Humans;Multiple Endocrine Neoplasia Type 2a;Positron-Emission Tomography;Tomography, Emission-Computed, Single-Photon",
        "Doc_meshqualifiers":"diagnosis;drug therapy",
        "_version_":1605920503145431040},
      {
        "Doc_abstract":"The most common gene involved in Hirschsprung's disease (HD) is protooncogene RET. More than 100 mutations of this gene have been described associated with HD. The mutations that change a cysteine with another aminoacid (mainly in exons 10 and 11) give a risk of familial medullary thyroid carcinoma (FTMC) and MEN 2A. These mutations are found in 5% of patients with HD and have an autosomal dominant inheritance. The FTMC is aggressive and the prophylactic thyroidectomy is the best treatment. We present our results in screening for RET protooncogene mutations associated with TMC in patients with HD.;We have treated 40 patients with HD in the last 15 years. We have classified the patients into two groups: A) high risk of RET protooncogene mutation associated with FTMC (family history of HD, long-segment and/or associated syndromes) and B) low risk (rectosigmoid involvement). We have identified the exons 7, 8, 9, 10, 11, 13, 14 and 15 of the RET protooncogene in 12 of 15 children from group A and 6 from 25 from group B.;We have found the p.Cys620Ser mutation (exon 10) in a girl from group A (long-segment). In the family study, we have found the same mutation in her mother, her oncle and her cousin.;The comprehensive management of children with HD requires screening for RET protooncogene mutations associated with FTMC. In the first-degree relatives of children with a mutation risk, screening is required.",
        "Doc_title":"[Hirschsprung's disease and medullary carcinoma of the thyroids: two diseases in a monogenetic disorder].",
        "Journal":"Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica",
        "Do_id":"23113396",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Carcinoma, Medullary;Child, Preschool;Female;Hirschsprung Disease;Humans;Male;Mutation;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms",
        "Doc_meshqualifiers":"complications;genetics;complications;genetics;genetics;complications;genetics",
        "_version_":1605873601582465024},
      {
        "Doc_abstract":"Multiple endocrine neoplasia (MEN) types 1 and 2 are hereditary cancer syndromes. They are characterized by the occurrence of many benign and malignant tumor types.;Carriers of a MEN1 or RET gene mutation can be identified before manifestation of the disease. Family screening allows the early diagnosis and therapy of gene carriers.;Early thyroidectomy in young patients with MEN2 results in a high cure rate of medullary thyroid carcinoma (MTC). Treatment with tyrosine kinase inhibitors (TKI), such as vadetanib and cabozantinib, represents an important new therapeutic option for patients with progressive metastatic MTC. Neuroendocrine tumors (MEN1) are treated surgically and progressive disease is treated with somatostatin or everolimus.;The most important imaging methods for monitoring of MTC are sonography of the neck and upper abdomen and computed tomography (CT) of the lungs. In cases of MEN1 metastases can be localized by DOTATOC positron emission tomography CT (PET/CT).;Using these methods up to 70% of tumors and metastases can be detected, depending on the localization, size and endocrine activity. Follow-up investigations with CT is an important tool for monitoring changes in tumor mass which are important criteria for decisions concerning TKI therapy.;Together with the doubling time of tumor markers, tumor progression monitored by imaging methods or response evaluation criteria In solid tumors (RECIST) are prognostic factors and provide indications for initiating systemic therapy (e.g.;Patients with MEN syndromes should be treated in specialized centers because of the complexity and rarity.",
        "Doc_title":"[Multiple endocrine neoplasia (MEN)].",
        "Journal":"Der Radiologe",
        "Do_id":"25223437",
        "Doc_ChemicalList":"Angiogenesis Inhibitors;Antineoplastic Agents",
        "Doc_meshdescriptors":"Angiogenesis Inhibitors;Antineoplastic Agents;Diagnostic Imaging;Humans;Minimally Invasive Surgical Procedures;Molecular Targeted Therapy;Multiple Endocrine Neoplasia",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;methods;methods;methods;diagnosis;therapy",
        "_version_":1605791028352122880},
      {
        "Doc_abstract":"Substantial improvement in the understanding of the oncogenic pathways in thyroid cancer has led to identification of specific molecular alterations, including mutations of BRAF and RET in papillary thyroid cancer, mutation of RAS and rearrangement of PPARG in follicular thyroid cancer, mutation of RET in medullary thyroid cancer, and mutations of TP53 and in the phosphatidylinositol 3'-kinase (PI3K)/AKT1 pathway in anaplastic thyroid cancer. Ultrasonography (US) and US-guided biopsy remain cornerstones in the initial workup of thyroid cancer. Surgery is the mainstay of treatment, with radioactive iodine (RAI) therapy reserved for differentiated subtypes. Posttreatment surveillance of thyroid cancer is done with US of the thyroid bed as well as monitoring of tumor markers such as serum thyroglobulin and serum calcitonin. Computed tomography (CT), magnetic resonance imaging, and fluorine 18 fluorodeoxyglucose positron emission tomography/CT are used in the follow-up of patients with negative iodine 131 imaging and elevated tumor markers. Certain mutations, such as mutations of BRAF in papillary thyroid carcinoma and mutations in RET codons 883, 918, and 928, are associated with an aggressive course in medullary thyroid carcinoma, and affected patients need close surveillance. Treatment options for metastatic RAI-refractory thyroid cancer are limited. Currently, Food and Drug Administration-approved molecularly targeted therapies for metastatic RAI-refractory thyroid cancer, including sorafenib, lenvatinib, vandetanib, and cabozantinib, target the vascular endothelial growth factor receptor and RET kinases. Imaging plays an important role in assessment of response to these therapies, which can be atypical owing to antiangiogenic effects. A wide spectrum of toxic effects is associated with the molecularly targeted therapies used in thyroid cancer and can be detected at restaging scans. ()RSNA, 2016. ",
        "Doc_title":"Current Concepts in the Molecular Genetics and Management of Thyroid Cancer: An Update for Radiologists.",
        "Journal":"Radiographics : a review publication of the Radiological Society of North America, Inc",
        "Do_id":"27618325",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605774442705715200},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 (MEN 2) is an uncommon autosomal dominant cancer syndrome which can be associated with nerve conduction abnormalities.;A 14-year-old boy with a family history of consanguinity developed progressive gait clumsiness, pes cavus, hypotonia, and mucosal tumors of the lips and tongue since the age of 3 years. At age 11 years, he was diagnosed with an hereditary motor neuropathy (Charcot-Marie-Tooth syndrome).;Physical examination revealed a Marfanoid habitus, mucocutaneous verrucous tumors, thyroid nodules, and cervical adenopathy. Genetic testing demonstrated the p.M918T mutation in the RET gene, and blood tests showed elevated levels of calcitonin.;Clinical suspicion in MEN2 is crucial for early diagnosis and subsequent therapy. Mucosal neuroma and a Marfanoid habitus are especially useful. Other neurologic manifestations should not disguise the endocrine disorder, because early diagnosis and treatment of medullary thyroid carcinoma determines the prognosis.",
        "Doc_title":"Axonal neuropathy, long limbs and bumpy tongue: think of MEN2B.",
        "Journal":"Muscle & nerve",
        "Do_id":"23225389",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Humans;Limb Deformities, Congenital;Male;Multiple Endocrine Neoplasia Type 2b;Peripheral Nervous System Diseases;Tongue Diseases",
        "Doc_meshqualifiers":"etiology;genetics;complications;genetics;pathology;etiology;genetics;etiology",
        "_version_":1605810672304652288},
      {
        "Doc_abstract":"Medullary carcinoma of the thyroid (MTC) is a rare tumour derived from thyroid C cells with serum calcitonin as a specific and sensitive marker. MTC is inherited in 25% of cases, with an autosomal dominant transmission, age-related penetrance and variable expressivity. MTC is an obligatory component of multiple endocrine neoplasia type 2 (MEN2), which comprises three well defined syndromes: MEN2A, which may be associated with pheochromocytoma and/or hyperparathyroidism; the much rarer MEN2B, which occurs early and is accompanied by developmental abnormalities; while in contrast, familial MTC (FMTC) is not associated with any endocrinopathy. The RET proto-oncogene is the causative gene of the MEN2 syndromes and mutations in this gene are found in >90% of inherited cases, allowing easier and more reliable family screening than pentagastrin stimulation tests. Nevertheless, the correlation between the genotype and the different clinical phenotypes is not perfect. The prognosis of MTC depends on its staging at presentation, and the early appearance of cervical lymph node metastases emphasizes the need for extensive surgery, although many patients still do not normalize calcitonin levels post-operatively, and they remain a challenge for the further management.",
        "Doc_title":"Diagnosis and treatment of medullary thyroid cancer.",
        "Journal":"Bailliere's best practice & research. Clinical endocrinology & metabolism",
        "Do_id":"11289739",
        "Doc_ChemicalList":"Drosophila Proteins;Proto-Oncogene Proteins;Calcitonin;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Calcitonin;Carcinoma, Medullary;Drosophila Proteins;Humans;Multiple Endocrine Neoplasia Type 2a;Mutation;Neoplasm Staging;Prognosis;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"blood;diagnosis;genetics;pathology;therapy;genetics;genetics;genetics;diagnosis;genetics;pathology;therapy",
        "_version_":1605759188593541120},
      {
        "Doc_abstract":"Papillary thyroid microcarcinoma (mPTC), is a very frequent incidental finding with a frequency varying from a few percent to 35% at postmortem histopathologic examinations. However, the presence of mPTC in patients undergoing thyroidectomy for multinodular goiter (MNG) and for Graves' disease (GD) has been found to be lower. Patients with medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) association have been published as anecdotal case reports, as well as kindred with familial MTC or multiple endocrine neoplasia (MEN) 2A with some members simultaneously affected by MTC and PTC. We studied the prevalence and the biological behavior of MTC associated with PTC, with particular attention to those cases in which a mPTC was incidentally found. Twenty-seven of 196 (13.8%) MTC cases showed an association with PTC and in particular 21 of 190 (11.05%) with an incidental mPTC. This percentage is higher than that reported in the literature on the association of mPTC with GD (2.8%-4.5%) and MNG (3%). Also the percentage of the more general association of MTC/PTC, not restricted to mPTC, found in our series (13.8%) is higher than that reported in studies that analyzed the prevalence of PTC (any size) in patients treated for MNG (7.5%). A similarly high percentage of MTC/PTC had not been reported before and in particular there are no reports on large series of MTC/PTC. We also analyzed the epidemiologic, clinical, and pathologic features of MTC associated and not associated with PTC without finding any difference. In particular the outcome of the MTC did not appear to be influenced by the presence of the PTC and the specific radioiodine treatments. Moreover, although we cannot completely exclude a shared pathogenic event as the cause of both MTC and PTC, the molecular analysis of RET gene alterations did not show any common mutation.",
        "Doc_title":"Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior.",
        "Journal":"Thyroid : official journal of the American Thyroid Association",
        "Do_id":"15671773",
        "Doc_ChemicalList":"Oncogene Proteins;Proto-Oncogene Proteins c-ret;RET protein, human;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Adult;Aged;Carcinoma, Medullary;Carcinoma, Papillary;Female;Germ-Line Mutation;Humans;Immunohistochemistry;Male;Middle Aged;Multiple Endocrine Neoplasia;Oncogene Proteins;Point Mutation;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Retrospective Studies;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;metabolism;pathology;therapy;genetics;metabolism;pathology;therapy;genetics;metabolism;pathology;therapy;genetics;genetics;genetics;metabolism;pathology;therapy",
        "_version_":1605909831824179200},
      {
        "Doc_abstract":"RET genotype analysis allows identification of asymptomatic carriers at risk of developing medullary thyroid carcinoma (MTC). However, there is still controversy regarding the ideal timing and extent of prophylactic thyroidectomy due to the wide spectrum of clinical presentation. Surveillance of a large number of young patients is crucial to advance our understanding of the natural course of the disease. This study aimed to describe the clinical presentation, oncological features, and treatment outcome of children and young adults harboring RET mutations followed at our institution from 1997 to 2007.;Forty-one individuals aged < or =25 years from 17 independent multiple endocrine neoplasia type 2A kindred were studied. Twenty-one individuals presented with thyroid nodules at diagnosis, and 20 were disease free at physical examination.;Preoperative basal calcitonin levels were elevated in 85.7% of patients with clinical disease and in 54.5% of asymptomatic carriers. Thyroid ultrasonography (US) showed one or more nodules in 69.0% of the patients. A positive correlation between age at surgery and tumor-node-metastasis (TNM) stages was observed (p < 0.001). None of the patients under 15 years of age presented lymph node or distant metastasis. After a follow-up of 4.4 +/- 1.4 years all asymptomatic patients were disease free based on physical examination, cervical US, and undetectable serum calcitonin levels. In the group of patients with clinical disease, 47.6% have persistent disease (follow-up of 12.0 +/- 5.9 years). Indeed, palpable thyroid nodule at diagnosis was significantly associated with persistent disease (p < 0.001, odds ratio [OR] 1.9, 95% confidence interval [CI 95%] 1.27-2.87). Of note, none of the patients who presented lymph node metastasis at diagnosis were cured by surgical intervention (p < 0.001, OR 5.0, CI 95% 1.45-17.0).;Our data show a time-dependent MTC progression. The presence of a palpable thyroid nodule and lymph node metastasis at diagnosis was associated with persistent or recurrent disease after surgical procedure.",
        "Doc_title":"Clinical and oncological features of children and young adults with multiple endocrine neoplasia type 2A.",
        "Journal":"Thyroid : official journal of the American Thyroid Association",
        "Do_id":"18991485",
        "Doc_ChemicalList":"Calcitonin;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Calcitonin;Carcinoma, Medullary;Child;Child, Preschool;Female;Humans;Lymphatic Metastasis;Male;Multiple Endocrine Neoplasia Type 2a;Proto-Oncogene Proteins c-ret;Recurrence;Risk;Thyroid Gland;Thyroid Neoplasms;Thyroid Nodule;Thyroidectomy;Treatment Outcome;Ultrasonography;Young Adult",
        "Doc_meshqualifiers":"blood;etiology;surgery;complications;genetics;surgery;genetics;diagnostic imaging;diagnostic imaging;etiology;genetics;surgery;complications;genetics;surgery",
        "_version_":1605764686937063424},
      {
        "Doc_abstract":"Multiple endocrine neoplasia (MEN) syndromes are characterized by the association of various endocrine neoplasias. Prophylactic thyroidectomy is the treatment of choice for patients with RET gene mutations. The age at which patients undergo prophylactic thyroidectomy may vary depending on the position of the RET gene codon. In cases of MEN2B, when the mutation is carried in codons 883, 918 or 922, prophylactic thyroidectomy is performed prior to 6months of age, due to the increased aggressiveness of these heterozygosities, which are capable of determining the onset of medullary cancer during the first months of life. We present two heterozygous twin patients with MEN 2B syndrome who were born 32weeks premature, and who underwent prophylactic thyroidectomy at 7months of age. The patients were carriers of the mutation at codon 918. We suggested the early surgery at 7months as, due to their prematurity, the patients were required to gain weight to improve their condition prior to surgery. The two patients had medullary thyroid carcinoma without lymph node involvement. In conclusion, for a truly prophylactic thyroidectomy, such patients should undergo surgery within the first month of life, particularly if these patients are carriers of the mutation in codons 883, 918 or 922.",
        "Doc_title":"The optimal age for performing surgery on patients with MEN 2B syndrome.",
        "Journal":"Oncology letters",
        "Do_id":"22866152",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605847115397857280},
      {
        "Doc_abstract":"Molecular genetics analyses have indicated that approximately 55% of medullary thyroid cancer (MTC) tumors bear activating mutations of the RET gene, including inherited and sporadic cases. Tumoral RET mutations, especially M918T, have a strong negative prognostic impact. RET is the most important target for recent systemic therapy trials of MTC, along with vascular endothelial growth factor receptors. This review discusses promising recent clinical trials data for multikinase inhibitors including motesanib, vandetanib, sunitinib, sorafenib, and cabozantinib/XL184. Across multiple studies reported to date, RET mutations, although prevalent in these subjects, have not proven so far to predict whether patients will respond to multikinase inhibitors. In addition to comparing available data for efficacy and toxicity of these agents, the review focuses on critical questions related to appropriate selection of MTC patients for systemic treatment, and how best to integrate these therapies with established modalities of surgery and radiation therapy.",
        "Doc_title":"Management of medullary thyroid cancer.",
        "Journal":"Minerva endocrinologica",
        "Do_id":"21460789",
        "Doc_ChemicalList":"Antineoplastic Agents;Genetic Markers;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Antineoplastic Agents;Carcinoma, Medullary;Chemotherapy, Adjuvant;Clinical Trials as Topic;Combined Modality Therapy;Genetic Markers;Humans;Mutation;Prognosis;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-ret;Radiotherapy, Adjuvant;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;diagnosis;genetics;therapy;methods;genetics;therapeutic use;genetics;diagnosis;genetics;therapy",
        "_version_":1605765323500290048},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2B syndrome is rarely reported in Chinese patients. A 25-year-old Chinese male presented with full-blown clinical features of this syndrome, including bilateral phaeochromocytomas, medullary thyroid carcinoma, and characteristic phenotypic features. One-stage surgical treatment was performed and subsequent genetic analysis confirmed a point mutation at codon 918 in exon 16 of the RET proto-oncogene. The mutation was arising de novo as there was no corresponding mutation found in both his parents or younger sister. Data published to date suggest there is no difference in the genetic and pathophysiologic basis, nor clinical characteristics of multiple endocrine neoplasia type 2B in Chinese patients. As the disease can be lethal, early diagnosis by prompt recognition of the characteristic phenotypic features followed by surgical treatment should improve the outcome. Family screening is essential to identify at-risk family members for prophylactic treatment.",
        "Doc_title":"Multiple endocrine neoplasia type 2B in a Chinese patient.",
        "Journal":"Hong Kong medical journal = Xianggang yi xue za zhi",
        "Do_id":"15181227",
        "Doc_ChemicalList":"Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Adrenalectomy;Adult;Asian Continental Ancestry Group;Humans;Lymphatic Metastasis;Male;Multiple Endocrine Neoplasia Type 2b;Neck Dissection;Point Mutation;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroidectomy",
        "Doc_meshqualifiers":"diagnosis;genetics;surgery;genetics;genetics",
        "_version_":1605841657067995136},
      {
        "Doc_abstract":"The incidence of thyroid cancer continues to increase and this neoplasia remains the most common endocrine malignancy. No effective systemic treatment currently exists for iodine-refractory differentiated or medullary thyroid carcinoma, but recent advances in the pathogenesis of these diseases have revealed key targets that are now being evaluated in the clinical setting. RET (rearranged during transfection)/PTC (papillary thyroid carcinoma) gene rearrangements, B-Raf gene mutations, and vascular endothelial growth factor receptor 2 (VEGFR-2) angiogenesis pathways are some of the known genetic alterations playing a crucial role in the development of thyroid cancer. Several novel agents have demonstrated promising responses. Of the treatments studied, multi-kinase inhibitors such as axitinib, sorafenib, motesanib, and XL-184 have shown to be the most effective by inducing clinical responses and stabilizing the disease process. Randomized clinical trials are currently evaluating these agents, results that may soon change the management of thyroid cancer.",
        "Doc_title":"Novel molecular targeted therapies for refractory thyroid cancer.",
        "Journal":"Head & neck",
        "Do_id":"21544895",
        "Doc_ChemicalList":"Angiogenesis Inhibitors;Anilides;Antineoplastic Agents;Benzamides;Benzenesulfonates;Benzoquinones;Bibenzyls;Boronic Acids;Depsipeptides;HSP90 Heat-Shock Proteins;Histone Deacetylase Inhibitors;Hydroxamic Acids;Imidazoles;Indazoles;Indoles;Lactams, Macrocyclic;Phenylurea Compounds;Piperazines;Piperidines;Protein Kinase Inhibitors;Pyrazines;Pyridines;Pyrimidines;Pyrroles;Quinazolines;Quinolines;Sulfonamides;cabozantinib;Niacinamide;tanespimycin;Thalidomide;vorinostat;Valproic Acid;Bortezomib;combretastatin;pazopanib;Imatinib Mesylate;sorafenib;axitinib;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-kit;Receptor Protein-Tyrosine Kinases;Receptor, Epidermal Growth Factor;Receptors, Vascular Endothelial Growth Factor;lenvatinib;lenalidomide;imetelstat;gefitinib;sunitinib;N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine",
        "Doc_meshdescriptors":"Angiogenesis Inhibitors;Anilides;Antineoplastic Agents;Benzamides;Benzenesulfonates;Benzoquinones;Bibenzyls;Boronic Acids;Bortezomib;Depsipeptides;HSP90 Heat-Shock Proteins;Histone Deacetylase Inhibitors;Humans;Hydroxamic Acids;Imatinib Mesylate;Imidazoles;Indazoles;Indoles;Lactams, Macrocyclic;Niacinamide;Phenylurea Compounds;Piperazines;Piperidines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Proto-Oncogene Proteins c-kit;Pyrazines;Pyridines;Pyrimidines;Pyrroles;Quinazolines;Quinolines;Receptor Protein-Tyrosine Kinases;Receptor, Epidermal Growth Factor;Receptors, Vascular Endothelial Growth Factor;Sulfonamides;Thalidomide;Thyroid Neoplasms;Valproic Acid",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;therapeutic use;therapeutic use;therapeutic use;therapeutic use;therapeutic use;therapeutic use;antagonists & inhibitors;therapeutic use;therapeutic use;therapeutic use;therapeutic use;therapeutic use;therapeutic use;analogs & derivatives;therapeutic use;therapeutic use;therapeutic use;therapeutic use;therapeutic use;antagonists & inhibitors;antagonists & inhibitors;therapeutic use;therapeutic use;therapeutic use;therapeutic use;therapeutic use;therapeutic use;antagonists & inhibitors;antagonists & inhibitors;antagonists & inhibitors;therapeutic use;analogs & derivatives;therapeutic use;drug therapy;therapeutic use",
        "_version_":1605928767773999104},
      {
        "Doc_abstract":"Thyroid nodules occur in 1-2% of children, and identifying which nodules are malignant is often challenging. Cytologic evaluation facilitates the diagnosis of thyroid lesions (TLs), but in 10-40% of cases the interpretation is indeterminate. Patients with indeterminate diagnoses are often treated with hemithyroidectomy followed by completion thyroidectomy, if cancer is found in the initial specimen. Exposing patients to multiple surgeries increases costs and morbidity. The American Thyroid Association states that a combination of molecular markers is likely to optimize the management of patients with indeterminate cytology. However, few studies have addressed the molecular alterations present in pediatric TL. Twenty-seven thyroid carcinomas from patients 10 to 19 years of age were tested for alterations common in adult TL, including BRAF V600E mutation, RET fusions, and TERT promoter mutations. Mutation-negative cases were subsequently analyzed with a next-generation sequencing (NGS) mutation panel to search for additional targets. Histologic diagnoses included 12 classic papillary thyroid carcinomas (PTCs), 13 follicular variant PTCs, 1 medullary thyroid carcinoma, and 1 follicular carcinoma. Fourteen cases showed lymph node involvement, and 13 cases demonstrated lymphovascular invasion. The BRAF V600E mutation was detected in 10/27 cases, and RET fusions were detected in 6/27 cases. No TERT promoter mutations were identified in any of the cases. The NGS panel revealed additional RET and CTNNB1 pathogenic missense mutations. Our results demonstrate that molecular abnormalities are common in pediatric TLs and suggest that incorporation of molecular testing will be helpful in optimizing patient management. ",
        "Doc_title":"Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.",
        "Journal":"Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society",
        "Do_id":"26366474",
        "Doc_ChemicalList":"Biomarkers, Tumor;CTNNB1 protein, human;beta Catenin;Proto-Oncogene Proteins c-ret;RET protein, human;BRAF protein, human;Proto-Oncogene Proteins B-raf;TERT protein, human;Telomerase",
        "Doc_meshdescriptors":"Adolescent;Age Factors;Biomarkers, Tumor;Biopsy;Carcinoma;Child;DNA Mutational Analysis;Female;Gene Fusion;Genetic Predisposition to Disease;High-Throughput Nucleotide Sequencing;Humans;Lymphatic Metastasis;Male;Molecular Diagnostic Techniques;Mutation;Neoplasm Invasiveness;Phenotype;Predictive Value of Tests;Prognosis;Promoter Regions, Genetic;Proto-Oncogene Proteins B-raf;Proto-Oncogene Proteins c-ret;Real-Time Polymerase Chain Reaction;Reverse Transcriptase Polymerase Chain Reaction;Risk Factors;Telomerase;Thyroid Neoplasms;Thyroid Nodule;Young Adult;beta Catenin",
        "Doc_meshqualifiers":"genetics;genetics;secondary;therapy;genetics;genetics;genetics;genetics;pathology;therapy;genetics;pathology;therapy",
        "_version_":1605818677475672064},
      {
        "Doc_abstract":"There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC.;Patients with advanced MTC were randomly assigned in a 2:1 ratio to receive vandetanib 300 mg/d or placebo. On objective disease progression, patients could elect to receive open-label vandetanib. The primary end point was progression-free survival (PFS), determined by independent central Response Evaluation Criteria in Solid Tumors (RECIST) assessments.;Between December 2006 and November 2007, 331 patients (mean age, 52 years; 90% sporadic; 95% metastatic) were randomly assigned to receive vandetanib (231) or placebo (100). At data cutoff (July 2009; median follow-up, 24 months), 37% of patients had progressed and 15% had died. The study met its primary objective of PFS prolongation with vandetanib versus placebo (hazard ratio [HR], 0.46; 95% CI, 0.31 to 0.69; P < .001). Statistically significant advantages for vandetanib were also seen for objective response rate (P < .001), disease control rate (P = .001), and biochemical response (P < .001). Overall survival data were immature at data cutoff (HR, 0.89; 95% CI, 0.48 to 1.65). A final survival analysis will take place when 50% of the patients have died. Common adverse events (any grade) occurred more frequently with vandetanib compared with placebo, including diarrhea (56% v 26%), rash (45% v 11%), nausea (33% v 16%), hypertension (32% v 5%), and headache (26% v 9%).;Vandetanib demonstrated therapeutic efficacy in a phase III trial of patients with advanced MTC (ClinicalTrials.gov NCT00410761).",
        "Doc_title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.",
        "Journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
        "Do_id":"22025146",
        "Doc_ChemicalList":"Piperidines;Placebos;Quinazolines;N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine",
        "Doc_meshdescriptors":"Carcinoma, Neuroendocrine;Disease Progression;Double-Blind Method;Female;Humans;Male;Middle Aged;Neoplasm Metastasis;Piperidines;Placebos;Quinazolines;Thyroid Neoplasms",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;adverse effects;therapeutic use;drug therapy;pathology",
        "_version_":1605795101553983488},
      {
        "Doc_abstract":"The aim of this study was to investigate whether younger age at surgery is associated with the increased incidence of postoperative complications after prophylactic thyroidectomy in pediatric patients with multiple endocrine neoplasia (MEN) 2. The shift toward earlier thyroidectomy has resulted in significantly less medullary thyroid carcinoma (MTC)-related morbidity and mortality. However, very young pediatric patients might have a higher morbidity rate compared with older patients. Hardly any literature exists on complications in the very young. A retrospective single-center analysis was performed on the outcomes of MEN2 patients undergoing a prophylactic total thyroidectomy at the age of 17 or younger. Forty-one MEN2A and 3 MEN2B patients with thyroidectomy after January 1993 and at least 6 months of follow-up were included, subdivided in 9 patients younger than 3 years, 15 patients 3 to 6 years, and 20 patients older than 6 years. Postoperative hypocalcemia and other complications were registered. Twelve (27%) patients developed transient hypocalcemia and 9 (20%) patients suffered from permanent hypocalcemia, with a nonsignificant trend toward higher incidence with decreasing age. Three (7%) patients had other complications, of whom 2 were younger than 3 years. For patients younger than 3 years, the average length of stay (LOS) was 6.7 days, versus 1.7 and 3.5 days, respectively, for the older patient groups (P < 0.05). Patients with complications had a longer LOS compared with patients without (5.0 vs 2.0, P < 0.01). None of the patients had clinical signs of recurrent MTC after a mean follow-up of 10.5 years. Prophylactic thyroidectomy in very young children is associated with a higher rate of complications, causing a significant increased LOS. Irrespective age of surgery, MTC did not recur in any patient. In planning optimal timing of surgery, clinicians should take the risk of complications into account. We advise not to perform total thyroidectomy before the age of 3 for patients defined high risk by the American Thyroid Association guideline.",
        "Doc_title":"Postoperative Complications After Prophylactic Thyroidectomy for Very Young Patients With Multiple Endocrine Neoplasia Type 2: Retrospective Cohort Analysis.",
        "Journal":"Medicine",
        "Do_id":"26200612",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Age Factors;Child;Child, Preschool;Female;Humans;Hypocalcemia;Infant;Length of Stay;Male;Multiple Endocrine Neoplasia Type 2a;Postoperative Complications;Retrospective Studies;Thyroidectomy",
        "Doc_meshqualifiers":"etiology;statistics & numerical data;surgery;adverse effects",
        "_version_":1605742117825544192},
      {
        "Doc_abstract":"We report the antineoplastic and anti-angiogenic activity of the pyrazolo[3,4-d]pyrimidine derivative CLM3 and the cyclic amide CLM94, both multiple tyrosine kinase inhibitors (TKIs), in human primary medullary thyroid cancer (P-MTC) cells, and in vitro in the medullary thyroid cancer (MTC) cell lines TT (harboring a RET C634W activating mutation) and MZ-CRC-1 (carrying the MEN2B RET mutation Met891Thr).;The antiproliferative and proapoptotic effects of CLM3 and CLM94 (1, 5, 10, 30, and 50 mol/L) were tested in P-MTC cells obtained at operation, and in TT cells. In addition, the antiproliferative effects of CLM3 and CLM94 (0.005, 0.05, 0.5, and 5 mol/L) were tested in TT and MZ-CRC-1 cells after 7 days of treatment to compare the results with those previously reported in the literature.;CLM3 and CLM94 (30 or 50 mol/L) inhibited (P < .01) the proliferation of the P-MTC cells, TT cells, and MZ-CRC-1 cells and increased the level of apoptosis in a dose-dependent manner at 10, 30, and 50 mol/L (P < .001), while having no effect on migration or invasion. The inhibition of proliferation by CLM3 and CLM94 was similar among P-MTC cells with/without RET mutations, and similar effects were observed regarding the increased level of apoptosis. Furthermore, CLM3 and CLM94 significantly decreased vascular endothelial growth factor-A expression in TT cells.;The antitumor activities of the multiple TKIs CLM3 and CLM94 were demonstrated in both primary MTC cultures as well as 2 established MTC cell lines in vitro, opening an avenue for future clinical evaluations.",
        "Doc_title":"Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro.",
        "Journal":"Surgery",
        "Do_id":"25151558",
        "Doc_ChemicalList":"4-chloro-N-(1,1,3-trioxo-2,3-dihydrobenzo(d)isothiazol-4-yl)benzamide;Benzamides;CLM3 compound;Pyrazoles;Pyrimidines;VEGFA protein, human;Vascular Endothelial Growth Factor A;Protein-Tyrosine Kinases;Saccharin",
        "Doc_meshdescriptors":"Apoptosis;Benzamides;Carcinoma, Medullary;Carcinoma, Neuroendocrine;Cell Movement;Cell Proliferation;Cell Survival;Cells, Cultured;Drug Screening Assays, Antitumor;Humans;Protein-Tyrosine Kinases;Pyrazoles;Pyrimidines;Saccharin;Thyroid Neoplasms;Vascular Endothelial Growth Factor A",
        "Doc_meshqualifiers":"drug effects;pharmacology;therapeutic use;drug therapy;drug effects;drug effects;drug effects;antagonists & inhibitors;pharmacology;therapeutic use;pharmacology;therapeutic use;analogs & derivatives;pharmacology;therapeutic use;drug therapy;antagonists & inhibitors",
        "_version_":1605880059967569920},
      {
        "Doc_abstract":"Familial neuroendocrine tumors are reviewed. The most dramatic advances have been in the application of molecular genetic techniques to define the affected genes and to develop predictive testing for patients with multiple endocrine neoplasia syndromes. Germline mutations at specific loci of the RET proto-oncogene have been demonstrated in patients with multiple endocrine neoplasia types IIA, IIB, and familial medullary thyroid carcinoma not associated with multiple endocrine neoplasia. This has led to direct DNA testing for these mutations in patients at risk for these syndromes. The approach to predictive testing, diagnosis, and early treatment of these patients is discussed as a model for the approach to hereditary cancers. Linkage testing with DNA markers is still required for patients with multiple endocrine neoplasia type I because the responsible gene has not yet been isolated. Efforts to clarify the etiologies of other familial neuroendocrine tumors not associated with multiple endocrine neoplasia continue. Familial pheochromocytoma, neuroblastoma, and carcinoid also are reviewed. The use of molecular genetic techniques as a powerful tool for the early identification and treatment of susceptible individuals is emphasized.",
        "Doc_title":"Familial neuroendocrine tumors as a model of hereditary cancer.",
        "Journal":"Current opinion in oncology",
        "Do_id":"9090493",
        "Doc_ChemicalList":"DNA, Neoplasm;Drosophila Proteins;Neoplasm Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Algorithms;Carcinoma, Medullary;DNA, Neoplasm;Drosophila Proteins;Female;Genes, Tumor Suppressor;Genetic Testing;Hirschsprung Disease;Humans;Male;Multiple Endocrine Neoplasia;Multiple Endocrine Neoplasia Type 1;Neoplasm Proteins;Neuroblastoma;Neuroendocrine Tumors;Pedigree;Pheochromocytoma;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Proto-Oncogenes;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms",
        "Doc_meshqualifiers":"genetics;genetics;genetics;diagnosis;genetics;genetics;genetics;physiology;genetics;genetics;genetics;genetics;physiology;genetics;physiology;genetics",
        "_version_":1605758200090460160},
      {
        "Doc_abstract":"To describe the specificities and complications of thyroid surgery in children and adolescents.;This retrospective study was based on 64 patients under the age of 18 who underwent thyroid surgery between January 2004 and March 2012, with two operations in one case. The following data were analysed: anatomical variants of the recurrent laryngeal nerve, postoperative recurrent laryngeal nerve paralysis rate, postoperative hypoparathyroidism rate, and histological results.;Two cases of right non-recurrent inferior laryngeal nerve were observed (2.2% of the 93 recurrent laryngeal nerves dissected). One case of persistent left recurrent laryngeal nerve paralysis was observed (1.1%) despite intraoperative recurrent laryngeal nerve monitoring. Eight cases of immediate postoperative hypocalcaemia were observed (23.5% of the 34 total thyroidectomies) and permanent hypocalcaemia was observed in 5 cases (14.7%) with a significantly lower immediate postoperative serum calcium than in the case of transient hypocalcaemia (P=0.035). Among the 11 patients operated for familial medullary thyroid carcinoma (MTC), 36.3% presented one or more sites of C-cell carcinoma. Among the 32 patients operated for thyroid nodule, 6.3% presented papillary adenocarcinoma. Histological results were benign in all other cases.;Thyroid surgery in children and adolescents is part of global multidisciplinary management of thyroid disorders in children. Recurrent laryngeal nerve paralysis is a rare complication, but may occur despite the use of intraoperative recurrent laryngeal nerve monitoring. Permanent hypoparathyroidism is the most common complication and is correlated with immediate postoperative serum calcium. Systematic prophylactic total thyroidectomy in patients with a RET proto-oncogene mutation allowed early diagnosis of MTC in one-third of cases. In view of the low rate of malignant nodules in our series, the malignant thyroid nodule rates reported in children in the literature may be overestimated.",
        "Doc_title":"Thyroid surgery in children and adolescents: a series of 65 cases.",
        "Journal":"European annals of otorhinolaryngology, head and neck diseases",
        "Do_id":"24993783",
        "Doc_ChemicalList":"Codon",
        "Doc_meshdescriptors":"Adenocarcinoma, Papillary;Adolescent;Carcinoma, Medullary;Child;Child, Preschool;Codon;Exons;Female;Humans;Hypocalcemia;Infant;Male;Monitoring, Intraoperative;Mutation;Recurrent Laryngeal Nerve;Retrospective Studies;Thyroid Diseases;Thyroidectomy;Vocal Cord Paralysis",
        "Doc_meshqualifiers":"pathology;surgery;pathology;surgery;etiology;abnormalities;genetics;pathology;surgery;adverse effects;etiology",
        "_version_":1605752717670612992},
      {
        "Doc_abstract":"Medullary thyroid cancer (MTC) has a variable clinical presentation. We present 3 patients with this endocrine tumour. The first patient, a 41-year-old woman complaining of diarrhoea, a painful abdomen, weight loss and sensibility disorders in both legs, had metastases of MTC in the spine, with little progression during 2 years of follow-up. The second patient, a 64-year-old woman suffering from a painful nodule in the neck and a painful shoulder, was diagnosed with MTC and liver, lung and bone metastases. She died after 14 months due to progressive disease. The third patient, an 81-year-old woman with hyperparathyroidism, was coincidentally diagnosed with MTC after goitre surgery at the age of 67. When she was evaluated for rising calcitonin levels, a pheochromocytoma was found. RET mutation analysis confirmed a MEN2A syndrome. Current diagnostic procedures of MTC may include positron emission tomography with 18F-deoxyglucose (FDG-PET) and 18F-diphenylalanine (DOPA-PET). MTC is usually treated surgically. Tyrosine kinase inhibitors appear to offer potential new therapeutic possibilities.",
        "Doc_title":"[Medullary thyroid cancer, a tumour with many appearances].",
        "Journal":"Nederlands tijdschrift voor geneeskunde",
        "Do_id":"20858319",
        "Doc_ChemicalList":"4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine;Enzyme Inhibitors;Pyrazoles;Pyrimidines",
        "Doc_meshdescriptors":"Adult;Aged, 80 and over;Diagnosis, Differential;Enzyme Inhibitors;Female;Humans;Middle Aged;Neoplasm Metastasis;Positron-Emission Tomography;Pyrazoles;Pyrimidines;Thyroid Neoplasms;Thyroid Nodule;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;therapeutic use;diagnosis;drug therapy;surgery;diagnosis;drug therapy;surgery",
        "_version_":1605784572753084416},
      {
        "Doc_abstract":"Lenvatinib is an oral multitargeted tyrosine kinase inhibitor of VEGFR1,2,3,4, FGFR1,2,3,4, PDGFR- as well as RET and KIT signaling network. Its activity against radioiodine-resistant differentiated thyroid cancer (DTC) has been recently demonstrated. Patients, who were given lenvatinib, showed significantly longer median progression free survival than placebo group, 18.3 vs 3.6 months, respectively. This review is focused on lenvatinib safety profile in patients treated due to DTC and medullary thyroid carcinoma. Among the most frequent lenvatinib-related adverse events (AEs) were hypertension, proteinuria, diarrhea, appetite decrease, weight loss, nausea and stomatitis. Although a lot of them were manageable, in 35-68% of patients dose reduction was required. Nevertheless, only 15% of subjects withdrew the drug due to its toxicity.;published results of clinical trials phase II and III investigating both safety and efficacy of lenvatinib in thyroid cancer.;Lenvatinib shows acceptable safety profile in patients with thyroid carcinoma. Treatment-related side effects are usually manageable by dose modifications or by concomitant non-pharmacological and pharmacological treatment. However, the early recognition of any potential drug toxicity is crucial to avoid serious complications as well as to keep a patient on drug as long as the treatment is beneficial.",
        "Doc_title":"Drug safety evaluation of lenvatinib for thyroid cancer.",
        "Journal":"Expert opinion on drug safety",
        "Do_id":"26484847",
        "Doc_ChemicalList":"Antineoplastic Agents;Phenylurea Compounds;Protein Kinase Inhibitors;Quinolines;lenvatinib",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Carcinoma, Neuroendocrine;Disease-Free Survival;Dose-Response Relationship, Drug;Humans;Phenylurea Compounds;Protein Kinase Inhibitors;Quinolines;Thyroid Neoplasms",
        "Doc_meshqualifiers":"administration & dosage;adverse effects;therapeutic use;drug therapy;pathology;administration & dosage;adverse effects;therapeutic use;administration & dosage;adverse effects;therapeutic use;administration & dosage;adverse effects;therapeutic use;drug therapy;pathology",
        "_version_":1605897691722678272},
      {
        "Doc_abstract":"Multiple cancers represent 2.42% of all human cancers and are mainly double or triple cancers. Many possible causes of multiple malignancies have been reported such as genetic alterations, exposure to anti-cancer chemotherapy, radiotherapy, immunosuppressive therapy and reduced immunologic response. We report a female patient with multiple sclerosis and quadruple cancers of different embryological origin. Patient was diagnosed with stage III (T3, N1a, MO) medullary thyroid carcinoma (MTC), multicentric micropapillary thyroid carcinoma, scapular and lumbar melanomas (Clark II, Breslow II), and lobular invasive breast carcinoma (T1a, NO, MO). All tumors present in our patient except micropapillary thyroid carcinomas were investigated for gene alterations known to have a key role in cancer promotion and progression. Tumor samples were screened for the p16 alterations (loss of heterozygosity and homozygous deletions), loss of heterozygosity of PTEN, p53 alterations (mutational status and loss of heterozygosity) and mutational status of RET, HRAS and KRAS. Each type of tumor investigated had specific pattern of analyzed genetic alterations. The most prominent genetic changes were mutual alterations in PTEN and p53 tumor suppressors present in breast cancer and two melanomas. These co-alterations could be crucial for promoting development of multiple malignancies. Moreover the insertion in 4(th) codon of HRAS gene was common for all tumor types investigated. It represents frameshift mutation introducing stop codon at position 5 which prevents synthesis of a full-length protein. Since the inactivated RAS enhances sensitivity to tamoxifen and radiotherapy this genetic alteration could be considered as a good prognostic factor for this patient. ",
        "Doc_title":"Genetic alterations in quadruple malignancies of a patient with multiple sclerosis: their role in malignancy development and response to therapy.",
        "Journal":"International journal of clinical and experimental pathology",
        "Do_id":"24817989",
        "Doc_ChemicalList":"Immunosuppressive Agents;KRAS protein, human;Neoplasm Proteins;P16 protein, human;Proto-Oncogene Proteins;Tumor Suppressor Protein p53;Proto-Oncogene Proteins c-ret;RET protein, human;PTEN Phosphohydrolase;PTEN protein, human;HRAS protein, human;Proto-Oncogene Proteins p21(ras);ras Proteins;Azathioprine",
        "Doc_meshdescriptors":"Adult;Azathioprine;Bone Neoplasms;Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Medullary;Carcinoma, Papillary;Combined Modality Therapy;Female;Humans;Immunosuppressive Agents;Melanoma;Multiple Sclerosis;Mutation;Neoplasm Proteins;PTEN Phosphohydrolase;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Proto-Oncogene Proteins p21(ras);Thyroid Neoplasms;Tumor Suppressor Protein p53;ras Proteins",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;genetics;therapy;genetics;therapy;genetics;therapy;genetics;therapy;genetics;therapy;adverse effects;therapeutic use;genetics;therapy;complications;drug therapy;genetics;genetics;genetics;genetics;genetics;genetics;genetics;therapy;genetics;genetics",
        "_version_":1605847132290416640},
      {
        "Doc_abstract":"The multiple endocrine neoplasia type 2A (MEN2A) is a monogenic disorder characterized by an autosomal dominant pattern of inheritance which is characterized by high risk of medullary thyroid carcinoma in all mutation carriers. Although this disorder is classified as a rare disease, the patients affected have a low life quality and a very expensive and continuous treatment. At present, MEN2A is diagnosed by gene sequencing after birth, thus trying to start an early treatment and by reduction of morbidity and mortality. We first evaluated the presence of MEN2A mutation (C634Y) in serum of 25 patients, previously diagnosed by sequencing in peripheral blood leucocytes, using HRM genotyping analysis. In a second step, we used a COLD-PCR approach followed by HRM genotyping analysis for non-invasive prenatal diagnosis of a pregnant woman carrying a fetus with a C634Y mutation. HRM analysis revealed differences in melting curve shapes that correlated with patients diagnosed for MEN2A by gene sequencing analysis with 100% accuracy. Moreover, the pregnant woman carrying the fetus with the C634Y mutation revealed a melting curve shape in agreement with the positive controls in the COLD-PCR study. The mutation was confirmed by sequencing of the COLD-PCR amplification product. In conclusion, we have established a HRM analysis in serum samples as a new primary diagnosis method suitable for the detection of C634Y mutations in MEN2A patients. Simultaneously, we have applied the increase of sensitivity of COLD-PCR assay approach combined with HRM analysis for the non-invasive prenatal diagnosis of C634Y fetal mutations using pregnant women serum.",
        "Doc_title":"Non-invasive prenatal diagnosis of multiple endocrine neoplasia type 2A using COLD-PCR combined with HRM genotyping analysis from maternal serum.",
        "Journal":"PloS one",
        "Do_id":"23236420",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Adult;Female;Genotype;Humans;Multiple Endocrine Neoplasia Type 2a;Mutation;Polymerase Chain Reaction;Pregnancy;Prenatal Diagnosis;Proto-Oncogene Proteins c-ret",
        "Doc_meshqualifiers":"diagnosis;genetics;methods;genetics",
        "_version_":1605747535872262144},
      {
        "Doc_abstract":"One of the components of trethe classical form of MEN2 syndromes is primary hyperparathyroidism (PHP). It occurs in 20-30% of the typical MEN2A syndrome. The prevalence is more rare in gene carriers as these frequently have familial MTC only. PHP is diagnosed more frequently in association with the exon 11, codon 634 mutation of the ret gene-so there is phenotype/genotype correlation. The clinical manifestations of PHP in MEN2 are usually mild and the peak age of diagnosis after the 3rd decade. The treatment is surgical excision of the enlarged gland(s). Although there can be multigland disease in the parathyroids, it is frequently the case that both hyperplasia and adenoma may coexist, or even a single adenoma may be found during the investigation and finally during the operation. Patients with MEN2 syndromes should be screened for PHP with serum calcium measurements. The intensity of the screening should be higher in those carrying the ret mutations most frequently associated with this manifestation.",
        "Doc_title":"Primary Hyperparathyroidism in MEN2 Syndromes.",
        "Journal":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer",
        "Do_id":"26494389",
        "Doc_ChemicalList":"Biomarkers, Tumor;Proto-Oncogene Proteins c-ret;RET protein, human;Calcium",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Calcium;Genetic Predisposition to Disease;Humans;Hyperparathyroidism, Primary;Multiple Endocrine Neoplasia Type 2a;Multiple Endocrine Neoplasia Type 2b;Mutation;Parathyroidectomy;Phenotype;Proto-Oncogene Proteins c-ret",
        "Doc_meshqualifiers":"genetics;blood;blood;diagnosis;etiology;surgery;complications;diagnosis;genetics;complications;diagnosis;genetics;genetics",
        "_version_":1605875841382744064},
      {
        "Doc_abstract":"Evaluation of prophylactic total thyroidectomy in childhood in case of MEN2A gene carriership.;Retrospective.;Prophylactic thyroidectomy was performed in 14 MEN2A gene carriers (7 boys, 7 girls; median age 9.1 year (range: 4.8-14.7)), in June 1993-July 1997 at the department Pediatric Surgery of the Wilhelmina Children's Hospital in Utrecht, the Netherlands. Median time between genetic investigation and operation was 5.5 months (range: 2-35). Lymph node dissection was not performed. The parathyroids were identified and left untouched as far as possible, autotransplantation was performed twice because of doubt about viability. Outpatient follow-up took place every 3-6 months.;One patient (13.4 year) showed macroscopic, the other 13 microscopic multifocal medullary thyroid carcinoma, 11 bilateral and 3 unilateral. In 1 child (6.2 year) neuroinvasive growth existed already. Surgical sections were free of tumour. After the operation temporary hoarseness occurred once, temporary hypocalcaemia three times and permanent hypoparathyroidism twice; after autotransplantation no hypocalcaemia occurred. Median follow-up was 3.2 year (range: 1 month-4.0 year). Mild psychological problems were observed in 4 patients, psychiatric problems in 1.;Prophylactic total thyroidectomy during the first decade is recommended. Additional lymph node dissection and total parathyroidectomy are unnecessary than. In order to prevent postoperative hypoparathyroidism, autotransplantation of at least one parathyroid is advisable.",
        "Doc_title":"[Prophylactic total thyroidectomy in childhood for multiple endocrine neoplasia type 2A: preliminary results].",
        "Journal":"Nederlands tijdschrift voor geneeskunde",
        "Do_id":"10086113",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Carcinoma, Medullary;Child;Child, Preschool;Female;Follow-Up Studies;Heterozygote;Humans;Hypocalcemia;Hypoparathyroidism;Male;Multiple Endocrine Neoplasia Type 2a;Neoplasms, Second Primary;Parathyroid Glands;Retrospective Studies;Thyroid Gland;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome",
        "Doc_meshqualifiers":"pathology;surgery;etiology;etiology;prevention & control;genetics;prevention & control;diagnosis;surgery;surgery;transplantation;pathology;pathology;prevention & control;methods",
        "_version_":1605785104612851712},
      {
        "Doc_abstract":"Cabozantinib (XL-184) is a potent inhibitor of MET, VEGFR 2/KDR, RET and other receptor tyrosine kinases, such as KIT, AXL and FLT3. Its efficacy against MTC has been demonstrated in a prospective, randomized, placebo-controlled study (EXAM). Cabozantinib comparing to placebo significantly prolonged progression free survival both in hereditary and sporadic MTC, 11.2 vs 4.0months, respectively. Final analysis showed no global differences in overall survival (OS) between cabozantinib and placebo. However, in a subgroup with RET M918T mutation the difference in OS was significant: 44.3 vs 18.9months, respectively. Among the most frequent cabozantinib-related adverse events (AEs), observed in >30% of patients were diarrhea, palmar-plantar erythrodysesthesia, decreased weight, decreased appetite, nausea, fatigue, dysgeusia, hair color changes and hypertension. Expert Commentary: Cabozantinib constitutes an effective treatment option with acceptable toxicity in MTC patients showing either germinal or sporadic tumor RET M918T mutation as the drug prolonged OS in these subjects. ",
        "Doc_title":"Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.",
        "Journal":"Expert review of clinical pharmacology",
        "Do_id":"26536165",
        "Doc_ChemicalList":"Anilides;Antineoplastic Agents;Protein Kinase Inhibitors;Pyridines;cabozantinib;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Anilides;Animals;Antineoplastic Agents;Carcinoma, Neuroendocrine;Disease Progression;Disease-Free Survival;Humans;Mutation;Neoplasm Metastasis;Protein Kinase Inhibitors;Proto-Oncogene Proteins c-ret;Pyridines;Survival Rate;Thyroid Neoplasms",
        "Doc_meshqualifiers":"adverse effects;pharmacology;therapeutic use;adverse effects;pharmacology;therapeutic use;drug therapy;genetics;pathology;adverse effects;pharmacology;therapeutic use;genetics;adverse effects;pharmacology;therapeutic use;drug therapy;genetics;pathology",
        "_version_":1605898267166507008},
      {
        "Doc_abstract":"Medullary thyroid cancer (MTC) arises from neural-crest-derived parafollicular C cells of the thyroid gland and accounts for approximately 4% of all thyroid cancers. Up to 25-30% of MTC cases occur as inherited disorders while the remaining cases represent the sporadic form of the disease. In this review, the structure and signalling properties of the RET proto-oncogene in its wild-type and mutant forms, and its role in hereditary and sporadic MTC, are discussed. A full data search was performed through PubMed over the years 2000-2008 with the key words 'medullary thyroid cancer, treatment, molecular biology, RET, molecular mechanism', and all relevant publications have been included, together with selected publications prior to that date. We also review novel therapies for metastatic MTC, especially the tyrosine kinase inhibitors which have activity at multiple receptor subtypes, and summarize the current ongoing trials in this area. While such tyrosine kinase inhibitors, particularly those affecting RET activity such as vandetanib, sorafenib and sunitinib, are promising, the low rate of partial responses and absence of complete responses in all of the various trials of monotherapy emphasize the need for new and more effective single agents or combinations of therapeutic agents with acceptable toxicity.",
        "Doc_title":"Medullary thyroid cancer: molecular biology and novel molecular therapies.",
        "Journal":"Neuroendocrinology",
        "Do_id":"19468197",
        "Doc_ChemicalList":"Antineoplastic Agents;Tumor Suppressor Proteins;Succinate Dehydrogenase;Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Humans;Proto-Oncogene Proteins c-ret;Signal Transduction;Succinate Dehydrogenase;Thyroid Neoplasms;Tumor Suppressor Proteins",
        "Doc_meshqualifiers":"pharmacology;genetics;metabolism;genetics;metabolism;drug therapy;genetics;metabolism;genetics;metabolism",
        "_version_":1605802276144807936},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 (MEN-2) is a hereditary syndrome that is transmitted in an autosomal dominant pattern. MEN-2A, MEN-2B, and familial medullary thyroid cancer (MTC) comprise the MEN-2 syndrome. A germline mutation in the RET proto-oncogene is responsible for the MEN-2 syndrome. Recent data indicate that in 99% of MEN-2 cases, a germline RET mutation can be identified by genetic testing. The phenotypic variation of MEN-2 is diverse and partly related to the codon and specific point mutation in the RET proto-oncogene. There are increasing data on the genotype-phenotype correlations in patients with MEN-2 and this information should be used for screening at-risk patients and treatment of RET mutation carriers. All patients (especially if young) with MTC or bilateral pheochromocytoma should have a careful family history taken and genetic screening for RET germline mutations. Patients who are RET germline mutation carriers but without clinical or biochemical evidence of MTC should have a prophylactic total thyroidectomy. The optimal age of thyroidectomy should be based on the RET genotype (eg, high-risk mutations within the first year of life, intermediate-risk mutations by 5 years of age, and low-risk mutations by 10 years of age). Patients who are diagnosed with clinical or biochemical evidence of MTC should have a total or a near total thyroidectomy and at least a central neck lymph node dissection. Patients who have pheochromocytoma and a unilateral adrenal tumor on a localizing study should have a unilateral laparoscopic adrenalectomy after preoperative alpha-blockade. However, patients with bilateral adrenal tumors on localizing studies should have bilateral laparoscopic adrenalectomy. A cortical-sparing (subtotal) adrenalectomy may be considered, if technically feasible, to avoid long-term steroid dependence and to reduce the risk of Addisonian crisis. Patients with biochemical evidence of primary hyperparathyroidism should have a bilateral neck exploration and total parathyroidectomy and autotransplantation (30-60 mg of the most normal parathyroid tissue) to the nondominant forearm if asymmetric parathyroid hyperplasia is present. Rarely, patients may have only single-gland disease and excision may be performed if the other parathyroid glands are not found with biopsy to be hyperplastic. All unresected parathyroid glands should be marked with a clip because patients with MEN-2A have a high risk of persistent and recurrent primary hyperparathyroidism. Patients with familial MTC may have not manifested the other features of MEN-2A, thus these patients should have continued follow-up for pheochromocytoma and primary hyperparathyroidism.",
        "Doc_title":"Multiple endocrine neoplasia type 2.",
        "Journal":"Current treatment options in oncology",
        "Do_id":"15233908",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adrenal Gland Neoplasms;Adrenalectomy;Antineoplastic Combined Chemotherapy Protocols;Carcinoma, Medullary;Chemotherapy, Adjuvant;Combined Modality Therapy;Female;Follow-Up Studies;Humans;Male;Multiple Endocrine Neoplasia Type 2a;Neoplasm Staging;Pheochromocytoma;Risk Assessment;Survival Analysis;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome",
        "Doc_meshqualifiers":"mortality;pathology;therapy;methods;administration & dosage;mortality;pathology;therapy;mortality;pathology;therapy;mortality;pathology;therapy;mortality;pathology;therapy;methods",
        "_version_":1605774229619343360},
      {
        "Doc_abstract":"Medullary thyroid cancer (MTC) is a malignancy of the calcitonin-producing parafollicular cells of the thyroid gland. Surgery is the only curative treatment for this cancer. External beam radiation therapy is reserved for adjuvant treatment of MTC with aggressive features. Targeted therapeutics vandetanib and cabozantinib are approved for the treatment of aggressive and metastatic tumors that are not amenable to surgery. The use of these multikinase inhibitors are supported by the observed overactivation of the RET oncoprotein in a large subpopulation of MTCs. However, not all patients carry oncogenic alterations of this kinase. Hence, there is still a need for comprehensive molecular characterization of MTC utilizing whole-genome and transcriptome-sequencing methodologies with the aim of identifying targetable mutations. Here, we describe the genomic profiles of two medullary thyroid cancers and report the presence of a putative oncogenic BRAF fusion in one. Such alterations, previously observed in other malignancies and known targets of available drugs, can benefit patients who currently have no treatment options. ",
        "Doc_title":"Putative BRAF activating fusion in a medullary thyroid cancer.",
        "Journal":"Cold Spring Harbor molecular case studies",
        "Do_id":"27148585",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605883611314126848},
      {
        "Doc_abstract":" MEN2A is a hereditary syndrome characterized by medullary thyroid carcinoma, hyperparathyroidism, and pheochromocytoma. Classically patients with a pheochromocytoma initially present with the triad of paroxysmal headaches, palpitations, and diaphoresis accompanied by marked hypertension. However, although reported as a rare presentation, spontaneous hemorrhage within a pheochromocytoma can present as an abdominal catastrophe. Unrecognized, this transformation can rapidly result in death. We report the only documented case of a thirty eight year old gentleman with MEN2A who presented to a community hospital with hemorrhagic shock and peritonitis secondary to an unrecognized hemorrhagic pheochromocytoma. The clinical course is notable for an inability to localize the source of hemorrhage during an initial damage control laparotomy that stabilized the patient sufficiently to allow emergent transfer to our facility, re-exploration for continued hemorrhage and abdominal compartment syndrome, and ultimately angiographic embolization of the left adrenal artery for control of the bleeding. Following recovery from his critical illness and appropriate medical management for pheochromocytoma, he returned for interval bilateral adrenal gland resection, from which his recovery was unremarkable. Our review of the literature highlights the high mortality associated with the undertaking of an operative intervention in the face of an unrecognized functional pheochromocytoma. This reinforces the need for maintaining a high index of suspicion for pheochromocytoma in similar cases. Our case also demonstrates the need for a mutimodal treatment approach that will often be required in these cases.",
        "Doc_title":"Spontaneous adrenal pheochromocytoma rupture complicated by intraperitoneal hemorrhage and shock.",
        "Journal":"World journal of emergency surgery : WJES",
        "Do_id":"21843357",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605825753863159808},
      {
        "Doc_abstract":"Medullary thyroid cancer (MTC) can vary in tumor biology and progression. The most important indicator of distant metastases, determiningclinical outcome, is lymph node metastasis to the neck and mediastinum. Surgical cure is within reach in node-negative tumors or node-positive tumors with fewer than 10 lymph node metastases. From a surgical point of view, compartment-oriented lymph node dissection, clearing gross, and occult metastases are important for locoregional tumor control. The discovery of missense germline mutations in the RET proto-oncogene and the close genotype-phenotype correlation in hereditary MTC promoted the worldwide breakthrough ofprophylactic thyroidectomy. The best approach to hereditary MTC affords the DNA-based/biochemical concept, whichis geared at limiting prophylactic surgery to total thyroidectomy at minimal surgical morbidity before the tumor can spread beyond the thyroid capsule. To improve outcome, routine calcitonin screening in nodular thyroid disease and DNA-based screening of the offspring in RET families are effective interventions. ",
        "Doc_title":"Surgical Treatment of Medullary Thyroid Cancer.",
        "Journal":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer",
        "Do_id":"26494390",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Carcinoma, Neuroendocrine;Genetic Predisposition to Disease;Heredity;Humans;Lymph Node Excision;Lymphatic Metastasis;Mutation;Neoplasm Recurrence, Local;Phenotype;Proto-Oncogene Proteins c-ret;Reoperation;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome",
        "Doc_meshqualifiers":"genetics;secondary;surgery;genetics;genetics;pathology;surgery",
        "_version_":1605852581549047808},
      {
        "Doc_abstract":"About one quarter of all medullary thyroid cancers (MTC) are determined genetically due to a mutation in the RET proto-oncogene. The most common site of mutation is in codon 634. Therapeutic approaches toward patients at risk for the development of MTC identified by family screening programs range from total thyroidectomy to total thyroidectomy with lymphadenectomy of all 4 compartments.;We report 17 patients (median age, 13 years; range, 4-36) carrying a mutation in codon 634 of the RET proto-oncogene who were operated on prophylactically at our department. All patients underwent thyroidectomy with bilateral cervicocentral lymphadenectomy. Current calcitonin level, overall survival, and disease-free survival were analyzed by contacting general practitioners and patients.;Tumor classification was as follows: C-cell hyperplasia, 18% (n = 3); T1 (<1 cm), 71% (n = 12); and T1 (>1 cm), 12% (n = 2). Only 2 patients had lymph node metastases (12%). These patients developed recurrent disease (median observation time, 147 months; range, 90-181). In 1 patient, the calcitonin level normalized after unilateral cervicolateral lymphadenectomy. The other patient (9 years old at primary operation) still has a persistently increased serum calcitonin level after 140 months of follow-up despite several operations for MTC.;Total thyroidectomy with bilateral cervicocentral lymphadenectomy is sufficient as routine \"prophylactic therapy\" for patients with mutations in codon 634 of the RET proto-oncogene. Cervicolateral lymphadenectomy is indicated if calcitonin remains elevated after primary surgery. Prophylactic thyroidectomy should be performed before the development of lymph node metastases.",
        "Doc_title":"Long-term outcome of \"prophylactic therapy\" for familial medullary thyroid cancer.",
        "Journal":"Surgery",
        "Do_id":"19744457",
        "Doc_ChemicalList":"Calcitonin;Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Adolescent;Adult;Calcitonin;Carcinoma, Medullary;Child;Child, Preschool;Female;Follow-Up Studies;Humans;Lymph Node Excision;Male;Mutation;Neck;Proto-Oncogene Proteins c-ret;Recurrence;Thyroid Gland;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome;Ultrasonography;Young Adult",
        "Doc_meshqualifiers":"blood;blood;genetics;pathology;prevention & control;diagnostic imaging;surgery;genetics;pathology;blood;genetics;pathology;prevention & control;adverse effects",
        "_version_":1605762643217350656},
      {
        "Doc_abstract":"The goal in managing patients who have MTC is to detect and surgically remove disease at an early stage. Tumor marker-based biochemical screening and DNA-based genetic screening have created the opportunity for effective prophylactic surgery in patients at risk for hereditary MTC. Complete surgical resection is critical for cure because cervical reoperation for persistent or recurrent disease benefits only select patients. With the advent of therapies that target the RET-activated pathways, new hope may be emerging for patients who have locally advanced or metastatic disease.",
        "Doc_title":"Medullary thyroid cancer.",
        "Journal":"Surgical oncology clinics of North America",
        "Do_id":"16882502",
        "Doc_ChemicalList":"Calcitonin;Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Calcitonin;Carcinoma, Medullary;Comorbidity;Humans;Lymph Node Excision;Multiple Endocrine Neoplasia Type 2a;Mutation, Missense;Prognosis;Proto-Oncogene Proteins c-ret;Reoperation;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"blood;diagnosis;epidemiology;genetics;therapy;epidemiology;genetics;genetics;diagnosis;epidemiology;genetics;therapy",
        "_version_":1605765740073320448},
      {
        "Doc_abstract":"This article summarizes the clinical features and molecular pathogenesis of medullary thyroid cancer (MTC) and focuses on the current use of molecular, biochemical, and imaging disease markers as a basis for selection of appropriate therapy. Clinicians treating patients who have MTC face the following challenges: (1) distinguishing MTC as early as possible from benign nodular disease and differentiated thyroid cancer to choose the appropriate initial surgery, (2) managing low-level residual cancer in otherwise asymptomatic individuals, and (3) treating progressive metastatic disease. Early clinical trials using small molecules targeting Ret or vascular endothelial growth factor receptors suggest that such approaches could be effective and well tolerated. This article highlights early progress in targeted therapy of MTC and significant challenges in disease monitoring to appropriately select and evaluate patients being treated with these therapies.",
        "Doc_title":"Medullary thyroid cancer: monitoring and therapy.",
        "Journal":"Endocrinology and metabolism clinics of North America",
        "Do_id":"17673130",
        "Doc_ChemicalList":"Angiogenesis Inhibitors;Biomarkers;Genetic Markers;Proto-Oncogene Proteins c-ret",
        "Doc_meshdescriptors":"Angiogenesis Inhibitors;Biomarkers;Carcinoma, Medullary;Diagnostic Imaging;Genetic Markers;Humans;Lymph Node Excision;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"therapeutic use;blood;diagnosis;genetics;radiotherapy;therapy;antagonists & inhibitors;diagnosis;genetics;radiotherapy;therapy",
        "_version_":1605874024876867584},
      {
        "Doc_abstract":"Vandetanib is a small-molecule inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET tyrosine kinases that has demonstrated clinical benefits in patients with medullary thyroid cancer (MTC). By identifying patients who are in greatest need of therapy, the risks of vandetanib can be balanced against the potential benefits in patients for whom there had been no effective therapy until now. This review discusses the development of vandetanib in patients with MTC and the benefits and risks in this patient population.",
        "Doc_title":"Vandetanib for the treatment of thyroid cancer.",
        "Journal":"Clinical pharmacology and therapeutics",
        "Do_id":"22158569",
        "Doc_ChemicalList":"Antineoplastic Agents;Piperidines;Quinazolines;Receptor, Epidermal Growth Factor;N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Clinical Trials as Topic;Humans;Piperidines;Quinazolines;Receptor, Epidermal Growth Factor;Thyroid Neoplasms;Treatment Outcome",
        "Doc_meshqualifiers":"therapeutic use;methods;therapeutic use;therapeutic use;antagonists & inhibitors;drug therapy;immunology",
        "_version_":1605760147285606400},
      {
        "Doc_abstract":"Medullary thyroid cancer (MTC) typically accounts for 3%-4% of all thyroid cancers. Although the majority of MTCs are sporadic, 20% of cases are hereditary. Hereditary MTC can be found in multiple endocrine neoplasia 2A or 2B or as part of familial MTC based on a specific germline mutation in the RET proto-oncogene. This article discusses the current approaches available for the diagnosis, evaluation, and management of patients and their family members with suspected MTC. The disease is predominantly managed surgically and typically requires a total thyroidectomy and lymph node dissection. A review of recent guidelines on the extent and timing of surgical excision is discussed. There are not very many effective systemic treatment options for MTC, but several emerging therapeutic targets have promise. ",
        "Doc_title":"Current understanding and management of medullary thyroid cancer.",
        "Journal":"The oncologist",
        "Do_id":"24037980",
        "Doc_ChemicalList":"Calcitonin;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Calcitonin;Carcinoma, Medullary;Carcinoma, Neuroendocrine;Germ-Line Mutation;Humans;Lymph Node Excision;Multiple Endocrine Neoplasia Type 2a;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"blood;blood;congenital;genetics;pathology;surgery;blood;genetics;pathology;surgery;genetics;blood;genetics;pathology;surgery",
        "_version_":1605825690717913088},
      {
        "Doc_abstract":"Surgery has been the treatment of choice for many disorders of the thyroid gland, both benign and malignant, for many decades. However, surgery has not been invariable but has continued to change in accordance with research results. In benign cases, surgery has generally evolved to be as organ preserving as possible. In several instances, however, a more radical extent of resection seems justified in order to ensure that the risk of recurrence is as low as possible. For instance, total thyroidectomy may be beneficial in patients with endemic multinodular goitre or young patients with Graves' disease and accompanying cold nodules or high levels of autoantibodies. Several tools, e.g. magnifying glasses, bipolar coagulation forceps and neuromonitoring, are available to identify and preserve the recurrent laryngeal nerve and the parathyroid glands, hence keeping the morbidity at a low level. Most recently, minimally invasive surgery has been successfully used in treating both benign and malignant disorders of the thyroid gland. In the case of malignant disorders, minimally invasive surgery may become an attractive alternative to open surgery if a limited surgical extent is justified, e.g. in patients with micro-PTC (papillary thyroid carcinoma, diameter less than 1 cm). Whether a limited surgical approach is also justified in other cases, e.g. in any patient with intrathyroidal PTC or patients with micro-FTC (follicular thyroid carcinoma), remains to be shown and is the subject of ongoing investigations. One of the most intriguing recent discoveries is the identification of genotype-phenotype correlations in patients with hereditary medullary thyroid carcinoma. In these patients, the timing and extent of surgery may depend not only on the patient's age and serum levels of the tumour marker calcitonin but also on the specific germline RET proto-oncogene mutation. Surgery will certainly continue to play an important role in the treatment of thyroid diseases and may be increasingly based on individual findings instead of general recommendations.",
        "Doc_title":"An update on thyroid surgery.",
        "Journal":"European journal of nuclear medicine and molecular imaging",
        "Do_id":"12192544",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adenocarcinoma, Follicular;Adenoma;Adult;Carcinoma, Medullary;Carcinoma, Papillary;Child;Goiter;Humans;Hypocalcemia;Lymph Node Excision;Middle Aged;Minimally Invasive Surgical Procedures;Monitoring, Intraoperative;Multiple Endocrine Neoplasia;Parathyroid Glands;Postoperative Complications;Recurrent Laryngeal Nerve Injuries;Thyroid Neoplasms;Thyroidectomy;Voice Disorders",
        "Doc_meshqualifiers":"surgery;surgery;genetics;surgery;surgery;surgery;etiology;genetics;surgery;injuries;etiology;surgery;adverse effects;instrumentation;methods;etiology",
        "_version_":1605879453677780992},
      {
        "Doc_abstract":"Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I.;We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiographic progression of metastatic MTC. Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo. The primary end point was progression-free survival (PFS). Additional outcome measures included tumor response rate, overall survival, and safety.;The estimated median PFS was 11.2 months for cabozantinib versus 4.0 months for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001). Prolonged PFS with cabozantinib was observed across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic). Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status. Kaplan-Meier estimates of patients alive and progression-free at 1 year are 47.3% for cabozantinib and 7.2% for placebo. Common cabozantinib-associated adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased weight and appetite, nausea, and fatigue and resulted in dose reductions in 79% and holds in 65% of patients. Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients.;Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease. This dose of cabozantinib was associated with significant but manageable toxicity.",
        "Doc_title":"Cabozantinib in progressive medullary thyroid cancer.",
        "Journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
        "Do_id":"24002501",
        "Doc_ChemicalList":"Anilides;Carcinoembryonic Antigen;Protein Kinase Inhibitors;Pyridines;cabozantinib;Calcitonin",
        "Doc_meshdescriptors":"Adult;Aged;Aged, 80 and over;Anilides;Calcitonin;Carcinoembryonic Antigen;Carcinoma, Neuroendocrine;Disease-Free Survival;Double-Blind Method;Female;Humans;Male;Middle Aged;Protein Kinase Inhibitors;Pyridines;Thyroid Neoplasms",
        "Doc_meshqualifiers":"adverse effects;therapeutic use;analysis;analysis;therapeutic use;adverse effects;therapeutic use;drug therapy;mortality",
        "_version_":1605881243756396544},
      {
        "Doc_abstract":"Differentiated thyroid carcinomas (DTCs) that arise from follicular cells account >90% of thyroid cancer (TC) [papillary thyroid cancer (PTC) 90%, follicular thyroid cancer (FTC) 10%], while medullary thyroid cancer (MTC) accounts <5%. Complete total thyroidectomy is the treatment of choice for PTC, FTC, and MTC. Radioiodine is routinely recommended in high-risk patients and considered in intermediate risk DTC patients. DTC cancer cells, during tumor progression, may lose the iodide uptake ability, becoming resistant to radioiodine, with a significant worsening of the prognosis. The lack of specific and effective drugs for aggressive and metastatic DTC and MTC leads to additional efforts toward the development of new drugs. Several genetic alterations in different molecular pathways in TC have been shown in the past few decades, associated with TC development and progression. Rearranged during transfection (RET)/PTC gene rearrangements, RET mutations, BRAF mutations, RAS mutations, and vascular endothelial growth factor receptor 2 angiogenesis pathways are some of the known pathways determinant in the development of TC. Tyrosine kinase inhibitors (TKIs) are small organic compounds inhibiting tyrosine kinases auto-phosphorylation and activation, most of them are multikinase inhibitors. TKIs act on the aforementioned molecular pathways involved in growth, angiogenesis, local, and distant spread of TC. TKIs are emerging as new therapies of aggressive TC, including DTC, MTC, and anaplastic thyroid cancer, being capable of inducing clinical responses and stabilization of disease. Vandetanib and cabozantinib have been approved for the treatment of MTC, while sorafenib and lenvatinib for DTC refractory to radioiodine. These drugs prolong median progression-free survival, but until now no significant increase has been observed on overall survival; side effects are common. New efforts are made to find new more effective and safe compounds and to personalize the therapy in each TC patient. ",
        "Doc_title":"Molecular Targeted Therapies of Aggressive Thyroid Cancer.",
        "Journal":"Frontiers in endocrinology",
        "Do_id":"26635725",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605759754365304832},
      {
        "Doc_abstract":"American Thyroid Association (ATA) guidelines suggest that thyroidectomy can be delayed in some children with multiple endocrine neoplasia syndrome 2A (MEN2A) if serum calcitonin (Ct) and neck ultrasonography (US) are normal. We hypothesized that normal US would not exclude a final pathology diagnosis of medullary thyroid cancer (MTC).;We retrospectively queried a MEN2A database for patients aged<18 years, diagnosed through genetic screening, who underwent preoperative US and thyroidectomy at our institution, comparing preoperative US and Ct results with pathologic findings.;35 eligible patients underwent surgery at median age of 6.3 (range 3.0-13.8) years. Mean MTC size was 2.9 (range 0.5-6.0) mm. The sensitivity of a US lesion5 mm in predicting MTC was 13% [95% confidence interval (CI) 2%, 40%], and the specificity was 95% [95% CI 75%, 100%]. Elevated Ct predicted MTC in 13/15 patients (sensitivity 87% [95% CI 60%, 98%], specificity 35% [95% CI 15%, 59%]). The area under the receiver operating characteristic curve (AUC) for using US lesion of any size to predict MTC was 0.50 [95% CI 0.33, 0.66], suggesting that US size has poor ability to discriminate MTC from non-MTC cases. The AUC for Ct level at 0.65 [95% CI 0.46, 0.85] was better than that of US but not age [AUC 0.62, 95% CI 0.42, 0.82].;In asymptomatic children with MEN2A diagnosed by genetic screening, preoperative thyroid US was not sensitive in identifying MTC of any size and, when determining the age for surgery, should not be used to predict microscopic MTC.",
        "Doc_title":"Ultrasonography should not guide the timing of thyroidectomy in pediatric patients diagnosed with multiple endocrine neoplasia syndrome 2A through genetic screening.",
        "Journal":"Annals of surgical oncology",
        "Do_id":"22890595",
        "Doc_ChemicalList":"Calcitonin;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Area Under Curve;Calcitonin;Carcinoma, Medullary;Child;Child, Preschool;Female;Humans;Male;Multiple Endocrine Neoplasia Type 2a;Practice Guidelines as Topic;Predictive Value of Tests;Proto-Oncogene Proteins c-ret;Retrospective Studies;Statistics, Nonparametric;Thyroid Neoplasms;Thyroidectomy;Ultrasonography",
        "Doc_meshqualifiers":"blood;blood;diagnosis;surgery;diagnostic imaging;genetics;surgery;genetics;blood;diagnosis;surgery",
        "_version_":1605901596366995456},
      {
        "Doc_abstract":"Prophylactic thyroidectomy can be curative for patients with hereditary medullary thyroid cancer (MTC) caused by RET proto-oncogene mutations. Calcitonin is a sensitive tumor marker used to follow patients. We suggest that thyroglobulin (Tg) levels should also be monitored postoperatively in these patients.;We reviewed patients with RET mutations who underwent prophylactic thyroidectomy between 1981 and 2011 at an academic endocrine surgery center. Patients were excluded if they had no postoperative Tg levels recorded.;Of the 22 patients who underwent prophylactic thyroidectomy, 14 were included in the final analysis. The average age at thyroidectomy was 9.8 years (range, 4-29). Tg levels were detectable 1.5 months to 31 years postoperatively in 11 patients (79%), all of whom were <15 years old at thyroidectomy. Median thyroid-stimulating hormone (TSH) was 2.5 mIU/L and 13.4 mIU/L in patients with undetectable and detectable Tg, respectively. Of those with detectable Tg, 5 had cervical ultrasonographic examination: Two showed no residual tissue in the thyroid bed, and 3 showed remnant thyroid tissue.;Tg levels can identify patients with remnant thyroid tissue after prophylactic thyroidectomy. Ultrasonography can determine whether thyroid tissue remains posterolaterally that is at risk of MTC recurrence. Maintaining normal TSH may prevent growth of remaining thyroid follicular cells.",
        "Doc_title":"Utility of serum thyroglobulin measurements after prophylactic thyroidectomy in patients with hereditary medullary thyroid cancer.",
        "Journal":"Surgery",
        "Do_id":"24882762",
        "Doc_ChemicalList":"Thyrotropin;Thyroglobulin;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Adult;Carcinoma, Medullary;Carcinoma, Neuroendocrine;Child;Child, Preschool;Female;Humans;Male;Multiple Endocrine Neoplasia Type 2a;Mutation;Neoplasm Recurrence, Local;Proto-Oncogene Proteins c-ret;Thyroglobulin;Thyroid Neoplasms;Thyroidectomy;Thyrotropin",
        "Doc_meshqualifiers":"blood;genetics;surgery;blood;genetics;surgery;prevention & control;genetics;blood;blood;genetics;surgery;blood",
        "_version_":1605750458590167040},
      {
        "Doc_abstract":"Multiple endocrine neoplasia type 2 (MEN-2) is an inherited multiglandular disease with age-related penetrance and variable expression. The prognosis of MEN-2 is linked to the carcinological evolution of medullary thyroid cancer (MTC), which depends mainly on the stage of discovery, and to the incidents related to pheochromocytomas. The emphasizes the need for early diagnosis and management of MEN-2. Since 1993, mutations evidenced on the protooncogene RET have allowed subjects at risk to be identified, thus leading to a three-step management of these patients. (1) For all the potentially affected members of a MEN-2 family, screening by molecular genetics of the ret gene enables one to identify the subjects at risk who bear the mutation. When no mutation is observed, a linkage analysis study may be proposed. (2) In the subjects at risk, early screening for the various types of endocrine lesions may then start in childhood and be performed using specific biological markers of MTC, pheochromocytoma and primary hyperparathyroidism, and particularly, basal and pentagastrin-stimulated calcitonin measurement, which is known to be the most sensitive marker for the monitoring of MTC. (3) This step of biological investigations enables the earliest possible treatment of any endocrine lesion detected before it is expressed clinically, thus improving the prognosis of MEN-2. When genetic screening cannot be performed, only annual clinical and biological monitoring remain available in all members of a family affected with MEN-2.",
        "Doc_title":"Multiple endocrine neoplasia type 2: management of patients and subjects at risk. French Study Group on Calcitonin-Secreting Tumors (GETC).",
        "Journal":"Hormone research",
        "Do_id":"9167955",
        "Doc_ChemicalList":"Drosophila Proteins;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Drosophila Proteins;Genetic Testing;Humans;Multiple Endocrine Neoplasia Type 2a;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Risk Factors",
        "Doc_meshqualifiers":"diagnosis;surgery;genetics;genetics",
        "_version_":1605746397344169987},
      {
        "Doc_abstract":"Surgical therapy of incidentally postoperative diagnosed small sporadic medullary thyroid cancer (MTC) is discussed controversially. In principle completion thyroidectomy with neck dissection and regulary tumor follow-up are under discussion. A total of 277 patients with MTC were treated between 1986 and 2004. In 22 cases diagnosis of a small (pT1 or pT2) sporadic MTC was incidental and only postoperatively confirmed. Normally total thyroidectomy with neck dissection is standard surgical therapy of a known MTC. Because of postoperative incidental diagnosis in all 22 cases surgical therapy was less then total thyroidectomy. Mutation analysis of RET Proto-Oncogen and familial history were negative in all cases. All patients were systematically followed-up in defined intervals by calcitonin, pentagastrin stimulation test, carcinoembryonic antigen and ultrasound. Median follow-up is 6.2 years (range: 2-13 years) and although a hemithyroidectomy or less was performed all 22 patients are cured by the MTC. We conclude that completion thyroidectomy and neck dissection are not mandatory in such patients, if the tumor is completely resected and genetic background is excluded. Indispensably a systematic long term follow-up of at least 10 years, better a life-long, is mandatory.",
        "Doc_title":"[Decision making in postoperative incidentally found small C-cell-carcinoma].",
        "Journal":"Zentralblatt fur Chirurgie",
        "Do_id":"16220440",
        "Doc_ChemicalList":"Biomarkers, Tumor",
        "Doc_meshdescriptors":"Adult;Aged;Biomarkers, Tumor;Carcinoma, Medullary;Decision Trees;Female;Follow-Up Studies;Goiter, Nodular;Humans;Incidental Findings;Lymph Node Excision;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Postoperative Complications;Prognosis;Reoperation;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"blood;diagnosis;genetics;pathology;surgery;surgery;diagnosis;genetics;pathology;surgery;diagnosis;pathology;surgery;diagnosis;genetics;pathology;surgery",
        "_version_":1605792400295329792},
      {
        "Doc_abstract":"Until only recently, few effective systemic therapies were available to treat patients with metastatic thyroid cancers. Recent advances in better understanding the pathogenesis and altered signaling pathways-especially in medullary and differentiated thyroid cancers (MTCs and DTCs)-have begun to change this situation substantially. Vandetanib, an orally bioavailable inhibitor of the RET kinase that is constitutively activated in MTC, has now been approved by the U.S. Food and Drug Administration (FDA) for use in progressive and symptomatic metastatic MTC; it has been shown to delay time to progression relative to placebo in a randomized phase III trial. Further, vascular endothelial growth factor receptor (VEGF-R) inhibitory agents including sorafenib, sunitinib, pazopanib, and axitinib that are already approved in the United States for use in advanced renal cell carcinoma have shown high response rates in treating advanced DTCs in multiple phase II trials, and have become commonly used in progressive radioiodine-refractory metastatic DTC. Yet additional agents are now in development, with several including XL184 (cabozantinib) also showing promise in DTC and MTC. In anaplastic thyroid cancer (ATC), progress has been slower, with the greatest apparent gains resulting more from the application of systemic therapies earlier in the disease course, especially when used in conjunction with initial surgical and radiation therapies. Despite recent progress, additional effective systemic therapeutic approaches remain sorely needed for treating metastatic MTC, DTC, and ATC. ",
        "Doc_title":"Systemic therapeutic approaches to advanced thyroid cancers.",
        "Journal":"American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting",
        "Do_id":"24451769",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"None",
        "Doc_meshqualifiers":"None",
        "_version_":1605841238974529536},
      {
        "Doc_abstract":"Thyroid cancer is an emerging public health concern. In the USA, its incidence has doubled in the past decade, making it the eighth most commonly diagnosed neoplasm in 2010. Despite this alarming increase, most thyroid cancer patients benefit from conventional approaches (surgery, radioiodine, radiotherapy, TSH suppression with levothyroxine) and are often cured. Nevertheless, a minority have aggressive tumors resistant to cytotoxic and other historical therapies; these patients sorely need new treatment options.;Herein the biology and molecular characteristics of the common histological types of thyroid cancer are reviewed to provide context for subsequent discussion of recent developments and emerging therapeutics for advanced thyroid cancers.;Several kinase inhibitors, especially those targeting VEGFR and/or RET, have already demonstrated promising activity in differentiated and medullary thyroid cancers (DTC, MTC). Although of minimal benefit in DTC and MTC, cytotoxic chemotherapy with anti-microtubule agents and/or anthracyclines in combination with intensity-modulated radiation therapy appears to extend survival for patients with locoregionally confined anaplastic thyroid cancer (ATC), but to have only modest benefit in metastatic ATC. Further discovery and development of novel agents and combinations of agents will be critical to further progress in treating advanced thyroid cancers of all histotypes.",
        "Doc_title":"Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.",
        "Journal":"Expert opinion on investigational drugs",
        "Do_id":"21910667",
        "Doc_ChemicalList":"Antineoplastic Agents",
        "Doc_meshdescriptors":"Antineoplastic Agents;Carcinoma, Medullary;Disease Progression;Humans;Molecular Targeted Therapy;Thyroid Neoplasms",
        "Doc_meshqualifiers":"chemistry;pharmacology;therapeutic use;diagnosis;drug therapy;genetics;pathology;diagnosis;drug therapy;genetics;pathology",
        "_version_":1605897787924283392},
      {
        "Doc_abstract":"There is no effective treatment for recurrent or metastatic medullary thyroid cancer (MTC). Hereditary MTC is associated with mutations in the RET protooncogene, which encodes for a tyrosine kinase. We postulated that Src tyrosine kinases regulate MTC proliferation. Proliferation of the human MTC cell line, TT, was examined in the presence of a Src-specific tyrosine kinase inhibitor, PP2, or genistein. Cell counts were performed with a Coulter counter or by flow cytometry. DNA synthesis was evaluated by bromodeoxyuridine incorporation. A cell death ELISA was used to assess apoptosis. Akt phosphorylation was determined by Western immunoblot. MAPK activity was measured using an immunoprecipitation kinase assay, and MAPK inhibition was achieved with SB202190 (p38 MAPK) and PD098059 (MAPK kinase). Data were analyzed by ANOVA. Compared with controls, PP2 reduced DNA synthesis, abolished Akt phosphorylation, and increased apoptosis. The MAPK kinase inhibitor, PD098059, attenuated DNA synthesis, whereas genistein caused modest declines in cell count and DNA synthesis and minimal changes in apoptosis. We conclude that Src-dependent MTC proliferation occurs via increased DNA synthesis and reduced apoptosis. The latter effect may be mediated by Akt survival signals. Modulation of Src activity is a potential therapeutic target in MTC.",
        "Doc_title":"Antiproliferative effects of Src inhibition on medullary thyroid cancer.",
        "Journal":"The Journal of clinical endocrinology and metabolism",
        "Do_id":"15240638",
        "Doc_ChemicalList":"2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one;AG 1879;Enzyme Inhibitors;Flavonoids;Imidazoles;Proto-Oncogene Proteins;Pyridines;Pyrimidines;Genistein;Phosphotransferases;Protein-Tyrosine Kinases;CSK tyrosine-protein kinase;src-Family Kinases;AKT1 protein, human;Protein-Serine-Threonine Kinases;Proto-Oncogene Proteins c-akt;Mitogen-Activated Protein Kinases;4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole",
        "Doc_meshdescriptors":"Apoptosis;Carcinoma, Medullary;Cell Division;Cell Line, Tumor;Enzyme Activation;Enzyme Inhibitors;Flavonoids;Genistein;Humans;Imidazoles;Mitogen-Activated Protein Kinases;Phosphorylation;Phosphotransferases;Protein-Serine-Threonine Kinases;Protein-Tyrosine Kinases;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-akt;Pyridines;Pyrimidines;Thyroid Neoplasms;src-Family Kinases",
        "Doc_meshqualifiers":"drug effects;pathology;physiopathology;drug effects;drug effects;pharmacology;pharmacology;pharmacology;pharmacology;metabolism;drug effects;antagonists & inhibitors;metabolism;antagonists & inhibitors;metabolism;pharmacology;pharmacology;pathology;physiopathology;antagonists & inhibitors",
        "_version_":1605824663849533440},
      {
        "Doc_abstract":"The cut-off values able to differentiate between reactive or neoplastic C-cell hyperplasia (CCH) or to predict sporadic medullary thyroid cancer (MTC) are still debated both for basal and stimulated calcitonin (bCT and sCT). In the present study, the prevalence and the histological patterns of CCH in 15 patients with multinodular goiter (MNG), bCT>10 pg/ml and sCT levels >50 pg/ml were studied. As controls, 16 patients with MNG and bCT levels <10 pg/ml and 4 patients with familial (FMTC) were included. For each case, calcitonin (CT) immunoreactive cells were counted in 60 consecutive high-power fields (400x) and CCH classified as focal, diffuse, nodular, or neoplastic. RET genetic analyses were performed at the germline and tissue levels in MTC and CCH cases. In patients with MNG, sCT levels >50 pg/ml were associated with CCH or MTC, being the total number of C-cells/60 fields significantly higher than that found in MNG with normal bCT (P = 0.0008) and comparable with that detected in FMTCs. In the group with sCT>50 pg/ml, the C-cells displayed a neoplastic phenotype. Neither germline nor somatic RET mutations were found. In conclusion, sCT levels >50 pg/ml were always associated with CCH, without correlation between CT levels and the number of C-cells or the final diagnosis. The C-cells had a morphology and distribution pattern similar to those observed in FMTC. Thus, sCT levels >50 pg/ml indicate the presence of CCH with a possible preneoplastic potential, suggesting the opportunity to perform a prophylactic surgical treatment.",
        "Doc_title":"Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia?",
        "Journal":"Endocrine-related cancer",
        "Do_id":"17639053",
        "Doc_ChemicalList":"Calcitonin;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adult;Aged;Brain Stem Neoplasms;Calcitonin;Female;Goiter, Nodular;Humans;Hyperplasia;Male;Middle Aged;Mutation;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms",
        "Doc_meshqualifiers":"diagnosis;pathology;blood;diagnosis;pathology;diagnosis;pathology;genetics;diagnosis;pathology",
        "_version_":1605746839361945600},
      {
        "Doc_abstract":"Autopsy studies show that C cells deriving from the ultimobranchial body and migrating into the thyroid do not reach the isthmus region and are distributed along the vertical axes of thyroid lobes. This was confirmed in a surgical series of 58 patients (34 with preoperatively normal and 24 with elevated serum calcitonin) where no calcitonin-positive cells were demonstrable immunohistochemically within separately investigated isthmi. Consequently, isthmus-preserving total bilateral lobectomy (IPTB) may be regarded as an adequate surgical procedure for C-cell hyperplasia (CCH).;IPTB was performed from October 2001 to December 2004 in 64 patients, 59 patients with nodular goiter and slightly to moderately elevated serum calcitonin (stimulated under 500 pg/ml) (group A, apparently sporadic cases) and in 5 patients undergoing prophylactic surgery for hereditary medullary thyroid carcinoma (MTC) with intermediate- or low-risk RET mutations (non-634) (group B). The surgical procedure focused on meticulous total extracapsular resection of both thyroid lobes, preservation of an isthmus remnant of about 3 ml (smaller in children), and histologic workup of the border zones of resection in addition to that of the completely removed lobes. When malignancy could be proven intraoperatively (7 patients) or when the isthmus turned out to contain nodular lesions (4 patients), completion total thyroidectomy (plus lymphadenectomy) was performed as a one-stage procedure. Second-stage total thyroidectomy was performed in 3 cases. Thus, IPTB was the definitive surgical procedure in 50 patients (45 of group A and all 5 of group B).;In all of the 50 definite IPTB cases, postoperative serum calcitonin was below the measurable limit (2 pg/ml); stimulated calcitonin was below the measurable limit in 47 (including all of group B) and was measurable in 3 sporadic cases in a lower-normal range between 2.4 and 3.5 pg/ml. Genetic screening of the apparently sporadic cases with CCH was positive in one (codon 791). The risk of recurrent laryngeal nerve paralysis seems not to be elevated (0% permanent); permanent hypocalcemia occurred in 1 patient (2%). Follow-up data of 37 patients, median 18 (6-36) months, showed continuously nonmeasurable serum calcitonin with one exception, where it was in the normal range after 18 months. All IPTB patients are still under substitution therapy with L-thyroxine (median 125 mug/day) with decreasing tendency in all 3 children after prophylactic operation, the latter also showing an increasing volume of well-vascularized isthmi (from 1.5 to 2.5 ml).;IPTB reliably removes all C cells. There may not be need for total thyroidectomy (TTx) in cases with CCH. When necessary, completion TTx can be performed easily without additional risk. IPTB leaves a functionally relevant remnant, corresponding to that of a subtotal resection. This might be of importance especially for prophylactic surgery in children where the isthmus can compensate for the loss of thyroid function with time.",
        "Doc_title":"Isthmus-preserving total bilobectomy: an adequate operation for C-cell hyperplasia.",
        "Journal":"World journal of surgery",
        "Do_id":"16680601",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Carcinoma, Medullary;Child;Female;Humans;Hyperplasia;Male;Middle Aged;Thyroid Diseases;Thyroid Gland;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"physiopathology;surgery;physiopathology;surgery;pathology;surgery;physiopathology;surgery;methods",
        "_version_":1605846653987717120},
      {
        "Doc_abstract":"In 2009, the American Thyroid Association (ATA) published consensus guidelines for timing of prophylactic thyroidectomy (PrThy) for treatment of hereditary medullary thyroid cancer (MTC). The aim of this study was to assess whether the clinical guidelines outlined in the ATA recommendations added to the specific mutation risk level could predict the presence of MTC on final pathology.;A retrospective study was performed of patients undergoing PrThy. We evaluated mutation-based risk levels in combination with 2009 ATA guidelines for resection.;Overall, 54 patients underwent PrThy between 1972 and 2009. The median age at PrThy was 11.5 years (range, 2-68). Only 4 patients (8%) underwent PrThy prior to age 5 years. Most patients with MTC (16/22, 73%) had a level C mutation, and the youngest age of MTC in a level C mutation carrier was 5 years. The youngest age of MTC in level A or B carriers was 15 years. The single factor that predicted an overall decreased risk of MTC at the time of PrThy was meeting all ATA mutation-based postponement guidelines for surgical intervention (P = .04).;ATA guidelines that includes risk assessment of RET mutation are important in predicting the presence of MTC in patients who are candidates for prophylactic thyroidectomy and in determining the timing of operative resection.",
        "Doc_title":"Do the recent American Thyroid Association (ATA) Guidelines accurately guide the timing of prophylactic thyroidectomy in MEN2A?",
        "Journal":"Surgery",
        "Do_id":"21134565",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Carcinoma, Neuroendocrine;Child;Child, Preschool;Consensus Development Conferences as Topic;Humans;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Practice Guidelines as Topic;Predictive Value of Tests;Proto-Oncogene Proteins c-ret;Risk Assessment;Societies, Medical;Thyroid Neoplasms;Thyroidectomy;United States",
        "Doc_meshqualifiers":"epidemiology;surgery;genetics;standards;genetics;surgery;methods",
        "_version_":1605750790642728960},
      {
        "Doc_abstract":"Medullary thyroid cancer (MTC) is genetically determined in 30% to 35% of cases, notably through multiple mutations in the RET protooncogene located on chromosome 10, for which a genotype-phenotype relationship determines age of onset. There are three phenotypes: MEN 2 A and B, and isolated familial MTC. The type of mutation determines 3 levels of aggressiveness. Current guidelines recommend thyroidectomy during the first months of life for patients with very-high-risk (level 3) mutations and before 5 years of age for high-risk (level 2) mutations. There are no precise recommendations for lower-risk mutations, for which the surgical decision also depends on the calcitonin level and family history. We describe 18 patients who underwent prophylactic surgery. Regardless of the mutation, all patients with a normal preoperative calcitonin level were cured. However, surgery was performed later than recommended, for various reasons, including late genetic diagnosis and parents' opposition.",
        "Doc_title":"[Prophylactic thyroidectomy in medullary thyroid cancer].",
        "Journal":"Bulletin de l'Academie nationale de medecine",
        "Do_id":"23815012",
        "Doc_ChemicalList":"Biomarkers, Tumor;Calcitonin;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Adult;Age of Onset;Biomarkers, Tumor;Calcitonin;Carcinoma, Medullary;Child;Child, Preschool;Early Detection of Cancer;Female;Humans;Infant;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Multiple Endocrine Neoplasia Type 2b;Mutation, Missense;Neoplastic Syndromes, Hereditary;Phenotype;Primary Prevention;Proto-Oncogene Proteins c-ret;Risk;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"blood;blood;genetics;prevention & control;genetics;surgery;genetics;surgery;genetics;surgery;genetics;blood;genetics;prevention & control",
        "_version_":1605819346133712896},
      {
        "Doc_abstract":"Medullary thyroid cancer (MTC) is a cancer of the parafollicular C cells that commonly presents with an inherited or acquired RET gene mutation. There is currently no effective systemic treatment for MTC.;The objective of this study was to investigate a systemic therapeutic approach to treat MTC. We studied the sensitivity of an MTC cell line and xenograft to irinotecan, alone and in combination with the tyrosine kinase inhibitor, CEP-751.;In TT cell culture and xenografts, irinotecan treatment was highly effective. This effect was augmented by treatment with CEP-751. Treatment of TT cell xenografts resulted in durable complete remission in 100% of the mice, with median time to recurrence of 70 d for irinotecan alone and more than 130 d for irinotecan plus CEP-751. Although irinotecan induced an S phase checkpoint arrest in TT cells, CEP-751 in combination with irinotecan resulted in a loss of this arrest. CEP-751 induced a loss in the induction of the DNA repair program marked by phospho-H2AX and the checkpoint pathway marked by the activated Chk1 pathway.;Irinotecan treatment was highly effective in a preclinical model of human MTC, resulting in complete remission in 100% of the xenografts treated. The duration of remission was further enhanced by combination with the kinase inhibitor, CEP-751. These results suggest that irinotecan, alone or in combination, may be useful for the treatment of MTC.",
        "Doc_title":"Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer.",
        "Journal":"The Journal of clinical endocrinology and metabolism",
        "Do_id":"16263812",
        "Doc_ChemicalList":"Antineoplastic Agents;Antineoplastic Agents, Phytogenic;CEP 751;Carbazoles;Enzyme Inhibitors;H2AFX protein, human;Histones;irinotecan;Protein Kinases;Protein-Tyrosine Kinases;CHEK1 protein, human;Checkpoint Kinase 1;Chek1 protein, mouse;CDC25A protein, human;Cdc25a protein, mouse;cdc25 Phosphatases;Camptothecin",
        "Doc_meshdescriptors":"Animals;Antineoplastic Agents;Antineoplastic Agents, Phytogenic;Blotting, Western;Camptothecin;Carbazoles;Carcinoma, Medullary;Cell Cycle;Cell Division;Cell Line, Tumor;Checkpoint Kinase 1;Enzyme Inhibitors;Histones;Humans;Mice;Mice, Nude;Neoplasm Transplantation;Protein Kinases;Protein-Tyrosine Kinases;S Phase;Signal Transduction;Thyroid Neoplasms;Transplantation, Heterologous;cdc25 Phosphatases",
        "Doc_meshqualifiers":"therapeutic use;therapeutic use;analogs & derivatives;therapeutic use;therapeutic use;drug therapy;genetics;pathology;drug effects;drug effects;therapeutic use;biosynthesis;genetics;biosynthesis;genetics;antagonists & inhibitors;drug effects;drug effects;physiology;drug therapy;genetics;pathology;biosynthesis;genetics",
        "_version_":1605907055278817280},
      {
        "Doc_abstract":"Medullary thyroid cancer (MTC) is derived from the parafollicular cells of the thyroid. Understanding the molecular biology behind specific mutations of the RET gene and their prognostic implications have led to the establishment of tailored treatment modalities for certain patients. We review the most recent studies on the molecular biology, calcitonin screening, diagnosis, imaging, and treatment of MTC.;Newly identified rearranged during transfection point mutations have helped with MTC prognosis and have resulted in the establishment of new treatment guidelines. Screening for MTC in the United States with basal serum calcitonin for patients with thyroid nodules would cost $11,793 per life-year saved (LYS), compared with colonoscopy and mammography screening. For metastatic or recurrent disease, neck ultrasound, chest computed tomography scan, liver MRI, bone scintigraphy, and axial skeleton MRI have been proven superior to 18F-FDG PET/computed tomography. For patients with nonoperable metastatic disease, novel chemotherapeutic agents, such as vandetanib, targeting rearranged during transfection, vascular endothelial growth factor receptor and epidermal growth factor receptor, are showing promise. Such agents are currently in phase II trials.;There have been several recent advances in the diagnosis, molecular biology, imaging, and treatment options of MTC. By potentially downstaging of disease, and treating metastatic disease more effectively, overall survival and outcomes of patients may improve.",
        "Doc_title":"Medullary thyroid cancer: early detection and novel treatments.",
        "Journal":"Current opinion in oncology",
        "Do_id":"19125012",
        "Doc_ChemicalList":"Fluorodeoxyglucose F18;Calcitonin",
        "Doc_meshdescriptors":"Antineoplastic Combined Chemotherapy Protocols;Calcitonin;Carcinoma, Medullary;Fluorodeoxyglucose F18;Humans;Positron-Emission Tomography;Prognosis;Thyroid Neoplasms;Tomography, X-Ray Computed",
        "Doc_meshqualifiers":"therapeutic use;blood;diagnosis;drug therapy;genetics;diagnosis;drug therapy;genetics",
        "_version_":1605746295871373315},
      {
        "Doc_abstract":"The development of biochemical and genetic screening tests for inherited endocrine diseases has dramatically changed our approach to surgical patients with endocrine tumors. Among more than 1800 patients with endocrine tumors and a possible inherited disease operated on between 1986 and 1997, there were 6.1% to 7.3% who were found to have a familial disease associated with familial medullary thyroid cancer, (MTC), multiple endocrine neoplasia type IIa (MEN-IIa), MEN-IIb, or MEN-I. Genetic testing for the RET proto-oncogene is therefore recommended for all patients with MTC, and testing for the MEN-I gene is recommended in patients with suspected MEN-I and in specific clinical subgroups with an increased probability of endocrine tumor heredity. Early treatment based on early diagnosis by genetic testing appears to improve survival and to decrease morbidity in these patients.",
        "Doc_title":"Genetic and biochemical screening for endocrine disease.",
        "Journal":"World journal of surgery",
        "Do_id":"9841744",
        "Doc_ChemicalList":"Biomarkers",
        "Doc_meshdescriptors":"Biomarkers;Endocrine System Diseases;Genetic Testing;Humans;Multiple Endocrine Neoplasia Type 1;Multiple Endocrine Neoplasia Type 2a;Pedigree;Thyroid Neoplasms",
        "Doc_meshqualifiers":"diagnosis;diagnosis;diagnosis;diagnosis",
        "_version_":1605765530903379968},
      {
        "Doc_abstract":"Thyroid tumors are rare in childhood and adolescence. A retrospective analysis was done of fifteen patients (8 female) with thyroid carcinoma attended in the Pediatric Endocrinology Unit of the HC-UFPR, from February 1988 to March 2003. The most frequent initial complaint was an anterior cervical nodule. Ten patients were papillary carcinoma (PTC) bearers, four had medullary carcinoma (MTC; three of them with MEN-2B) and one had follicular carcinoma. Two patients with MEN-2B have de novo proto-oncogene RET mutation (Met918Thr). Fine needle aspiration (FNA) was performed in ten patients and was malignancy positive in only five of them. All patients underwent total thyroidectomy. Adjuvant radioiodine (131I) therapy was made in ten patients. Two patients died from unrelated diseases. Nine patients presented no clinical or laboratorial evidence of disease; one (PTC) developed recurrence 5 years after initial treatment and three (1 PTC, 2 MTC) have disease evidence yet. Our prognosis and clinical manifestations data are according to the literature. However, MTC prevalence (27%), sex distribution and FNA results differ from the majority of published casuistics, that can be attributed to the number of cases reported here.",
        "Doc_title":"[Thyroid cancer in childhood and adolescence--report of 15 cases].",
        "Journal":"Arquivos brasileiros de endocrinologia e metabologia",
        "Do_id":"15761557",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Child;Female;Follow-Up Studies;Humans;Male;Retrospective Studies;Thyroid Neoplasms",
        "Doc_meshqualifiers":"diagnosis;surgery",
        "_version_":1605818573057425409},
      {
        "Doc_abstract":"Medullary thyroid cancer (MTC) is a rare thyroid cancer accounting for 5% of all thyroid malignancies. The purpose of our study was to design a predictive nomogram for cancer-specific mortality (CSM) utilizing clinical, pathological, and biochemical variables in patients with MTC.;MTC patients managed entirely at Memorial Sloan-Kettering Cancer Center between 1986 and 2010 were identified. Patient, tumor, and treatment characteristics were recorded, and variables predictive of CSM were identified by univariable analyses. A multivariable competing risk model was then built to predict the 10-year cancer specific mortality of MTC. All predictors of interest were added in the starting full model before selection, including age, gender, pre- and postoperative serum calcitonin, pre- and postoperative CEA, RET mutation status, perivascular invasion, margin status, pathologic T status, pathologic N status, and M status. Stepdown method was used in model selection to choose predictive variables.;Of 249 MTC patients, 22.5% (56/249) died from MTC, whereas 6.4% (16/249) died secondary to other causes. Mean follow-up period was 8767months. The seven variables with the highest predictive accuracy for cancer specific mortality included age, gender, postoperative calcitonin, perivascular invasion, pathologic T status, pathologic N status, and M status. These variables were used to create the final nomogram. Discrimination from the final nomogram was measured at 0.77 with appropriate calibration.;We describe the first nomogram that estimates cause-specific mortality in individual patients with MTC. This predictive nomogram will facilitate patient counseling in terms of prognosis and subsequent clinical follow up.",
        "Doc_title":"Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer.",
        "Journal":"Annals of surgical oncology",
        "Do_id":"25366585",
        "Doc_ChemicalList":"Calcitonin",
        "Doc_meshdescriptors":"Adult;Age Factors;Aged;Blood Vessels;Calcitonin;Carcinoma, Neuroendocrine;Female;Follow-Up Studies;Humans;Lymphatic Metastasis;Male;Middle Aged;Multivariate Analysis;Neoplasm Invasiveness;Neoplasm Staging;Nomograms;Postoperative Period;Predictive Value of Tests;Sex Factors;Survival Rate;Thyroid Neoplasms",
        "Doc_meshqualifiers":"pathology;blood;mortality;pathology;surgery;mortality;pathology;surgery",
        "_version_":1605846274824732672},
      {
        "Doc_abstract":"The genetic landscape of medullary thyroid cancer (MTC) is not yet fully understood, although some oncogenic mutations have been identified. To explore genetic profiles of MTCs, formalin-fixed, paraffin-embedded tumor tissues from MTC patients were assayed on the Ion AmpliSeq Cancer Panel v2. Eighty-four sporadic MTC samples and 36 paired normal thyroid tissues were successfully sequenced. We discovered 101 hotspot mutations in 18 genes in the 84 MTC tissue samples. The most common mutation was in the ret proto-oncogene, which occurred in 47 cases followed by mutations in genes encoding Harvey rat sarcoma viral oncogene homolog (N = 14), serine/threonine kinase 11 (N = 11), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (N = 6), mutL homolog 1 (N = 4), Kiesten rat sarcoma viral oncogene homolog (N = 3) and MET proto-oncogene (N = 3). We also evaluated anaplastic lymphoma kinase (ALK) rearrangement by immunohistochemistry and break-apart fluorescence in situ hybridization (FISH). Two of 98 screened cases were positive for ALK FISH. To identify the genomic breakpoint and 5' fusion partner of ALK, customized targeted cancer panel sequencing was performed using DNA from tumor samples of the two patients. Glutamine:fructose-6-phosphate transaminase 1 (GFPT1)-ALK and echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusions were identified. Additional PCR analysis, followed by Sanger sequencing, confirmed the GFPT1-ALK fusion, indicating that the fusion is a result of intra-chromosomal translocation or deletion. Notably, a metastatic MTC case harboring the EML4-ALK fusion showed a dramatic response to an ALK inhibitor, crizotinib. In conclusion, we found several genetic mutations in MTC and are the first to identify ALK fusions in MTC. Our results suggest that the EML4-ALK fusion in MTC may be a potential driver mutation and a valid target of ALK inhibitors. Furthermore, the GFPT1-ALK fusion may be a potential candidate for molecular target therapy. ",
        "Doc_title":"Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.",
        "Journal":"PLoS genetics",
        "Do_id":"26295973",
        "Doc_ChemicalList":"EML4-ALK fusion protein, human;Oncogene Proteins, Fusion;GFPT1 protein, human;Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing);Proto-Oncogene Proteins c-ret;RET protein, human;Receptor Protein-Tyrosine Kinases;anaplastic lymphoma kinase",
        "Doc_meshdescriptors":"Adult;Base Sequence;Carcinoma, Neuroendocrine;DNA Mutational Analysis;Female;Genetic Predisposition to Disease;Genome, Human;Genome-Wide Association Study;Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing);Humans;Male;Middle Aged;Oncogene Proteins, Fusion;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms;Young Adult",
        "Doc_meshqualifiers":"genetics;genetics;genetics;genetics;genetics;genetics",
        "_version_":1605758273830518784},
      {
        "Doc_abstract":"The gene predisposing to multiple endocrine neoplasia type 2A (MEN 2A) has been assigned to chromosome 10, and affected gene carriers can be identified before the development of associated malignancy in some informative families. We applied these advances in gene mapping to clinical screening for possible pediatric surgery. A family with MEN 2A, consisting of 88 members and their spouses, was studied to test the reliability of the provocation of plasma calcitonin with pentagastrin and the possibility of DNA diagnosis of mutated gene carriers with DNA probes closely linked to the MEN2A gene including RBP3 and FNRB genes. Nineteen of the 88 were diagnosed as MEN 2A carriers. Twelve of them were treated surgically and the others died of medullay thyroid carcinoma (MTC) or pheochromocytoma. A strikingly sensitive response of calcitonin was observed in all those with MTC. The genotypes cosegregating with the abnormal allele at MEN2A in this family could be deduced from clinically established affected members. The early detection of gene carriers allows us to concentrate our screening efforts on children at high risk and to release non gene carriers from repeated unnecessary testing. MEN2A is one of the first cancer syndromes for which DNA screening permits early detection of members at high risk.",
        "Doc_title":"Prediction of affected MEN2A gene carriers by DNA linkage analysis for early total thyroidectomy: a progress in clinical screening program for children with hereditary cancer syndrome.",
        "Journal":"Journal of pediatric surgery",
        "Do_id":"1355790",
        "Doc_ChemicalList":"Calcitonin;DNA;Pentagastrin",
        "Doc_meshdescriptors":"Adolescent;Adult;Calcitonin;Child;Child, Preschool;DNA;Female;Genetic Linkage;Genetic Testing;Genotype;Heterozygote Detection;Humans;Male;Middle Aged;Multiple Endocrine Neoplasia;Pedigree;Pentagastrin;Thyroidectomy",
        "Doc_meshqualifiers":"blood;analysis;methods;methods;diagnosis;genetics;prevention & control",
        "_version_":1605846069672935424},
      {
        "Doc_abstract":"Incidental C cell hyperplasia (CCH) following thyroidectomy for other indications may rarely be encountered, which may raise concerns about its clinical significance and proper management. CCH can be classified as physiological (reactive) or neoplastic. Reactive CCH has no malignant potential and can be observed in association with many other thyroid diseases (including differentiated thyroid cancer); in contrast, neoplastic CCH should be considered as a preneoplastic stage in the spectrum of C cell disease, ultimately leading to the development of medullary thyroid cancer (MTC). Neoplastic CCH is commonly observed in patients with germ-line mutations in the RET oncogene (commonly in families with a history of hereditary MTC, i.e. familial MTC or multiple endocrine neoplasia type 2 (MEN2)). CCH should be considered in patients with hypercalcitoninemia without nodular thyroidopathy. Total thyroidectomy, which is commonly performed for the majority of thyroid diseases, is an adequate treatment and achieves cure, even in patients with neoplastic CCH. There is no role for cervical lymph node dissection in patients with pure CCH. In conclusion, reactive CCH has no malignant potential, in contrast to neoplastic CCH. Total thyroidectomy achieves cure of patients with CCH.",
        "Doc_title":"Incidental thyroid C cell hyperplasia: clinical significance and implications in practice.",
        "Journal":"Oncology research and treatment",
        "Do_id":"25966772",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Humans;Hyperplasia;Thyroid Gland;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"pathology;classification;pathology;surgery",
        "_version_":1605908012391727104},
      {
        "Doc_abstract":"Cabozantinib (Cometriq()) is an orally administered small molecule inhibitor of multiple tyrosine kinase receptors, including those involved in the pathogenesis of medullary thyroid cancer (MTC) [i.e. rearranged during transfection (RET), MET and vascular endothelial growth factor receptor (VEGFR)-2]. Cabozantinib is indicated for the treatment of adults with progressive, unresectable locally advanced (in the EU) or metastatic (in the EU and USA) MTC. Compared with placebo, cabozantinib significantly prolonged progression-free survival, reflecting a 72% reduction in the risk of disease progression or death, in patients with unresectable, locally advanced or metastatic MTC participating in a multinational, phase III study. A significantly higher proportion of patients receiving cabozantinib than those receiving placebo achieved an objective response or disease stabilization (i.e. a complete or partial response, or stable disease). The overall survival benefit with cabozantinib is as yet unclear, with no significant benefit observed in two interim analyses (one prespecified, and one unplanned and conducted at the request of the US FDA). The tolerability profile of oral cabozantinib is typical for a small molecule targeting the VEGFR and other tyrosine kinase-mediated pathways, with adverse events associated with the inhibition of the VEGF pathway (e.g. gastrointestinal perforation, haemorrhage, hypertension and venous thrombosis) reported in the phase III study. Treatment-emergent adverse events were generally managed with supportive therapy, dose reductions and/or dose interruptions. Although final overall survival data are awaited, current evidence suggests cabozantinib to be a valuable treatment option for adults with progressive, unresectable locally advanced or metastatic MTC.",
        "Doc_title":"Cabozantinib: a review of its use in patients with medullary thyroid cancer.",
        "Journal":"Drugs",
        "Do_id":"25056653",
        "Doc_ChemicalList":"Anilides;Antineoplastic Agents;Pyridines;Vascular Endothelial Growth Factors;cabozantinib",
        "Doc_meshdescriptors":"Anilides;Antineoplastic Agents;Carcinoma, Neuroendocrine;Humans;Pyridines;Thyroid Neoplasms;Vascular Endothelial Growth Factors",
        "Doc_meshqualifiers":"adverse effects;pharmacology;therapeutic use;adverse effects;pharmacology;therapeutic use;adverse effects;pharmacology;therapeutic use;drug therapy;metabolism;antagonists & inhibitors;metabolism",
        "_version_":1605748355913220096},
      {
        "Doc_abstract":"Genetic screening for germline RET proto-oncogene mutation in hereditary medullary thyroid cancer (MTC) is accurate and allows for preventive total thyroidectomy to be performed early in patients who are gene carriers. We report 3 children who underwent preventive total thyroidectomy based on the finding of a RETgene germline mutation, but who had no evidence of MTC or C-cell hyperplasia on permanent histology, even after calcitonin immunostaining. Review of the English literature of patients undergoing preventive thyroidectomy for a positive RETgene germline mutation, shows that 3.4% of these patients (a total of 209 patients) had normal thyroid glands. Also, 8.6% of patients undergoing preventive total thyroidectomy with prophylactic central neck node dissection had cervical node metastases. We conclude that preventive thyroidectomy in patients screened early for germline RETgene mutation allows for earlier diagnosis and treatment of patients, sometimes even before any hyperplasia or neoplasia can be demonstrated because cervical node metastases can occur early and be demonstrated even with small tumors (< 1 cm), we recommend prophylactic central neck node dissection at the time of preventive thyroidectomy.",
        "Doc_title":"Normal thyroid pathology in patients undergoing thyroidectomy for finding a RETgene germline mutation: a report of three cases and review of the literature.",
        "Journal":"Thyroid : official journal of the American Thyroid Association",
        "Do_id":"10090311",
        "Doc_ChemicalList":"Drosophila Proteins;Proto-Oncogene Proteins;Calcitonin;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Ret oncogene protein, Drosophila",
        "Doc_meshdescriptors":"Adolescent;Calcitonin;Carcinoma, Medullary;Child;Child, Preschool;Drosophila Proteins;Female;Humans;Male;Multiple Endocrine Neoplasia Type 2a;Mutation;Pedigree;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Gland;Thyroid Neoplasms;Thyroidectomy",
        "Doc_meshqualifiers":"analysis;genetics;pathology;genetics;genetics;genetics;pathology;genetics;pathology",
        "_version_":1605758306167554048},
      {
        "Doc_abstract":"Medullary thyroid cancer is a rare neoplasm that arises from the parafollicular C cells. It occurs in a sporadic form, or less commonly as a hereditary form, as part of multiple endocrine neoplasia syndromes types 2A and 2B. The RET proto-oncogene is currently the primary factor that is implicated in the hereditary forms of this neoplasm. The knowledge about the genetic makeup of the neoplasm impacts upon management as it allows for screening, early detection, and prophylactic treatment. Surgery is the main modality that offers a cure. This entails a total thyroidectomy and vigilant management and surveillance of the neck. Prognosis of patients with MTC is variable, but the more constant factors that affect it are the stage of disease and the age of the patient. The emerging molecular genetic understanding of this malignancy will provide the foundation for prognostic and therapeutic decision-making in the future. Interdisciplinary management by surgeons, endocrinologists, pathologists, radiotherapists, radiologists, and medical oncologists should be sought.",
        "Doc_title":"Medullary thyroid cancer.",
        "Journal":"Otolaryngologic clinics of North America",
        "Do_id":"12803011",
        "Doc_ChemicalList":"Biomarkers, Tumor;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases",
        "Doc_meshdescriptors":"Biomarkers, Tumor;Carcinoma, Medullary;Humans;Multiple Endocrine Neoplasia;Neoplasm Staging;Predictive Value of Tests;Prognosis;Proto-Oncogene Proteins;Proto-Oncogene Proteins c-ret;Receptor Protein-Tyrosine Kinases;Thyroid Neoplasms",
        "Doc_meshqualifiers":"complications;diagnosis;genetics;therapy;complications;diagnosis;genetics;therapy;genetics;genetics;complications;diagnosis;genetics;therapy",
        "_version_":1605754243086548992},
      {
        "Doc_abstract":"Pheochromocytomas, intra-adrenal paraganglioma, and extra-adrenal sympathetic and parasympathetic paragangliomas are neuroendocrine tumors derived from adrenal chromaffin cells or similar cells in extra-adrenal sympathetic and parasympathetic paraganglia, respectively. Serious morbidity and mortality rates associated with these tumors are related to the potent effects of catecholamines on various organs, especially those of the cardiovascular system. Before any surgical procedure is done, preoperative blockade is necessary to protect the patient against significant release of catecholamines due to anesthesia and surgical manipulation of the tumor. Treatment options vary with the extent of the disease, with laparoscopic surgery being the preferred treatment for removal of primary tumors. Medullary thyroid cancer (MTC) is a malignancy of the thyroid C cells or parafollicular cells. Thyroid C cells elaborate a number of peptides and hormones, such as calcitonin, carcinoembryonic antigen, and chromogranin A. Some or all of these markers are elevated in patients with MTC and can be used to confirm the diagnosis as well as to follow patients longitudinally for recurrence. Medullary thyroid cancer consists of a spectrum of diseases that ranges from extremely indolent tumors that are stable for many years to aggressive types associated with a high mortality rate. Genetic testing for RET mutations has allowed identification of familial cases and prophylactic thyroidectomy for cure. The only curative treatment is complete surgical resection.",
        "Doc_title":"The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer.",
        "Journal":"Pancreas",
        "Do_id":"20664475",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Humans;Neuroendocrine Tumors;Paraganglioma;Pheochromocytoma;Thyroid Neoplasms",
        "Doc_meshqualifiers":"diagnosis;therapy;diagnosis;therapy;diagnosis;therapy;diagnosis;therapy",
        "_version_":1605797666357248000},
      {
        "Doc_abstract":"Thyroid cancers are largely divided into medullary (MTC) and non-medullary (NMTC) cancers , depending on the cell type of origin. Familial non-medullary thyroid cancer (FNMTC) comprises about 5-15% of NMTC and is a heterogeneous group of diseases, including both non-syndromic and syndromic forms. Non-syndromic FNMTC tends to manifest papillary thyroid carcinoma , usually multifocal and bilateral . Several high-penetrance genes for FNMTC have been identified, but they are often confined to a few or single families, and other susceptibility loci appear to play a small part, conferring only small increments in risk. Familial susceptibility is likely to be due to a combination of genetic and environmental influences. The current focus of research in FNMTC is to characterise the susceptibility genes and their role in carcinogenesis. FNMTC can also occur as a part of multitumour genetic syndromes such as familial adenomatous polyposis , Cowden's disease , Werner's syndrome and Carney complex . These tend to present at an early age and are multicentric and bilateral with distinct pathology. The clinical evaluation of these patients is similar to that for most patients with a thyroid nodule. Medullary thyroid cancer (MTC) arises from the parafollicular cells of the thyroid which release calcitonin. The familial form of MTC accounts for 20-25% of cases and presents as a part of the multiple endocrine neoplasia type 2 (MEN 2) syndromes or as a pure familial MTC (FMTC). They are caused by germline point mutations in the RET oncogene on chromosome 10q11.2. There is a clear genotype-phenotype correlation, and the aggressiveness of FMTC depends on the specific genetic mutation, which should determine the timing of surgery.",
        "Doc_title":"Diagnosis and Management of Hereditary Thyroid Cancer.",
        "Journal":"Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer",
        "Do_id":"27075347",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Genetic Predisposition to Disease;Genetic Testing;Genotype;Humans;Neoplastic Syndromes, Hereditary;Phenotype;Thyroid Neoplasms",
        "Doc_meshqualifiers":"diagnosis;genetics;therapy;diagnosis;genetics;therapy",
        "_version_":1605819468244582400},
      {
        "Doc_abstract":"Activating mutations of the oncogene BRAF or rearrangements of the tyrosine kinase receptor RET are observed in up to 80% of papillary thyroid carcinomas (PTCs). The predominant BRAF V600E mutation has not been detected in benign thyroid tissue so far, so consequently, this assumedly pathognomonic alteration is qualified to improve the preoperative diagnosis of PTC.;Two hundred ninety preoperatively harvested fine-needle aspiration biopsies (FNABs) underwent routine cytologic assessment. BRAF V600E mutation analysis was performed by mutation-specific PCR using the same cell material; a hybrid-specific RT-PCR assay was used for detection of RET/PTC1 rearrangements. Detected genetic alterations were verified by direct sequencing. Definitive histopathology was obtained in 93/290 lesions following surgery of the respective thyroid nodule.;While cytology alone diagnosed 13/30 malignancies (22 PTCs, 4 FTCs, 1 MTC, 1 UTC, 2 metastases), five additional malignancies were identified by supplementary mutation analysis. Cytology classified eight FNABs as benign, while postoperative histology demonstrated a thyroid malignancy (6 PTCs, 1 FTC, 1 metastasis). In four of these eight cases, the genetic analysis detected a BRAF V600E mutation or a RET/PTC1 rearrangement. Classifying both suspicious and malignant FNAB results as positive cytology results, supplementary genetic testing increased the overall sensitivity of FNAB from 70.4 to 85.7%, the positive predictive value (PPV) from 59.4 to 64.9%, and the negative predictive value (NPV) from 84.0 to 91.3%.;Supplementary mutation analysis of RET and especially of the BRAF V600E mutation in FNABs is a fast and probably cost-effective assay in routine diagnostic setting. Mutation analyses of PTC-specific genetic alterations improve the preoperative identification and prognostic assessment of thyroid malignancies and therefore enable an optimized surgical strategy.",
        "Doc_title":"Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules.",
        "Journal":"World journal of surgery",
        "Do_id":"20652698",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret;RET protein, human;BRAF protein, human;Proto-Oncogene Proteins B-raf",
        "Doc_meshdescriptors":"Adenocarcinoma, Papillary;Biopsy, Fine-Needle;Humans;Mutation;Proto-Oncogene Proteins B-raf;Proto-Oncogene Proteins c-ret;Thyroid Neoplasms;Thyroid Nodule",
        "Doc_meshqualifiers":"genetics;pathology;genetics;genetics;genetics;pathology;genetics;pathology",
        "_version_":1605746322982305792},
      {
        "Doc_abstract":"DNA extracted from the peripheral blood leukocytes of 36 members of five families with multiple endocrine neoplasia (MEN) type 2A was analyzed for mutations of exons 10, 11, 13, 14, and 16 of the RET proto-oncogene by nonisotopic polymerase chain reaction-single-strand conformation polymorphism analysis and automated DNA sequencing. Germline mutations were found in all 9 of the affected individuals and in 6 of the 27 individuals of unknown status. A 70-year-old man who had been completely asymptomatic before genetic diagnosis underwent left adrenalectomy and total thyroidectomy, and was found to have pheochromocytoma and multifocal micromedullary thyroid carcinoma (MTC). A 32-year-old man and a 15-year-old boy, with elevated calcitonin levels detected by the C-cell-stimulation test, but no evident thyroid tumor, underwent total thyroidectomy. Histopathological diagnosis revealed multiple micro MTCs. A 7-year-old girl without evidence of a thyroid tumor or an elevated calcitonin level is being followed up. The remaining two subjects with an evident thyroid tumor and elevated calcitonin levels refused surgery. These results suggest that genetic screening for MEN type 2 afflicted family members can facilitate the presymptomatic detection of gene carriers. Thus, we must carefully evaluate whether immediate prophylactic total thyroidectomy is indicated for gene carriers of MEN 2A without an evident thyroid tumor or elevated calcitonin levels.",
        "Doc_title":"Presymptomatic detection and treatment of Japanese carriers of the multiple endocrine neoplasia type 2A gene.",
        "Journal":"Surgery today",
        "Do_id":"10489126",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adolescent;Adult;Aged;Female;Genetic Testing;Heterozygote;Humans;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Point Mutation;Polymerase Chain Reaction;Polymorphism, Single-Stranded Conformational;Proto-Oncogenes;Thyroidectomy",
        "Doc_meshqualifiers":"epidemiology;genetics;surgery",
        "_version_":1605756245490270208},
      {
        "Doc_abstract":"Pheochromocytoma (PCC) manifests in up to 50% of MEN2 patients. We correlated the clinico-pathological features of MEN2-associated PCC (MEN-PCC) with RET mutations and compared them with non-MEN adrenal-PCCs.;In this retrospective single institution study on a large PCC database (n = 208, 1997-2014) 24 MEN-PCC patients with known RET mutations were reviewed. Excluding 7 with incomplete data, the study cohort of 17 MEN-PCC patients from 11 kindreds (M:F::7:10) was identified. Clinical, biochemical, pathological attributes, and outcomes in the MEN-PCC group were correlated with the genotype, and further compared with non-MEN, apparently sporadic adrenal-PCCs (n = 132, excluding 37 extra-adrenal and 15 VHL/NF1/SDH-associated PCC).;Components of MEN2 encountered included MTC in 13(76.5%), Marfanoid habitus in 2, and PHPT, cutaneous lichen amyloidosis and mucosal neuromas in 1 patient each. In 11(64.7%), PCC was the first detected MEN2 component (Symptomatic:8, Incidentaloma:3). Four (23.5%) were normotensive; 8(47.1%) had bilateral PCC (7 synchronous, 1 metachronous). Surgery for PCC included laparoscopic adrenalectomy in 12; and cortical-sparing adrenalectomy in 2 of 8 bilateral PCC patients. Mean MEN-PCC tumor size was 6.9  3.9 cm, and 6(35%) had additional adrenal medullary hyperplasia. Four different genotypes were encountered, commonest involving codon 634, others being 804 and 918. Mean age in MEN-PCC (27.7  12.2 years) was lower than non-MEN PCC (39.4  15.7, p = 0.018). Proportion of pediatric patients (35.3% in MEN-PCC vs. 12.9% in non-MEN-PCC, p = 0.007), bilateral tumors (47.1% in MEN-PCC, 4.5% in non-MEN-PCC, p < 0.001), and adrenal medullary hyperplasia (35.2% in MEN-PCC, 0.7% in non-MEN-PCC, p < 0.001) were different. Median 24-hour urinary metanephrines was significantly higher in index MEN-PCC patients, than non-MEN-PCC (634 vs. 214 mcg/24 h, p value = 0.006), but was non-significantly higher in non-index MEN-PCC patients. Mean tumor sizes were comparable in the two groups. None of MEN-PCC patients had malignant PCC, compared to 7(5.3%) in non-MEN-PCC.;In this cohort of MEN-PCC from India, the commonest causative RET mutations for MEN-PCC involved codon 634. MEN-PCC patients were younger, and more frequently had bilateral PCC than non-MEN disease. MEN-PCC patients in India are diagnosed with large tumors and extremely high catecholamine/metanephrine levels.",
        "Doc_title":"Genotype-Phenotype Correlation in Indian Patients with MEN2-Associated Pheochromocytoma and Comparison of Clinico-Pathological Attributes with Apparently Sporadic Adrenal Pheochromocytoma.",
        "Journal":"World journal of surgery",
        "Do_id":"26438242",
        "Doc_ChemicalList":"Codon;DNA, Neoplasm;Mitogens;Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Adrenal Gland Neoplasms;Adrenal Glands;Adult;Codon;DNA Mutational Analysis;DNA, Neoplasm;Female;Genetic Association Studies;Genotype;Humans;Incidence;India;Male;Middle Aged;Mitogens;Multiple Endocrine Neoplasia Type 2a;Mutation;Pheochromocytoma;Proto-Oncogene Proteins c-ret;Retrospective Studies;Young Adult",
        "Doc_meshqualifiers":"epidemiology;genetics;pathology;metabolism;pathology;genetics;epidemiology;genetics;pathology;surgery;epidemiology;genetics;pathology;genetics",
        "_version_":1605798011334557696},
      {
        "Doc_abstract":"The diagnosis of Hirschsprung's disease (HSCR) should take place early in the neonatal period, because without an effective diagnosis and appropriate treatment, a considerable proportion of infants will go on to develop serious complications such as acute enterocolitis or toxic megacolon. Because no more than 10 % of HSCR cases have a late presentation with classical chronic constipation and megacolon, the clinician has to make a difficult, early diagnosis, which is the crux of the clinical problem. The aim of this review paper is to present all tools currently available to make a clear HSCR diagnosis and to discuss the problems facing the clinician and the pediatric surgeon in the correct identification of HSCR and of other intestinal dysganglionoses.;Based on the current state of knowledge and 24 years' personal experience in clinical practice and basic research in this field, I describe an algorithmic approach that enables clinicians and surgeons to rationalize and maximize the clarity of diagnosis through a complementary set of procedures and enzyme-histochemical reactions.;Two innovative techniques, added to the protocol in the last four years, are described: the lyophilized HSCR diagnostic kit, and the one-trocar transumbilical laparoscopic intestinal full-thickness biopsy technique (OTTLB).;The rational, algorithmic diagnostic pathway proposed in this review paper aims to optimize every diagnosis by the stepwise application of a complementary set of procedures and enzyme-histochemical reactions as they become appropriate. In the interests of simplifying genetic molecular diagnosis, I suggest the following guidelines: 1) only in cases of total colonic aganglionosis (TCA) is it advisable to carry out full RET mutation screening (the mutation rate is up to 70 %); and 2) all HSCR patients should be tested only for standard MEN2A and MTC mutations. If these are present, the patients should be followed up carefully with proper surveillance and biochemical testing of other susceptible family members as they are at risk of developing neuroendocrine tumors.",
        "Doc_title":"Hirschsprung's disease, one of the most difficult diagnoses in pediatric surgery: a review of the problems from clinical practice to the bench.",
        "Journal":"European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie",
        "Do_id":"18493886",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Algorithms;Biopsy;Hirschsprung Disease;Humans;Infant;Infant, Newborn;Intestines;Laparoscopy",
        "Doc_meshqualifiers":"diagnosis;genetics;pathology",
        "_version_":1605891951380398080},
      {
        "Doc_abstract":"The influence of oral aminophylline (Phyllotemp ret., 2 X 225 mg) on the mucociliary clearance of the lung and on sperm motility was examined in 13 patients with asthenospermia vs. placebo because the anatomic structure of the cilia of the sperm cells and of the respiratory epithelium cells is similar. The mucociliary clearance was measured by means of radioactive tagged (99 mTc) monodisperse particles (erythrocytes from the patients). To attain a reproducible deposition pattern, the particles were inhaled during a slow inspiratory vital capacity maneuvre. The i.v. application of aminophylline (6 mg/kg body weight) to four normal subjects increased the mucociliary clearance in three of the four volunteers vs. placebo. The elimination rate of the particles increased under treatment with aminophylline from 29% +/- 12% to 46% +/- 19%, but only in seven of the 13 patients with asthenospermia. Sperm motility increased in all of the patients from 33% +/- 12% to 54% +/- 14%. No correlation was found between the increase in the mucociliary clearance and the sperm motility. The reasons for this difference will be discussed. Theophylline can be recommended for the treatment of male infertility in cases of asthenospermia.",
        "Doc_title":"[Stimulation of limited sperm motility and mucociliary clearance of the lung with theophyllin-ethylendiamin].",
        "Journal":"Klinische Wochenschrift",
        "Do_id":"6843050",
        "Doc_ChemicalList":"Aminophylline",
        "Doc_meshdescriptors":"Aminophylline;Cilia;Humans;Infertility, Male;Lung;Male;Mucous Membrane;Mucus;Radionuclide Imaging;Sperm Motility",
        "Doc_meshqualifiers":"administration & dosage;pharmacology;drug effects;physiopathology;diagnostic imaging;drug effects;drug effects;drug effects;drug effects",
        "_version_":1605876314159448064},
      {
        "Doc_abstract":"Recent advances in genetic screening have ushered in a new era in diagnosis and management of medullary thyroid cancer (MTC). However, the same is not true for a resource-poor country, where clinicians are still struggling to diagnose and adequately manage this relatively uncommon thyroid malignancy. We hereby present our experience of managing MTC at a tertiary care referral center in North India.;This was a retrospective study conducted between January 1990 and July 2009. Demographics, clinical profiles, details of surgical procedures, and follow-up records were reviewed.;A total of 71 patients with MTC were identified. Mean age of this group was 39.914.1 years, and men outnumbered women 1.7:1. Some 84.5% of patients had seemingly sporadic MTC, and 15.5% had familial MTC (MEN2a=14.1%, MEN 2b=1.4%). All patients had a thyroid nodule at the time of presentation. Mean tumor diameter was 4.9 cm. Cervical lymphadenopathy, mediastinal lymphadenopathy, extrathyroidal invasion, and distant metastases were present in 59%, 7.2%, 10%, and 4.2% of patients, respectively. Staging showed that 4.8% of patients were stage I, 17.5% stage II, 14.3% stage III, and 63.6% stage IV. Treatment was as follows: 92.6% of patients had total thyroidectomy (primary or secondary); 67.6% central compartment lymph node dissection, 62.3% lateral cervical lymph node dissection, and 7.2% trans-sternal mediastinal lymph node dissection performed. Some 66.7% of patients suffered from persistent hypercalcitoninemia, and 11.4% of those underwent reoperation. The 5-year and 10-year overall survival (OS) was 74.6% and 58%, respectively.;The majority of the patients with MTC presented at stage IVa, contributing to the high rate of persistent hypercalcitoninemia. Despite a policy of observation and intervening only in overtly symptomatic patients with persistent hypercalcitoninemia, overall survival (OS) in our study was comparable to other series, reinforcing the belief that persistent hypercalcitoninemia has an indolent course in most patients.",
        "Doc_title":"Medullary thyroid cancer: clinico-pathological profile and outcome in a tertiary care center in North India.",
        "Journal":"World journal of surgery",
        "Do_id":"21479684",
        "Doc_ChemicalList":"None",
        "Doc_meshdescriptors":"Adult;Biopsy, Needle;Carcinoma;Carcinoma, Medullary;Cohort Studies;Female;Follow-Up Studies;Humans;Immunohistochemistry;India;Kaplan-Meier Estimate;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Neoplasm Invasiveness;Neoplasm Recurrence, Local;Neoplasm Staging;Neoplastic Syndromes, Hereditary;Postoperative Complications;Proportional Hazards Models;Referral and Consultation;Retrospective Studies;Risk Assessment;Survival Analysis;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"mortality;pathology;surgery;mortality;pathology;surgery;pathology;mortality;pathology;mortality;pathology;surgery;mortality;physiopathology;statistics & numerical data;mortality;pathology;surgery;adverse effects;methods",
        "_version_":1605755006705729536},
      {
        "Doc_abstract":"Cabozantinib is approved in the treatment of progressive, metastatic medullary thyroid cancer (MTC). It is a small molecule inhibitor, which targets multiple receptors, including vascular endothelial growth factor receptor, tyrosine kinase with Ig and epidermal growth factor homology domains-2 and the proto-oncogenes MET (mesenchymal-epithelial transition factor) and RET (rearranged during transfection). The drug is currently in phase I/II/III clinical trials for a number of other solid tumours and haematological malignancies. The adverse event (AE) profile is similar to that of other newer angiogenesis inhibitors. Hand-foot skin reaction (HFSR) is an important dose-limiting dermatological adverse event of this class of drugs.;To ascertain the incidence and risk of HFSR in patients with cancer during treatment with cabozantinib.;Electronic databases (PubMed, Web of Science) and the American Society of Clinical Oncology Meeting Library were queried from inception to July 2014. Only phase II/III studies investigating cabozantinib for the treatment of cancer were shortlisted. The incidence, relative risk (RR) and 95% CI were calculated using random- or fixed-effects models, depending on the heterogeneity of the included studies.;We included 831 patients treated with cabozantinib for various solid malignancies in the analysis. The overall incidence was 35.3% (95% CI 27.9-43.6%) for all-grade and 9.5% (95% CI 7.6-11.7%) for high-grade HFSR. The RR of all-grade and high-grade HFSR with cabozantinib, compared with controls, was increased for both all-grade (27.3; 95% CI 6.9-108.3; P<0.001) and high-grade (28.1; 95% CI 1.7-457; P<0.02) HFSR, respectively.;The incidence and risk of developing HFSR with cabozantinib are high. Timely recognition of this dose-limiting AE is critical to direct supportive care efforts including patient counselling, and to institute preventative and/or treatment interventions.",
        "Doc_title":"Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.",
        "Journal":"Clinical and experimental dermatology",
        "Do_id":"26009777",
        "Doc_ChemicalList":"Anilides;Antineoplastic Agents;Protein Kinase Inhibitors;Pyridines;cabozantinib",
        "Doc_meshdescriptors":"Anilides;Antineoplastic Agents;Hand-Foot Syndrome;Humans;Incidence;Protein Kinase Inhibitors;Pyridines;Risk Factors",
        "Doc_meshqualifiers":"adverse effects;adverse effects;etiology;adverse effects;adverse effects",
        "_version_":1605791199401082880},
      {
        "Doc_abstract":"Pheochromocytoma occurs in nearly 50% of MEN 2A (multiple endocrine neoplasia, type 2A) cases. Many issues related to this tumor are still the subject of debate: the diagnostic management in patients who have had positive genetic study results (RET mutation), variations related to mutation, the best surgical option, and the real relapse rate during long-term follow-up. The aim of this study is to present our experience with this unusual disease, looking for answers to some of these questions.;Of 169 patients belonging to 19 MEN 2A families, 54 (32%) presented with pheochromocytoma. The following variables have been studied: (1) clinical and diagnostic data [age, mutation, clinical features, results of catecholamines and catabolites in a 24-h urine sample, computerized tomography (CT) scan and iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy results, and the means of diagnostic, clinical, or genetic screening]; (2) surgical treatment; and (3) follow-up and recurrence. The mean follow-up time was 92.5 months (range: 12-120 months).;The mean age of the 54 patients was 37.9 years (range: 14-71 years); 33 were women. Most (96.3%) mutations were found in exon 11. The most frequent mutations were Cys634Tyr (in 33 cases [61.1%]) and Cys634Arg (in 14 [25.9%]). The diagnosis of pheocromocytoma was made after the diagnosis of MTC in 26 cases (48.2%), simultaneously in 21 (38.9%), and prior in the 7 remaining cases (12.9%). At the time of diagnosis 28 patients (51.8%) were asymptomatic and 26 (48.2%) had clinical features related to pheochromocytoma. In 6 patients (11.1%), the values of catecholamines and catabolites in urine were normal. In the cases with high values, the most useful isolated determination was that of metanephrines (82%), followed by adrenaline (76%). The CT scan did not provide a correct diagnosis in 6 patients with bilateral lesions, and one patient with a bilateral tumor was not diagnosed by MIBG. The combination of CT scan and MIBG diagnosed 100% of cases. The pheochromocytoma was bilateral in 27 cases, with a total number of 81 pathological glands detected. A laparascopic approach was used in 30 cases and a laparotomy in 24. The mean tumor size was 4.5 cm (range: 1-18 cm). Five patients with unilateral resection relapsed (18.5%), and the mean relapse time was 43.2 months (range: 12-120 months). There was a greater frequency of pheochromocytoma in those subjects who had the Cys634Arg mutation (p < 0.03). In addition, the Cys634Arg mutation is more frequent in bilateral cases. There are no prognostic factors for recurrence.;Pheochromocytoma in MEN 2A is related to the type of mutation, which can be early onset and is frequently asymptomatic. Its diagnosis requires catecholamines determinations as well as a CT scan. Correct diagnosis of bilaterality is established by CT and MIBG. Laparoscopic adrenalectomy is the treatment of choice.",
        "Doc_title":"Pheochromocytoma in MEN 2A syndrome. Study of 54 patients.",
        "Journal":"World journal of surgery",
        "Do_id":"18795243",
        "Doc_ChemicalList":"Proto-Oncogene Proteins c-ret;RET protein, human",
        "Doc_meshdescriptors":"Adolescent;Adrenal Gland Neoplasms;Adrenalectomy;Adult;Aged;Cohort Studies;Female;Humans;Laparoscopy;Male;Middle Aged;Multiple Endocrine Neoplasia Type 2a;Mutation;Pheochromocytoma;Proto-Oncogene Proteins c-ret;Retrospective Studies;Treatment Outcome;Young Adult",
        "Doc_meshqualifiers":"diagnosis;genetics;surgery;complications;pathology;therapy;genetics;diagnosis;genetics;surgery;genetics",
        "_version_":1605831086737195008}]
  }}
